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Summary of Contents 
 
Beta-blockers and non-steroidal anti-inflammatory drugs (NSAIDs) are often avoided in 
asthma over risk of bronchospasm which may vary according to drug selectivity and 
duration of administration. This thesis attempts to quantify the risk of beta-blocker and 
NSAID exposure in asthma by synthesising clinical trial evidence and conducting 
observational studies using linked electronic medical records.  
 
As part of this thesis, three systematic reviews of clinical trials were conducted 
evaluating: the prevalence of aspirin-exacerbated respiratory disease (AERD); risk of 
selective NSAIDs/COX-2 inhibitors in people with AERD; and risk of acute beta-
blocker exposure in people with asthma. Electronic primary care data from the Clinical 
Practice Research Datalink (CPRD) was used to define a cohort of people with active 
asthma, measure the prevalence of beta-blocker and NSAID prescribing, and perform a 
series of nested case control studies evaluating asthma death, asthma hospitalisation and 
primary care asthma exacerbations (PCAE). A self-controlled case-series was 
performed for PCAE as well. 
 
Based upon work in this thesis, the prevalence of AERD in people with asthma was 
around 9%. Selective NSAIDs triggered respiratory symptoms in 8% of people with 
AERD whilst no significant changes in lung function or symptoms occurred with COX-
2 inhibitors. Acute non-selective beta-blocker exposure caused a significant mean fall in 
FEV1 of 10%, a significant increase in respiratory symptoms in around 1 in 13 and a 
non-significant increase in falls in FEV1 of ≥20% in around 1 in 9. Acute selective beta-
blocker exposure caused a significant mean fall in FEV1 of 7%, significant falls in 
18 
 
FEV1 of ≥20% in around 1 in 8 and a non-significant increase in respiratory symptoms 
in around 1 in 33.  
 
The prevalence of selective beta-blocker prescribing in asthma rose by around 200% 
over the 12 year period whilst the prevalence of non-selective beta-blocker prescribing 
rose by around 90%. Changing trends in NSAID prescribing occurred over the 12 year 
period with COX-2 inhibitors now rarely prescribed. Using the nested case control 
design, both incident and high-dose non-selective beta-blocker exposure was associated 
with significantly increased risk of asthma morbidity (hospitalisation and PCAE). In 
contrast, no significant increased risk of asthma morbidity occurred with any type of 
selective beta-blocker exposure. Consistent findings were seen for PCAE using the self-
controlled case series. No significantly increased risk was seen with different oral 
NSAIDs apart from weak evidence of an association between asthma death and non-
selective NSAID exposure which is unlikely to be causal. 
 
Significant numbers of people with asthma are prescribed beta-blockers and NSAIDs. 
Evidence from clinical trials and observational studies demonstrate that non-selective 
beta-blockers significantly increase asthma morbidity with risk appearing to vary 
according to dose and duration of administration. Although selective beta-blockers have 
the potential to cause significant changes in lung function, no significant increase in 
asthma morbidity was observed in observational studies. Although around 9% of 
asthmatics may be susceptible to NSAIDs, no strong evidence was found to suggest that 
the current practice of NSAID prescribing increases asthma morbidity. At the same 
time, COX-2 inhibitors are infrequently prescribed despite apparently being well 
tolerated by people with AERD.
19 
 
 
Chapter 1: Introduction  
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This section provides a background discussion on asthma and its clinical and wider 
importance, and the pharmacology of beta-blockers and non-steroidal anti-inflammatory 
drugs with a specific emphasis on how the pharmacology relates to adverse respiratory 
effects in asthma. The overall aim of the introduction is to put this thesis into context, 
with the more specific literature relating to the risks of these drugs presented in chapters 
3 to 5 which report systematic reviews.  
 
1.1 Asthma 
Asthma is a common chronic respiratory disease characterised by expiratory airflow 
obstruction and acute exacerbations. Patients with asthma develop symptoms such as 
wheeze, cough, chest tightness and breathlessness which are traditionally episodic in 
nature (1, 2). The London physician Henry Salter described the episodic nature of 
asthma in 1860 as "Paroxysmal dyspnoea of a peculiar character, generally periodic 
with intervals of healthy respiration between the attacks” and highlighted the role of 
bronchial smooth muscle contraction (3). Since then, knowledge regarding the 
pathophysiology of asthma has advanced significantly.  
 
Several environmental triggers for asthma exist which act in combination with a 
person’s genetic susceptibility. It is well established that asthma can run in families and 
that the risk of asthma is significantly increased if people have a first-degree relative 
affected by asthma (4). Environmental triggers include: allergens such as dust mites, pet 
dander, pollens, food and moulds; viruses; air pollution; tobacco smoke; occupational 
irritants; medications including beta-blockers and non-steroidal anti-inflammatory 
drugs; stress; rhinitis; exercise; and cold (5). Understanding environmental triggers 
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forms an important part of interventions to help patients alter their lifestyle in an 
attempt to avoid or manage their individual triggers. 
 
1.2 Chronic airway inflammation 
1.2.1 Mediators of chronic airway inflammation 
Large numbers of cells and mediators are involved in the inflammatory process in 
asthma including eosinophils, helper T-lymphocytes, mast cells and macrophages. The 
airway epithelium acts as a protective barrier and releases inflammatory mediators in 
response to environmental factors including allergens, pathogens, cigarette smoke and 
pollution (6). In patients with allergic asthma, inhaled allergen binds to dendritic cells 
on the airway epithelium causing differentiation of T-helper (Th) lymphocytes into the 
Th2 phenotype (7). Th2 cells produce cytokines and chemokines such as interleukin 
(IL) 4, 5 and 13 which in turn cause B lymphocytes to produce immunoglobulin E (IgE) 
(8). Chemokines are released and recruit inflammatory cells into the airways whilst 
cytokines coordinate the inflammatory cascade. This Th2 cell-dependent IgE-mediated 
response activates eosinophils and causes degranulation of mast cells promoting the 
allergic inflammatory cascade. Key mediators of this cascade include cysteinyl 
leukotrienes and histamine which are potent bronchoconstrictors released by mast cells, 
whilst activated eosinophils damage airway epithelium by releasing mediators such as 
eosinophil major basic protein (9). Once damaged, airway epithelium releases several 
other mediators which activate Th2 cell-dependent airway inflammation independent of 
allergens, such as damage associated with microbial or viral infection (10). 
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1.2.2 Effects of chronic airway inflammation 
Asthma affects the large and small airways of the lung including the trachea, bronchi 
and bronchioles. Airway inflammation can persist and become chronic even though 
symptoms may be episodic and may lead to the pathophysiological changes associated 
with asthma. Damage to the airway epithelium leads to epithelial shedding thereby 
exposing deeper airway structures to environmental stimuli. This contributes to airway 
hyper-responsiveness through increased allergen penetration and stimulation of exposed 
sensory nerves leading to smooth muscle hyper-excitability (11). Airway inflammation 
causes secretion and exudation of proteins from airway epithelium and mucus glands 
leading to characteristic viscous mucus plugs. Inflammatory mediators are released 
from damaged airway epithelium and activate inflammatory cells causing proliferation 
of airway smooth muscle, thickening of the basement membrane and airway smooth 
muscle hypertrophy and hyperplasia (12). Increased smooth muscle mass reduces 
airway diameter and contributes to airway hyper-responsiveness by enhancing the force 
associated with bronchoconstrictor stimuli. The combination of chronic inflammation, 
epithelial damage, airway smooth muscle proliferation and mechanical stress associated 
with bronchoconstriction leads to airway remodelling and fibrosis, which in turn 
contributes to disease development and progression. 
 
1.3 Airway smooth muscle 
Under normal circumstances, airway calibre is maintained by the bronchomotor tone in 
airway smooth muscle. In asthma, control of airway smooth muscle is regulated by 
complex interactions between inflammatory cells and neural processes (13). Neural 
processes control bronchomotor tone through the balance of sympathetic and 
parasympathetic drive mediated by the neurotransmitters adrenaline/noradrenaline and 
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acetylcholine respectively. In this regard, sympathetic stimulation by catecholamines 
causes airway smooth muscle relaxation whilst parasympathetic stimulation by 
acetylcholine causes airway smooth muscle contraction (14). Airway smooth muscle 
contains no direct sympathetic innervation and sympathetic stimulation is mediated by 
circulating catecholamines binding to and stimulating pulmonary beta2-adrenoceptors. 
Stimulation of the pulmonary beta2-adrenoceptors causes stimulatory G-protein 
activation which in turn activates the enzyme adenylyl cyclase leading to increased 
levels of the intracellular messenger cAMP and smooth muscle relaxation. In contrast, 
parasympathetic stimulation is mediated through muscarinic-2 (M2) and M3 receptors, 
which activate inhibitory G-proteins. These in turn inhibit adenylyl cyclase leading to 
smooth muscle contraction. This understanding has led to the use of inhaled 
bronchodilators which stimulate the pulmonary beta2-adrenoceptor causing 
bronchodilatation and are recommended first line agents for the acute relief of asthma 
symptoms. 
 
1.4 Diagnosis of asthma 
Asthma is a clinical diagnosis, based upon symptoms and the demonstration of 
reversible or variable airflow obstruction (1, 2). Asthma can be difficult to diagnose due 
to heterogeneity in presentation, severity and results of different investigations. Lung 
function testing is routinely performed in patients over the age of 5 with suspected 
asthma and several different methods for assessing airflow obstruction exist. Spirometry 
is the most commonly used method to detect and quantify airflow obstruction. A forced 
expiratory manoeuvre is used to measure forced expiratory volume in one second 
(FEV1) and forced vital capacity (FVC), with a ratio of FEV1:FVC of less than 0.7 
suggestive of airflow obstruction.  Reversibility and variability are used to describe 
24 
 
changes in lung function which occur naturally or in response to treatment. The 
presence of reversibility and variability supports the diagnosis of asthma, however 
normal results do not exclude the diagnosis of asthma especially if patients are 
asymptomatic at the time of testing. The amount of FEV1reversibility in response to 
inhaled bronchodilators required for the diagnosis of asthma is 12%, with at least a 
200ml change from baseline values (1). These changes are important to differentiate 
between other causes of airflow obstruction including chronic obstructive pulmonary 
disease (COPD) which typically results in fixed airflow obstruction. Other methods to 
measure airflow obstruction include peak expiratory flow which may be used to assess 
diurnal variability as a measure of reversibility. Diurnal variability is defined by the 
percentage difference between the highest & lowest peak flow reading with values less 
than 8% regarded as normal. However, peak flow measurements can underestimate 
airflow obstruction and poor technique is common, often leading to unreliable 
measurements. Spirometry is preferred for diagnosis because it is highly reproducible, 
although peak flow is more useful for monitoring asthma control because it requires no 
specialised equipment. 
 
In patients with symptoms but without objective airflow obstruction, testing for airway 
hyper-responsiveness is needed. Airway hyper-responsiveness measures the sensitivity 
of the airways to direct and indirect airway challenges representing triggers and are 
typically reported as the dose causing a specific fall in FEV1 (usually of 20%), often 
referred to as the provocative concentration (PC). Direct challenges use inhaled 
histamine and metacholine to directly stimulate receptors on airway smooth muscle 
causing contraction. The PC20 in response to histamine and metacholine suggestive of a 
diagnosis of asthma is less than 8mg per ml. In comparison, indirect challenges use 
25 
 
inhaled mannitol and exercise to trigger the release of mediators from inflammatory 
cells including cysteinyl leukotrienes and histamine which lead to airway smooth 
muscle contraction (15). Challenge tests have high sensitivity in detecting asthma when 
people have normal lung function, with direct challenges being more sensitive but less 
specific than indirect challenges (16, 17). Other non-invasive tests which have been 
used to detect airway inflammation include sputum eosinophilia count and exhaled 
nitric oxide levels (FE(NO)). Although not widely available in current routine clinical 
practice, positive results with several of these tests appear to predict response to inhaled 
corticosteroid (ICS) therapy in asthma (18, 19). 
 
In summary, asthma is a chronic condition associated with episodic symptoms and 
exacerbations triggered by a variety of stimuli. The main pathophysiology of asthma 
involves the complex interplay between chronic airway inflammation and airway hyper-
responsiveness mediated in part through the effects of airway smooth muscle tone. This 
pathophysiology is important for understanding the adverse respiratory effects of beta-
blockers and non-steroidal anti-inflammatory drugs (NSAIDs) in asthma discussed later 
in the thesis. It is important to consider that patients with asthma may have different 
susceptibility to triggers representing different clinical phenotypes. The diagnosis of 
asthma is important to understand and evaluate the methods and results used in 
subsequent chapters. 
 
1.5 Clinical asthma phenotypes 
Asthma is a condition with several clinical phenotypes which may vary over time as a 
result of the underlying pathophysiology of chronic airway inflammation and airway 
hyper-responsiveness (1). Asthma was traditionally characterised in terms of the type of 
26 
 
symptoms experienced and by severity. Asthma severity is typically defined by clinical 
factors such as symptoms, lung function, dose or number of medications required in 
achieving full control and the need for rescue therapy. Asthma has also been defined as 
allergic or atopic asthma if there is a family history of allergic disease, eczema or 
rhinitis (20). More recently, cluster analysis in adults has distinguished possible clinical 
phenotypes using clinical variables such as age of onset, body mass index (BMI), 
eosinophil count, lung function, gender and symptom scores. Haldar et al. applied 
cluster analysis to 371 patients with either mild-to-moderate asthma managed in 
primary care or refractory asthma managed in secondary care (21). Analysis revealed 
clustering of patient characteristics as follows: early-onset atopic asthma associated with 
eosinophilia; late-onset non-eosinophilic asthma associated with obesity (predominantly 
affecting women); and late-onset eosinophilic asthma (predominantly affecting men) 
(21). In a larger analysis involving 726 patients, Moore et al. generated clusters based 
around age of onset, the presence of atopy, gender, symptom scores and medication use 
(22). This analysis revealed clustering of patients into the following early-onset atopic 
asthma phenotypes: normal lung function and low health care use; normal lung function 
and increased health care use; and reduced lung function and high health care use. This 
analysis also revealed an association between late-onset non-atopic asthma and obesity 
(predominantly affecting women) associated with reduced lung function and high health 
care use. These studies suggest that asthma has several underlying phenotypes with 
similar symptoms associated with a different response to therapy and clinical outcomes. 
Despite this, no consensus exists on whether these phenotypes make any difference to 
clinical management, especially as most cases of asthma are mild and treated in primary 
care. As such, clinical phenotyping may be more important for the secondary care 
management of refractory asthma (23).  
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1.7 Importance of asthma 
1.7.1 Epidemiology 
Asthma is a common chronic respiratory disease affecting millions of people globally. 
In 2004, 300 million people were estimated to have active asthma worldwide (24). The 
largest standardised study estimating the global prevalence of asthma is the 
International Study of Asthma and Allergies in Childhood (ISAAC). This was a cross-
sectional self-reported questionnaire survey conducted between 2000 and 2003 among 
106 centres in 56 countries around the world. The study involved 193,404 children aged 
6-7 years and 304,679 children aged 13-14 years (25). The global prevalence of asthma 
symptoms (defined as wheeze in the last 12 months) in the 13-14 year age group was 
14.1%, of which 6.9% had symptoms of severe asthma (defined as 4 or more attacks of 
wheeze,  ≥1 night per week with disturbed sleep or ≥1 episode of wheeze affecting 
speech in the previous year) (26). Figures for the 6-7 year age group were 11.5% and 
4.9% respectively. This study also demonstrated significant geographical variation in 
the prevalence of asthma with English speaking countries having a higher prevalence of 
symptoms. The prevalence of current wheeze and lifetime prevalence of asthma in the 
United Kingdom for children aged 13-14 was 27.1% and 22.9% respectively (27). In 
reality, determining the true prevalence of asthma is difficult because of heterogeneity 
in investigation results and the interpretation and recognition of symptoms between 
countries. In addition, wheeze may be due to other conditions and is not diagnostic of 
asthma which may limit interpretation of self-reported questionnaire surveys based 
upon symptoms.  
 
One UK based study has investigated the incidence and prevalence of clinician-
diagnosed asthma among children and adolescents using routine electronic healthcare 
28 
 
data from primary care. The 18-year prevalence of clinician-diagnosed asthma among 
24,112 children followed from birth was 25.2% for boys and 20.2% for girls, with an 
overall prevalence of 22.9% (28). However, asthma prevalence is known to peak in 
childhood and subsequently falls in adulthood (29). In this regard, routine primary and 
secondary healthcare data have provided national statistics on the prevalence of asthma 
in Scotland. Using data from around 60 Scottish general practices, the estimated 
prevalence of asthma in Scotland in 2011 to 2012 was 5.0% (4.3% for men and 5.6% 
for women) (30). This estimate used a definition of patients consulting for asthma in the 
last year and may therefore reflect patients more likely to have active asthma. The UK 
Quality and Outcomes Framework (QOF) are evidence-based indicators used to 
measure achievement of general practitioners in the UK and include asthma quality 
indicators (30).  Using data contained in QOF registers for asthma, the prevalence of 
asthma in Scotland in 2011 to 2012 was 6.0%, a figure which is based on the number of 
people with an asthma Read Code ever recorded prescribed an asthma-related drug in 
the previous twelve months. In comparison, it is estimated that 8.2% of adults and 9.5% 
of children in the US have asthma (31). 
 
1.7.2 Economic impact 
Asthma causes a large number of scheduled and unscheduled healthcare visits and is 
associated with a high economic burden.  Costs associated with asthma can be divided 
into direct and indirect costs. Direct costs include hospitalisation, emergency 
department visits, medication costs, diagnostic tests and education. In contrast, indirect 
costs typically include the number of school or work days lost and lost productivity 
associated with traveling, waiting or caring for someone with asthma. The direct cost of 
asthma for the UK National Health Service is estimated to be £1 billion per year with a 
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loss of around 1.1 million working days accounting for a large proportion of indirect 
costs (32). A study published in 2000 using UK audit data from general practice 
estimated the average cost for managing people with an asthma exacerbation was over 
3.5 times higher than for people with stable asthma equating to an additional £273 per 
patient per year (33). Since then the cost of asthma care has increased significantly. In a 
population-based cohort study assessing trends in direct costs for asthma (2002 to 2007) 
in the province of British Columbia, Canada (population 4.5 million), direct costs for 
asthma were C$315.9 million with hospitalisations, doctor visits and medication costs 
accounting for 16.0%, 15.7% and 68.2% respectively (34). During this time, direct cost 
related to asthma increased by C$5.3 million (a 10.7% increase) mainly due to increased 
medicine costs and a rising prevalence of disease. A subsequent systematic review 
investigating the clinical, economic, and humanistic burden of asthma in Canada 
reported an average direct cost per patient with asthma of between C$366 and C$647 
associated with high rates of psychological impact and reduced quality of life compared 
to people without asthma (35). In contrast, a 2011 study on the cost of asthma in the US 
reported an incremental direct cost of asthma of $3259 per patient per year with an 
average indirect cost associated of $301 per patient per year. The total incremental cost 
associated with asthma in the US for the years 2002 to 2007 was approximately $56 
billion (36). In this regard, asthma management remains a priority for many healthcare 
systems worldwide.    
 
1.7.3 Severe asthma exacerbations and asthma death 
Asthma is a chronic condition with episodes of acute exacerbations which may lead to 
hospitalisation and death.  In 2010 in the US there were 14.2 million ambulatory care 
attendances for asthma and 1.8 million emergency department visits resulting in 
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439,000 hospitalisations, with an average length of stay of 3.6 days (31). Between 1981 
and 1997 asthma hospital admission rates in Scotland increased from 106.7 to 236.7 per 
100,000 population, a rise of 122%, (37). Similar increases in hospital attendances for 
severe asthma have been reported elsewhere, whilst in the US emergency department 
visits and hospitalisations have been stable (38, 39). Currently there are approximately 
8,000 hospital attendances with asthma per year in Scotland with some evidence that 
hospital attendances are falling (40). Although hospitalisation is a proxy for severe 
asthma morbidity, A&E attendance or primary care management of an acute asthma 
exacerbation are both good measures of significant uncontrolled asthma morbidity.  
 
Mortality rates for asthma vary globally being highest in China and Russia (36.7 and 
28.6 per 100,000 persons with asthma respectively, for patients aged 5-34 years) (24). 
Comparable mortality rates for English speaking countries such as the US and Scotland 
during this period were 5.2 and 3.0 per 100,000 persons respectively despite having a 
higher prevalence of asthma. In the US, in-hospital mortality from asthma was 
estimated at 0.5% compared to 0.9% in Scotland (41, 42). However, this US study used 
data from 2000 to 2010 whilst the Scottish study used data from 1981 to 2009 and also 
included deaths soon after discharge. Other studies have reported lower in-hospital 
mortality rates for asthma both in the UK (0.43%) and Australia (0.14%) (43, 44). This 
heterogeneity in mortality could be explained by differences in healthcare provision but 
may also be related to the using different observation periods at a time when mortality 
rates for asthma have been falling (39, 42, 45). The US national vital statistics report for 
2010 reported an asthma mortality rate of 1.1 per 100,000 person years (pyrs) which 
was comparable to Scotland for the same period (31). 
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1.7.4 Risk factors for severe asthma exacerbations and asthma death 
Gender 
Although women appear to be at increased risk of asthma hospitalisation, there are 
inconsistent reports of gender influencing in-hospital mortality. A prospective cohort 
study involving 64 emergency departments in North America found that the risk of 
asthma hospitalisation was twice as great in women than men (46). In another study 
involving 59,983 admissions from Taiwan women had increased duration of inpatient 
stay and cost associated with asthma (47). In contrast, one study found that men had a 
39% increased risk of in-hospital mortality, a finding which has been noted by others 
(41, 47). Other studies have either reported an increased risk of asthma death in women 
or that gender is a non-significant predictor of in-hospital mortality (39, 42). 
 
Age 
There is an association between increasing age and increased risk of death from asthma. 
In a UK study investigating factors associated with the 30 day case fatality following 
hospitalisation for asthma, risk of death from asthma increased incrementally with age 
and was greatest in patients over the age of 65 (OR 12.3) (42), an association which has 
been reported elsewhere (39, 41, 47). In addition, there is also an association between 
increasing age and poor asthma control in general practice (48). 
 
Smoking 
Smoking is associated with poor asthma control and reduced response to ICS. In a study 
evaluating asthma morbidity in 950 patients from general practice, patients who smoked 
were half as likely to have good asthma control as non-smokers (48).  Among 85 
pregnant women with asthma, the number of asthma exacerbations was significantly 
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increased among current smokers than those who never smoked (52% and 35% 
respectively) (49). Following multivariate analysis, ACQ6 scores (a validated asthma 
control questionnaire for assessing the severity of waking at night, morning symptoms, 
limited activity, breathlessness, wheeze, beta2-agonist use and lung function consistent 
with asthma morbidity) were significantly elevated in current smokers compared to 
never smokers. Maternal smoking is also an independent predictor of hospitalisation for 
asthma in children (10). Also, smoking cessation can improve airway hyper-
responsiveness and ACQ6 scores and introduction of smoke free legislation in the UK 
was associated with an immediate 4.9% fall in emergency admissions for asthma 
resulting in the prevention of an estimated 1900 emergency admissions for asthma 3 
years following its introduction (50, 51).  
 
Obesity  
In a community-based adult asthma cohort, obesity was associated with increased 
asthma morbidity in terms of asthma-specific quality of life scores and an increase in 
health service use measured by emergency department and urgent care visits (52). 
Additionally, pregnant women with asthma and higher BMI have more severe 
exacerbations during pregnancy (49). In a prospective study involving 85,911 people 
aged 26 to 46 followed up for 4 years, patients with higher BMI were at a significantly 
increased risk of developing asthma (relative risk 2.7 for patients with BMI over 30 
compared to patients in the normal range) (53). In contrast, weight reduction in obese 
asthma patients may improve lung function, reduce symptoms, and reduce rescue 
medication use and exacerbations (54). 
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Comorbidity 
Several studies have demonstrated an increased risk of asthma hospitalization and death 
in people with comorbidities. In a retrospective case study from Scotland risk of asthma 
death was significantly increased in people with cancer, coronary heart disease, 
respiratory infection and renal failure (adjusted odds ratios 1.6-2.6) (42). In a large US 
study involving 65,381 asthma hospitalisations, mortality was significantly associated 
with increasing comorbidity as assessed by the Charlson comorbidity index (a validated 
score which predicts the ten-year mortality for people with a range of comorbid 
conditions) (41). Other studies have shown in increased risk in asthma death following 
hospitalisation in people with co-existing respiratory disease, cardiovascular disease, 
endocrine disease, genitourinary disease and cancer (47). 
 
Other risk factors 
Other risk factors for poor asthma control, hospitalisation and death from asthma exist. 
Patients treated with oral steroids for asthma, people receiving nebulised asthma 
medication and people receiving asthma medication other than beta-agonists and ICS 
appear to have a significantly increased risk of asthma hospitalisation (46). Other 
factors such as medication adherence and objective measurements related to the severity 
of an exacerbation at the time of presentation (e.g. respiratory rate and PEFR) are 
important in predicting risk of asthma hospitalisation and death. 
 
An important case-series analysis of 283 cases of asthma deaths in people under the age 
of 70 from Australia found that 60% of asthma deaths actually occurred at home. 
Among the case series, 65% of patients were from deprived socioeconomic areas with 
only 37% of deceased patients in employment (55). In addition, psychosocial factors 
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such as co-existing mental health illnesses were present in just under half of fatalities. 
Drug and alcohol use was found to be an important factor in 34% of fatalities whilst 
inadequate treatment (self-management and the provision of asthma care) was a factor 
in 18%. Other potential risk factors for asthma death included living rurally and delay in 
seeking help. Of the people who died, 46% suffered sudden onset asthma exacerbations 
not preceded by a gradual deterioration in symptom control. Other triggers included 
food, beta-blockers, non-steroidal anti-inflammatory drugs (NSAIDs) and exposure to 
smoke and fumes (55). In total around 70% of fatalities were considered potentially 
preventable. The National Review of Asthma Deaths is a similar case series analysis led 
by the Royal College of Physicians in the UK to better understand the circumstances 
surrounding asthma deaths which occurred between February 2012 and January 2013. 
This review found that 45% of asthma deaths occurred in people not seeking medical 
attention and that around half of patients had a previous history of hospital admission 
(56). In addition, 43% of people who died of asthma did not attend a primary care based 
asthma review in the year before death. Overall it was felt that 46% of asthma deaths 
could have been prevented. 
 
In summary, asthma is a common problem globally. It affects people of all ages, causes 
a high degree of morbidity and is associated with a high economic burden. This 
highlights the importance of properly quantifying the risk factors for asthma 
exacerbations which affect large numbers of patients and may be preventable. This 
knowledge will help understand the methods and results used in subsequent chapters. 
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1.8 Pharmacological management of asthma 
The aim of asthma management is to achieve complete asthma control defined as the 
absence of all of daytime symptoms, night-time wakening, need for rescue therapy, 
acute exacerbations and restrictions to daily living, whilst normalising lung function and 
minimising side effects of therapy (2). There is a stepwise approach to the 
pharmacological management of asthma whereby patients commence at the step most 
appropriate to the severity of their symptoms. Control is then achieved and maintained 
through the addition or withdrawal of medications in a stepwise fashion following 
checks of adherence and inhaler technique. In this regard, the number of asthma 
medications or the management step a patient is at can be an important marker of 
asthma severity.  
 
The first step for mild intermittent asthma is to use an inhaled short-acting beta2-agonist 
(SABA) which causes temporary bronchodilation and provides short-term relief of 
asthma symptoms. As SABAs do not treat the underlying cause of asthma (airway 
inflammation) they are often referred to as relievers. However, frequent need for 
reliever therapy (using more than 2 canisters of SABA per month) is a marker of poor 
asthma control and a risk factor for asthma death and should prompt medical review 
(57). Medications which alter the underlying airway inflammatory process are often 
referred to as preventers. Regular preventer therapy with an ICS is used at step 2 of the 
guidance. Different types of ICS exist with beclometasone and budesonide having 
equivalent clinical doses whilst fluticasone, mometasone and ciclesonide are 
approximately equivalent at half the dose (2). When used appropriately, ICS are 
considered the most effective anti-inflammatory therapy to achieve full asthma control 
and should be considered in patients with persistent asthma using SABA three or more 
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times per week, and/or with symptoms causing night-time wakening, or in those who 
have received oral steroids for asthma in the last two years. In a Cochrane systematic 
review evaluating inhaled beclometasone versus placebo for chronic asthma involving 
6542 patients, 400mcg per day of inhaled beclometasone over four weeks in steroid 
naïve patients lead to improved lung function (improvements in FEV1 of 360ml and in 
PEFR of 36 L/min), reduction in the use of SABA therapy (-2.3 puffs/day) and 
reduction in the risk of an asthma exacerbation (relative risk 0.25, 95%CI 0.12 to 0.51). 
In people treated with maintenance oral steroids, inhaled beclometasone lead to a 
greater reduction in daily oral steroid use and increased the chance of oral steroid 
withdrawal (IRR 8.02, 95% CI 3.23 to 19.92) (58). Regular use of ICS in asthma is also 
associated with a reduced risk of death (59). However, ICS only help to control airway 
inflammation and symptoms may recur following discontinuation (60).  
 
ICS therapy is generally considered safe although common side effects include 
dysphonia and oropharyngeal candidiasis. Adrenal suppression is a rare side effect in 
children on high doses of ICS. In contrast there is no consensus that ICS significantly 
alter bone mineral density leading to an increased fracture risk, although this is well 
recognised with the use of systemic corticosteroids (61-63). One meta-analysis of case-
control studies demonstrated that in older adults, the relative risk of non-vertebral 
fractures increased by approximately 12% for each 1000mcg/day increase in 
beclometasone equivalent dose and was far less than other common risk factors for 
fractures (64). 
 
Step 3 consists of initial add-on therapy with either a long-acting beta2-agonist (LABA; 
generally recommended as first choice) or a leukotriene receptor antagonist. LABAs 
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improve lung function and quality of life however, chronic LABA exposure may cause 
tolerance to the effects of beta-agonists raising concerns over their use in asthma (65). 
The SMART (Salmeterol Multi-Centre Asthma Research Trial) randomised controlled 
trial involved 26355 patients randomised to a LABA (salmeterol) or placebo in addition 
to their usual care, and reported an increase in asthma-related deaths in LABA-treated 
patients (IRR 4.37, 95% CI 1.3 to 15.3) (66). This risk was potentially confined to 
patients using LABA monotherapy only, which is why LABAs are only recommended 
for the management of asthma in combination with ICS. Leukotriene receptor 
antagonists inhibit the production of cysteinyl leukotrienes (potent bronchoconstrictors 
in asthma) and can improve lung function, airway inflammation and reduce 
exacerbations (1). In contrast to LABAs, leukotriene antagonists are generally 
recommended as the second choice add-on therapy although results from a pragmatic 
clinical trial suggest that either add-on therapy is equally effective (67). Step 4 consists 
of adding a fourth drug such as oral theophylline which acts as a bronchodilator but 
commonly causes adverse effects due to its narrow therapeutic window. Step 5 is the 
frequent or continuous use of oral steroids. This stepwise approach can be managed in 
primary and secondary care. Other therapies available for poorly controlled patients 
with asthma include omaluzimab (an anti-IgE monoclonal antibody reserved for poorly 
controlled atopic patients) but are typically only administered in secondary care. 
 
In summary, there is a stepwise approach to the pharmacological management of 
asthma based on a patient’s underlying severity of symptoms. This highlights the 
importance of establishing severity and/or current patterns of asthma medication use 
when attempting to quantify the risk of triggers such as beta-blockers and NSAIDs in 
asthma. 
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1.9 Beta-blockers and asthma 
1.9.1 Beta-adrenoceptors 
The actions of endogenous and exogenous circulating catecholamines are mediated 
through alpha- and beta-adrenergic receptors present on cell membranes in different 
tissue types in the body including blood vessels, heart and lungs. Beta-adrenoceptors are 
located on the walls of blood vessels and vascular smooth muscle cells, where they 
cause vasodilation in response to catecholamine stimulation. Although beta-1 and beta-2 
adrenoceptors have been detected in blood vessels, their distribution appears to differ 
according to the type of blood vessel. Beta-1 adrenoceptors appear to have a dominant 
role in mediating vasodilation whilst beta-2 adrenoceptors mediate vasodilation in 
major blood vessels only such as the aorta, carotid arteries and portal vein (68). The 
heart contains beta-1, beta-2 and beta-3 adrenoceptors. Stimulation of myocardial beta-1 
and beta-2 adrenoceptors results in positive inotropy (increased force of contraction) 
and chronotropy (increase heart rate). In contrast, beta-3 adrenoceptors tend to inhibit 
inotropy when stimulated. The beta2-adrenoceptor is the predominant pulmonary 
adrenoceptor subtype responsible for airway smooth muscle relaxation and 
bronchodilation, although small numbers of beta-1 and beta-3 subtypes have been 
detected in human bronchial epithelial cells as well (69). 
 
1.9.2 Beta-blockers 
Beta-blockers first came into clinical use in the 1960s after Sir James Black 
demonstrated that the non-selective beta-blocker propranolol lowered myocardial 
oxygen demand by inhibiting the effects of catecholamines, an observation which led to 
major clinical advances in the management of several cardiovascular diseases (70). 
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However, it soon became apparent that non-selective beta-blockers may cause adverse 
respiratory effects in people with asthma. In an attempt to avoid adverse effects novel 
beta-blockers where manufactured with greater subtype selectivity for the beta-1 
adrenoceptor, including those with partial agonist and alpha-adrenergic activity. The 
first selective beta-blocker in clinical use was practolol, but was withdrawn from the 
market because it caused retroperitoneal fibrosis (71).  
 
Although beta-blockers are now classified as either selective or non-selective, 
significant differences in their relative affinities to the beta-1 and beta-2 adrenoceptor 
exist. Among non-selective beta-blockers, timolol has the highest affinity for the beta-2 
adrenoceptor (25.7-fold beta-2 selective) followed by nadolol (23.4-fold), sotalol (12.0-
fold), propranolol (8.3-fold), carvedilol (4.5-fold) and labetalol (2.5-fold) (72). Among 
selective beta-blockers, bisoprolol has the highest affinity for the beta-1 adrenoceptor 
(13.5-fold more beta-1 selective) followed by betaxolol (6.8-fold), atenolol (4.3-fold), 
acebutolol (2.4-fold) and metoprolol (2.3-fold). Some beta-blockers are described as 
having intrinsic sympathomimetic activity (partial agonist activity) which occurs when 
antagonist binding causes some stimulation of the receptor. However it is generally 
regarded that beta-blocker ISA does not confer any particular clinical advantage. 
 
1.9.3 Clinical indications for beta-blockers 
Beta-blockers are recommended first line drugs for the relief of angina. In a meta-
analysis of clinical trials comparing beta-blockers to calcium channel antagonists and 
nitrates, beta-blockers were better at preventing episodes of angina and were better 
tolerated than other agents (although no difference in cardiovascular mortality was 
found) (73). Beta-blockers have been shown to reduce mortality following myocardial 
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infarction (74). Although beta-blockers are licenced for the treatment of hypertension, 
they are not currently recommended as first line agents because they are considered less 
effective than diuretics, calcium channel blockers and renin angiotensin system 
inhibitors (75). Beta-blockers are also used in the treatment of anxiety and migraine. In 
a meta-analysis of 58 trials involving 5072 patients, propranolol was associated with 
clear short term benefits in migraine prophylaxis over placebo (76). Topical beta-
blocker eye drops such as timolol and betaxolol are commonly used in the treatment of 
ocular hypertension and can prevent visual field loss in glaucoma (OR 0.7 (95%CI 0.5-
1.0)) (77). However, despite being applied locally, systemic absorption and adverse 
effects may occur.   
 
Beta-blockers are indicated in the treatment of heart failure. In heart failure, reduced 
peripheral oxygen levels stimulate an excess release of endogenous catecholamines 
leading to short-term improvements in myocardial contractility. In this regard, beta-
agonists such as dobutamine were once routinely used in the treatment of heart failure 
but were subsequently found to increase mortality (78). Chronic exposure to several 
beta-blockers including bisoprolol, metoprolol and carvedilol has been proven to 
significantly reduce mortality by around 30% and hospitalisations in patients with left 
ventricular systolic dysfunction (79).  Although acute beta-blocker exposure in heart 
failure may cause transient reductions in myocardial contractility, beta-blockers are 
often well tolerated if initiated at a low dose with gradual dose escalation (80).  
 
1.9.4 Beta-blockers in asthma 
Soon after their introduction it became apparent that beta-blockers triggered 
exacerbations in susceptible people with asthma. In a study published in 1966 in the 
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Lancet, intravenous propranolol caused marked reductions in FEV1 and symptoms in 4 
of 10 patients with asthma (81). This adverse respiratory effect is caused by antagonism 
of endogenous catecholamines at the pulmonary beta2-adrenoceptor leading to 
unopposed cholinergic tone. 
 
As a result of these adverse respiratory effects in susceptible people, it was 
recommended that all beta-blockers should be contraindicated in people with asthma; 
recommendations which continue to appear in current asthma guidelines (1, 2). Asthma 
deaths associated with beta-blocker exposure (including topical agents) have been 
reported, often in people with uncontrolled asthma or in those receiving high doses of 
acute non-selective beta-blocker therapy (55, 82, 83). Despite these safety concerns, 
beta-blockers are still prescribed to patients with asthma. In a cross-sectional study 
which I carried out before starting the PhD, beta-blockers were prescribed to 2.2% of 
adult patients with asthma over the course of a year, many of whom received repeat 
prescriptions (84). On the one hand, this observation may suggest inappropriate 
prescribing but equally there may be strong clinical indications for using beta-blockers 
in some people. From this perspective, beta-blockers are also often withheld in people 
with asthma who also have strong cardiovascular indications. In a study investigating 
the current use of beta-blockers in patients hospitalised with acute coronary syndrome, 
patients with reversible airways disease were 42% less likely to be prescribed a beta-
blocker (85, 86), probably because the risk was assumed to outweigh the benefits. 
However, the adverse respiratory effect of beta-blockers in asthma has been poorly 
quantified.  
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In reality, most beta-blockers used in cardiovascular disease are subtype selective and 
may not have the same risk because they preferentially antagonise the beta1-
adrenoceptor more than the beta2-adrenoceptor. The adverse respiratory effect of 
selective beta-blockers in patients with reversible airways disease (asthma and COPD) 
has previously been systematically evaluated. This meta-analysis of 19 clinical trials 
evaluating single dose selective beta-blocker exposure reported only small mean falls in 
FEV1 of 7.46% with no significant increase in symptoms among patients from included 
studies (87). However, this analysis is potentially limited as the effects of selective beta-
blockers may vary by dose and by individual susceptibility in which case use of mean 
values alone may mask a clinically significant risk in a proportion of people. In contrast, 
the adverse respiratory effect of non-selective beta-blocker exposure in asthma has not 
been systematically evaluated even though a small proportion of patients with asthma 
are prescribed non-selective agents periodically. Additionally, beta2-agonists are first-
line rescue therapy for acute bronchoconstriction and in theory their efficacy could be 
reduced in patients taking beta-blockers. Chapter 3 reports a systematic review and 
meta-analysis of the fairly numerous small clinical trials evaluating the effect of beta-
blocker exposure in patients with asthma, including evaluating the proportion with a 
clinically significant reduction in FEV1, and the effects of non-selective beta-blockers. 
  
The effect of beta-blocker exposure in asthma still remains largely uncertain. In this 
regard, two observational studies have attempted to evaluate the risk of hospitalisation 
in patients with either asthma or COPD exposed to beta-blockers. In a retrospective 
cohort study by Brooks et al., selective beta-blockers were associated with a 
significantly increased risk of emergency department visits (relative risk 1.47) whilst 
non-selective beta-blockers were associated with a significantly increased risk of 
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hospitalisation (relative risk 2.47) (88). However, this analysis did not adjust for 
potential confounders. In contrast, a similar study involving patients with asthma and 
COPD also demonstrated significantly higher rates for hospitalisation in patients taking 
selective (11.6%) and non-selective (9.4%) beta-blockers compared to controls (8.3%). 
Following adjustment however, the risk for hospitalisation in both classes of beta-
blocker was not significantly different to controls (OR 1.16, 95%CI 0.98-1.35 and 1.11, 
95%CI 0.73-1.69 respectively) suggesting that underlying confounding may have 
explained the increased risk with the analysis in the previous study (89). Chapters 7 and 
8  report a nested case control study evaluating the effect of beta-blocker exposure in 
patients with asthma, including evaluating risk associated with incident and prevalent 
exposure. 
 
In summary, beta-blockers antagonise the effects of catecholamines at beta-
adrenoceptors. Several beta-adrenoceptor subtypes exist which are differentially 
distributed throughout the body. Different beta-blockers exhibit different degrees of 
beta-adrenoceptor subtype selectivity and their effects in asthma may differ according to 
acute or chronic exposure. The adverse respiratory effect of beta-blockers is 
traditionally thought to affect all people with asthma equally but individual 
susceptibility may occur. Risk of beta-blockade in asthma has not been well quantified 
despite the strong warnings against their use in asthma, which is important for people 
where beta-blockers would have major benefit.  
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1.10 Non-steroidal anti-inflammatory drugs and asthma 
1.10.1 Mechanism of action of aspirin and NSAIDs 
Aspirin and other NSAIDs are effective anti-inflammatory, analgesic and antipyretic 
agents which irreversibly inhibit cyclooxygenase enzymes (COX) and reduce 
prostaglandin synthesis from their precursor arachidonic acid. Two isoforms of COX 
exist. COX-1 is constitutively expressed in most tissues whilst COX-2 is induced by 
inflammatory stimuli such as cytokines (90). Inhibition of COX-2 is thought to account 
for the therapeutic effects of aspirin and other NSAIDs whilst inhibition of COX-1 is 
thought to account for many of their side effects. This prompted the development of 
newer more selective NSAIDs specifically targeting COX-2. In a similar fashion to 
beta-blockers, aspirin and other NSAIDs have been classified as having differing COX-
2 selectivity which varies by agent. In an in vitro analysis, aspirin, ibuprofen, naproxen, 
indomethacin, ketorolac, diclofenac, piroxicam and sulindac fully inhibited COX-1 and 
COX-2 and were considered to have relatively poor selectivity. In contrast, meloxicam 
and nimesulide showed preferential COX-2 selectivity (>5 fold) whilst the COX-2 
inhibitors generally had the greatest degree of preferential COX-2 selectivity (>50 fold) 
(91).  
 
1.10.2 Clinical indications for NSAIDs 
NSAIDs are recommended in guidelines for the chronic management of 
musculoskeletal conditions and for the short-term management of pain and febrile 
illnesses (92). In contrast aspirin is primarily used in the secondary prevention of 
cardiovascular conditions due to its antiplatelet effects. Aspirin and NSAIDs are 
commonly prescribed. In 2010 in the US, an estimated 43 million adults took aspirin 
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(defined as three or more times per week for 3 months) and a further 29 million adult 
took NSAIDs, an increase of 57% and 41% respectively since 2005 (93). 
 
1.10.3 Aspirin-exacerbated respiratory disease 
In susceptible people with asthma, COX-1 inhibition by aspirin alters the balance 
between proinflammatory and anti-inflammatory mediators, leading to increased levels 
of cysteinyl leukotrienes (LT) and bronchoconstriction (94, 95). Arachidonic acid is 
usually converted to leukotriene A4 (LTA4) by the enzyme 5-lypoxygenase (5-LO). 
LTA4 is then subsequently converted to LTC4 by the action of LTC4 synthase enzyme 
which is often overexpressed in susceptible patients. Cysteinyl leukotrienes then bind to 
specific G-protein transmembrane receptors in the airway (CysLT1 and 2) causing 
bronchoconstriction (90). By inhibiting the COX pathway in susceptible individuals, 
aspirin diverts more arachadonic acid through the lypoxygenase pathway thus 
increasing leukotriene production whilst at the same time reducing the synthesis of 
prostaglandin E2 (PGE2). PGE2 helps to regulate the inflammatory system by 
inhibiting 5-LO, cholinergic tone and the release of mediators from mast cells (96). 
 
Although initially described with aspirin, cross-reactivity with other nonselective 
NSAIDs is thought to occur in the majority of patients with this phenotype, usually 
referred to as aspirin-exacerbated respiratory disease (AERD) (97). Patients with the 
AERD phenotype are more likely to have chronic rhinosinusitis and nasal polyposis and 
aspirin can also trigger upper respiratory symptoms such as rhinorrhoea and nasal 
obstruction. Few large scale observational studies investigating AERD have been 
performed. One European-wide survey involving ten European centres and 500 
participants with AERD demonstrated that AERD often developed according to a 
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sequence of events commencing with rhinitis followed by asthma, aspirin-intolerance 
and lastly nasal polyposis starting around the age of 30 years (98).  
 
However, the prevalence of AERD is inconsistently reported in the literature, varying 
between 4% and 44%, mainly as a result of heterogeneity in AERD definition, patient 
selection and study design. For example, McDonald et al. pre-selected asthma patients 
with nasal polyps or severe asthma, exposed them to 320mg of aspirin and determined 
AERD by a fall in FEV1 of ≥50% (99). In contrast, other investigators have used 
unselected patients, lower doses of aspirin and lower values of FEV1 to define aspirin 
sensitivity. Most studies attempting to establish the prevalence of AERD have either 
used self-reported patient questionnaires or oral challenge tests.  One previous 
systematic review attempting to estimate the prevalence of AERD reported a figure of 
21% for adults and 5% for children with asthma suggesting that AERD is perhaps more 
prevalent than previously thought (97). However this systematic review included 
several unblinded and uncontrolled provocation challenge tests aimed at detecting 
AERD which could be subject to bias or placebo-effect. Chapter 4 reports a systematic 
review and meta-analysis of small clinical trials and population based surveys 
measuring the prevalence of AERD in patients with asthma. 
 
In patients with AERD, risk from NSAIDs is considered greatest after acute exposure, 
with reactions typically occurring within 3 hours of ingestion. These reactions can be 
severe, with case reports of serious adverse events and fatalities as a result of NSAID 
exposure (100). Guidelines for the management of asthma currently recommend asking 
people about past reactions before prescribing an NSAID or advise avoiding NSAIDs 
althogether (2, 101). This in itself can be problematic because self-awareness of 
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NSAID-induced symptoms in people with asthma is not universal (98). As such, these 
recommendations have important clinical implications for the use of NSAIDs, to the 
extent that NSAIDs are often either withheld or prescribed with uncertain clinical 
consequences. In one large observational study, between 15.7% and 21.5% of 
asthmatics had an NSAID prescription in the last 12 months (102). Additionally, 
patients might be unwilling to accept the risk associated with first (incident) exposure or 
conversely might risk exposure from over-the-counter medications without appropriate 
medical supervision.  
 
In people with suspected AERD, all NSAIDs are contraindicated by the US Food and 
Drug Administration, with no comment regarding risk from the newer selective agents 
(103). This contraindication is mirrored in the United Kingdom by the Medicines and 
Healthcare Products Regulatory Agency–approved Summary of Product Characteristics 
for COX-2 inhibitors, which clearly states that COX-2 inhibitors should not be taken if 
patients have a history of asthma symptoms after taking aspirin or any other NSAID 
(104). Selective NSAIDs, such as meloxicam, and COX-2 inhibitors, such as celecoxib, 
act through preferential inhibition of COX-2 over COX-1, leaving the balance between 
proinflammatory and anti-inflammatory mediators unaltered and cysteinyl leukotriene 
levels unchanged (105). Therefore selective NSAIDs, COX-2 inhibitors, or both would 
be expected to have a lower risk of adverse respiratory effects in patients with AERD. 
Several clinical trials evaluating the effect of selective NSAID and COX-2 inhibitor 
exposure in patients with AERD have been conducted, and chapter 5 reports a 
systematic review and meta-analysis of these trials. In summary, aspirin and other 
NSAIDs are widely used medications that can cause bronchoconstriction in susceptible 
people with asthma. In a similar fashion to beta-blockers, NSAIDs also exhibit differing 
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degrees of selectivity to COX enzymes and their effects in people with asthma may 
differ according to their degree of selectivity. Uncertainty regarding the prevalence of 
AERD still remains which is a problem in appreciating risk from aspirin and NSAIDs at 
a population level. 
 
1.11 Summary 
Asthma is a common complex condition often associated with comorbidity and high 
health care utilisation. Beta-blockers and NSAIDs are widely prescribed medicines that 
have long been known to trigger exacerbations in susceptible people with asthma. It is 
now becoming established that asthma is a heterogeneous condition associated with 
different phenotypes like AERD. The adverse respiratory effect of beta-blockers leading 
to unopposed cholinergic tone is traditionally thought to affect all people with asthma. 
However, it could be that some people with asthma may tolerate beta-blockers well.  
 
Guideline recommendations typically rely on a historic evidence base conducted at a 
time when use of ICS and other asthma medications were not widespread. These 
recommendations have led to the avoidance of beta-blockers and NSAIDs in some 
people who may benefit from their use or conversely may be prescribed inappropriately 
leading to adverse respiratory events. The effectiveness of these agents in the 
management of cardiovascular disease and pain has been well established. In contrast, 
risk from beta-blockers and NSAIDs in asthma has been relatively poorly quantified 
making it difficult for clinicians to be certain if the risks outweigh potential benefits. 
Evidence to quantify adverse effects of drugs can come from controlled clinical trials 
and observational studies. Controlled clinical trials establish causality and are 
considered to provide evidence that has strong internal validity but results may not be 
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generalizable due to the highly selected people eligible to participate. In contrast, 
observational studies can provide evidence with strong external validity and are good at 
detecting uncommon adverse drug events. However, causation may be more difficult to 
establish with observational studies which can suffer from residual confounding. In this 
regard, using both types of evidence should provide robust evidence to quantify the risk 
of these agents in people with asthma.  
 
1.12 Study aims 
The aim of this thesis is to quantify the risk of beta-blocker and NSAID exposure in 
people with asthma by systematically synthesising clinical trial evidence and 
conducting new observational studies using routine linked electronic health care 
records. 
 
1.13 Research questions 
The research questions designed to meet the above aims of the thesis include: 
1. Among people with asthma, what is the prevalence of beta-blocker and NSAID 
prescribing? 
2. How frequently do beta-blockers and NSAIDs trigger changes in lung function and 
respiratory symptoms in people with asthma? 
3. Do the frequency and severity of reactions vary among different classes of beta-
blockers and NSAIDs? 
The next chapter will provide a detailed outline of the general methods used in a variety 
of analyses in this thesis.
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Chapter 2: General Methods  
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2.1 Introduction 
This chapter provides background to the different methods used in this thesis. In the 
first phase, existing evidence from clinical trials was synthesized to quantify how 
frequently beta-blockers and NSAIDs trigger changes in lung function and respiratory 
symptoms in people with asthma. This was conducted using the principles of systematic 
review and meta-analysis set out in this chapter. Following this, the population at risk 
from beta-blocker and NSAID exposure was defined using routine electronic health care 
records from the Clinical Practice Research Datalink (CPRD) and the prevalence of 
beta-blocker and NSAID prescribing for a twelve year period in the UK measured. 
Lastly, several nested case control and self-controlled case series studies using data 
from CPRD were conducted to estimate the frequency and severity of adverse 
respiratory events associated with beta-blocker and NSAID exposure with a particular 
emphasis on whether risk varied by class, duration of administration and dose where 
appropriate. 
 
2.2 Systematic reviews and meta-analyses 
This section presents details of the methods for systematic reviewing and meta-analysis 
which are common to the three systematic reviews in this thesis. Specific methods or 
issues unique to each systematic review and meta-analysis are described in the relevant 
chapter. 
 
2.2.1 Systematic review search strategies 
Systematic searches of MEDLINE, EMBASE and the Cochrane Central Register of 
Controlled Trials (CENTRAL) databases were performed to identify all clinical trials 
published on or before April 2013 which evaluated acute exposure to the drug of 
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interest. In this regard, pre-specified search strategies were used and focused upon three 
main concepts namely; ‘asthma’,’ clinical trials’ and ‘the drug of interest’. The 
exception to this was for the systematic review on the prevalence of aspirin-exacerbated 
respiratory disease (AERD) which additionally evaluated the prevalence of AERD using 
population studies using self-reported history (chapter 4). The detailed search strategies 
for OvidSP MEDLINE for each systematic review are shown in appendix 1. A meta-
analysis of observational studies evaluating risk of exposure was not performed because 
the number of studies identified on scoping was small and meta-analysis would have 
been methodologically more complex. 
 
2.2.2 Systematic review selection criteria 
For each systematic review conducted, pre-specified selection criteria were established 
to select published studies for inclusion. These selection criteria followed a standard 
PICOS approach which consisted of the following: 
P = defining the population of interest including inclusion and exclusion criteria 
I = defining the intervention of interest namely acute exposure to the drug of interest 
C = defining the comparator namely placebo 
O = defining the outcomes of interest namely changes in lung function and symptoms 
S = defining the study designs to be included within each systematic review 
 
2.2.3 Systematic review data processing and extraction 
For each systematic review, all identified references were compiled into an Endnote 
database. Identified references were then independently screened by me and a second 
reviewer. References clearly not meeting the eligibility criteria were rejected, with 
ambiguous titles/abstracts retained for full text review. Full texts were then 
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independently appraised by the two reviewers. At each stage the decision to include 
articles was based upon consensus between reviewers. Manual searches from the 
reference lists of included studies were performed to identify additional articles. Only 
English language publications were included in the systematic. Only published data 
from eligible studies were extracted and used in the systematic review and meta-
analyses. This was a pragmatic decision based upon the resources and time available. A 
standardised data extraction form was used to extract data from included studies. 
 
2.2.4 Systematic review data analysis 
For each systematic review and meta-analysis, extracted data from included studies 
were entered into an SPSS v21 database. Outcomes of interest included: 
 Mean percentage change in forced expiratory volume in one second (FEV1)  
 Falls in FEV1 of 20% or greater in order to better assess individual susceptibility 
 Incidence of respiratory symptoms to better distinguish between symptomatic and 
asymptomatic changes in lung function 
 
These outcomes were calculated for both placebo and the exposure of interest. All 
measures of FEV1 were calculated relative to original baseline FEV1 values. For meta-
analyses which included the mean percentage change in FEV1 (continuous outcome) as 
an outcome (specifically the beta-blocker meta-analyses, chapters 3) results are 
presented as the mean difference. The mean difference measures the absolute difference 
in mean percentage change between two groups when values are measured using the 
same scale (in this case FEV1). Falls in FEV1 of 20% or greater and the incidence of 
patient-recognised respiratory symptoms were defined as outcomes to better assess 
individual response. For example, some people with asthma may be extremely sensitive 
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to the effects of beta-blockers because they heavily rely upon sympathetic drive to 
maintain airway smooth muscle tone and risk in these individuals may not be fully 
appreciated with group means. For falls in FEV1 of 20% or greater and the incidence of 
respiratory symptoms (dichotomous outcomes), outcome measures were defined in 
terms of the risk difference (RD). The risk difference is the difference in observed risk 
between two groups and provides a measure of absolute effect. The risk difference was 
used because it is an absolute measure which allows the numbers needed to harm to be 
calculated by dividing 1 by the risk difference. Another advantage of the risk difference 
compared to the risk ratio is that it can be estimated between groups with no events so 
that these studies may still be included in the meta-analysis.  
 
Mantel-Haenszel summary risk difference for dichotomous outcomes 
Meta-analysis was performed in Review Manager (RevMan) version 5.1 (Copenhagen: 
The Nordic Cochrane Centre, The Cochrane Collaboration, 2011). A Mantel-Haenszel 
method of analysis was used to calculate the risk difference for dichotomous outcomes 
(equation 1). The Mantel-Haenszel method is typically used when events are few or 
sample sizes are small as with many of the included studies. For dichotomous outcomes 
where there are few events or small sample sizes, the Mantel-Haenszel method is 
considered to perform better than other methods such as the inverse variance method. 
The Mantel-Haenszel summary risk difference (RDMH) was calculated as the weighted 
sum of the risk differences for the i individual studies (RDi) (106): 
                                                                
Equation 1. Mantel-Haenszel summary risk difference. 
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Each study’s risk difference is given weight (wMH,i) as follows, where (i) is the study, n1i 
is the number of participants in the experimental group and n2i is the number of 
participants in the placebo group for study i, and Ni is the total number of participants in 
study i: 
 
Equation 2. Weighting the risk difference for each study. 
 
The summary risk difference has a standard error (SE) of: 
 
Equation 3. Standard error for the Mantel-Haenszel summary risk difference. 
 
Where ai and ci are the number of events in the treatment and control groups 
respectively, and bi and di are the number with no event in the experimental and control 
groups respectively, and J and K are given by: 
 
Where a, b and n represent the sample size for each respective group as shown in table 
1. 
 
Table 1. Reference groups used to calculate the Mantel-Haenszel summary risk 
difference 
Binary data Study i  Event  No event  Total  
Experimental  ai  bi  n1i  
Control  ci  di  n2i  
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Generic inverse-variance for mean difference, mean provocative dose  
Inverse-variance weighting is an approach whereby the weight given to each study is 
the inverse of the variance of the effect estimate (107). In this regard, larger studies 
which have smaller standard errors are given more weight than smaller studies with 
larger standard errors. The following approach was used in estimating the summary 
effect estimates using the mean difference (chapter 3) and the mean provocative dose 
(chapter 4). The study effect estimates were calculated using inverse-variance weighting 
to pool effect estimates from studies in which the standard deviation could be derived.  
Standard deviations were then converted to standard errors (SE) using the following 
formula, were N is the sample size (108): 
𝑆𝐸 =
𝑆𝐷
√𝑁
 
Equation 4. Calculating the standard error from the standard deviation. 
 
The fixed-effect inverse-variance weighted mean (ES) was then calculated as follows 
were Xi is the group mean for study i and SEi is the standard error for the group: 
𝐸𝑆 =
∑ 𝑋𝑖 (1 𝑆𝐸𝑖
2)⁄
∑ (1 𝑆𝐸𝑖
2)⁄
 
Equation 5. Calculating the inverse-variance weighted mean 
 
The standard error of the inverse-variance weighted mean (ES) was then calculated as 
follows: 
𝑆𝐸𝐸𝑆 = √
  1
∑(1 𝑆𝐸𝑖
2⁄ )
 
Equation 6. Calculating the standard error of the inverse-variance weighted mean 
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The 95% confidence interval of the inverse-variance weighted mean was calculated as 
follows: 
𝐿𝑜𝑤𝑒𝑟 = 𝐸𝑆 − 1.96 (𝑆𝐸𝐸𝑆) 
𝑈𝑝𝑝𝑒𝑟 = 𝐸𝑆 + 1.96 (𝑆𝐸𝐸𝑆) 
Equation 7. Calculating 95% confidence intervals using the standard error 
 
Firstly, studies reporting the mean difference between groups were identified and the 
mean difference extracted. When studies did not specifically report the mean difference, 
it was obtained by calculating the difference in means as follows: 
𝑀𝐷 =  𝑀𝑇 − 𝑀𝑃 
Equation 8. Calculating the mean difference 
 
Where MD is the mean difference and MT and MP are the mean for the treatment and 
placebo measurements respectively. 
 
Estimating the standard deviation from the range 
For some included studies in the meta-analysis assessing the mean provocative dose 
(chapter 4) no other measure of variability or precision apart from the minimum and 
maximum threshold doses for the group (the range) were reported. In this instance, 
standard deviations were estimated from the range according to the method described by 
Hozo et al. (109). Briefly, this method states that for group sample sizes between 15 and 
70, the standard deviation can be closely estimated by dividing the range by 4 assuming 
a normal distribution (where the range is the difference between maximum and 
minimum threshold dose for the group). For sample sizes greater than 70, range divided 
by 6 is suggested as the most appropriate estimator for the standard deviation. For 
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sample sizes less than 15, the variance can be estimated using the following formula 
providing the median (m) is known: 
𝑆𝐷2 ≈
1
12
{
(𝑎 − 2𝑚 + 𝑏)2
4
+ (𝑏 − 𝑎)2} 
Equation 9. Calculating the standard deviation using the range 
Where a and b are the minimum and maximum threshold doses for the group. 
 
Estimating the standard deviation for a continuous outcome using P-values  
In order to meta-analyse continuous outcomes, data on the mean, standard deviation and 
sample size is required. Many of the studies identified and included in the systematic 
review and meta-analyses were cross-over trials reporting change from baseline values. 
Although baseline and post-intervention means may be reported with their respective 
standard deviations, it is not possible to calculate the standard deviation of the mean 
difference directly which is potentially problematic when performing meta-analysis 
(108). Several methods for dealing with this problem have been proposed which were 
applied to the beta-blocker meta-analysis reported in chapter 3.  
 
Ideally, additional data would be requested from authors, but this was not done as the 
majority of studies were published 15 or more years ago reducing the likelihood of 
obtaining useful information. It was judged that there was insufficient time available to 
pursue this option for what would likely be a small return. Therefore, when standard 
deviations for the mean difference were missing, studies were first inspected to see if 
they reported individual patient data. Individual patient data were then extracted into a 
SPSSv21 database and used to calculate the standard deviation of the mean percentage 
difference using a paired t-test.  
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In the absence of individual patient data, standard deviations for mean differences may 
be calculated providing a standard error, confidence interval, t-value or P-value relating 
to the differences between the means of the two groups is provided (108). These 
calculations assume that the standard deviations associated with the outcome 
measurements are the same for both groups. In this setting the standard deviation is then 
used for both the treatment and placebo groups. The method for obtaining each value 
described in the meta-analyses is shown below. The standard deviation for the mean 
percentage difference was calculated using the p-value from a paired analysis through a 
three step process which involved calculating the t-score, the standard error and finally 
the standard deviation as follows (108): 
 
1. Calculating the t-value from the p-value 
Where p-values from a paired t-test were used to estimate the standard deviation, t-
values were obtained by using the following formula in a Microsoft Excel spreadsheet: 
t-value =tinv(p-value, df) 
Equation 10. Calculating the t-value 
 
tinv is a Microsoft Excel command which estimates the t-value of the Student's t-
distribution as a function of the probability and the degrees of freedom and df are the 
degrees of freedom given by:  
NT + NC – 2 
Equation 11. Calculating the degrees of freedom for estimating the t-value 
 
Where NT and NC are the sample sizes in the treatment and control groups respectively.  
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2. Calculating the standard error from the t-value 
The t-value is the ratio of the mean difference to the standard error of the mean 
difference (108). Therefore, the standard error of the mean difference can be calculated 
by dividing the mean difference (MD) by the t-value: 
𝑆𝐸 =
𝑀𝐷
𝑡
 
Equation 12. Calculating the standard error of the mean difference 
 
3. Calculating the standard deviation from the standard error 
The missing standard deviation for mean percentage change was calculated from the 
standard error (SE) as follows: 
𝑆𝐷 =
𝑆𝐸
√
1
𝑁𝑇
+
1
𝑁𝐶
 
Equation 13. Calculating the standard deviation for the mean difference 
 
Where NE and NC represent sample sizes for the treatment and control groups 
respectively. Using this approach, the standard deviation is used for both groups 
because it is the mean of the standard deviations of the treatment and control groups. 
 
However, p-values for significant results were not always reported accurately, 
sometimes only being reported as being below particular threshold (e.g. p<0.05). In this 
instance the standard deviation of the mean difference can still be estimated. In this 
instance, the standard approach is to round the p-value up and to use this to calculate a 
conservative estimate of standard deviation (110). Therefore, for a study reporting a 
significant analysis as p<0.05, the standard deviation would be calculated as described 
above assuming p=0.05. However, this approach was not used for p-values reported as 
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non-significant e.g. p>0.05 since there is then no threshold to round up to. In this 
instance, studies which provided individual patient data were re-analysed and non-
significant p-values pooled. The median non-significant p-value was then used to 
estimate the standard deviation. For the small number of standard deviations which 
could not be estimated using one of these methods, the median standard deviation of the 
group under investigation was imputed. Sensitivity analyses were performed to check 
the robustness of results using the minimum and maximum imputed p-value to ensure 
conclusions remained unchanged. 
 
Statistical heterogeneity 
Meta-analysis was used to statistically combine the results from separate studies, a 
process which relies on pooling the weighted average of the effect estimates between 
different studies in order to increase power and improve precision of the effect estimate. 
For each meta-analysis, a summary statistic was first produced for each study which 
was then pooled to generate a summary effect estimate which is weighted by the 
number of participants and the variance in each study. The variance between each study 
is referred to in meta-analysis as statistical heterogeneity which can result from clinical 
differences between participants, outcomes or methodological approach (107). 
Heterogeneity among studies is important to assess in order to determine whether or not 
a fixed-effect or random-effects method of analysis was chosen. Other forms of non-
statistical heterogeneity are not discussed but could also be important. In a fixed-effect 
meta-analysis, the assumption is that the same fixed intervention effect is being 
estimated across all studies. In contrast, in random-effects meta-analysis the assumption 
is that any intervention effects follow a normal distribution across studies. 
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For each meta-analysis, heterogeneity among studies was assessed using the I
2
 statistic 
with a cut off value of greater than 40% suggesting heterogeneity (107). The I
2
 statistic 
is a measure used to assess statistical heterogeneity and is preferred to the standard 
Cochran’s Q as it assesses the degree of heterogeneity and is calculated as follows: 
𝐼2 = (
𝑄 − 𝑑𝑓
𝑄
) × 100% 
Equation 14. Calculating the I
2
 statistic 
 
Where ‘Q’ is the Cochran chi-squared test assessing whether observed differences 
between results are likely to result from chance and ‘df’ are the degrees of freedom 
(107). The following is a guide to interpreting the results of the I
2
 test: 
 Up to 40%: may not be important; 
 40-60%: may represent moderate heterogeneity; 
 60-90%: may represent substantial heterogeneity; 
 90-100%: considerable heterogeneity. 
Note that like the Cochran’s Q it will have low power when few studies are included. 
 
Dealing with statistical heterogeneity 
Several actions were taken when statistical heterogeneity was suspected in the meta-
analyses carried out. Firstly, the study-level data was checked to ensure that no 
inaccuracies had occurred in the data extraction process. Secondly, if the I
2
 statistic was 
above 40% a random-effects method of analysis was used. Statistical heterogeneity was 
also explored using subgroup analysis. Subgroup analyses were performed based upon 
clinical and methodological characteristics relevant to the topic of interest in each meta-
analysis, details of which are described in relevant chapters (chapters 3-5). 
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Sensitivity analyses 
For each meta-analysis, prespecified sensitivity analyses were performed to test the 
robustness of the results. Sensitivity analyses used in all systematic reviews included 
whether or not studies explicitly defined patients with asthma (according to one or more 
of the following: American Thoracic Society/British Thoracic Society guidelines; 
reversibility in FEV1 in response to beta2-agonist stimulation; and response to 
metacholine/histamine provocation challenges), and whether trials stated they withheld 
beta2-agonists at least 6 hours prior to testing. Additional sensitivity analyses unique to 
each meta-analysis are described in the relevant chapters. 
 
Quality assessment 
Systematic reviews synthesise and collect data on all studies that meet pre-specified 
eligibility criteria in an attempt to minimise bias. However, bias may still occur because 
of failings in study design, conduct, analysis and reporting. For each systematic review 
and meta-analysis, methodological quality and risk of bias were evaluated using the 
Cochrane Collaboration tool for assessing risk of bias (111). This tool helped to make a 
decision regarding risk of bias for the following aspects of each trial: blinding of 
participants and personnel; blinding of outcome assessment; incomplete outcome data; 
selective outcome reporting; random sequence generation; and allocation concealment. 
 
Another important type of bias which may affect the validity of systematic reviews 
results is publication bias, in which studies with positive findings are more likely to be 
published than studies with non-significant findings. Publication bias was assessed 
using funnel plots to examine for asymmetry by creating a simple scatter plot of the 
effect estimates from individual studies against the standard error of the risk difference 
64 
 
for each study. An asymmetrical appearance is suggestive of publication bias which 
could result from smaller studies with non-significant findings being unpublished. In 
circumstances where funnel plot asymmetry was suspected, the Egger test was 
performed (a form of regression recommended to test for funnel plot asymmetry) (112). 
The systematic reviews were reported according to PRISMA (Preferred Reporting Items 
for Systematic Reviews) requirements (113). 
 
2.3 Observational studies using linked electronic health data 
This section describes the methodology relating to the pharmacoepidemiology studies 
reported in this thesis which are: 
 Descriptive epidemiology estimating the incidence of asthma exacerbations over a 
12 year period 
 Drug utilisation studies estimating the prevalence of beta-blocker and NSAID 
exposure over a 12 year period 
 Nested case control studies as the primary analysis for quantifying the risk from 
exposure to beta-blockers and to NSAIDs (a between-person analysis) 
 Self-controlled case series as the secondary analysis for quantifying the risk from 
acute exposure to beta-blockers and NSAIDs (a within-person analysis) 
Specific details unique to each analysis in question are described in chapters 7-9 along 
with the findings. 
 
2.3.1 Observational studies data source 
The pharmacoepidemiology analyses were conducted using electronic primary care 
health data from the Clinical Practice Research Datalink (CPRD) in the UK, formerly 
known as the General Practice Research Database. This database was chosen because it 
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is one of the world’s largest longitudinal databases containing electronic medical 
records from over 680 UK general practices. CPRD has over 11 million patient records, 
around 5 million of which are currently deemed as being active. CPRD contains linked 
electronic health care data about patient demographics, prescriptions, clinical events, 
medical diagnoses, symptoms, hospital referrals, admissions and deaths. Medical 
diagnoses and clinical events within CPRD are recorded using the Read Code system of 
classification which is a hierarchical thesaurus of coded clinical terms used in UK 
primary care electronic records (114).  
 
Recording guidelines are issued to every practice contributing data to CPRD 
demonstrating the correct method of recording significant morbidity events in each 
patient’s electronic medical record. General practices contributing to CPRD are required 
to meet defined quality standards of electronic medical record data recording in order to 
contribute data. Each practice provides raw data which is subject to quality control and 
validity checking by staff at the Medicines and Healthcare products Regulatory Agency 
before release. Although principally collected for routine clinical use, data present in 
CPRD is generally considered to be of high quality with validation studies suggesting 
that most diagnoses coded in CPRD are well recorded with incidence and prevalence 
estimates based on CPRD data broadly similar to other UK population-based sources 
(115, 116). 
 
CPRD contains data on hospitalisation through linkage to the Hospital Episode 
Statistics (HES) database which contains details of all admissions to NHS hospitals in 
England. The HES database contains patient care data from admissions occurring from 
1989 onwards and is managed by Northgate Information Solutions on behalf of The 
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NHS Information Centre for health & social care (117). Patients in CPRD are linked to 
the HES database by means of their NHS number, gender, and partial date of birth. 
CPRD also contains mortality data through linkage to the Office for National Statistics 
(ONS) database for a similar subset of English practices. ONS uses routinely collected 
information from death certificates in England and Wales which is subject to a number 
of automatic validation processes to highlight inconsistencies. ONS data is typically 
first matched to HES data using patient identifiable fields described above and then to 
practice data within CPRD using probabilistic linkage. 
 
2.3.2 Observational analysis study population 
The individual analyses used defined subsets of a broader cohort of adult patients with 
active asthma. This consisted of patients aged 18 and over present at any point in CPRD 
between 1 January 2000 and 31 December 2011, who had a Read Code for asthma ever 
recorded in the patient’s electronic medical record and had received prescriptions for 
asthma medication (appendix 2). Subjects were eligible for entry into the cohort if they 
were permanently registered with a general practice for at least one year prior to cohort 
entry, had an asthma Read Code ever recorded, were issued two or more prescriptions 
for asthma medications during their period of registration and were defined by CPRD as 
being acceptable for use in research (meaning that data contained within their EMR had 
met certain quality standards). An open cohort design was used and cohort entry was 
defined: on or after the date of the first asthma medication occurring; on or after 1st 
January 2000; on or after the patient’s 18th birthday; and before the patient’s 80th 
birthday. Asthma medications were defined as: inhaled short-acting beta2-agonists 
(SABA); inhaled corticosteroids (ICS); inhaled long-acting beta2-agonists (LABA); 
oral leukotriene antagonists; and oral methylxanthines. Prescriptions for asthma 
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medication were included in the definition in order to identify patients with active 
asthma, because asthma remits in some individuals and therefore Read Code recording 
alone would include some individuals who had not had any asthma related symptoms 
for many years in which risk may be different. 
 
All patients within this cohort were followed up until the earliest of either: the date of 
death; deregistration from the practice; one year following the last asthma medication 
prescribed; or the end of the study period (31 December 2011). Patients recorded with 
the following diagnoses at any point in their primary care electronic medical record or 
secondary care Hospital Episodes Statistics (HES) database were excluded from the 
cohort to minimize misclassification with other respiratory diseases in which beta-
blockers and NSAIDs may be better tolerated (appendix 2): chronic obstructive 
pulmonary disease (COPD); restrictive lung diseases; and bronchiectasis. Patients were 
also excluded if they had ever been prescribed immunosuppressant therapy 
(azathioprine, ciclosporin, leflunomide, mercaptopurine, and methotrexate) or had a 
recorded diagnosis of polymyalgia rheumatica at any point in the electronic medical 
record. This was done to avoid misclassification of oral steroid use that was not related 
to asthma. All subjects whose practices were not linked to the HES database of 
hospitalisation records and ONS database of death registrations were excluded from 
these analyses so that the different types of event could be evaluated in the same 
population (complete outcome ascertainment). 
2.3.3 Observational analysis outcomes of interest 
Asthma events were divided into a hierarchy of events reflecting the severity of the 
asthma exacerbation namely:  
 Asthma death;  
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 Asthma hospitalisation;  
 Primary care asthma exacerbations (PCAE)  
 
Asthma deaths were identified through linkage to the ONS database of death 
registrations using the International Statistical Classification of Diseases and Related 
Health Problems 9
th
 and 10th Revision (ICD 9 and 10) codes for asthma as the 
underlying cause of death (recorded in cause 1, cause 2 or cause 3) as provided by 
CPRD. This was considered synonymous to part 1a, 1b and 1c of UK ONS 
requirements for death registration. Hospitalisations for asthma were identified through 
linkage to the secondary care HES database using ICD10 codes (appendix 2) for asthma 
recorded as the primary discharge diagnosis (i.e. asthma recorded in the first position) 
as provided by CPRD. PCAE were defined as the prescription of rescue oral steroid 
courses where same day prescriptions (duplicate steroid prescriptions) were ignored and 
classed as single events to avoid clustering. Due to the large variation in steroid regimes 
and doses used in primary care, patients were only included in the nested case-control 
analysis of primary care asthma exacerbations if oral steroid prescriptions could be well 
defined. Patients were therefore excluded from the nested case-control study of PCAE if 
they were issued any of the following types of oral prednisolone prescriptions during 
their observation period:  
 Prednisolone prescriptions with incomplete information on dosing, frequency and 
quantity of tablets;  
 Prednisolone prescriptions for 1mg or 2.5mg strength tablets suggestive of chronic 
steroid exposure; and  
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 Prednisolone prescriptions lasting greater than 2 weeks in duration (calculated by 
dividing the total quantity of tablets in the prescription by the frequency of tablets 
recommended each day) 
All patients considered as cases therefore had well defined oral steroid prescriptions 
broadly in keeping with rescue oral steroid treatment doses recommended in guidelines 
for the management of asthma (2). This was done in order to minimize any potential 
misclassification related to the outcome of interest. 
 
2.3.4 Observational studies exposures 
Beta-blockers were defined according to their selectivity for the beta1-adrenoceptor 
whilst NSAIDs were defined according to their selectivity to COX1. This was done 
because the risk of asthma outcomes may differ according to differences in selectivity. 
The following drugs were considered to be selective beta-blockers (118): acebutolol, 
atenolol, betaxolol, bisoprolol, celiprolol, and metoprolol. The following drugs were 
considered to be non-selective beta-blockers: carteolol, carvedilol, labetalol, 
levobunolol, metipranolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, and 
timolol. NSAIDs were divided into the following groups according to published IC80 
COX-1/COX-2 ratios (91, 119): COX-2 inhibitors (celecoxib, etoricoxib, lumiracoxib, 
rofecoxib, valdecoxib); other NSAIDs with 5-50 fold COX-2 selectivity (etodolac, 
meloxicam, nimesulide); other NSAIDs with less than 5 fold COX-2 selectivity 
(diclofenac, piroxicam, mefenamic acid); non-selective NSAIDs (ibuprofen, 
indomethacin, ketoprofen, naproxen) and aspirin.  
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All data were anonymised and approval to conduct the study was obtained from the 
ISAC (Independent Scientific Advisory Committee) for Medicines and Healthcare 
products Regulatory Agency Database Research (protocol number 12_061R3). 
 
2.3.5 Observational studies primary analysis using nested case control 
methods 
The primary method of analysis used to estimate the association between beta-
blocker/NSAID exposure and the incidence of asthma events was the nested case 
control study (chapters 7-9). I had considered a cohort study with time-dependent 
variables which provides an absolute measure of association compared to case control 
studies which traditionally provide a relative measure of association only (120). 
However, large cohort studies involving time-dependent variables are computationally 
demanding and more than one time-dependent variable would need to be adjusted for. I 
therefore chose the nested case-control study design because controlling for time-
dependent confounding is computationally more efficient and can be used to produce 
odds ratios which reflect unbiased estimators of incidence rate ratios whilst maintaining 
precision (121). The nested case-control studies in this thesis have four main stages: 
1. Accurately defining the cohort (specifically defining cohort entry and eligibility);  
2. Following the cohort until the outcome of interest;  
3. Generating a risk set involving cases and controls who are present in the cohort at 
the time of the outcome); and 
4. Randomly selecting controls from each risk set. 
For each individual analysis, a subset of the CPRD adult active asthma cohort defined 
above was selected. Details of subset cohort selection for each individual analysis are 
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provided in each relevant chapter e.g. for the NSAIDs’ analysis cohort entry was 
additionally defined by the prescription of an analgesic (chapter 9). Once cohort entry 
was established, all patients were followed until either of the following: the first asthma 
event being studied; death; end of general practice registration; one year following the 
last asthma medication; or end of the study period (31 December 2011). 
 
Case ascertainment 
For all analyses, the date of the first asthma event was the index date for case subjects. 
A separate nested case-control study was performed for each type of event (asthma 
death, asthma hospitalisation and PCAE) resulting in three analyses for each exposure 
of interest. 
 
Control selection 
Up to 10 controls were randomly selected and matched to each case on, age (categorised 
into deciles), gender, calendar year of cohort entry and whether patients were diagnosed 
with asthma before the age of 45, using incidence density sampling. Incidence density 
sampling is a technique in which controls present within the cohort are sampled at the 
exact time of the index event. Therefore, all controls were alive, registered with their 
general practice when matched to their corresponding case, and had a similar duration 
of follow-up at the risk set date. The date of the risk set was the index date for the cases 
and subjects were eligible to be used as controls in multiple sampled risk sets. In 
addition, controls could later be included as cases, and the same patient could be 
selected as a control for different cases. When a case could not be matched to one or 
more controls, the process was repeated matching on gender, calendar year of cohort 
entry and diagnosis of asthma before the age of 45 only.  
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Exposures 
For all cases and controls, information was obtained on drugs prescribed between cohort 
entry and the index date including oral beta-blockers and NSAIDs. For cases and 
controls, beta-blocker and NSAID exposure was categorised into mutually exclusive 
time periods as follows:  
 Current user was defined as a prescription for the exposure of interest issued in the 
risk window immediately prior to the index date; and  
 Nonuser when there was no prescription issued in the risk window immediately 
prior to the index date.  
Current user was further subdivided into;  
 Incident user when the prescription was issued in the risk window and no previous 
prescription was issued in the remaining 365 days prior to the index date; and  
 Prevalent user when the prescription was issued during the risk window and also 
during the remaining 365 days prior to the index date.  
 
In this regard, exposure among incident users corresponds to acute exposure whilst 
exposure among prevalent users is likely to correspond to chronic exposure. A 30 day, 
60 day and 90 day risk window were chosen to assess risk of beta-blocker and NSAID 
exposure. These risk periods were chosen in order to assess whether risk of exposure 
attenuates with time and because the exact date the patient started taking the medication 
was not known. 
 
Among current users, exposure to oral beta-blockers was additionally evaluated 
according to dose. Low to moderate daily dose and high daily dose of oral beta-blockers 
were defined using cut-off values based upon beta-blocker equivalency doses published 
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in heart failure guidelines (122). High dose oral beta-blocker were defined by daily 
doses greater than the following: acebutolol 200mg, atenolol 50mg, bisoprolol 5mg, 
carvedilol 25mg, celiprolol 200mg, labetaolol 200mg, metoprolol 100mg, nadolol 
80mg, oxprenolol 80mg, pindolol 10mg, propranolol 80mg, sotalol 160mg, and timolol 
10mg. 
 
Confounders 
For each outcome, an exploratory nested case control analysis using the entire active 
asthma population matched only on year of cohort entry and whether people were 
diagnosed with asthma before the age of 45 years was used to determine significant risk 
factors associated with each asthma event. This analysis excluded beta-blockers and 
NSAIDs from in the model. This was done in order to inform the choice of potential 
confounders for subsequent analyses, results of which are presented in chapter 6. 
Variables identified as being known potential risk factors for asthma exacerbations and 
significant confounders were then used for risk adjustment of the crude effect estimates 
for each event following an assessment of model fit. Model fit was assessed using the 
Akaike information criterion (AIC) using a smaller is better approach. 
 
The list of variables used for confounding adjustment for each outcome is shown in 
each analysis chapter (chapters 7-9). A potential list of confounding variables was 
chosen for assessment a priori. These variables were then assessed for significance in 
the initial risk factor models presented in chapter 6. Significant variables from this 
model were then used for confounding adjustment in later analyses. All analyses were 
adjusted for prescription of the following asthma medications in the 90 days preceding 
the index date: inhaled corticosteroids (ICS); long-acting beta2-agonists (LABA); 
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leukotriene antagonists; oral methylxanthines; total number of short-acting beta2-
agonists (SABA) prescriptions; and prescription of oral steroids (not included in the 
PCAE analysis). This was done to adjust for asthma severity whereby people with more 
severe asthma are treated with asthma medication in a stepwise fashion and because 
these variables were significant in the initial risk factor models presented in chapter 6. 
Additional risk adjustment was made for the following in all analyses: whether the 
patient had ever been hospitalized for asthma; whether there was a recorded respiratory 
tract infection (RTI) within the risk window prior to the index date; exact age, smoking 
status (categorised into current, ex-smoker and non-smoker); body mass index 
(determined as weight/height squared); social deprivation (based upon deciles of the 
postcode defined Index of Multiple Deprivation); a past medical history of nasal polyps; 
and the Charlson co-morbidity index. For PCAE additional adjustment was made for 
attendance at a primary care asthma review within 365 days of the index date because it 
was significant in the initial model evaluating risk factors for PCAE presented in 
chapter 6. 
 
The Index of Multiple Deprivation uses data on income, employment, health, education, 
crime, access to services and living environment to create scores which are ranked into 
deciles to provide a measure of overall deprivation. The Charlson comorbidity index 
was used to perform risk adjustment for comorbidity. The Charlson comorbidity index 
is a widely used and validated index of comorbidity based upon 17 categories of 
comorbid disease weighted on their association to predict mortality which takes into 
account the number and severity of conditions (123). The Charlson index was 
determined from coded diagnoses present in both the CPRD primary care database and 
the HES database of hospitalisation and calculated using STATA v13. Smoking was 
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defined by smoking status recorded within three years of the index date. Height and 
weight were determined as a mean of all adult values recorded in the patient electronic 
medical record. If smoking status, height or weight was not recorded in the specified 
time frames, then multiple imputation for missing data was used as described later. 
 
Data management 
Multiple imputation is a statistical method for analysing incomplete data sets with the 
aim of generating valid inferences for statistical estimates from incomplete data. 
Multiple imputation has three main stages. The first stage is to randomly generate 
realistic imputed values to replace missing values in the data set resulting in a number 
of complete data sets. The second stage is to analyse each imputed data set to generate 
an statistical estimate and the third stage is to pool these individual estimates into one 
statistical estimate which combines variation within and between the imputed data sets.  
Multiple imputation was used to impute missing data on height, weight and smoking 
status with the assumption that data was missing at random (124). Fully conditional 
specification is a semi-parametric and flexible approach that specifies the multivariate 
model by a series of conditional models, on a variable by variable basis. The amount of 
missing data for each nested case control analysis is presented in each chapter but was 
generally less than 10%. The imputation model included all variables relating to clinical 
characteristics, asthma events, asthma medication and the exposure of interest. Multiple 
imputation was carried out using fully conditional specification, with linear regression 
for continuous variables and logistic regression for categorical variables using 5 
imputed data sets, which is an adequate number based upon a standard approach and the 
low level of missing data (125). The multiply imputation was performed using the mi 
impute chained command in STATA v13. 
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Data analysis 
Data for cases and controls are presented as means (standard deviation, SD) for 
continuous variables and as numbers (percentage, %) for categorical variables. Analysis 
of variance was used to determine significant differences between patient characteristics 
expressed as a continuous variable. Chi-squared tests were conducted to determine 
significant differences between patient characteristics expressed as a categorical 
variable. For differences involving samples with five or less subjects, the Chi-squared 
test with continuity correction was used to prevent overestimation of statistical 
significance for small data.  
 
Conditional logistic regression was used to compute odds ratios for the association 
between events and beta-blocker or NSAID exposure using a 30 day, 60 day and 90 day 
risk window. These risk periods were chosen in order to assess whether risk of exposure 
attenuates with time and because the exact date the patient started taking the medication 
was not known. By using incidence density sampling to select controls the odds ratios 
are unbiased estimators of incidence rate ratios because the controls are providing an 
estimate of the proportion of exposed to unexposed person-time. In the primary 
analysis, current users were compared to nonusers according to selectivity, duration of 
administration (incident vs. prevalent) and where appropriate by dose. Descriptive 
analysis was carried out using SPSS v21 and conditional logistic regression using 
STATA v13. 
 
Sensitivity analyses 
For each nested case control analysis, several sensitivity analyses were performed to test 
the robustness of the results. Firstly, the analysis was repeated by excluding patients 
77 
 
hospitalised within the risk period. This was done because medications prescribed 
during episodes of hospitalisation are not recorded within CPRD potentially introducing 
immortal time bias. Secondly, the analysis was repeated by excluding patients over the 
age of 40 years who smoked and also by excluding patients diagnosed with asthma over 
the age of 45 years. These two sensitivity analyses were performed to test for any 
potential misclassification of patients with COPD in which the exposure of interest may 
be better tolerated (and risk therefore underestimated). Thirdly, the analysis was 
repeated excluding risk sets in which cases could not originally be matched to controls 
on age. The number of affected cases is presented in each chapter but generally affected 
less than 5% of cases. Lastly, a complete case analysis was performed and compared to 
the analysis using multiply imputed data.  
 
2.3.6 Observational studies secondary analysis using self-controlled case 
series methods 
For each nested case control study a secondary analysis using the self-controlled case 
series method was used to determine whether consistency in results was seen using a 
different method. This method was chosen because it can be used to investigate risk 
associated with incident (acute) exposures whilst at the same time eliminating fixed 
within-person confounding which may still be present in the nested case control study 
design. The nested case-control study is a between-person design where the relative 
incidence of events is estimated between different subjects using a risk window. In 
contrast, the self-controlled case-series (SCCS) is a within-person design where the 
relative incidence of events is compared between periods of exposure and non-exposure 
in the same individual (126). As such, each person acts as their own control and analysis 
only uses individuals who are cases (i.e. people with the event of interest). In this way 
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all fixed within-person confounding relating to factors such as gender, social 
deprivation and genetics are eliminated although the analysis can still be affected by 
time-dependent confounding. A case-exposure SCCS design was used in which only 
cases with incident beta-blocker or NSAID exposure were evaluated. 
 
Observation period 
The SCCS was conducted over a 360 day time period during which events are assumed 
to occur according to a non-homogenous Poisson distribution (126). The beginning of 
the observation period was defined as 180 days prior to the date of an incident 
prescription for the exposure of interest (defined as above as the prescription of a beta-
blocker or NSAID with no prescription of the same drug class in the 365 days prior to 
the index prescription) and the end of the observation period was defined as 180 days 
following this incident prescription. For each patient, incident exposure was defined as 
the first beta-blocker or NSAID prescription in the file in people with at least 1 year of 
follow up prior to the first prescription. In this regard, all patients used in the SCCS 
analysis were cases who had the exposure of interest. 
 
Events 
One limitation of the SCCS is that it requires that the probability of exposure is not 
affected by the occurrence of an event. This assumption is required for the conditioning 
argument that is used to derive the case series likelihood. The greatest threat to this 
assumption is when the outcome is a censoring event such as death. For this reason, the 
event of interest chosen for the SCCS analyses presented in this thesis was restricted to 
PCAEs (a frequent recurrent event) using a pre-risk period to account for potentially 
short-lived event dependent exposures (detail provided below). PCAEs were defined by 
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rescue oral steroid prescriptions occurring during the study period as defined above. 
Oral steroid prescriptions issued within fourteen days of each other were considered to 
be for the same event in order to avoid clustering and potential overestimation of the 
relative incidence. 
 
Risk periods 
The greatest risk from beta-blocker and NSAID in asthma is typically thought to result 
from incident (acute) exposure. The nested case-control study evaluated three risk 
windows covering a 30 day, 60 day and 90 day period respectively. To establish 
whether the incidence of PCAE increased immediately following incident prescription, 
three risk periods of the same duration were defined in the SCCS. The start date for the 
risk period was the date of the incident beta-blocker or NSAID prescription among 
cases. These risk periods were chosen so that results could be directly comparable to the 
nested case control study. 
 
The end of beta-blocker or NSAID exposure was determined by estimating exposure 
duration using prescriptions issued within the observation period. The estimated 
duration was calculated by dividing the total quantity of tablets in the prescription by 
the frequency of tablets recommended each day. In a minority of instances duration 
could not be calculated due to missing prescription information, in which case 
prescription duration of 28 days was assumed and imputed. For the purpose of this 
analysis, exposure extending beyond the acute risk period was defined as chronic 
exposure. 
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Because it is unlikely that people with asthma will be prescribed beta-blockers or 
NSAIDs for the first time during an asthma exacerbation, an immediate 30 day pre-risk 
period was defined. Person time and events occurring within the pre-risk period were 
then excluded from the analysis to account for possible short-lived event-dependent 
exposures between primary care asthma exacerbations and the exposure of interest. 
Failure to account for this in the design potentially overestimates the relative incidence 
of events because baseline incidence is reduced producing a biased result (126). A 
description of the SCCS method used is shown in figure 1. Incident exposure 
(representing the acute risk period) was centred within the 360 day observation period 
(chosen to reduce the potential impact of time-varying confounding and because 
investigating the acute risk period was the primary focus). If exposure extended beyond 
the acute risk period it was classed as prevalent exposure and partitioned as shown 
below. Apart from the pre-risk period which accounts for short lived event dependent 
exposures, all remaining time was classed as baseline observation. The incidence of 
events was then counted between periods of exposure and non-exposure within the 
same individual. Prescriptions issued during periods of hospitalisation are not recorded 
in CPRD which potentially introduces immortal time bias. For this reason, any 
hospitalisations occurring during the SCCS study period were identified and the 
duration of hospitalisation calculated. This person time was then subtracted from the 
corresponding exposure group. 
 
 
Figure 1. Diagrammatic representation of the self-controlled case series design used.  
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Confounders 
Although the SCCS controls for all time-fixed confounding, it does not account for 
time-varying confounding. In order to reduce the potential impact of time-varying 
confounding, the study observation period was restricted to a 360 day time period 
centred on the exposure of interest. Time-varying exposure to the following medications 
issued within each 90 day consecutive period was then adjusted for in the analysis: ICS; 
inhaled LABAs; leukotriene antagonists; methlyxanthines; and the total number of 
SABA prescriptions. Additional risk adjustment was also made for seasonal variation.  
 
Data analysis 
Data for cases are presented as means for continuous variables and as numbers 
(percentage, %) for categorical variables. The SCCS was analysed using conditional 
Poisson regression producing incidence rate ratios, with analyses stratified by selectivity 
as well as by dose where appropriate (126). Although age in years is unlikely to have a 
significant impact over a one year observational period, the impact of adjusting for age 
in the model was investigated by introducing an age term after 180 days of the study 
period. However, for this analysis age was not found to be a significant time-varying 
confounder and inclusion of age caused a worse model fit as assessed by the AIC. Age 
effects were therefore not included in the final model. Descriptive analysis was carried 
out using SPSS v21 and conditional Poisson regression using STATA v13. 
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2.4 Summary 
The first half of this chapter describes the general systematic review and meta-analysis 
methodology used to evaluate the adverse respiratory effect of beta-blockers and 
NSAIDs using existing clinical trial evidence with strong internal validity with results 
presented in chapters 3-5. The second half of this chapter describes the population used 
to measure the risk from beta-blocker and NSAID prescribing, with the primary analysis 
using the nested case control study and secondary analysis using self-controlled case 
series to quantify the frequency and severity of adverse respiratory events among people 
with asthma. The results from these observational studies are presented in chapters 7-9. 
All studies have some individual elements of methods, for example in terms of the 
cohort definitions in the observational analyses, and these are described in the 
individual results chapters where appropriate.
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Chapter 3: Acute Beta-Blocker 
Exposure in Asthma: Systematic 
Review and Meta-Analysis of 
Controlled Clinical Trials 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
84 
 
3.1 Introduction 
The first half of this thesis focuses on synthesising clinical trial evidence for the 
exposure of interest because this type of evidence has strong internal validity. This 
chapter will synthesise clinical trial evidence evaluating acute beta-blocker exposure on 
respiratory function in people with asthma. Beta-blockers cause bronchoconstriction in 
people with asthma as a result of antagonising the effects of catecholamines at the 
pulmonary beta2-adrenoceptor which alters the balance between sympathetic and 
parasympathetic drive controlling airway smooth muscle tone. A previous systematic 
review has been performed evaluating beta-blockers in people with reversible airways 
disease (consisting of asthma and COPD). That systematic review included 19 trials 
evaluating single-dose treatment with selective beta-blockers and reported a 7.5% mean 
fall in FEV1, a 4.6% increase in FEV1 following beta2-agonist, and no significant 
increase in respiratory symptoms compared to placebo (87). However, the degree of fall 
in FEV1 following exposure may also vary according to individual susceptibility. From 
this perspective, a small change in mean FEV1 in the whole population might be 
consistent with a minority of individuals having large and clinically significant falls, 
and this analysis therefore also evaluates the proportion of participants with a ≥20% fall 
in FEV1 and the proportion experiencing respiratory symptoms in addition to mean 
changes in FEV1.  
 
These potential effects were not evaluated in the previous systematic review, nor were 
variation by beta-blocker selectivity. It is known that there are differences in the degree 
of beta1:beta2-adrenoceptor selectivity among individual selective beta-blockers, and 
subtype selectivity may vary according to dose. Selective beta-blockers, which the 
previous systematic review focused on, are not the only type of beta-blocker which need 
85 
 
evaluating because the cross-sectional study I conducted as pilot work demonstrated 
that 1.1% of adults with asthma were prescribed non-selective beta-blockers over the 
course of a year (84). Also, other types of beta-blockers are indicated for certain 
conditions, but are often avoided in people with asthma. For instance, the non-selective 
beta-blocker and alpha-blocker labetalol is a first-line treatment for pregnancy-induced 
hypertension but is contraindicated in asthma (127). 
 
Finally, beta2-agonists are typically considered first-line rescue therapy for the 
management of acute bronchoconstriction in asthma and in theory their efficacy could 
be reduced when co-administered with beta-blockers. Even if beta-blockers were well 
tolerated, blunting the beta2-agonist response during episodes of bronchoconstriction 
triggered by other factors would be hazardous. However, the previous systematic review 
demonstrated a 4.6% increase in FEV1 with beta2-agonist compared to placebo 
following administration of single dosing with selective beta-blockers which is 
surprising given the pathophysiology. In contrast, beta2-agonist response in the 
presence of non-selective beta-blockade has not previously been systematically 
reviewed. 
 
 3.2 Aim 
The first aim of this analysis was to quantify the changes in lung function which occur 
following acute beta-blocker exposure and to assess the incidence of respiratory 
symptoms among people with asthma. The second aim of this chapter was to determine 
the efficacy of beta2-agonists following acute beta-blocker exposure to better inform 
their use in people with asthma. 
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3.3 Methodology 
Search strategy and selection criteria 
The systematic review was conducted using methodology described in the general 
methods chapter (chapter2, page 50). A pre-specified search strategy (appendix 1) was 
used to search MEDLINE, EMBASE and CENTRAL databases. The PICOS approach 
used in this chapter is described in table 2. Beta-blockers were evaluated in people with 
asthma and people with COPD were excluded. Studies evaluating exposure in people 
with prior beta-blocker sensitivity were excluded because these people have a different 
risk of bronchospasm and are not representative of all people with asthma. Studies 
evaluating acute exposure to oral, intravenous or topical beta-blockers through the use 
of randomised, blinded, placebo-controlled trials were eligible for inclusion. Acute 
exposure was defined as exposure lasting under 7 days. Dichotomous outcomes 
included fall in FEV1 of 20% or greater and respiratory symptoms. Continuous 
outcomes included mean fall in FEV1. 
 
Table 2. PICOS approach used for the beta-blocker systematic review. 
Population Included Patients with asthma* 
 Excluded Patients with COPD
Ω
 and healthy patients 
Intervention Included Oral, intravenous or topical beta-blocker exposure 
 Excluded Inhaled beta-blocker exposure 
Comparator Included Placebo 
Outcomes Included Symptoms 
  Fall in FEV1 ≥20% 
  Mean per cent change in FEV1 
  FEV1 response to beta2-agonist 
 Excluded Other measures of airway resistance  
Studies Included Randomized controlled trials in humans 
  Single or double-blinded 
  Selection not based on prior response
¥
 
Ω
COPD = emphysema and chronic bronchitis 
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Data processing and extraction 
Data processing and extraction followed the standard methodology set out in the general 
methods chapter (chapter 2, page 52). 
 
Data analysis 
Data analysis followed the standard methodology set out in the general methods chapter 
(chapter 2, page 52). Mean fall in FEV1 was presented as the absolute mean percentage 
difference in FEV1, compared to placebo. Falls in FEV1 of 20% or greater and 
respiratory symptoms were presented as the risk difference, compared to placebo. 
Beta2-agonist response was calculated immediately following administration of beta-
blockers or placebo and presented as the mean percentage difference in FEV1. All 
changes in FEV1 were calculated relative to baseline FEV1 values. Subgroup analyses 
were performed to evaluate the mean fall in FEV1 for individual drugs and dose-
response relationships where feasible. These subgroup analyses were chosen because 
beta-blockers differ in beta1:beta2-adrenoceptor subtype selectivity within class and 
response may also vary by dose of exposure. Subgroup analysis was performed for the 
following individual drugs: atenolol, celiprolol, labetalol, metoprolol, and propranolol. 
Dose response was assessed for atenolol, bisoprolol and metoprolol. This could not be 
done for all drugs due to the limited number of trials. A random-effects method of 
analysis was performed because significant heterogeneity was detected using the I
2
 
statistic (>50%). 
 
Sensitivity analyses 
Sensitivity analyses were performed for mean change in FEV1 restricting attention to 
studies using different definitions of asthma (whether asthma was simply stated to be 
present or was explicitly defined according to one or more of American Thoracic 
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Society/British Thoracic Society guideline criteria, reversibility in FEV1 in response to 
beta2-agonists, or through bronchial provocation challenge testing) and whether or not 
studies withheld beta2-agonists for at least 6 hours (chapter 2, page 63). Further 
sensitivity analysis was performed evaluating mean change in FEV1 using the minimum 
and maximum p-values for the calculation of missing standard deviations (chapter 2, 
page 60). 
 
3.4 Results 
Of 1989 references screened 32 studies evaluating acute oral or intravenous beta-
blocker exposure were included in the main analysis (figure 2 and table 3). Sixteen 
studies evaluated selective beta-blockers, 6 studies evaluated non-selective beta-
blockers and 10 studies evaluated both selective and non-selective agents. No 
randomized blinded placebo-controlled studies evaluating acute topical beta-blockers in 
patients unselected on the basis of prior exposure were found, and topical beta-blockers 
are not further considered. For selective oral or intravenous beta-blockers, a total of 23 
studies provided data on mean per cent change in FEV1, 13 studies provided data on 
symptoms, 5 studies provided data on fall in FEV1 of 20% or greater and 17 studies 
provided data on beta2-agonist response. For non-selective oral or intravenous beta-
blockers, a total of 14 studies provided data on mean per cent change in FEV1, 6 studies 
provided data on symptoms, 3 studies provided data on fall in FEV1 of 20% or greater 
and 9 studies provided data on beta2-agonist response.  
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Figure 2. PRISMA flow diagram for study selection in the beta-blocker systematic review. 
 
Records identified through  
database searching  
(n = 1,973) 
Additional records 
identified through other 
sources  
(n = 16) 
Records after duplicates removed  
(n = 1,292) 
Records screened  
(n = 1,292) 
Records excluded  
(n = 1,188) 
Full-text articles assessed 
for eligibility  
(n = 104) 
Full-text articles excluded, 
with reasons:  
Not randomized = 19 
No useable outcome = 17 
No placebo = 12 
Not blinded = 7 
Selected on prior response = 6 
Reported more than once = 5 
Not asthmatic = 2 
Exposure >1week = 2 
Not a clinical trial = 1 
No design provided = 1 
 
 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 32) 
Selective  
Beta-blockers 
(Oral/IV) 
(n = 16) 
Topical  
Beta-blockers  
(n = 0) 
Non-selective 
Beta-blockers 
(Oral/IV) 
(n = 6) 
Both 
Classes 
(Oral/IV) 
(n = 10) 
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Table 3. Characteristics of included studies in the beta-blocker systematic review. 
Study 
(reference)
 Exposure Patients Route Asthma
¥ 
SABA
Ω 
Outcome Beta-blocker Exposure 
Benson 1978 
(128) 
SD 12 O Yes Yes M, S Atenolol, Propranolol, Pindolol 
Beumer 1978 
(129) 
SD 12 O Yes No M Propranolol, pindolol, mepindolol 
Boye 1977 
(130) 
SD 10 IV No No M Atenolol 
Cannon 1982 (131)
 
SD 15 O Yes No S, F Pindolol 
Chatterjee 1986 
(132) 
SD 12 O Yes Yes M, S Atenolol, bisoprolol 
Chodosh 1988 
(133) 
SD 16 O Yes Yes M, S, F Metoprolol, dilevalol 
Dal Negro 2002 
(134) 
SD 12 O Yes Yes M, S Nebivolol 
Devereux 1998 
(135) 
SD 16 O Yes Yes M, S Sotalol 
Doshan 1986 A 
(136) 
SD 15 O Yes Yes M Atenolol, celiprolol 
Doshan 1986 B 
(137) 
SD 34 O Yes Yes M Atenolol, celiprolol, propranolol 
Ellis 1981 
(138) 
SD 10 O No Yes M Atenolol, propranolol 
Ellis 1984 
(139) 
SD 8 O Yes Yes M, S, F Atenolol, metoprolol 
Falliers 1985
δ
 
(140) 
SD 18 O Yes Yes M Labetalol 
Falliers 1986 
(141) 
SD 18 O Yes Yes M Metoprolol, labetalol 
Fogari 1990 
(142) 
7 days 10 O Yes Yes M, S Atenolol, celiprolol, propranolol, oxprenolol 
Jackson 1983 
(143) 
SD 11 O No Yes M, F Atenolol, labetalol 
Lammers 1985 
(144) 
SD 8 O Yes Yes M Atenolol, bevantolol 
Larsson 1982 
(145) 
SD 14 IV No Yes M, S Propranolol, labetalol, practolol 
Lawrence 1982*
 (146) 
SD 14 O Yes Yes M, S Atenolol, metoprolol, propranolol 
Lofdhal 1981 
(147) 
SD 8 O Yes Yes M Atenolol, metoprolol 
Lofdhal 1988 
(148) 
SD 10 O Yes Yes S Atenolol, metoprolol 
Matthys 1985*
δ
 
(149) 
SD 12 O No Yes M Celiprolol, propranolol 
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¥ 
Whether or not studies defined asthma as per ATS/BTS guidelines, reversibility of ≥15% in response to SABA or positive histamine/metacholine 
provocation test.
Ω 
Whether or not studies withheld short-acting beta2-agonists (SABA) for at least 6 hours.* Data combined from duplicated studies in 
Lawrence 1983 (160), Matthys 1986 (161), and Sue 1981 (162).
δ 
Studies used in subgroup analysis of celiprolol and labetalol only as patients selected 
on basis of prior sensitivity to propranolol. SD = single dose; O = oral; IV = intravenous; + = yes; - = no. Oxpr=oxprenolol. M = mean change in FEV1. 
S = symptoms. F =FEV1 fall ≥20%. 
 
 
Mue 1979 
(150) 
SD 34 O Yes Yes S Acebutolol 
Nair 1981 
(151) 
2 days 10 O No Yes M Acebutolol 
Nicolaescu 1972 
(152) 
3 days 10 O Yes Yes M, S, F Practolol 
Nicolaescu 1973 
(153) 
3 days 10 O Yes Yes M, S, F Practolol 
Repsher 1986
 (154) 
SD 18 O Yes Yes M, S Metoprolol, labetalol 
Skinner 1975 
(155) 
SD 10 IV No Yes M Propranolol, labetalol 
Sue 1982* 
(156) 
SD 23 IV No No M Pindolol 
Suzuki 1981 
(157) 
SD 24 O Yes Yes M Atenolol 
Tantucci 1990 
(158) 
SD 12 O No Yes M, S Atenolol, metoprolol 
Thiringer 1976 
(159) 
SD 8 O Yes Yes M Metoprolol, practolol, propranolol 
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Table 4. Dose range of beta-blockers from included studies. 
Beta-blocker Oral IV 
Selective    
Acebutolol 300-400mg - 
Atenolol 50-200mg 3mg 
Bevantolol 400mg - 
Bisoprolol 10-20mg - 
Celiprolol 200-600mg - 
Dilevalol 400mg - 
Metoprolol 50-200mg - 
Nebivolol 5mg - 
Practolol 200mg 10mg 
Non-selective    
Labetalol 100-400mg 20mg 
Mepindolol 5mg - 
Oxprenolol 80-100mg - 
Pindolol 5-15mg 0.4mg 
Propranolol 40-100mg 5mg 
Sotalol 240mg - 
Timolol 10mg - 
 
 
The most common selective beta-blockers evaluated were atenolol (15 studies) and 
metoprolol (9 studies) and the most common non-selective beta-blockers to be 
evaluated were propranolol (9 studies) and labetalol (6 studies, tables 3 and 4). For oral 
and intravenous administration, a total of 600 acute selective beta-blocker exposures 
were evaluated in 330 patients with asthma (mean age 46 years, 67.5% male). A total of 
301 acute non-selective beta-blocker exposures were evaluated in 218 patients with 
asthma (mean age 40.5 years, 68.9% male). Mean baseline FEV1 for patients exposed 
to selective and non-selective beta-blockers were 2.28L and 2.50L respectively. Of the 
trials identified 28 (88%) were single-dose studies with respiratory measurements taken 
on average 108 minutes post-dose. 
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Acute selective beta-blockade  
Compared to control, acute selective beta-blocker exposure caused a mean percentage 
change in FEV1 of -6.9% (95% CI -8.5 to -5.2, p<0.01 figure 3) with an I
2
 statistic of 
23% (p=0.16). The risk difference for fall in FEV1 of 20% or greater was 0.13 (95% CI 
0.01 to 0.24, p=0.03 figure 4) equating to a number needed to treat of 8 to produce a fall 
in FEV1 of 20% or greater in one person. The risk difference for symptoms was 0.03 
(95% CI -0.01 to 0.06, p=0.18 figure 5) equating to a number needed to treat of 33 to 
cause symptoms in one person but was not statistically significant compared to control. 
 
 
Figure 3. Mean percentage change in FEV1 following acute selective beta-blocker 
exposure. 
 
 
Figure 4. Fall in FEV1 of 20% or greater following acute selective beta-blocker exposure. 
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Figure 5. Symptoms following acute selective beta-blocker exposure. 
 
Acute non-selective beta-blockade 
Compared to control, acute non-selective beta-blocker exposure caused a mean 
percentage change in FEV1 of -10.2% (95% CI -14.7 to -5.6, p<0.01 figure 6) with an I2 
statistic of 84% (p0.000). The risk difference for fall in FEV1 of 20% or greater was 
0.11 (95% CI -0.04 to 0.26, p=0.14 figure 7) equating to a number needed to treat of 9 
to cause a fall in FEV1 of 20% or greater in one person, which was not statistically 
significant compared to control. The risk difference for symptoms was 0.08 (95% CI 
0.01 to 0.15, p=0.02 figure 8) equating to a number needed to treat of 13 to cause 
symptoms in one person. 
 
Figure 6. Mean percentage change in FEV1 following acute non-selective beta-blocker 
exposure. 
95 
 
 
Figure 7. Fall in FEV1 of 20% or greater following acute non-selective beta-blocker 
exposure. 
 
 
Figure 8. Symptoms following acute non-selective beta-blocker exposure. 
 
Beta2-agonist response following acute beta-blockade  
Compared to control, acute selective beta-blocker exposure caused a mean percentage 
change in FEV1 following SABA stimulation of -10.2% (95%CI -14.0 to -6.4, p<0.01 
figure 9) relative to baseline with an I2 statistic of 64% (p<0.001).  This means that 
acute exposure to selective beta-blockers blunted the FEV1 response to beta2-agonists 
by 10.2%. Compared to control, acute non-selective beta-blocker exposure caused a 
mean percentage change in FEV1 following SABA stimulation of -20.0% (95%CI -29.4 
to -10.7, figure 10) relative to baseline with an I2 statistic of 90% (p<0.001). This means 
that acute exposure to non-selective beta-blockers blunted the FEV1 response to beta2-
agonists by 20.0%. Response to beta2-agonist is summarised in figure 11. Following 
selective and non-selective beta-blockers mean FEV1 was -6.9% and -10.2% 
respectively. Following the administration of beta2-agonist, mean FEV1 response was 
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+22.7% for placebo, +16.0% following exposure to selective beta-blockers, and -0.7% 
following exposure to non-selective beta-blockers. 
 
 
Figure 9. Mean percentage difference in response to beta2-agonist following acute selective 
beta-blockade. 
 
 
 
Figure 10. Mean percentage difference in response to beta2-agonist following acute non-
selective beta-blockade. 
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Figure 11. Mean percentage change in FEV1 and response to beta2-agonist relative to 
baseline following acute beta-blocker exposure.  
N=number of participants. 
 
Subgroup analysis  
Individual selective beta-blocker comparisons 
Selective beta-blockers appeared to vary to the degree of fall in FEV1 following acute 
exposure. For selective beta-blockers, celiprolol appeared to have the least effect on 
FEV1 whilst acebutolol had the greatest (figure 12). Among each class of beta-blocker, 
individual agents had similar patterns of response to beta2-agonists but varied in size of 
that response. In this respect, beta2-agonists caused an increase in FEV1 with all 
selective beta-blockers typically causing an increase in FEV1 well beyond baseline 
levels. 
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Figure 12. Mean percentage change in FEV1 and response to beta2-agonist relative to 
baseline following acute selective beta-blocker exposure.  
*Baseline represented by dotted line. Dose = mean dose; N = number of participants. 
 
Sufficient data was available to evaluate mean percent change in FEV1 for several 
selective beta-blockers. Celiprolol caused a mean percentage change in FEV1 of 1.8% 
(95% CI -2.3 to 5.8, figure 13). In comparison, metoprolol caused a mean percentage 
change in FEV1 of -9.3% (95% CI -12.0 to -6.6, figure 14) and atenolol caused a mean 
percentage change in FEV1 of -10.2% (95% CI -12.6 to -7.8, figure 15). There was 
sufficient data to evaluate a dose-response relationship for metoprolol, atenolol and 
bisoprolol which showed an increasing dose-response relationship (figures 16 to 18). 
Mean percentage change in FEV1 following acute exposure to 50mg, 100mg and 
200mg of metoprolol was -6.0%, -8.9% and    -13.0% respectively. Mean percentage 
change in FEV1 following acute exposure to 50mg, 100mg, and 200mg of atenolol was 
-5.4%, -11.4% and -10.9% respectively. Mean percentage change in FEV1 following 
acute exposure to 10mg and 20mg of bisoprolol was -5.8% and -7.5% respectively.
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Figure 13. Mean percentage change in FEV1 following acute celiprolol exposure. 
 
 
 
Figure 14. Mean percentage change in FEV1 following acute metoprolol exposure. 
 
 
 
Figure 15. Mean percentage change in FEV1 following acute atenolol exposure. 
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Figure 16. Dose response relationship for metoprolol (mean change in FEV1). 
 
 
 
 
Figure 17. Dose response relationship for atenolol (mean change in FEV1). 
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Figure 18. Dose response relationship for bisoprolol (mean change in FEV1). 
 
Individual non-selective beta-blocker comparisons 
For non-selective beta-blockers, labetalol appeared to have the least effect on FEV1 
whilst propranolol had the greatest falls in FEV1 (figure 19). Compared to control, 
labetalol caused a mean percentage change in FEV1 of -2.7% (95%CI -9.6 to 4.1, figure 
20). In comparison, propranolol caused a mean percentage change in FEV1 of -17.0% 
(95%CI -21.4 to -12.6, figure 21). Beta2-agonists caused an increase in FEV1 beyond 
baseline with labetalol and pindolol only. 
      
Figure 19. Mean percentage change in FEV1 and response to beta2-agonist relative to 
baseline following acute non-selective beta-blocker exposure. 
*Baseline represented by dotted line. Dose = mean dose; N=number of participants. 
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Figure 20. Mean percentage change in FEV1 following acute labetalol exposure. 
 
 
Figure 21. Mean percentage change in FEV1 following acute propranolol exposure. 
 
Sensitivity analysis and risk of bias 
Subgroup sensitivity analyses assessed whether mean change in FEV1 varied between 
studies with unstated vs clearly defined diagnostic criteria for asthma, or varied 
depending on whether beta2-agonists were withheld prior to testing. These factors had 
no significant influence on mean fall in FEV1. For selective beta-blockers, mean fall in 
FEV1 was -6.4% (95% CI -8.3 to -4.5) for studies diagnosing asthma with specific 
criteria withholding beta2-agonists versus -8.7% (95% CI -12.0 to -5.4) for those which 
did not. For selective beta-blockers, this sensitivity analysis mainly evaluated the 
definition of asthma because only 1 study failed to report whether beta2-agonists were 
withheld prior to testing. For non-selective beta-blockers: mean fall in FEV1 was -8.6% 
(95% CI -13.7 to -3.5) for studies using explicit criteria for the diagnosis of asthma 
versus -12.6% (95% CI -21.6 to -3.7) for those which did not. Mean fall in FEV1 was -
10.0% (95% CI -15.2 to -4.8) for studies withholding beta2-agonists versus -9.3% (95% 
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CI -17.9 to -0.7) for those which did not. The final sensitivity analysis consisted of 
using the minimum and maximum p-value to calculate missing standard deviations as 
per the methods chapter. The results from this sensitivity analysis were similar to the 
main analysis. For selective beta-blocker, mean percent change in FEV1 using the 
minimum imputed p-value was -6.9% (95% CI -8.6 to -5.2) and -7.7% (95% CI -10.1 to 
-5.4) using the maximum imputed p-value. For non-selective beta-blockers, mean 
percent change in FEV1 using the minimum imputed p-value was -9.5% (95% CI -
13.38 to -5.66) and -11.1% (95% CI -16.1 to -6.2) using the maximum imputed p-value. 
 
For many of the methodological qualities assessed there was an unclear risk of bias as 
studies did not provide explicit detail to make an informed judgement (figure 22). For 
studies evaluating mean percentage change in FEV1, funnel plot asymmetry was 
observed for selective beta-blockers (figure 23). Because funnel plot asymmetry was 
observed, the Egger test was performed and was statistically significant for selective 
beta-blockers (p-value=0.005) but not for studies evaluating non-selective beta-blockers 
(p-value=0.111). 
 
 
Figure 22. Cochrane collaboration risk of bias tool for included studies in the beta-blocker 
systematic review. 
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Figure 23. Funnel plot for studies reporting mean percentage change in FEV1 following 
acute selective beta-blocker exposure.  
SE(MD)=standard error of the mean difference. 
 
3.5 Discussion 
This meta-analysis used clinical trial data to systematically quantify the degree of 
bronchoconstriction caused by acute exposure to a variety of beta-blockers. Using data 
from 25 clinical trials I found that acute selective beta-blocker exposure caused 
relatively small mean reductions in FEV1 and a non-significant increase in respiratory 
symptoms compared to placebo. However, selective beta-blockers did cause a 
statistically significant fall in FEV1 of 20% or greater in 13% of people (number needed 
to harm approximately one in eight). For both mean fall in FEV1 and respiratory 
symptoms, findings were similar to the meta-analysis by Salpeter et al. evaluating 
selective beta-blockers in people with reversible airways disease who included people 
with COPD demonstrating that including people with COPD in their study did not bias 
their results (87). Apart from only evaluating selective beta-blockers, this meta-analysis 
did not evaluate fall in FEV1 of 20% or greater as a distinct outcome which was an 
important finding from this study. Although the incidence of respiratory symptoms 
following selective beta-blocker exposure failed to reach statistical significance, this 
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result in combination with falls in FEV1 of 20% or greater suggest that acute selective 
beta-blocker exposure is not free from potential harm and that detrimental respiratory 
effects are likely to occur in a significant minority of susceptible people, even if the 
majority remain unaffected.  
 
Compared to placebo, the FEV1 response to beta2-agonist therapy was blunted by 
10.2% following acute selective beta-blocker exposure. This is in contrast to the meta-
analysis by Salpeter et al. which reported a 4.6% increase in response to beta2-agonists 
following single-dose exposure. An increase in beta2-agonist response following single 
doses of beta-blocker exposure is not biologically plausible given the pathophysiology. 
This difference can be explained by the use of different baseline definitions from which 
FEV1 response to beta2-agonists was calculated between studies. In this analysis, 
response to beta2-agonists was calculated as the mean percentage change in FEV1 
relative to baseline FEV1 whilst in the meta-analysis by Salpeter et al. mean percentage 
change in FEV1 was calculated using post-exposure FEV1 biasing the results. However, 
blunting of this magnitude in response to beta2-agonists is possibly of limited clinical 
significance as pulmonary function typically increased well beyond original baseline 
FEV1 values. 
 
There is no published meta-analysis examining non-selective beta-blockers that I am 
aware of.  Compared to placebo, acute exposure to non-selective beta-blockers caused a 
mean reduction in FEV1 of 10.2% and a significant increase in respiratory symptoms 
affecting 8% of patients (numbers needed to harm approximately one in thirteen). 
Compared to selective agents, non-selective beta-blockers caused a similar but non-
significant proportion of participants to have a fall in FEV1 of 20% or greater (11% and 
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13% respectively), and blunted FEV1 response to beta2-agonists by a much greater 
amount (20.0%).  
 
Three recent studies published after the search was completed have further examined 
response to beta2-agonist therapy in people with asthma exposed to non-selective beta-
blockers, none of which would have been eligible for this review. In each of these 
studies, short-acting beta2-agonists were evaluated in response to experimentally 
induced bronchoconstriction in patients with beta-blocker exposure, which potentially 
more closely mimics a real life scenario in which people established on beta-blockers 
have a fall in FEV1 as a result of infection or some other trigger. In the study by Short 
et al, a high dose of nebulised beta2-agonist (salbutamol 5mg) completely reversed a 
10% fall in FEV1 induced by histamine following acute exposure to oral propranolol 
(doses ranging from 10 to 20mg) in thirteen steroid treated asthmatics (163). In the 
study by Hanania et al, nebulised salbutamol (at a dose of 2.5mg) completely reversed 
the effects of metacholine challenge in 18 steroid naïve mild asthmatics receiving 
chronic nadolol dosing (mean dose 30mg) (164). A subsequent study evaluated the 
effect of nebulised salbutamol (5mg) in18 steroid treated asthmatics receiving chronic 
exposure to propranolol 80mg once daily after an initial period of dose titration. There 
was a 2.4% fall in FEV1 among people with chronic propranolol exposure compared to 
placebo and a mean 5.3% fall in FEV1 when salbutamol was administered following a 
histamine challenge. Despite these small changes, no significant changes in asthma 
control questionnaire or quality of life were found (165). In contrast, results from this 
systematic review evaluate the response to beta2-agonist rescue therapy against falls in 
FEV1 induced directly by acute exposure to beta-blockers (i.e. at the time of their 
initiation) thus measuring a different effect.  
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No eligible studies evaluating topical beta-blocker eye drops were found and it has not 
been possible to quantify the risk from topical beta-blockers. Two randomized placebo 
controlled trials were ineligible for this systematic review because people were selected 
on the basis of prior adverse respiratory effects from topical timolol eye drops. In the 
study by Friren et al, a single drop of the non-selective beta-blocker timolol caused a 
mean fall in FEV1 of 14.2% (166). In the other study by Schoene et al, a single drop of 
the selective beta-blocker betaxolol caused a mean fall in FEV1 of 9.6% (167). I chose 
not to include patients selected on the basis of prior beta-blocker response in this 
systematic review as this would likely evaluate exposure in a subgroup of patients at 
different risk of bronchospasm and these patients are unlikely to be representative of all 
people with asthma.  
 
Heterogeneity in treatment effect 
It was possible to investigate heterogeneity in this systematic review due to the large 
number of eligible trials. Heterogeneity was present as demonstrated by a significant I
2
 
test in some analyses and through differences between individual drugs and dose 
response. The subgroup analysis involving individual beta-blockers suggests that 
clinically important differences in treatment effect vary within class, particularly in 
relation to celiprolol and labetalol in which mean changes in FEV1 were not significant. 
The degree of beta1-adrenoceptor selectivity is known to vary among different selective 
beta-blockers. In this respect, the beta1:beta2-affinity ratios range from 13.5 for 
bisoprolol to 4.7 for atenolol and 2.3 for metoprolol (72). This is important as variation 
in beta1-adrenoceptor selectivity may also contribute to heterogeneity in treatment 
effect in meta-analyses of clinical trials investigating mortality from beta-blockers in the 
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perioperative setting (168). Celiprolol is a selective beta-blocker with partial agonist 
activity shown to have greater beta1-selectivity than both atenolol and bisoprolol and 
this greater beta1-selectivity may explain the non-significant mean change in FEV1 
following acute exposure (169, 170). However, labetalol is a non-selective beta-blocker 
with alpha-blocking properties and in this instance beta1-adrenoceptor selectivity 
cannot be the sole reason for better respiratory tolerance. Although labetalol was 
associated with only small falls in FEV1 following acute exposure significant 
heterogeneity was present and it is not possible to provide sufficient details on 
symptoms, fall in FEV1 of 20% or greater and response to beta2-agonist separately to 
comprehensively evaluate its safety for patients with pregnancy-induced hypertension 
and asthma. 
 
The method of administration and dose of short-acting beta2-agonists used in trials from 
this systematic review varied.  In many studies a standard dose of inhaled salbutamol 
(200 mcg) was administered following relatively high doses of beta-blockers. It is 
therefore be possible that using higher doses of SABA would have a similar therapeutic 
effect in terms of response to FEV1 in people given beta-blockers compared to people 
without beta-blocker exposure. In addition, change in respiratory function was evaluated 
using FEV1 which may be less sensitive at assessing pulmonary function following 
beta-blockade than other methods such as impulse oscillometry (171).   
 
Strengths and limitations 
Although studies in this meta-analysis administered clinically recommended doses of 
beta-blockers, in many instances these doses would be considered high initiation doses 
(e.g. atenolol 100mg). In reality, most people with (or without asthma) would initiate 
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treatment at lower doses. No studies titrated the beta-blocker dose in order to minimise 
adverse effects, as is conventional practice in the treatment of heart failure. As such, the 
risk presented in this review may not be representative of beta-blockers initiated at 
much lower doses which are then titrated upwards and may be better tolerated. In many 
instances the results in this chapter provide important information on the worst case 
scenario which could occur with unintended beta-blocker exposure. Beta-blockers were 
also evaluated in patients with mild to moderate asthma and the changes in lung 
function and symptoms presented in this chapter may not be applicable to patients with 
more severe or unstable asthma. Many of the included studies were reported at a time 
when therapeutic options for the management of asthma were limited and it is uncertain 
whether this may have influenced the results (e.g. through the availability of inhaled 
corticosteroids which may reduce risk further). In many instances an unclear risk of bias 
existed mainly because studies failed to describe in detail aspects of study design upon 
which an informed judgement could be made. Even with the apparent dose-response 
relationship and observed differences among individual beta-blockers, the possibility 
that some heterogeneity may be due to bias cannot be excluded. However, I chose to 
include only randomised blinded placebo controlled trials which are considered to be 
the gold standard for clinical research and the best method to prevent bias and 
confounding.  
 
3.6 Summary 
Based on a systematic review of all published clinical trial evidence, acute exposure to 
beta-blockers causes detrimental changes in lung function in susceptible people with 
asthma. However, the size of lung function changes and incidence of respiratory 
symptoms is dependent upon the class of beta-blocker and the dose of administration. 
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This would imply that beta-blockers should only be initiated in people with asthma 
where there is a compelling clinical indication to use a beta-blocker, in which case beta-
blockers with greater beta1-selectivity are likely to be safer and should be initiated at 
the smallest possible dose. Given that around one in eight people with asthma in the 
trials experienced a clinically significant decline in FEV1, observation of initiation 
would be sensible, particularly where asthma is more severe or has been relatively 
unstable in the past. This is especially important because response to conventional doses 
of short-acting beta2-agonists is blunted, particularly by non-selective beta-blockers.  
 
An evaluation of the effects of chronic beta-blocker exposure in asthma was beyond the 
scope of this systematic review. Observational studies describing the pattern of beta-
blocker prescribing among people with asthma and comparing beta-blocker risk using 
routine health data, including associations with both acute and chronic exposure would 
provide a useful comparison. The results of these observational studies are reported in 
chapter 7 and chapter 8. The next chapter will report a systematic review on the 
prevalence of aspirin-sensitivity in asthma using clinical trials and self-reported history.
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Chapter 4: Aspirin-Exacerbated 
Respiratory Disease: Systematic 
Review and Meta-Analysis of 
Prevalence and Mean Provocative Dose 
of Aspirin 
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4.1 Introduction 
Aspirin triggers exacerbations in susceptible patients with asthma. Although referred to 
as aspirin-exacerbated respiratory disease (AERD), complete cross-reactivity to other 
NSAIDs occurs. The prevalence of AERD varies widely among the literature. This 
uncertainty is surprising because asthma is a highly prevalent disease, whilst aspirin and 
NSAIDs are drugs which are widely used and the susceptibility of some people with 
asthma to these drugs has long been recognised. These inconsistencies in prevalence 
appear to relate to the different methods used to diagnose AERD including 
heterogeneity in study design and in the dose of aspirin administered.  
 
For example, in a study by McDonald et al., forty two patients with an unknown history 
of aspirin sensitivity but selected on the basis of having a history of nasal polyps or 
chronic sinusitis were challenged with a 320mg single dose of aspirin (99). In this 
study, reactions were considered positive if the forced expiratory volume in 1 second 
(FEV1) fell by 50% or greater. In contrast, in a study by Spector et al. graded doses of 
aspirin were administered to various groups of asthmatic patients including those with: 
no history of AERD with aspirin ingestion in the preceding month; those with no 
history of AERD without aspirin ingestion in the preceding month; those with uncertain 
history of AERD; and those with a positive history of aspirin-induced respiratory 
reactions (172). In this study, a fall in FEV1 of 20% or greater was considered a 
positive reaction. This heterogeneity means it is difficult to make proper comparisons 
between studies. 
 
The most widely cited estimate of prevalence of AERD comes from a single systematic 
review on the topic published in 2004 which reported an overall prevalence of AERD of 
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21% for adults and 5% for children (97). Although that systematic review synthesised 
studies using oral provocation challenge tests to determine the prevalence AERD, it 
included studies with heterogeneity in the threshold of FEV1 used to define a positive 
reaction and different dosing regimens. It therefore included studies such as those 
described above by McDonald et al. and Spector et al. potentially biasing the estimate 
of prevalence. Additionally, several reported inaccuracies in the description of included 
studies appear in that systematic review. For example, the study by Rachelefsky et al. 
published in 1975 was described as an open challenge study involving 32 children when 
it was actually a double-blind placebo controlled study involving 50 children (173). The 
study by Marquett et al. was described as a randomised double-blind placebo-controlled 
study when in fact it was a retrospective cohort study and the study by Vally et al. was 
described as a single-blind placebo-controlled study conducting oral provocation 
challenges when it actually measured the prevalence of AERD through a survey of self-
reported history (174, 175). These discrepancies potentially affect the validity of their 
results. 
 
The prevalence of AERD in people with asthma can be measured from self-reported 
history or provocation challenge tests. Self-reported histories rely on a degree of self-
awareness of aspirin-induced respiratory symptoms which may not be widespread and 
surveys may be subject to bias depending upon the population sampled (98).  
 
The gold standard method for diagnosing AERD is typically considered to be the oral 
provocation challenge test, although its validity may be affected through the 
introduction of bias if inappropriately conducted, for example due to the absence of: a 
placebo control; blinding of participants (or personnel); random allocation of exposure; 
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and inappropriate patient selection. The most commonly established method for 
conducting oral provocation challenge testing for the diagnosis of AERD uses placebo 
and exposure to incremental doses of aspirin given in single blind fashion over two 
consecutive days without random allocation of exposure (176). In this regard placebo 
testing typically occurs on day one with graded aspirin exposure occurring on day 2. 
The oral provocation challenge test is then considered positive for a diagnosis of AERD 
when a fall in FEV1 of 20% or greater occurs following exposure to aspirin but not 
placebo.  
 
Aspirin is a commonly prescribed drug in adults (93). High dose aspirin (≥300mg) is 
recommended for the management of acute coronary syndrome and low dose aspirin (75 
to 100mg) is recommended for secondary prevention of cardiovascular (CVS) events 
with some international guidelines recommending aspirin for primary prevention (177). 
Increasing evidence demonstrates that aspirin may also reduce cancer-specific mortality 
potentially prompting wider use among the general population (178, 179). In order to 
inform the safe use of aspirin in people with asthma, it is important to accurately 
determine the prevalence of AERD and the provocative dose of aspirin triggering such 
reactions.  
 
Although the use of self-reported histories has been criticised for the reasons described 
above, the degree of inaccuracy in measuring the prevalence of AERD compared to oral 
provocation challenge testing has not definitively been proven or quantified. The 
systematic review previously discussed measured the prevalence of AERD using oral 
provocation challenge test studies with varying risk of bias whilst the prevalence of 
AERD determined using population based surveys of self-reporting remains uncertain. 
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In addition, the provocative dose of aspirin triggering such events has never been 
quantified and may guide clinical decision making. 
 
4.2 Aim 
The aim of this chapter was to determine the mean provocative dose of aspirin 
triggering respiratory reactions in people with AERD and to estimate the prevalence of 
AERD using studies involving oral provocation challenge testing or self-reported 
history using selection criteria aimed at minimising bias. 
 
4.3 Methodology 
Search strategy and selection criteria 
The systematic review was conducted using methodology described in the general 
methods chapter (chapter 2, page 51).  A pre-specified search strategy (appendix 1) was 
used to search MEDLINE, EMBASE and CENTRAL databases. The PICOS approach 
used in this chapter is described in table 5. The mean provocative dose of aspirin 
(MPDA) was calculated for adults or children with confirmed AERD only because this 
is the population at risk.  Although nasal challenge testing is possible, the systematic 
review was restricted to oral provocation challenge testing from which MPDA could be 
calculated. 
 
For oral provocation challenge tests (OPCT), studies involving adults and children with 
asthma with unknown AERD status were included. This population therefore had no 
prior exposure. Although AERD may be triggered by other NSAIDs, the systematic 
review was restricted to studies performing oral provocation testing with aspirin only.  
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Table 5. PICOS approach used in the AERD systematic review. 
  
OPCT Population surveys MPDA
¥
 
Population Included Adults and children 
with asthma 
Adults and children 
with asthma 
Adults and children 
with AERD 
 Excluded COPD
*
 and healthy people COPD
*
 and healthy people Aspirin-tolerant asthma 
  Known AERD status   
Intervention Included Oral aspirin exposure Self-reported history 
of AERD 
Graded aspirin exposure 
 Excluded Other NSAIDs  Other NSAID exposure 
  Nasal or bronchial exposure   
Comparator Included Placebo Not applicable Placebo 
  Aspirin-tolerant asthma   
Outcomes Included Fall in FEV1 of ≥20% 
Respiratory symptoms 
Prevalence of AERD Fall in FEV1 of ≥20% 
     
 Excluded Other measures of airway 
resistance 
  
Studies Included Blinded placebo-controlled Cross-sectional studies  
*Chronic obstructive airways disease. 
¥
Mean provocative dose of aspirin. 
OPCT= oral provocation challenge test. AERD=aspirin-exacerbated respiratory disease. 
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All included challenge test studies were required to be controlled and blinded in order to 
avoid any placebo effect. Included studies were required to define a positive challenge 
test by falls in FEV1 of 20% or greater in order to make results more comparable. I 
included studies measuring the prevalence of AERD using population based surveys 
which relied upon a self-reported history of respiratory reactions to aspirin or other 
NSAIDs among adults or children. In this setting, by definition patients were not 
required to be unselected on the basis of prior exposure. 
 
Data processing and extraction 
Data processing and extraction followed the standard methodology set out in the general 
methods chapter (chapter 2, page 52). 
 
Data analysis 
The MPDA was calculated for people with AERD undergoing OPCTs using inverse-
variance weighting to pool mean threshold doses from studies. For studies reporting the 
dose range only, standard deviations were estimated as described by Hozo et al. (chapter 
2, page 57).  
 
To estimate prevalence using OPCT studies, falls in FEV1 of 20% or greater and the 
incidence of respiratory symptoms were calculated in people with asthma with unknown 
AERD status and presented as the risk difference (RD). For OPCTs, subgroup analysis 
was performed evaluating differences between adults and children and whether trials 
were randomised. These subgroup analyses were chosen specifically because 
differences between adults and children have previously been reported and because lack 
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of randomisation may introduce bias. For studies measuring AERD by self-reporting, 
the prevalence of asthma was estimated by calculating the total number of people with 
self-reported AERD (numerator) divided by the total number of people with asthma 
(denominator). Subgroup analysis was then performed according to whether people 
were surveyed in specialist centres or among the general asthma population.  
 
Heterogeneity among studies was assessed using the I
2
 statistic with values of greater 
than 40% indicating heterogeneity. Meta-analysis was performed using a random-
effects method of analysis. 
 
Sensitivity analyses 
In addition to the standard sensitivity analyses involving the asthma definition, and 
whether or not beta2-agonists had been withheld for at least 6 hours (chapter 2, page 
63), further sensitivity analysis was performed for MPDA according to whether 
standard deviations were reported or imputed as described Hozo et al. 
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4.4 Results 
Mean provocative dose of aspirin 
A total of 1768 references were screened from the three databases. Of these, 20 studies 
reported oral provocation challenges with aspirin from which the MPDA could be 
calculated were included (figure 24). The MPDA was reported for 476 people (mean 
age 44.6 years, 43.6% male) with doses ranging from 30mg to 1000mg (table 6). For 
adults, the MPDA was 89.0mg (95% CI 75.8 to 102.1mg).  The MPDA for children 
based upon a single small study was 20.6mg (95%CI 4.9 to 36.3mg). 
 
Prevalence of AERD 
A total of 7 oral provocation challenge test studies providing data on fall in FEV1 of 
20% or greater in people with asthma and unknown AERD status were included. Three 
studies provided data on respiratory symptoms whilst 4 studies involved children only 
(table 6). For the main outcomes of fall in FEV1 of 20% or greater and respiratory 
symptoms, aspirin was evaluated in 381 adults (mean age 41.2 years, 38.6% male) and 
156 children (mean age 13 years, 60% male).  
 
Aspirin caused a fall in FEV1 of 20% or greater in 9.0% of adults (95% CI 6.0 to 
12.0%, p<0.001) and 11.0% of children (95% CI 5.0 to 17.0%, p<0.001) with an overall 
prevalence of 10.0% (95% CI 7.0 to 12.0%, p<0.001, figure 25). Respiratory symptoms 
occurred in 19% of children (95% CI 10 to 28%, p<0.001), but symptoms were not 
reported in any studies involving adults.  
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Figure 24. PRISMA flow diagram for study selection in the AERD systematic review. 
 
 
Records identified through 
database searching  
(n = 1762) 
Additional records identified 
through other sources  
(n =6) 
Records after duplicates removed  
(n = 1,297) 
Records screened  
(n = 1,297) 
Records excluded  
(n = 1,200) 
Full-text articles assessed 
for eligibility  
(n = 97) 
Studies included in 
quantitative synthesis  
(n = 34) 
Full-text articles excluded 
(N=63):  
No useable outcome = 15 
Other NSAID = 9 
Conference abstract = 8 
Exposure >1week = 6 
Not a clinical trial = 4 
No placebo = 4 
Not blinded = 6 
Prior response ineligible = 3 
Exposure ineligible = 3 
Not asthmatic = 3 
Post-exercise = 2 
 
 
Mean 
provocative 
dose of aspirin  
(n = 20) 
Oral 
provocation 
challenge test  
(n = 7) 
Population 
surveys  
(n = 9) 
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Table 6. Studies reporting mean provocative dose of aspirin using oral challenge testing. 
 
¥ Whether or not studies defined asthma as per sensitivity analyses. MPDA = mean provocative dose of aspirin. 
Ω Whether or not studies withheld short-acting beta2-agonists (SABA) for at least 6 hours prior to challenge testing.  
SD = standard deviation. *Standard deviations estimated from the range. δ Mean standard deviation imputed. 
 
 
 
  
 
  MPDA (mg) 
Study 
(reference)
 Patients Asthma
¥ 
SABA
Ω
 Population Dose SD 
MPDA       
Bavbek 2007 
(180) 
13
 
Yes Yes Adults 163.4 143.9 
Berges-Gimeno 2003 
(181) 
38 Yes No Adults 58.0 108.1δ 
Celejewska-Wójcik 2012 
(182)
  8 Yes Yes Adults 111.0 108.1δ 
Christie 1991 
(183) 
6 No Yes Adults 31.7 15.9 
Falliers 1983 
(184) 
15 No No Adults 142.2 248.6 
Israel 1993 
(185) 
8 Yes Yes Adults 90.0 70.0* 
Kowalski 1984 
(186) 
29 Yes Yes Adults 140.0 154.3 
Kowalski 1985 
(187) 
11 Yes Yes Adults 141.8 173.5 
Mastalerz 2000 
(188)
 17 Yes Yes Adults 188.0 197.7 
Micheletto 2006 
(189) 
19 Yes Yes Adults 68.3 12.4 
Nizankowska 2000 
(176)
 24 Yes Yes Adults 66.1 99.3* 
Spector 1979 
(172) 
189 Yes Yes Adults 119.1 137.3 
Stevenson 1984 
(190) 
25 Yes No Adults 364.0 263.3* 
Stevenson 2001 
(191) 
60 No Yes Adults 61.0 30.0* 
Swierczynska 2003 
(192) 
15 Yes No Adults 103.7 93.0 
Szczelkik 2001 
(193)
 
 
12 Yes Yes Adults 98.3 30.8* 
Vedanthan 1977 
(194) 
52 Yes Yes Children 20.6 11.3 
Weber 1979 
(46)
 12 No No Adults 250.0 93.8* 
Woessner 2002 
(195) 
60 Yes No Adults 69.0 30.0* 
Woessner 2004 
(196)
 
 
56 Yes No Adults 57.0 30.0* 
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Figure 25. Fall in FEV1 of 20% or greater following oral provocation tests with aspirin. 
 
Table 7. Studies measuring prevalence of aspirin-exacerbated respiratory disease using 
self-reported histories. 
Study Population Patients Prevalence 
% 
Prevalence 
95%CI 
OPCT studies     
Ahmetaj 2009 Adults 172 9.3  5.8-14.6 
Fischer 1983  Children 25 4.0  0.1-19.5 
Rachelefsky 1975  Children 50 12.0  5.6-23.8 
Spector 1979  Adults 189 9.0  5.7-13.9 
Tarlo 1982  Adults 20 10.0  2.8-30.1 
Towns 1984  Children 29 20.7  9.9-38.4 
Vedanthan 1977  Children 52 9.6  4.2-20.6 
Population surveys     
Bavbek 2012 Adults 1344 12.4 10.4-14.7 
Eriksson 2014* Adults 1727 5.1 4.2-6.2 
Hedman 1999* Adults 158 8.8 5.4-14.3 
Kasper 2003 Adults 703 4.3 3.0-6.0 
Kasper 2009 Adults 582 1.9 1.1-3.4 
Mascia 2005 Adults 3307 13.9 12.7-15.1 
Moon 2013 Adults 1173 5.8 4.6-7.3 
Sabry 2010 Adults 365 12.6 9.6-16.4 
Vally 2002* Adults 644 12.3 10.0-15.0 
            CI = confidence interval. 
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There was no significant difference in falls in FEV1 of 20% or greater according to 
whether or not aspirin was randomly allocated (9% (95% CI 6 to 13%) for randomised 
vs 10% (95% CI 6 to 14%) for non-randomised studies), although all of the non-
randomised studies only involved children. No significant heterogeneity was detected 
by the I
2
 test. 
 
A total of 9 studies involving 10,011 people with asthma (mean age 46.6 years, 63.2% 
female) provided data on the prevalence of AERD measured using self-reported history 
(table 7). The overall prevalence of AERD among these studies was 9.6% (95% CI 9.1 
to 10.2%). The prevalence of AERD among people sampled from specialist centres was 
significantly larger than the general asthma population (10.5% (95% CI 9.8 to 11.2%) 
vs. 6.9% (95% CI 5.9 to 8.0%) respectively, difference 3.6% (95% CI 1.8 to 5.3%)). 
 
Sensitivity analysis and risk of bias 
For oral provocation challenge test studies, asthma was defined using explicit best 
practice criteria described in the general methods chapter in all but one study involving 
adults only. The prevalence of AERD in the study without an explicit definition of 
asthma by Ahmetaj et al. was 9% (95% CI 5 to 14%) and was similar to the results of 
the main analysis. A total of three studies performing oral provocation challenge tests 
provided no information on whether beta2-agonists were withheld prior to testing but 
results were similar to those studies which did (prevalence 9% (95% CI 6 to 13%) and 
10% (95% CI 6 to 15%) for studies withholding and not withholding beta2-agonists 
respectively). The MPDA was similar for studies reporting the standard deviation 
compared to those which were estimated as per the methods section (MPDA 84.0mg for 
studies reporting the standard deviation vs. 76.6mg for those in which it was estimated).  
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For many of the methodological qualities assessed risk of bias was either low or unclear 
whilst a high risk of bias was attributed to the absence of random allocation of aspirin 
exposure (figure 26). No funnel plot asymmetry was found upon visual inspection of 
studies measuring the prevalence of AERD using oral provocation challenge tests 
(figure 27). 
 
 
Figure 26. Risk of bias table for included studies performing oral provocation challenge 
tests.  
High risk of bias relates mainly to the non-random administration order of placebo and aspirin. 
 
Comparison with previous evidence synthesis 
Table 8 lists the OPCT studies which were excluded from this systematic review on the 
basis of pre-specified selection criteria but which were included in the systematic 
review by Jenkins et al. along with the prevalence of AERD from each study. A total of 
five studies present in the systematic review by Jenkins et al. with an overall prevalence 
of AERD of 23.4% were excluded by our review because they did not meet the 
eligibility criteria in terms of FEV1 used to diagnose AERD, no use of blinding or 
placebo and using a population suspected of having AERD. The overall prevalence of 
AERD among three studies included in both reviews was 9.6% and the overall 
prevalence of AERD among new studies (or those previously unavailable to Jenkins et 
al.) was 10.2%. 
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Figure 27. Funnel plot for studies reporting falls in FEV1 of 20% or greater in AERD 
studies. 
SE(RD) = standard error of the risk difference.  
 
Table 8. Prevalence of aspirin-exacerbated respiratory disease among studies included and 
excluded in the systematic review by Jenkins et al. 
Studies Prevalence 
(%) 
No.  
Patients 
Included   
Rachelefsky 1975 12.0 50 
Spector 1979 9.0 189 
Vedanthan 1977 10.0 52 
Overall  9.6 291 
Excluded   
Delaney 1976 19.1 230 
Weber 1979 50.0 30 
Stevenson 1975 24.6 122 
Schuhl 1979 20.7 29 
Overall  23.4 411 
New*   
Ahmetaj 2009 9.0 172 
Fischer 1983 4.0 25 
Tarlo 1982 10.0 20 
Towns 1984 21.0 29 
Overall  10.2 246 
                                       *Or previously unavailable to Jenkins et al. (97). 
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4.5 Discussion 
The mean provocative dose of aspirin was around 89 mg. These doses are clinically 
relevant because guidelines recommending aspirin for the primary or secondary 
prevention of cardiovascular (CVS) disease advocate doses of 75 to 100mg. Indeed, 
several large randomised clinical trials are currently underway investigating the safety 
and efficacy of 100mg aspirin daily as primary prevention in people at increased CVS 
risk (177).  
 
It was not possible from this study to determine the prevalence of AERD triggered by 
different clinical doses of aspirin in order to quantify the potential risk reduction in 
using 75mg of aspirin compared to 100mg. However, individual susceptibility to aspirin 
varied considerably and potentially not all people with AERD will have adverse 
respiratory events triggered by low dose aspirin although more people would be 
expected to be symptomatic with higher doses such as those recommended in acute 
coronary syndrome (≥300 mg). Recommendations on the safe use of aspirin in the 
management of CVS disease typically consider the net clinical benefit where harms are 
heavily weighted towards risk of bleeding (gastrointestinal and intracranial). For people 
with asthma, the risk of adverse respiratory events in people with AERD should also be 
considered especially if aspirin becomes more widely prescribed as a putative anti-
cancer agent. 
 
The prevalence of AERD in asthma was found to be 9% in adults as determined by falls 
in FEV1 of 20% or greater using blinded, placebo-controlled oral provocation challenge 
tests and 9.6% as determined using population surveys reliant upon self-reported 
history. The previous systematic review of oral provocation challenge tests by Jenkins 
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et al. reported a prevalence of AERD affecting 21% of adults and 5% of children with 
asthma (97). That review included several oral provocation challenge test studies which 
were unblinded or uncontrolled potentially biasing the results. The systematic review by 
Jenkins et al. also included studies with heterogeneity in FEV1 values used to define 
positive reactions and studies in which some patients underwent oral provocation 
challenge tests for suspected AERD rather than using a general asthma population with 
unknown AERD status, potentially causing selection bias leading to the prevalence 
being overestimated.  
 
The study by Delaney et al. was not included because around half of people had a prior 
history of aspirin sensitivity (197). The study by Weber et al. was not included because 
it was an open label study performed in people suspected of having asthma triggered by 
aspirin (198). The study by Stevenson et al. was not included because of an unclear 
description of the oral challenge testing procedure performed although it did reference 
the methodology by McDonald et al implying a similar approach was taken. This study 
by McDonald et al. selected people on the basis of having a history of nasal polyps or 
chronic sinusitis, were challenged with a 320mg single dose of aspirin and reactions 
were considered positive if FEV1 fell by 50% or greater, criteria which would make it 
ineligible for this systematic review (99). Finally, the study by Schuhl et al. performed 
provocation challenge tests which were not subject to blinding, were uncontrolled and 
used changes in peak expiratory flow rather than FEV1 to determine a positive reaction 
(199).  
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Strengths and limitations 
The estimate for the prevalence of AERD based upon oral provocation challenge testing 
in this chapter is lower than in the previous systematic review because the approach I 
took aimed to minimise bias whilst also including additional studies not previously 
evaluated. These four additional studies had a similar overall prevalence to studies 
which were included in both systematic reviews. Although the systematic review of oral 
provocation studies which I undertook was designed to minimise bias, the oral 
provocation studies in this systematic review may still not truly be representative of the 
general asthma population as many studies involved people referred to specialist centres 
for the management of asthma. In which case, a prevalence of 10% may still be an 
overestimate.  
 
One included study estimating the prevalence of AERD using self-reported history also 
performed oral provocation challenge testing among a small number of respondents 
(200). Several people with a positive history of AERD subsequently had negative 
challenge tests and vice versa suggesting that the diagnosis of AERD by self-reporting 
can still be unreliable at an individual level. Despite these limitations and previous 
criticisms around the reliability of studies based upon self-reporting, the prevalence of 
AERD measured in this way was remarkably similar to that determined by oral 
provocation studies in our review. This demonstrates some degree of validity in using 
population surveys of self-reporting to determine the prevalence of AERD at a 
population level. When the prevalence of AERD measured by self-reporting was 
stratified by population type, those studies sampling people from the general population 
had a significantly lower prevalence of AERD compared to people evaluated from 
specialist centres. A possible explanation for this is that people with AERD appear to 
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have more severe asthma and be at increased risk of asthma morbidity compared to 
people with aspirin-tolerant asthma and people with AERD are more likely to be 
referred to specialist centres (200, 201). In addition, specialist centres may also be better 
at suspecting and testing for AERD. 
 
The prevalence of AERD among adults and children undergoing oral provocation 
challenge testing were also similar. Although usually considered to be more commonly 
a condition of adulthood, aspirin sensitivity has been known to cause severe reactions in 
children with AERD suggesting that development of chronic rhinosinusitis (a classical 
feature of AERD) is still an important factor when considering the diagnosis in younger 
people. In reality though, children are not generally exposed to aspirin due to concerns 
over Reyes’ syndrome and the main safety concern in this population is the prevalence 
of cross-reactivity to other NSAIDs which occurs in most aspirin-sensitive subjects if 
sufficient doses are administered (97). Only one randomised blinded placebo-controlled 
trial has evaluated the prevalence of NSAID sensitivity among children with asthma. 
This trial evaluated ibuprofen (10mg/kg) in 100 children (mean age 11 years) and 
reported a prevalence of ibuprofen sensitivity of only 2% (202). This trial excluded 
children with known ibuprofen sensitivity and included children who had previously 
used NSAIDs as long as exposure had not occurred within 24 hours of study entry thus 
potentially underestimating the true prevalence of AERD in patients. In this instance, 
the most appropriate study population in which to determine an unbiased estimate of 
ibuprofen sensitivity would have been children without any prior history of aspirin or 
NSAID exposure. Although our systematic review included oral provocation studies 
with non-random allocation of aspirin exposure, sensitivity analysis revealed no 
significant difference when compared suggesting that inclusion of these studies did not 
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bias the result. In contrast, respiratory symptoms were reported in non-randomised 
studies involving children only and bias in this setting is perhaps more difficult to 
assess. 
 
4.6 Summary 
On average, AERD was triggered by clinically relevant doses of aspirin suggesting that 
reasonably large numbers of people with asthma would potentially be at risk of adverse 
respiratory events associated with aspirin and NSAID exposure. The estimated 
prevalence of AERD as determined by falls in FEV1 of 20% or greater from blinded, 
controlled oral challenge tests was 9% in adults and 11% in children. The prevalence of 
AERD as determined through self-reported history was 9.6% in adults. The prevalence 
of AERD was higher among people referred to specialist centres. This supports the 
importance of investigating potential adverse respiratory effects associated with the 
prescribing of these drugs to people with asthma in the community using electronic 
primary health care records presented in chapter 9. The next chapter will focus upon 
quantifying whether selective NSAIDs and COX-2 inhibitors have different risk profiles 
among people with AERD using a systematic review and meta-analysis of controlled 
clinical trials. 
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Chapter 5: Acute Exposure to Selective 
NSAIDs or COX-2 Inhibitors in People 
with AERD: Systematic Review and 
Meta-Analysis of Controlled Clinical 
Trials 
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5.1 Introduction 
The systematic review reported in chapter 4 estimated the prevalence of aspirin-
exacerbated respiratory disease (AERD) among people with asthma from studies 
performing oral provocation challenge tests and surveys measuring self-reported 
history. Aspirin and other non-selective NSAIDs cause bronchoconstriction in 
susceptible people with asthma as a result of inhibiting the COX-1 enzyme which leads 
to increased levels of cysteinyl leukotrienes (94, 95). The systematic review by Jenkins 
et al. also measured cross-reactivity to other non-selective NSAIDs in people with 
aspirin-sensitivity. That review evaluated three studies meeting their inclusion criteria 
and found that the incidence of cross-reactivity was 98% for ibuprofen (at an oral dose 
of ≤400mg), 100% for naproxen (at an oral dose of ≤100mg) and 93% for diclofenac (at 
an oral dose of ≤40mg) (97). Reactions to aspirin and non-selective NSAIDs are thought 
to occur within several hours of ingestion forming the basis for oral provocation 
challenge testing. These reactions also commonly trigger upper respiratory symptoms 
including rhinorrhoea and nasal obstruction which may affect quality of life (172, 190, 
203). This has led to recommendations by regulatory agencies that all NSAIDs should 
be contraindicated in people with AERD which can be found on corresponding 
summaries of product characteristics. Without routine provocation testing, it is difficult 
to advise people with asthma on the safe use of non-selective NSAIDs unless they have 
already exposed themselves to an NSAID or aspirin. 
 
Selective NSAIDs and COX-2 inhibitors act through preferential inhibition of COX-2 
over COX-1, potentially leaving the balance between pro-inflammatory and anti-
inflammatory mediators unaltered and cysteinyl leukotriene levels unchanged (105). 
Therefore selective NSAIDs, COX-2 inhibitors, or both would be expected to have a 
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lower risk of adverse respiratory effects in people with AERD. However, the degree of 
COX1: COX-2 selectivity for NSAIDs varies between different drugs and selective 
NSAIDs are less selective than COX-2 inhibitors, especially at higher doses (204). 
Selective NSAIDs may be an attractive therapeutic option for people with AERD or in 
those people with asthma with an unknown AERD status who are unwilling to accept 
the risk from incident exposure when provocation challenge testing is not routinely 
available. Unlike cross-reactivity to non-selective NSAIDs, a systematic review has 
never been performed quantifying the degree of cross-reactivity to selective NSAIDs 
and COX-2 inhibitors in people with AERD. 
 
5.2 Aim 
The aim of this chapter was to assess the incidence of adverse respiratory events from 
clinical trials evaluating acute exposure to selective NSAIDs and COX-2 inhibitors in 
people with AERD in order to better inform their use. 
 
5.3 Methodology 
Search strategy and selection criteria 
The systematic review was conducted using methodology described in the general 
methods chapter (chapter 2, page 51). A pre-specified search strategy (appendix 1) was 
used to search MEDLINE, EMBASE and CENTRAL databases. The PICOS approach 
used in this chapter is described in table 9. Only studies evaluating oral selective 
NSAIDs and COX-2 inhibitors among people with AERD were included because cross-
reactivity to non-selective NSAIDs has already been well quantified and selective 
NSAIDs/COX-2 inhibitors are potentially a useful safe alternative. Only blinded 
placebo-controlled studies were included to minimise bias. 
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Table 9. PICOS approach used in the selective NSAID and COX-2 inhibitor systematic 
review. 
Population Included Patients with AERD 
 Excluded Patients without AERD, or with COPD
*
 or healthy patients 
Intervention Included Oral selective NSAID exposure 
 Excluded Topical or nasal exposure 
Comparator Included Placebo 
Outcomes Included Respiratory symptoms and falls in FEV1 ≥20% 
 Excluded Other measures of airway resistance  
Studies Included Controlled clinical trials in humans 
  Single or double-blinded 
         *Chronic obstructive pulmonary disease 
 
AERD was defined by respiratory reactions to aspirin or other non-selective NSAIDs in 
people with a history of asthma. For studies which evaluated selective NSAIDs or 
COX-2 inhibitors in mixed populations experiencing other types of NSAID-intolerant 
reactions (e.g. cutaneous reactions or angioedema) as well as respiratory reactions, only 
people with asthma were included in the analysis from the mixed population. 
 
Data processing and extraction 
Data processing and extraction followed the standard methodology set out in the general 
methods chapter (chapter 2, page 52). 
 
Data analysis 
Data analysis followed the standard methodology set out in the general methods chapter 
(chapter 2, page 53). The outcomes of interest were falls in FEV1 of 20% or greater and 
the incidence of respiratory symptoms presented as the risk difference (RD). 
Respiratory symptoms were defined as lower respiratory symptoms (consisting of 
wheezing, dyspnoea, or cough) and upper respiratory tract symptoms (consisting of 
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rhinorrhoea or nasal obstruction). This was done because upper respiratory reactions are 
common in AERD and may still affect quality of life even if lower respiratory reactions 
are absent. Subgroup analysis was performed evaluating the effect of not withholding 
leukotriene antagonists prior to oral provocation testing. This is because leukotriene 
antagonists theoretically may mask reactions from NSAIDs in AERD suggesting they 
are safe. Subgroup analysis was also performed evaluating whether trials were 
randomised because lack of randomisation may introduce bias. A fixed-effect method of 
analysis was used because no statistical heterogeneity was identified using the I
2
 test. 
 
Sensitivity analyses 
In addition to the standard subgroup sensitivity analyses assessing the definition of 
asthma and withholding beta2-agonists for at least 6 hours (chapter 2, page 63), further 
sensitivity analysis was performed evaluating whether diagnosis of AERD was based 
upon history or as a result of confirmatory challenge testing at the start of the trial.  
 
5.4 Results 
The same database search was used as in chapter 3 producing 1768 references from 
which 14 trials were included (figure 28). All 14 included trials provided data on lower 
respiratory tract symptoms, 12 provided data on falls in FEV1 of 20% or greater and 9 
provided data on upper respiratory tract symptoms. A total of 485 oral selective NSAID 
or COX-2 inhibitor acute exposures were evaluated in 426 adult patients with AERD 
(mean age, 46 years; 38% male). Celecoxib and rofecoxib were the most commonly 
evaluated COX-2 inhibitors, and meloxicam was the most commonly evaluated 
selective NSAID. All studies evaluated between one and four single-dose exposures 
performed over consecutive days.  
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Figure 28. PRISMA flow diagram for study selection in the selective NSAID and COX-2 
inhibitor systematic review. 
 
 
 
 
 
 
Records identified through 
database searching  
(n = 1762) 
Additional records identified 
through other sources  
(n =6) 
Records after duplicates removed  
(n = 1,297) 
Records screened  
(n = 1,297) 
Records excluded  
(n = 1,217) 
Full-text articles assessed 
for eligibility  
(n = 80) 
Studies included in 
quantitative synthesis  
(n = 14) 
Full-text articles excluded 
(n=66):  
No useable outcome = 12 
Other NSAID = 15 
Conference abstract = 8 
Exposure >1week = 6 
Not a clinical trial = 4 
No placebo = 4 
Not blinded = 6 
Prior response ineligible = 3 
Exposure ineligible = 3 
Not asthmatic = 3 
Post-exercise = 2 
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Characteristics of included studies are summarized in table 10. Three trials evaluated 
selective NSAIDs whilst twelve trials evaluated COX-2 inhibitors. Asthma was defined 
as per the methods chapter (chapter 2, page 61) in 2 trials evaluating selective NSAIDs 
and 7 trials evaluating COX-2 inhibitors. Short-active beta2-agonists were withheld at 
least 6 hours prior to testing in 1 trial evaluating selective NSAIDs and 4 trials 
evaluating COX-2 inhibitors. Leukotriene receptor antagonists were withheld in 1 trial 
evaluating selective NSAIDs and 4 trials evaluating COX-2 inhibitors. For selective 
NSAIDs: the dose of meloxicam evaluated ranged from 7.5mg to 15mg; the dose of 
nimesulide evaluated was 100mg; and the dose of nabumetone evaluated ranged from 
1000mg to 2000mg. For COX-2 inhibitors: the dose of rofecoxib evaluated ranged from 
25mg to 50mg; the dose of celecoxib ranged from 200mg to 400mg; and the dose of 
etoricoxib ranged from 60mg to 120mg. 
 
Challenge testing with COX-2 inhibitors 
Among people with AERD, no significant difference was found in falls in FEV1 of 20% 
or greater following placebo-controlled oral challenge testing with COX-2 inhibitors 
(RD 0.00 (95% CI -0.02 to 0.02) p=0.77, figure 29). Among people with AERD, no 
significant difference was found in the incidence of lower respiratory symptoms (RD -
0.01 (95% CI -0.03 to 0.01) p=0.57, figure 30) and upper respiratory symptoms (RD -
0.01 (95% CI -0.04 to 0.02) p=0.42, figure 31) following placebo-controlled oral 
challenge testing with COX-2 inhibitors. 
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 Table 10. Characteristics of included studies in the selective NSAID and COX-2 inhibitor systematic review. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a. Only patients with AERD selected from included studies. 
b. Whether or not studies defined asthma as per the general methods chapter (chapter 2, page 61). 
c. Whether or not studies withheld short-acting beta2-agonists (SABA) for at least 6 hours as per the general methods chapter (chapter 2, page 61). 
d. Whether or not studies withheld leukotriene antagonists. 
*COX-2 inhibitors (remaining unmarked drugs are classed as selective NSAIDs).    
 
Study 
(reference)
 
 
Design 
 
Patients
a
 
 
Asthma
b 
 
SABA
c
 
 
LKT
d
 
Selective NSAID  
or COX2 inhibitor  
Bavbek 2004 
13 
NR 31 Yes No No Meloxicam, nimesulide, rofecoxib* 
Bavbek 2007 
14 
NR 13
 
Yes Yes No Meloxicam 
El Miedany 2006 
17 
NR 77 Yes Yes No Etoricoxib* 
Gylfors 2003 
20 
R 33 No Yes Yes Celecoxib* 
Martin-Garcia 2002 
21 
NR 40 No No Yes Rofecoxib* 
Martin-Garcia 2003 
22 
NR 33 No No Yes Celecoxib* 
Micheletto 2006 
23 
NR 19 Yes Yes No Rofecoxib* 
Prieto 2007 
24 
NR 29 No No Yes Nabumetone, meloxicam 
Stevenson 2001 
27 
R 32 No No No Rofecoxib* 
Szczelkik 2001 
28 
NR 12 Yes Yes No Rofecoxib* 
Valero 2002*
 31 
NR 43 No No No Rofecoxib*  
Woessner 2002 
32 
NR 25 Yes No No Celecoxib* 
Woessner 2004 
33 
NR 22 Yes No No Rofecoxib* 
Yoshida 2000*
δ
 
34 
R 17 Yes No Yes Celecoxib* 
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Figure 29. Fall in FEV1 of 20% or greater following acute selective NSAID or COX-2 
exposure in patients with aspirin-exacerbated respiratory disease. 
 
 
Figure 30. Lower respiratory symptoms following acute selective NSAID or COX-2 
inhibitor exposure in patients with aspirin-exacerbated respiratory disease. 
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Figure 31. Upper respiratory symptoms following acute selective NSAID or COX-2 
exposure in patients with aspirin-exacerbated respiratory disease. 
 
Selective NSAIDs 
Among people with AERD, placebo-controlled oral challenge testing with selective 
NSAIDs caused a significant increase in lower respiratory symptoms (RD 0.08 (95% CI 
0.02 to 0.14), p=0.01) which equated to a number needed to treat of 13 to cause lower 
respiratory symptoms in 1 person with AERD. Effect sizes for falls in FEV1 of 20% or 
greater (RD 0.08 (95% CI -0.11 to 0.27), p=0.77) and nasal symptoms (RD 0.07 (95% 
CI -0.05 to 0.18), p=0.26) were similar in size but were not statistically significant 
(figures 29 to 31). 
 
Subgroup analyses 
Leukotriene antagonists. Among people with AERD, leukotriene antagonist exposure 
had no significant impact on effect estimates for falls in FEV1 of 20% or greater (RD 
0.00 (95% CI -0.02 to 0.02) for studies not withholding leukotriene antagonists versus 
0.00 (95% CI -0.03 to 0.03) for those which did), lower respiratory symptoms (RD 0.02 
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(95% CI -0.01 to 0.06) for studies not withholding leukotriene antagonists versus 0.01 
(95% CI -0.02 to 0.03) for those which did) or upper respiratory tract symptoms (RD 
0.05 (95% CI -0.05 to 0.14) for studies not withholding leukotriene antagonists versus   
-0.01 (95% CI -0.05 to 0.02) for those which did). 
 
Random allocation of exposure. Among people with AERD, random allocation of 
exposure had no significant impact on falls in FEV1 of 20% or greater (RD 0.00 (95% 
CI -0.02 to 0.02) for both randomised and non-randomised studies), lower respiratory 
tract symptoms (RD 0.01 (95% CI -0.01 to 0.03) for non-randomised studies versus 
0.00 (95% CI -0.02 to 0.02) for randomised) or upper respiratory tract symptoms (RD 
0.00 (95% CI -0.03 to 0.02) for non-randomised studies versus -0.05 (95% CI -0.13 to 
0.03) for randomised). 
 
Sensitivity analyses and risk of bias 
The definition of asthma as per the general methods chapter appeared to have no 
significant influence on the risk difference for falls in FEV1 of 20% or greater (RD 0.00 
(95% CI -0.03 to 0.03) for studies which met this definition versus 0.00 (95% CI -0.02 
to 0.02) for those which did not), lower respiratory tract symptoms (RD 0.01 (95% CI   
-0.02 to 0.04) for studies which met this definition versus 0.02 (95% CI -0.01 to 0.04) 
for those which did not) or upper respiratory tract symptoms (RD 0.00 (95% CI -0.03 to 
0.03) for studies which met this definition versus -0.01 (95% CI -0.07 to 0.05) for those 
which did not). 
 
Withholding SABA for at least 6 hours prior to oral challenge testing appeared to have 
no significant influence on the risk difference for falls in FEV1 of 20% or greater (RD 
0.00 (95% CI -0.03 to 0.03) for studies which withheld SABA versus 0.00 (95% CI       
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-0.02 to 0.02) for those which did not), lower respiratory tract symptoms (RD -0.01 
(95% CI -0.04 to 0.03) for studies which SABA versus 0.02 (95% CI -0.00 to 0.03) for 
those which did not) or upper respiratory tract symptoms (RD 0.02 (95% CI -0.06 to 
0.10) for studies which withheld SABA versus  -0.01 (95% CI -0.04 to 0.02) for those 
which did not). 
 
The definition of AERD determined by history of testing or by oral provocation testing 
at the beginning of the trial appeared to have no significant influence on the risk 
difference for falls in FEV1 of 20% or greater (RD 0.00 (95% CI -0.02 to 0.02) for 
studies which relied upon prior history of testing versus 0.00 (95% CI -0.03 to 0.03) for 
those which performed oral provocation testing at the beginning of the trial), lower 
respiratory tract symptoms (RD 0.01 (95% CI -0.01 to 0.03) for studies which relied 
upon prior history of testing versus 0.01 (95% CI -0.02 to 0.05) for those which 
performed oral provocation testing at the beginning of the trial) or upper respiratory 
tract symptoms (RD 0.00 (95% CI -0.09 to 0.09) for studies which relied upon prior 
history of testing versus 0.00 (95% CI -0.04 to 0.03) for those which performed oral 
provocation testing at the beginning of the trial). 
 
No significant heterogeneity was found using the I
2
 statistic. For the methodological 
qualities assessed risk of bias was either low or unclear when studies failed to provide 
explicit detail from which to make an informed judgement. A high risk of bias was 
detected related to the lack of random allocation of exposure in some studies which did 
not appear to influence the effect estimates when the above subgroup analysis was 
performed (figure 32). No funnel plot asymmetry was observed to suggest publication 
bias (figure 33).  
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Figure 32. Risk of bias table for included studies in the selective NSAID and COX-2 
inhibitor systematic review.  
High risk of bias mainly relates to non-random administration order of placebo and NSAID. 
 
 
 
 
Figure 33. Funnel plot for all studies reporting falls in FEV1 of 20% or greater following 
oral selective NSAIDs and COX-2 inhibitors.  
SE(RD) = standard error of the risk difference. 
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5.5 Discussion 
In this meta-analysis, COX-2 inhibitors did not cause any significant adverse respiratory 
effects compared to placebo in people with AERD. In contrast a small but statistically 
significant risk of lower respiratory tract reactions occurred with selective NSAIDs in 
approximately 1 in 13 patients with AERD. Assuming a prevalence of AERD of around 
10%, this would equate to selective NSAIDs causing lower respiratory symptoms in 
approximately 0.8% of the general asthmatic population, whereas COX-2 inhibitors 
appear safe to use.  
 
Compared to non-selective NSAIDs, selective NSAIDs evaluated in this chapter have at 
least 10-fold more selectivity for COX-2 than COX-1. Although COX-2 inhibitors are 
generally considered to be more than 100 times more selective for COX-2 in human 
subjects celecoxib has been shown in one study to have a COX-2/COX-1 selectivity 
ratio similar to meloxicam and nimesulide as determined using a human whole blood 
assay (205). However, this is in contrast to data derived using recombinant human 
COX-1 and COX-2 where celecoxib was between 155- and 3,200-fold more selective 
for COX-2 than COX-1 (206). 
 
In people with AERD, cysteinyl leukotriene levels typically increase during NSAID-
induced reactions, and theoretically may be attenuated by exposure to leukotriene 
antagonists. As such, failure to discontinue such medications at the time of oral 
challenge testing could potentially mask or underestimate the true risk from selective 
NSAID or COX-2 inhibitor exposure. This study demonstrated that COX-2 inhibitors 
appear safe even when exposure to leukotriene receptor antagonist was withheld.  
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Strengths and limitations 
The systematic review reported in this chapter is the largest evaluation of clinical trial 
evidence on the safety of selective NSAIDs and COX-2 inhibitors in people with 
AERD. Only blinded placebo-controlled studies were included in order to minimise 
bias. Although not all studies randomly allocated NSAID exposure as part of their 
challenge test procedures (potentially introducing bias), subgroup analysis between 
randomised and non-randomised studies led to the same conclusions. The studies 
included in this systematic review predominantly evaluated selective NSAIDs or COX-
2 inhibitors in people with AERD who had stable, mild to moderate asthma. As such the 
results from this meta-analysis may not be applicable to patients with unstable asthma 
or in those who have experienced severe life-threatening reactions requiring intubation 
following aspirin or NSAID exposure (207). In this regard, subclinical effects are more 
likely to become evident in people with poorly controlled asthma when only small 
changes in levels of cysteinyl leukotrienes may precipitate bronchospasm. Therefore it 
would be safest for people to commence these agents for the first time following 
optimisation of their asthma. 
 
This analysis was restricted to include only people with asthma who had documented 
aspirin or NSAID respiratory intolerance. Therefore these results may not be applicable 
to people suffering other types of NSAID-induced reactions including anaphylaxis, 
angioedema or cutaneous reactions. Although anaphylactic reactions to COX-2 
inhibitors have been reported, these events are rare and possibly distinct to isolated 
respiratory or nasal reactions commonly encountered by AERD patients (208). In a 
similar fashion, the occurrence of cutaneous reactions with selective NSAIDs or COX-2 
inhibitors in people with AERD has not been evaluated although cross-reactivity with 
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these agents is believed to be low. This systematic review evaluated moderate doses of 
selective-NSAIDs or COX-2 inhibitors administered during oral challenge testing and 
the possibility of reactions occurring following acute high-dose exposure cannot be 
excluded since selectivity is at least partly dose dependent for some drugs. As such, safe 
initiation of COX-2 inhibitors in people with AERD is initially likely to involve a low 
dose with gradual dose titration. 
 
5.6 Summary 
According to the available clinical trial evidence, COX-2 inhibitors appear safe to use in 
people with asthma and AERD whilst selective NSAIDs cause respiratory symptoms in 
around one in 13 people. The use of COX-2 inhibitors could therefore provide a safe 
and effective means to anti-inflammatory and analgesic treatment in people with asthma 
who have true AERD or in those people unwilling to accept the potential risk from non-
selective NSAID exposure when oral challenge tests are not routinely available. As with 
many clinical trials however, this evidence comes from a selected population and 
generalising these results to all people with asthma is difficult especially if adverse 
respiratory effects are rare. For this reason, there is still a need to evaluate risk from 
NSAIDs prescribed to a large general population with asthma which could be achieved 
through the analysis of routine health data to ensure the results have external validity 
and are generalizable. The results of these analyses are reported in chapter 9. The next 
chapter will define the clinical practice research datalink (CPRD) asthma cohort and 
measure the incidence of asthma events and prevalence of beta-blocker and NSAID 
prescribing over a twelve year period. This cohort will form the basis for subsequent 
observational studies reported in chapters 7 to 9. 
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Chapter 6: Clinical Practice Research 
Datalink Cohort, Incidence of Asthma 
Events, and Drug Utilisation Studies 
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6.1 Introduction 
The electronic primary care data used in this thesis comes from CPRD which contains 
electronic medical records from over 680 UK general practices, with approximately 
50% of English CPRD practices additionally linked to the HES database of 
hospitalisation. Measures of disease occurrence calculated using CPRD data are 
considered broadly similar to other UK population-based sources. In a study by Booth 
et al., smoking prevalence estimates for adults over 30 years of age were compared in 
CPRD and the Health Survey for England between 2007 and 2011, and differences in 
current and non-smoking estimates occurred in <1% of people (209).  In contrast 
outcome events may be underestimated using CPRD general practice data alone. In a 
study by Herrett et al., although risk factors had a similar prevalence among people 
identified in CPRD, HES and other registry sources (such as ONS and the Myocardial 
Ischaemia National Audit Project, MINAP), relying solely on CPRD underestimated the 
incidence of acute myocardial infarction by around 25% compared to an approach using 
linked health records (210). This highlights the importance of using linked healthcare 
data to avoid biased estimates. 
 
The pharmacoepidemiological studies in this thesis use a cohort of people with active 
asthma with cohort entry defined by both Read Coding for asthma and prescriptions for 
asthma medication. The validity of these studies relies in part on accurate outcome 
ascertainment. One way of checking this is to compare the incidence of outcomes using 
linked healthcare data in CPRD with national statistics. Measuring the incidence of 
asthma morbidity and mortality will also allow a better appreciation of the attributable 
risk associated with the exposures of interest. In the context of this thesis, identifying 
significant risk factors for asthma exacerbations using linked healthcare data from 
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CPRD will guide the choice of confounders used for statistical adjustment in subsequent 
analysis. Finally, understanding patterns of drug utilisation are an important part of 
pharmacovigilance by providing a better appreciation of the population at risk and how 
generalizable these results may be to real life clinical practice. 
 
6.2 Aim 
The aim of this chapter was to provide background to subsequent chapters by describing 
the CPRD active asthma cohort, and in this cohort: 
1. Calculating incidence rates for asthma morbidity and mortality  
2. Identifying risk factors for asthma events and potential confounders 
3. Examining beta-blockers and NSAID drug utilisation. 
 
6.3 CPRD Cohort 
6.3.1 CPRD cohort - methodology 
The CPRD active asthma cohort is described in chapter 2 (page 66). In summary, active 
asthma was defined by Read Codes for asthma (appendix 2) recorded in the patient’s 
electronic medical record and by prescriptions for asthma medication. The cohort 
consisted of people aged ≥18 present in CPRD from 1 January 2000 to 31 December 
2011. Subjects were eligible for cohort entry if they were permanently registered with a 
general practice for at least one year, were defined by CPRD as being acceptable for use 
in research, had a Read Code for asthma recorded ever, and were issued two or more 
prescriptions for asthma medications during their period of registration. An open cohort 
design was used and cohort entry was defined as the date of the first asthma medication 
occurring on or after: 1st January 2000; the patient’s 18th birthday; or before the 
patient’s 80th birthday. Asthma medications were defined as: inhaled short-acting 
150 
 
beta2-agonists (SABA); inhaled corticosteroids (ICS); inhaled long-acting beta2-
agonists (LABA); oral leukotriene antagonists; and oral methylxanthines. Prescriptions 
for asthma medication were included in the definition to identify patients with active 
asthma during follow-up. All patients in the cohort were followed up until the first of: 
an asthma event; deregistration from the practice; one year following the last asthma 
medication prescription; or end of the study period (31 December 2011). Patients 
recorded with the following at any point in their electronic medical record or Hospital 
Episodes Statistics (HES) database were excluded from the cohort: chronic obstructive 
pulmonary disease (COPD); restrictive lung diseases; and bronchiectasis. Patients 
prescribed immunosuppressant therapy or with a record of polymyalgia rheumatica 
were excluded. Characteristics of the active asthma cohort were calculated using means 
(standard deviation, SD) for continuous variables and numbers (percentage, %) for 
categorical variables. 
 
6.3.2 CPRD cohort - results 
Figure 34 shows how the active asthma cohort was defined by the application of these 
criteria. A total of 573276 potentially eligible adult patients with a Read Code for 
asthma and two or more prescriptions for asthma medications during the period of 
follow-up (active asthma) were identified from CPRD. Of these, 84259 patients (14.7%) 
were excluded because of comorbidity (COPD, bronchiectasis or restrictive lung 
disease), 4873 patients (0.9%) were excluded because of immunosuppressant use and 
202190 patients (35.3%) were excluded because they were not linked to the HES 
database of hospitalisation. Characteristics of the active asthma cohort are shown in 
table 11. The active asthma cohort consisted of 281954 eligible adult patients with mean 
follow up of 3.0 years per patient
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Figure 34. Flow diagram showing derivation of the active  
asthma cohort.   
Adult patients coded  
with asthma  
(n=573276) 
After deletion for  
comorbidity  
(n=489017) 
Comorbidity* 
(n= 84259) 
 
After deletion for 
immunosuppressant use             
(n= 484144) 
Immunosuppressant  
use / PMR (n= 4873) 
After deletion for  
HES/ONS linkage 
(n= 281954) 
Not HES/ONS linked 
(n= 202190) 
 
 
 
Characteristic No. patients 
Mean years of follow up (SD) 3.0 (3.3) 
Mean age at baseline (SD) 38.5 (16.1) 
Baseline age category (%)  
 18-29 98882 (35.1) 
 30-39 65092 (23.1) 
 40-49 47231 (16.8) 
 50-59 33016 (11.7) 
 60-69 23698 (8.4) 
 >=70 14035 (5.0) 
Gender (%)  
 Male 119008 (42.2) 
 Female 162946 (57.8) 
Smoking Status (%)  
 Current 61730 (21.9) 
 Ex 64347 (22.8) 
 Never 128088 (45.4) 
 Missing  27789 (9.1) 
Previous hospitalisation* (%) 7497 (2.7) 
Mean BMI (SD) 26.2 (7.8) 
*Ever been hospitalised for asthma at cohort entry 
Mean BMI based on 222589 patients (79.0%) with baseline data. 
 
Table 11. Baseline patient characteristics for the active asthma cohort. 
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The mean age at cohort entry was 38.5 years and there were more women than men in 
the cohort (57.8% vs. 42.2% respectively). Baseline data on smoking status and body 
mass index (BMI) were missing for 9.9% and 21.0% of patients respectively. 
 
6.3.3 CPRD cohort - discussion 
The active asthma cohort had more women than men, consistent with the established 
epidemiology where women have both a higher incidence and prevalence of asthma. A 
population based study from Finland involving 4300 people reported a higher 
prevalence of asthma in women compared to men (211). A UK population based study 
reported higher age-standardized rates of asthma for women compared to men (5.6 vs. 
4.8 per 1000 person years for the year 2005) whilst another UK population based study 
using CPRD data demonstrated consistently higher primary care consultation rates for 
asthma in adult women than men (29, 212).  
 
Approximately 87% of patients from the CPRD active asthma cohort were under the 
age of 60. Although excluding people coded with comorbidities may have influenced 
these figures, they are still in keeping with the current epidemiology showing a greater 
prevalence of asthma in younger than older people (212). People with comorbidities 
were excluded in order to avoid misclassification with other diseases where risk from 
beta-blockers or NSAIDs is reduced or absent which would underestimate risk in 
subsequent analyses. In the CPRD active asthma cohort, 45% of patients with asthma 
were non-smokers, 23% were ex-smokers and 22% were current smokers at baseline. 
This distribution of smoking status is comparable with data from the Finnish population 
based study in which 49% of people with asthma were non-smokers, 19% were ex-
smokers and 24% were current smokers (211). These baseline characteristics are 
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comparable providing some validity that the CPRD asthma cohort is broadly 
representative of people with asthma, albeit those with active asthma, important for 
subsequent analyses in this thesis. 
 
6.4 Incidence of asthma outcomes 
6.4.1 Incidence of asthma outcomes - methodology  
The incidence of asthma deaths, hospitalisations and primary care asthma exacerbations 
(PCAE) were calculated among people from the active asthma cohort linked to the ONS 
and HES databases for complete outcome assessment. The incidence of asthma death, 
asthma hospitalisation recorded in the primary position in death certificates and hospital 
discharges, and oral steroids for asthma was estimated for the active asthma cohort by 
dividing the total number of events occurring during the study period by the total person 
years of follow up for each type of event, with 95% confidence intervals (95% CIs) 
based on the Poisson distribution. For the purpose of this analysis, oral steroids for 
asthma were defined as any prednisolone prescription containing ≥5mg strength tablets 
with the assumption that prescriptions issued within 14 days of the previous prescription 
were for the same PCAE and were counted only once. 
 
For each type of event, the overall incidence was estimated stratified by age and gender. 
The incidence of asthma death was calculated per 10,000 person-years of follow up and 
the incidence of asthma hospitalisation and primary care asthma exacerbations was 
calculated per 1,000 person-years of follow up. The yearly incidence for each outcome 
of interest was then stratified by gender. Because the observed rates for the population 
may differ according to age, direct standardisation was used to control for any changes 
in the age structure of the active asthma cohort over the 12 year observation period. In 
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this regard, the European standard population was used to estimate directly age-
standardised rates. Directly standardised incidence rates were obtained by first 
estimating the age-specific event rate for each year and gender. The event rate for each 
age category per year was then multiplied by the European standard population of the 
corresponding age category to generate the expected number of events. The expected 
number of events was then summed for each year and then divided by the European 
standard population for of all age groups to provide the standardised rate for each year. 
The absolute change in incidence of events during the 12 year period was determined by 
subtracting the incidence of events in the year 2000 from the incidence of events in the 
year 2011, with 95% CIs. Incidence rates were calculated in STATA v.13.  
 
6.4.2 Incidence of asthma outcomes - results 
Among the 281954 patients within the active asthma cohort, a total of 142 asthma 
deaths and 7511 asthma hospitalisations occurred with an overall incidence 1.5 (95% CI 
1.3 to 1.8) per 10,000 person-years and 7.8 (95% CI 7.6 to 7.9) per 1,000 person-years 
respectively (table 12). Among the 281954 active asthma patients, a total of 287518 oral 
steroid prescriptions were issued. To prevent clustering, whereby multiple oral steroid 
prescriptions may be issued to treat the same PCAE, oral steroid prescriptions issued 
within 14 days of each other were assumed to be related to the same asthma 
exacerbation and deleted. A total of 248143 oral steroid prescriptions remained giving 
an overall incidence of 259.1 (95% CI 258.0 to 260.1) per 1,000 person-years. Of these 
248143 prescriptions, 22874 (9.2%) consisted of either 1 mg or 2.5 mg strength 
prednisolone tablets rarely used for the management PCAE in adults. After exclusion of 
these prescriptions, the overall incidence of PCAE was 235.3 (95% CI 234.3 to 236.2) 
per 1,000 person-years.  
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Table 12. Incidence of asthma death, asthma hospitalisation, and primary care asthma 
exacerbation. 
 
 
 
 
 
 
 
 
 
Death = per 10,000 person-years. Hospitalisation = per 1,000 person-years.  
PCAE = primary care asthma exacerbation, per 1,000 person-years. 
 
The incidence of asthma events stratified by age and gender are shown in table 12. The 
incidence of asthma death, asthma hospitalisation and PCAE were higher in women 
than men. The incidence of asthma death increased with age and was highest in patients 
aged 70 and over (incidence 4.8 (95% CI 3.9 to 5.8) per 10,000 person-years vs. 0.3 
(95% CI 0.1 to 0.6) per 10,000 person years for patients aged between 18 and 29). In 
contrast, the incidence of asthma hospitalisation fell with age, being lowest in patients 
aged 70 and over (incidence 4.8 (95% CI 4.5 to 5.1) per 1,000 person years vs. 11.4 
(95% CI 11.1 to 11.8) per 1,000 person-years for patients aged between 18 and 29). 
Similar to asthma deaths, the incidence of PCAE increased with age and was highest in 
patients aged 70 and over (incidence 354.6 (95% CI 352.0 to 357.1) per 1,000 person-
years vs. 150.1 (95% CI 148.9 to 151.3) per 1,000 person years for patients aged 
between 18 and 29).  
 
 
Characteristic 
Death 
(95%CI) 
Hospitalisation 
(95%CI) 
PCAE  
(95%CI) 
Gender    
  Men 1.36 (1.02-1.78) 5.5 (5.3-5.7) 186.5 (185.2-187.9) 
  Women 1.86 (1.49-2.30) 9.4 (9.2-9.7) 271.0 (269.6-272.4) 
Age    
  18-29 0.32 (0.14-0.63) 11.4 (11.1-11.8) 150.1 (148.9-151.3) 
  30-39 0.68 (0.45-1.00) 9.0 (8.7-9.3) 190.2 (188.8-191.6) 
  40-49 1.41 (1.06-1.83) 7.9 (7.7-8.2) 236.5 (234.9-238.0) 
  50-59 1.45 (1.06-1.95) 5.4 (5.1-5.7) 271.8 (269.9-273.7) 
  60-69 1.85 (1.35-2.46) 5.2 (4.9-5.4) 292.5 (290.4-294.7) 
  >=70 4.80 (3.91-5.84) 4.8 (4.5-5.1) 354.6 (352.0-357.1) 
Overall 1.50 (1.26  -1.78) 7.8 (7.6-7.9) 235.3 (234.3-236.2) 
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The directly age-standardised rates of asthma death, asthma hospitalisation and PCAE 
between 2000 and 2012 are shown in table 13. Over the 12 year period, the incidence of 
asthma death did not significantly change (incidence 1.8 (95% CI 1.1 to 2.5) per 10,000 
person-years in 2000 compared to 0.8 (95% CI 0.4 to 1.3) per 10,000 person-years in 
2011, figure 35). The incidence of asthma hospitalisation initially fell in 2001 and then 
steadily rose from a low of 6.3 (95% CI 5.7 to 6.9) per 1,000 person-years in 2001 to 
9.3 (95% CI 8.6 to 10.0) per 1,000 person-years in 2011, a significant relative rise of 
47.6% (95% CI 27.0 to 68.3) per 1,000 patient years. The rising incidence of asthma 
hospitalisation was more pronounced in women than men, with a significant relative 
rise of 54.0% (95% CI 36.8 to 72.4) per 1,000 patient years for women vs. a significant 
relative rise of 31.9% (95% CI 10.6 to 55.3) per 1,000 person-years in men (figure 36). 
 
The incidence of PCAE initially fell in 2001 and then rose from a low of 195.3 (95% CI 
192.2 to 198.5) per 1,000 person-years in 2001 to 249.4 (95% CI 245.9-253.0) per 1,000 
person-years in 2011, a significant relative rise of 27.7% (95% CI 24.3 to 31.1) per 
1,000 person-years (table 13). Again, the rising incidence of PCAE was more 
pronounced in women than men, with a significant relative rise of 32.3% (95% CI 29.0 
to 35.6) per 1,000 person-years in women vs. a significant relative rise of 20.2% (95% 
CI 16.5 to 23.8) per 1,000 person-years in men, between 2001 and 2011 (figure 37). 
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Table 13. Directly age-standardised incidence of asthma death, asthma hospitalisation and primary care asthma exacerbations. 
 
Death = per 10,000 person-years. Hospitalisation = per 1,000 person-years.  
PCAE = primary care asthma exacerbation, per 1,000 person-years. 
 Incidence in women (95%CI) Incidence in men (95%CI) 
Year Death Hospitalisation PCAE Death Hospitalisation PCAE 
 2000 1.01 (0.40-2.00) 9.9 (9.2-10.6) 231.7 (228.3-235.2) 2.50 (1.50-3.90) 5.7 (5.2-6.3) 183.8 (180.8-186.9) 
 2001 1.19 (0.50-2.20) 7.6 (7.0-8.2) 217.4 (214.1-220.7) 0.88 (0.30-1.80) 4.7 (4.2-5.2) 166.3 (163.4-169.2) 
 2002 1.78 (0.90-3.00) 7.9 (7.3-8.6) 231.8 (228.4-235.3) 2.43 (1.40-3.80) 4.4 (4.0-4.9) 177.6 (174.6-180.6) 
 2003 1.33 (0.60-2.40) 9.4 (8.7-10.1) 236.7 (233.3-240.1) 1.27 (0.60-2.30) 5.4 (4.9-6.0) 167.6 (164.7-170.5) 
 2004 1.94 (1.00-3.10) 9.4 (8.7-10.1) 236.8 (233.4-240.3) 0.60 (0.20-1.40) 6.1 (5.5-6.6) 174.9 (171.9-177.9) 
 2005 0.65 (0.20-1.40) 10.0 (9.3-10.7) 250.7 (247.1-254.2) 1.74 (0.90-2.90) 6.2 (5.7-6.8) 176.3 (173.4-179.3) 
 2006 1.58 (0.80-2.70) 9.6 (8.9-10.3) 252.0 (248.4-255.5) 1.10 (0.50-2.10) 5.3 (4.8-5.8) 176.4 (173.4-179.3) 
 2007 1.09 (0.50-2.10) 10.8 (10.0-11.5) 274.6 (271.0-278.3) 1.65 (0.80-2.80) 6.0 (5.4-6.5) 196.1 (193.0-199.2) 
 2008 0.91 (0.40-1.80) 12.2 (11.4-13.0) 290.5 (286.7-294.3) 0.54 (0.10-1.30) 5.9 (5.3-6.4) 203.8 (200.6-207.0) 
 2009 0.72 (0.20-1.60) 11.5 (10.8-12.3) 282.5 (278.8-286.3) 1.10 (0.50-2.10) 5.6 (5.1-6.1) 196.5 (193.4-199.6) 
 2010 2.32 (1.40-3.60) 10.7 (10.0-11.4) 287.6 (283.8-291.4) 1.49 (0.70-2.60) 5.1 (4.7-5.7) 203.9 (200.8-207.1) 
 2011 0.84 (0.30-1.80) 11.7 (11.0-12.5) 287.2 (283.4-291.0) 0.74 (0.20-1.60) 6.2 (5.7-6.8) 199.9 (196.7-203.0) 
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Figure 35. Direct age-standardised incidence of asthma death 2000 to 2012. 
 
 
Figure 36. Direct age-standardised incidence of asthma hospitalisation 2000 to 2012. 
 
 
Figure 37. Direct age-standardised incidence of PCAE 2000 to 2012.
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6.4.3 Incidence of asthma outcomes - discussion 
The incidence of asthma death in the CPRD active asthma cohort was 1.5 per 10,000 
person-years, increased with age and remained fairly level over the study period. 
National statistics such as those available from the Scottish Public Health Observatory 
in Scotland and the Office for National Statistics in England report death statistics for 
asthma. In England in 2013, 344 adult asthma deaths occurred in men and 742 in 
women however no death rate was provided to directly compare (213). In Scotland in 
2012, 20 asthma deaths occurred in men and 69 in women with an overall asthma death 
rate of 1 per 100,000 in men and 3 per 100,000 total population in women (45). 
However, the denominator used for the 2012 Scottish death rate was the general 
population as opposed to an asthma population so direct comparison is again not 
possible. Despite these limitations national statistics from both England and Scotland 
show strong associations between increasing age and increasing numbers of asthma 
deaths. A large UK study describing trends in asthma events from 1955 to 2004 also 
demonstrated increasing asthma death rate with age. In that study asthma death rate 
among people aged 15 to 44 was approximately 0.6 per 100,000 person years compared 
to approximately 12 per 100,000 person years in people aged 65 years and over. 
Similarly, the recently published National Review of Asthma Deaths in the UK also 
demonstrated that asthma death was more common among older adults (56).  
 
The overall incidence of asthma hospitalisation in the CPRD active asthma cohort was 
7.8 per 1,000 person-years. The incidence of asthma hospitalisation was higher in 
women than men, increased over the study period (particularly in women) and fell 
significantly with increasing age. From 2011 to 2012, 40243 asthma hospitalisations 
occurred in the UK in people aged 15 years and over (56). In Scotland from 2012 to 
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2013, the incidence of asthma hospitalisation in men and women was 51.1 and 70.2 per 
100,000 population respectively and consistently higher for women as seen with the 
CPRD active asthma cohort (40). However, Scottish rates defined incidence as first 
hospital admission for asthma without a previous hospital admission for asthma and 
therefore do not account for multiple admissions for the same individual making direct 
comparisons difficult. Other Scottish national statistics have reported an incidence of 
asthma hospitalisation for 2011 to 2012 of 152 per 100,000 population (which includes 
all ages and genders) (214). Meanwhile, a study investigating the effectiveness of ICS at 
preventing asthma hospitalisation in Canada reported a higher incidence of asthma 
hospitalisation of 42.4 per 1,000 asthma patients per year although this was for a 
population aged 5 to 44 years in which the incidence of asthma hospitalisation is also 
known to be greater (215).  
 
The rate of asthma hospitalisation in the CPRD active asthma cohort increased between 
2001 and 2011 by around 54% for women and 32% for men. In comparison, the 
incidence of asthma hospitalisation (defined as first ever admission with asthma) rose 
by 122% in Scotland between 1981 and 1997, again with greater increases in women 
than men (143% vs. 101%) (37). Data from HES in England also confirms the increased 
asthma hospitalisation rate in women compared to men and among younger people with 
asthma compared to older people. 
 
The overall incidence of PCAE in the CPRD active asthma cohort was 235.3 per 1,000 
person years. The incidence of PCAE was higher in women than men, increased 
significantly with increasing age and increased over the study period. Over this period, 
national statistics for the urgent management of asthma in primary care have not been 
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produced so no figures are available for comparison. It is possible that the incidence of 
PCAE measured in this chapter is an overestimate because steroids have a wide range of 
uses in primary care (although the selection criteria were intended to minimise this), but 
whether or by how much any overestimation has occurred is uncertain. 
 
In many instances direct comparisons with national statistics were not possible because 
different denominators were used, although changing patterns according to age and 
gender are reassuringly similar. It should therefore be highlighted that the incidence of 
asthma hospitalisation and PCAE appear to be increasing particularly in women, and 
future research to further examine the reasons for these increases is required. 
 
6.5 Risk factor assessment 
6.5.1 Risk factor assessment - methodology 
A nested case-control study was used to determine risk factors for each asthma event as 
previously defined (chapter 2, page 70), in order to inform the subsequent modelling. 
For asthma deaths and hospitalisations, up to 10 controls were randomly selected and 
matched to each case on calendar year of cohort entry and whether patients were 
diagnosed with asthma before the age of 45 using incidence density sampling. For 
PCAEs, up to 4 controls were randomly selected in the same manner, the smaller 
number reflecting that there were many more individuals with PCAE reducing the 
potential pool of controls. The date of the risk set was the index date for the cases and 
subjects were eligible to be used as controls in multiple sampled risk sets. For all cases 
and controls, information was obtained on age, gender, social deprivation (as measured 
by the index of multiple deprivation), BMI, smoking status, Charlson comorbidity 
score, asthma medication, primary care asthma reviews, history of nasal polyps, chronic 
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rhinosinusitis, urticaria, allergy, anxiety, respiratory tract infections and previous 
asthma hospitalisation. Exposure to asthma medication was based upon prescriptions 
issued within 90 days of the index date. 
 
Multiple imputation with fully conditional specification was used to impute missing 
data on height, weight and smoking status. The nested case control study was analysed 
as per the general methods chapter (chapter 2, page 70). In summary, Chi-squared test 
and analysis of variance was used to determine significant differences between 
categorical and continuous patient characteristics respectively. Multivariate conditional 
logistic regression using a fully saturated model was used to compute adjusted 
incidence rate ratios (IRR) for selected risk factors assessed using a 90 day risk window.  
 
6.5.2 Risk factor assessment - results 
Asthma deaths 
Table 14 describes the characteristics of 142 cases of asthma death and their 1420 
controls. Cases died of asthma at a mean age of 60 years and were more likely to be 
women (62%). Cases were significantly older than controls and had significantly higher 
use of LABAs, leukotriene antagonists, methylxanthines, oral steroids and SABAs in 
the 90 days prior to the index date. There were significantly more current smokers and 
significantly fewer ex-smokers and non-smokers among cases than controls. Cases were 
significantly more likely to have: been hospitalised for asthma in the past; had a RTI in 
the 90 days before index date; a lower BMI; and a higher Charlson co-morbidity score.  
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Table 14. Characteristics of patients for the analysis of asthma deaths in the risk factor 
analysis. 
 
Characteristics 
Cases 
N=142 
Controls 
N=1420 
 
p-value 
Age (years) 60.0 (17.3) 54.0 (16.5) 0.000* 
Female gender 88 (62.0) 871 (61.3) 0.882 
Asthma medication in the last 90 days    
 ICS 61 (43.0) 628 (44.2) 0.772 
 LABA 27 (19.0) 142 (10.0) 0.001 
 LABAICS 33 (23.2) 289 (20.4) 0.447 
 Leukotriene antagonist 8 (5.6) 44 (3.1) 0.108 
 Methylxanthine  15 (10.6) 31 (2.2) 0.000 
 Mean no. of SABA prescriptions 2.5 (2.5) 1.1 (1.3) 0.000* 
 Oral steroid 49 (34.5) 105 (7.4) 0.000 
Comorbidity    
 Nasal polyps 10 (7.0) 68 (4.8) 0.240 
 Urticaria 6 (4.2) 79 (5.6) 0.543 
 Allergy 41 (28.9) 391 (27.5) 0.734 
 Anxiety¥ 5 (3.5) 30 (2.1) 0.280 
 Mean BMI (SD) 26.1 (5.3) 28.0 (6.1) 0.001* 
 Mean Charlson co-morbidity score 1.8 (1.3) 1.5 (1.1) 0.002* 
Smoking status    
 Current smoker 32 (22.5) 212 (14.9) 0.017 
 Ex-smoker 39 (27.5) 523 (36.8) 0.027 
 Non-smoker 40 (28.2) 619 (43.6) 0.000 
 Missing 31 (21.8) 66 (4.6) 0.000 
Previous hospitalisation for asthma 44 (31.0) 56 (3.9) 0.000 
RTI 23 (16.2) 95 (6.7) 0.000 
Asthma review
¥
 56 (39.4) 565 (39.8) 0.935 
*Continuous variable analysed using ANOVA, otherwise variables are categorical analysed using the 
Chi-square test. SD = standard deviation, ICS = inhaled corticosteroid, LABA = long-acting beta2-
agonist, LABAICS = long-acting beta2-agonist in combination inhaler with ICS, SABA = short-acting 
beta2-agonist, RTI = respiratory tract infection, BMI = Body mass index. 
¥
 Within 365 days of the index 
date. Cases and controls matched on calendar year of cohort entry and whether patients were diagnosed 
with asthma under the age of 45 years only. 
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Asthma hospitalisations 
Table 15 describes the characteristics of 5016 cases of asthma hospitalisation and their 
50140 controls. Cases were hospitalised for asthma at a mean age of 41.4 years and 
were more likely to be female (68%). Cases were significantly younger than controls 
but differences were small in absolute terms (41.4 vs. 42.6 years respectively). Cases 
had significantly higher use of all types of asthma therapy in the 90 days prior to the 
index date. Cases were significantly more likely to have a history of nasal polyps, 
urticaria, allergy and anxiety. There were significantly more current smokers and non-
smokers among cases than controls. Cases were significantly more likely to have: been 
hospitalised for asthma in the past; had a RTI in the 90 days before index date; had an 
asthma review in the preceding year; and have a higher BMI.  
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Table 15. Characteristics of patients for the analysis of asthma hospitalisations in the risk 
factor analysis. 
 
Characteristics 
Cases 
N=5016 
Controls 
N=50140 
 
p-value 
Age (years) 41.4 (16.9) 42.6 (16.5) 0.000* 
Female gender 3416 (68.1) 28512 (56.9) 0.000 
Asthma medication in the last 90 days    
 ICS 2168 (43.2) 19164 (38.2) 0.000 
 LABA 882 (17.6) 3211 (6.4) 0.000 
 LABAICS 1326 (26.4) 8036 (16.0) 0.000 
 Leukotriene antagonist 406 (8.1) 1088 (2.2) 0.000 
 Methylxanthine  251 (5.0) 554 (1.1) 0.000 
 Mean no. of SABA prescriptions 2.0 (1.9) 1.0 (1.2) 0.000* 
 Oral steroid 1824 (36.4) 2612 (5.2) 0.000 
Comorbidity    
 Nasal polyps 209 (4.2) 1488 (3.0) 0.000 
 Urticaria 344 (6.9) 2940 (5.9) 0.005 
 Allergy 1377 (27.5) 11633 (23.2) 0.000 
 Anxiety¥ 152 (3.0) 1173 (2.3) 0.002 
 Mean BMI (SD) 28.2 (7.0) 27.2 (6.1) 0.000* 
 Mean Charlson co-morbidity 
score 
1.3 (0.9) 1.3 (0.8) 0.000* 
Smoking status    
 Current smoker 1338 (26.7) 10259 (20.5) 0.000 
 Ex-smoker 1448 (28.9) 14805 (29.5) 0.329 
 Non-smoker 1946 (38.8) 21972 (43.8) 0.000 
 Missing 284 (5.7) 3104 (6.2) 0.137 
Previous hospitalisation for asthma 1016 (20.3) 1305 (2.6) 0.000 
RTI 800 (15.9) 2949 (5.9) 0.000 
Asthma review
¥
 2046 (40.8) 18833 (37.6) 0.000 
*Continuous variable analysed using ANOVA, otherwise variables are categorical analysed using the 
Chi-square test. SD = standard deviation, ICS = inhaled corticosteroid, LABA = long-acting beta2-
agonist, LABAICS = long-acting beta2-agonist in combination inhaler with ICS, SABA = short-acting 
beta2-agonist, RTI = respiratory tract infection, BMI = Body mass index. 
¥
 Within 365 days of the index 
date. Cases and controls matched on calendar year of cohort entry and whether patients were diagnosed 
with asthma under the age of 45 years only. 
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Primary Care Asthma Exacerbations 
Table 16 describes the characteristics of 31771 cases of PCAE and their 127080 
controls. Cases experienced their PCAE at a mean age of 42.9 years and were more 
likely to be female (63%). Cases were significantly older than controls but differences 
were small in absolute terms (42.9 vs. 42.2 years respectively). Cases had significantly 
higher use of all types of asthma therapy in the 90 days prior to the index date. Cases 
were significantly more likely to have a history of nasal polyps, urticaria, allergy and 
anxiety. There were significantly more current smokers and ex-smokers and fewer non-
smokers among cases than controls. Cases were significantly more likely to: have been 
hospitalised for asthma in the past; have had a RTI in the 90 days before index date; 
have had an asthma review in the preceding year; have a higher BMI; and have a lower 
Charlson co-morbidity score.  
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Table 16. Characteristics of patients for the analysis of primary care asthma exacerbations 
in the risk factor analysis. 
 
Characteristics 
Cases 
N=31771 
Controls 
N=127080 
 
p-value 
Age (years) 42.9 (16.7) 42.2 (17.2) 0.000* 
Female gender 19951 (62.8) 69906 (55.0) 0.000 
Asthma medication*     
 ICS 14225 (44.8) 48407 (38.1) 0.000 
 LABA 2022 (6.4) 5152 (4.1) 0.000 
 LABAICS 4783 (15.1) 14163 (11.1) 0.000 
 Leukotriene antagonist 601 (1.9) 1369 (1.1) 0.000 
 Methylxanthine  283 (0.9) 697 (0.5) 0.000 
 Mean no. of SABA prescriptions 1.2 (1.2) 0.9 (1.0) 0.000* 
 Oral steroid - -  
Comorbidity    
 Nasal polyps 933 (2.9) 2705 (2.1) 0.000 
 Urticaria 2029 (6.4) 6144 (4.8) 0.000 
 Allergy 7729 (24.3) 25652 (20.2) 0.000 
 Anxiety¥ 873 (2.7) 2764 (2.2) 0.000 
 Mean BMI (SD) 27.8 (7.7) 27.0 (6.4) 0.000* 
 Mean Charlson co-morbidity 
score 
1.2 (0.8) 1.3 (0.8) 0.000* 
Smoking status    
 Current smoker 7514 (23.7) 25218 (19.8) 0.000 
 Ex-smoker 9172 (28.9) 35830 (28.2) 0.017 
 Non-smoker 13111 (41.3) 56533 (44.5) 0.000 
 Missing 1974 (6.2) 9499 (7.5) 0.000 
Previous hospitalisation for asthma 1500 (4.7) 2551 (2.0) 0.000 
RTI* 4160 (13.1) 6644 (5.2) 0.000 
Asthma review
¥
 11845 (37.3) 42543 (33.5) 0.000 
*Continuous variable analysed using ANOVA, otherwise variables are categorical analysed using the 
Chi-square test. SD = standard deviation, ICS = inhaled corticosteroid, LABA = long-acting beta2-
agonist, LABAICS = long-acting beta2-agonist in combination inhaler with ICS, SABA = short-acting 
beta2-agonist, RTI = respiratory tract infection, BMI = Body mass index. 
¥
 Within 365 days of the index 
date. Cases and controls matched on calendar year of cohort entry and whether patients were diagnosed 
with asthma under the age of 45 years only. 
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Multivariate risk factor analysis using conditional logistic regression 
Table 17 summarizes the adjusted incidence rate ratios (IRR) for different risk factors 
and asthma outcomes. The following risk factors were significantly associated with an 
increase in the relative incidence of asthma death: age (greatest in patients aged 70 and 
older IRR 37.14 (95% CI 7.93 to 174.1) compared to people aged 18 to 29); SABA 
prescription (IRR 1.52 (95% CI 1.33 to 1.74) for each additional prescription); 
treatment with an oral steroid (IRR 3.40 (95% CI 1.85 to 6.25)); and previous 
hospitalisation for asthma (IRR 9.04 (95% CI 4.80 to 17.00)). 
 
The following risk factors were significantly associated with a decrease in the relative 
incidence of asthma death: treatment with an ICS (IRR 0.41 (95% CI 0.24 to 0.70); 
treatment with a LABAICS (IRR 0.48 (95% CI 0.25 to 0.94)); increasing BMI (IRR 
0.92 (95% CI 0.89 to 0.96)) and being a non-smoker (IRR 0.52 (95% CI 0.29 to 0.94)). 
The relative incidence of asthma death was higher in patients with increasing Charlson 
co-morbidity score and increasing social deprivation but this association was not 
statistically significant (IRR 1.11 (95% CI 0.94 to 1.31) and IRR 1.06 (95% CI 0.98 to 
1.15) per decile of the index of multiple deprivation respectively). There were no 
significant differences with any other risk factor assessed. 
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Table 17. Association between asthma outcomes and risk factor assessment in the risk 
factor analysis. 
 Death Hospitalisation PCAE 
Characteristic IRR 95%CI IRR 95%CI IRR 95%CI 
Age category       
 18-29 Ref Ref Ref Ref Ref Ref 
 30-39 3.28 0.86-12.55 0.78 0.71-0.86 1.10 1.06-1.15 
 40-49 7.00 1.93-25.43 0.60 0.54-0.67 1.16 1.11-1.22 
 50-59 12.41 3.09-49.83 0.49 0.42-0.57 1.20 1.13-1.28 
 60-69 13.41 3.01-59.84 0.51 0.43-0.62 1.31 1.22-1.41 
 >=70 37.14 7.93-174.1 0.47 0.38-0.58 1.31 1.21-1.43 
Female gender 0.87 0.54-1.39 1.44 1.34-1.55 1.37 1.33-1.41 
Increasing deprivation
€
 1.06 0.98-1.15 1.02 1.01-1.03 1.03 1.02-1.03 
Asthma therapy*       
 ICS 0.41 0.24-0.70 0.84 0.78-0.92 1.13 1.09-1.16 
 LABA 1.35 0.70-2.62 2.13 1.91-2.37 1.48 1.40-1.57 
 LABAICS 0.48 0.25-0.94 1.22 1.11-1.34 1.37 1.31-1.43 
 Leukotriene antagonist 0.84 0.27-2.61 1.23 1.05-1.44 1.39 1.24-1.55 
 Methylxanthine  2.08 0.83-5.25 1.39 1.13-1.72 1.16 1.00-1.36 
 No. of SABAs¥ 1.52 1.33-1.74 1.38 1.34-1.41 1.24 1.23-1.26 
 Oral steroid 3.40 1.85-6.25 6.35 5.83-6.93 n/a n/a 
Comorbidity       
 Nasal polyps 1.23 0.49-3.06 1.31 1.10-1.57 1.49 1.37-1.62 
 Urticaria 0.80 0.28-2.29 1.00 0.87-1.15 1.28 1.21-1.36 
 Allergy 0.86 0.52-1.41 0.99 0.91-1.07 1.20 1.16-1.24 
 Anxiety 1.82 0.54-6.07 1.07 0.88-1.31 1.12 1.02-1.22 
 BMI¥ 0.92 0.89-0.96 1.01 1.01-1.02 1.01 1.01-1.01 
 Charlson score¥ 1.11 0.94-1.31 1.07 1.03-1.10 0.92 0.90-0.93 
Smoking status       
 Current smoker Ref Ref Ref Ref Ref Ref 
 Ex-smoker 0.54 0.28-1.04 0.86 0.78-0.94 0.96 0.92-0.99 
 Non-smoker 0.52 0.29-0.94 0.81 0.74-0.88 0.90 0.87-0.93 
Prior asthma 
hospitalisation  
9.04 4.80-17.00 6.27 5.62-7.00 2.18 2.02-2.35 
RTI* 1.95 0.97-3.92 1.63 1.46-1.81 2.44 2.32-2.56 
Asthma review
δ
 0.92 0.53-1.60 0.96 0.88-1.04 1.39 1.34-1.44 
PCAE= Primary care asthma exacerbation. Ref = reference category. *= In the 90 days prior to index 
date. €= Per increasing unit change in IMD decile. δ = In the 365 days prior to index date. ¥ = Mean 
value. Cases and controls matched on calendar year of cohort entry and whether patients were diagnosed 
with asthma under the age of 45 years only. 
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The following risk factors were significantly associated with an increase in the relative 
incidence of asthma hospitalisation (table 17): SABA prescription (IRR 1.38 (95% CI 
1.34 to 1.41) for each additional prescription); treatment with an oral steroid (IRR 6.35 
(95% CI 5.83 to 6.93); treatment with a LABA or LABAICS (IRR 2.13 (95% CI 1.91 to 
2.37) and IRR 1.22 (95% CI 1.11 to1.34) respectively); treatment with a leukotriene 
antagonist or methylxanthine (IRR 1.23 (95% CI 1.05 to 1.44) and IRR 1.39 (95% CI 
1.13 to 1.72) respectively); previous hospitalisation for asthma (IRR 6.27 (95% CI 5.62 
to 7.00)); developing a RTI (IRR 1.63 (95% CI 1.46 to 1.81)); female gender (IRR 1.44 
(95% CI 1.34 to 1.55)); a history of nasal polyposis (IRR 1.31 (95% CI 1.10 to 1.57)); 
increasing BMI (IRR 1.01 (95% CI 1.01 to 1.02)); increasing Charlson co-morbidity 
score (IRR 1.07 (95% CI 1.03 to 1.10)) and increasing social deprivation (IRR 1.02 
(95% CI 1.01 to 1.03) per decile of the index of multiple deprivation). The following 
risk factors were significantly associated with a decrease in the relative incidence of 
asthma hospitalisation: increasing age, being smallest in patients aged 70 years and 
older (IRR 0.47 (95% CI 0.38 to 0.58)); treatment with an ICS (IRR 0.84 (95% CI 0.78 
to 0.92)); being an ex-smoker (IRR 0.86 (95% CI 0.78 to 0.94)) or a non-smoker (IRR 
0.81 (95% CI 0.74 to 0.88)).  
 
The following risk factors were significantly associated with an increase in the relative 
incidence of PCAE (table 17): SABA prescription (IRR 1.24 (95% CI 1.23 to 1.26) for 
each additional prescription); treatment with an ICS (IRR 1.13 (95% CI 1.09 to 1.16)); 
treatment with a LABA or LABAICS (IRR 1.48 (95% CI 1.40 to 1.57) and IRR 1.37 
(95% CI 1.31 to1.43) respectively); treatment with a leukotriene antagonist or 
methylxanthine (IRR 1.39 (95% CI 1.24 to 1.55) and IRR 1.16 (95% CI 1.00 to 1.36) 
respectively); previous hospitalisation for asthma (IRR 2.18 (95% CI 2.02 to 2.35)); 
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developing a RTI (IRR 2.44 (95% CI 2.32 to 2.56)); female gender (IRR 1.37 (95% CI 
1.33 to 1.41)); increasing age being greatest in people over 60 years of age (IRR 1.31 
(95% CI 1.21 to 1.43)); a history of nasal polyposis (IRR 1.49 (95% CI 1.37 to 1.62)); a 
history of urticaria and allergy (IRR 1.28 (95% CI 1.21 to 1.36) and IRR 1.20 (95% CI 
1.16 to 1.24) respectively); a recent history of anxiety (IRR 1.12 (95% CI 1.02 to 1.22)); 
increasing BMI (IRR 1.01 (95% CI 1.01 to 1.01)); and attending an asthma review in 
the previous year (IRR 1.39 (95 CI 1.34 to 1.44)); and increasing social deprivation 
(IRR 1.03 (95% CI 1.02 to 1.03) per decile of the index of multiple deprivation). The 
following risk factors were significantly associated with a decrease in the relative 
incidence of PCAE: being an ex-smoker (IRR 0.96 (95% CI 0.92 to 0.99)) or a non-
smoker (IRR 0.90 (95% CI 0.87 to 0.93)); and increasing Charlson co-morbidity score 
(IRR 0.92 (95% CI 0.90 to 0.93)). 
 
 6.5.3 Risk factor assessment - discussion 
In the CPRD active asthma cohort, the relative incidence of asthma death and PCAE 
increased with age. This association has also been found in a retrospective cohort study 
where 30 day case-fatality following hospitalisation for asthma in adults in Scotland 
increased with age (42). In primary care, increasing age has also been associated with 
poor asthma control in general practice (48). This association is consistent with 
incidence rates reported in this thesis and with national statistics as previously discussed 
in this chapter.  
 
The falling incidence of asthma hospitalisation with increasing age has not previously 
been described. National statistics do not report asthma hospitalisation rates by age 
group making it difficult to know whether this result is biased. Evidence from the 
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National Enquiry of Asthma Deaths suggests that accuracy of coding may be more 
unreliable for older adults (56). In that enquiry, the expert panel agreed that clinical 
findings matched the coding of asthma as the underlying cause of death in only around 
50% of people aged 75 years and older. However, agreement could not be reached in 
several of these cases due to insufficient information rather than coding error. This 
finding may also be an artefact of excluding people with comorbid respiratory 
conditions or due to differences in asthma discharge recording in older adults. Incidence 
of asthma hospitalisation depended upon asthma recorded in the primary position and it 
may be that older adults may have other comorbidities recorded in the primary position 
upon discharge than younger adults. However, including cases where asthma is 
recorded in other positions would affect the sensitivity of this measure when 
investigating risk associated with beta-blockers and NSAIDs in subsequent chapters.  
 
Unlike asthma hospitalisation and PCAE, gender was not a significant risk factor for 
asthma death in the adjusted analysis as previously reported in a study of 30 day case-
fatality following asthma hospitalisation in adults (42). ICS therapy in this study was 
significantly associated with a reduced rate of asthma death and hospitalisation by 57% 
and 27% respectively. A previous nested case control study investigating the 
effectiveness of ICS reported a 21% reduced rate of asthma death with each additional 
canister of ICS used in the previous year with the rate of asthma death increasing in the 
three months following discontinuation compared to those people who continued ICS 
therapy (59). In a separate nested case control study involving asthma patients aged 5 to 
44 years, regular use of ICS was associated with a 31% reduction in the rate of asthma 
hospitalisation and a 39% reduction in the rate of asthma hospital readmission (215). 
However, current use of ICS was associated with an increased risk of PCAE in the 
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CPRD active asthma cohort. This is more likely to reflect the persons underlying 
severity of asthma (i.e. people at step 2 may have more severe asthma than those at step 
1) or that people were commenced on ICS shortly before an asthma exacerbation which 
was not prevented by ICS therapy alone. The increasing use of SABAs, oral steroids 
and previous hospitalisation for asthma were consistently associated with an increased 
risk of adverse asthma events as previously established. Indeed, frequent need for 
reliever therapy such as using more than 2 canisters of SABA per month is a marker of 
poor asthma control and a risk factor for fatal attacks (57). The association with 
remaining asthma medications is again likely to reflect the persons underlying severity 
of asthma rather than to be causal although large clinical trials attempting to clarify the 
safety of LABAs in asthma have been mandated by the FDA and are currently 
underway.  
 
Within the CPRD active asthma cohort, ex-smokers and non-smokers had a reduced rate 
of asthma events compared to smokers. This is in keeping with the current 
understanding that smoking is associated with poor asthma control and adverse 
respiratory events (48). People with a history of nasal polyps had an increased rate of 
asthma hospitalisation and PCAE which probably represents the increased asthma 
morbidity which occurs in people with the AERD phenotype (201). Increasing BMI was 
associated with an increased rate of asthma hospitalisation and PCAE but a reduced rate 
of asthma death which cannot be fully explained. Leptin and adiponectin levels may 
influence airway hyper-responsiveness including pro-inflammatory and anti-
inflammatory cytokines and a recent study found that increasing BMI was 
independently associated with AERD (201). Increasing comorbidity was associated 
with increased rate of asthma death and hospitalisation which has been reported 
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elsewhere however the reduced rate of PCAE with increasing comorbidity again cannot 
be fully explained (42). Other risk factors were significantly associated with PCAE such 
as allergy and attendance at primary care asthma reviews but had no significant 
relationship on asthma deaths and hospitalisations. 
 
Overall, the risk factor assessment conducted with the CPRD active asthma cohort 
identified similar risk factors which have been reported elsewhere such as SABA use, 
the effect of ICS therapy and smoking status. This provides some reassurance to the 
quality of the data and its representativeness of people with active asthma, and identifies 
important confounders to adjust for in the main analyses. Some findings remain difficult 
to explain such as the falling incidence of asthma hospitalisation with age, the 
relationship between BMI and asthma deaths, and the relationship between comorbidity 
and PCAE which would benefit from further investigation. However, some other 
potential risk factors have not been evaluated because the data is not available in GP 
clinical records, including environmental risk factors such as air pollution and area of 
residence  
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6.6 Drug utilisation studies 
6.6.1 Drug utilisation studies - methodology 
For patients in the active asthma cohort, the prevalence of oral beta-blocker and NSAID 
prescribing was calculated on a quarterly basis between 1 January 2000 and 31 
December 2011. The numerator consisted of the number of patients issued one or more 
beta-blocker or NSAID prescriptions in any particular quarter and the denominator 
consisted of the total number of patients with active asthma present in the cohort during 
the same quarter. The prevalence of beta-blocker or NSAID prescribing was determined 
by dividing the numerator by the denominator (as previously defined) and multiplied by 
100. The relative change in the prevalence of beta-blocker and NSAID prescribing over 
the study period was determined by subtracting the prevalence during the first quarter of 
2000 from the prevalence during the last quarter of 2011, with 95% confidence intervals 
(95%CIs). Oral beta-blockers were grouped into selective and non-selective agents 
whilst NSAIDs were grouped into one of four categories: COX-2 inhibitors; other 
NSAIDs with 5-50 fold COX-2 selectivity; other NSAIDs with <5 fold COX-2 
selectivity; and non-selective NSAIDs. Please refer to chapter 2 (page 69) for further 
details. 
 
6.6.2 Drug utilisation studies - results 
Oral beta-blockers 
A total of 10266 patients from the active asthma cohort (3.6%, 95% CI 3.6 to 3.7) were 
prescribed 154664 oral beta-blocker prescriptions during cohort follow-up. Of the 
10266 patients prescribed an oral beta-blocker, 4006 patients (39.0%, 95% CI 38.1 to 
40.0) received an average of 8.9 prescriptions (95% CI 8.3 to 9.4) for non-selective 
beta-blockers compared to 6633 patients (64.6%, 95% CI 63.7 to 65.5) who received an 
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average of 18.0 prescriptions (95% CI 17.4 to 18.6) for selective beta-blockers. 
Selective beta-blockers accounted for 77.1% of all oral beta-blocker prescriptions 
issued. Oral beta-blocker prescribing to patients with active asthma varied significantly 
by age and gender (table 18). Selective beta-blocker prescribing steadily increased with 
age (Chi-square test p<0.001) being greatest in patients aged 70 and over compared to 
non-selective beta-blockers which were more commonly prescribed to younger patients. 
Women were prescribed significantly more beta-blockers (both selective and non-
selective) than men (72.5% of patients prescribed non-selective and 58.1% of patients 
prescribed oral selective beta-blockers were women, Chi-square test p<0.001).  
 
Of the 4006 patients prescribed non-selective beta-blockers, the most commonly 
prescribed drugs were propranolol (67.0%) and sotalol (16.1%) with a mean daily dose 
of 69.8 mg (95% CI 66.3 to 67.8) and 111.6 mg (95% CI 109.7 to 113.5) respectively 
(table 19). 2290 patients (57.2%) were issued more than one oral non-selective beta-
blocker prescription. 
 
Of the 6633 patients prescribed selective beta-blockers, the most commonly prescribed 
drugs were atenolol (50.3%) and bisoprolol (37.8%) with a mean daily dose of 46.6 mg 
for atenolol (95% CI 46.4 to 46.8) and 4.1 mg for bisoprolol (95% CI 4.1 to 4.1). 5581 
patients (84.1%) were issued more than one oral selective beta-blocker prescription.  
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Table 18. Distribution of oral beta-blocker exposure at any point during cohort follow-up 
by age, gender and selectivity in patients with active asthma. 
 
Variable 
Selective 
No. (%) 
Non-selective 
No. (%) 
Any beta-
blocker 
No. (%) 
Age group    
 18-29 174 (18.0) 808 (82.0) 969 (100.0) 
 30-39 385 (29.9) 936 (70.1) 1287 (100.0) 
 40-49 928 (53.0) 868 (47.0) 1750 (100.0) 
 50-59 1598 (72.0) 693 (28.0) 2219 (100.0) 
 60-69 2015 (81.3) 552 (18.7) 2477 (100.0) 
 >=70 2355 (86.7) 465 (13.3) 2716 (100.0) 
Gender    
 Male 2776 (74.0) 1101 (26.0) 3748 (100.0) 
 Female 3857 (59.2) 2905 (40.8) 6518 (100.0) 
     Percentages are row percentages 
 
Table 19. Characteristics of oral beta-blocker exposure at any point during cohort follow-
up in patients with active asthma. 
Beta-blocker No. prescriptions 
(%) 
Mean daily dose 
(SD) 
Non-selective Carvedilol 3740 (10.6) 20.8 (26.7) 
 Labetalol 870 (2.5) 332.7 (305.2) 
 Nadolol 178 (0.5) 40.2 (29.0) 
 Oxprenolol 948 (2.7) 108.0 (74.4) 
 Pindolol 56 (0.2) 7.5 (4.9) 
 Propranolol 23751 (67.0) 69.8 (58.6) 
 Sotalol 5713 (16.1) 111.6 (72.3) 
 Timolol 192 (0.5) 14.7 (8.7) 
 Total 35448 (100.0) - 
Selective Acebutolol 129 (0.11) 431.0 (425.7) 
 Atenolol 59935 (50.3) 46.6 (25.1) 
 Bisoprolol 45036 (37.8) 4.1 (3.2) 
 Celiprolol 2330 (2.0) 244.7 (111.4) 
 Metoprolol 7432 (6.2) 93.3 (272.8) 
 Nebivolol 4354 (3.7) 4.3 (1.9) 
 Total 119216 (100.0) - 
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The quarterly prevalence of oral beta-blocker prescribing is shown in figure 38. 
Between the first quarter of 2000 and the last quarter of 2011, the quarterly prevalence 
of any oral beta-blocker prescribing (both non-selective and selective) rose from a low 
of 1.2% (95% CI 1.1 to 1.2) in the first quarter of 2000 to a high of 3.4% (95% CI 3.3 to 
3.5) in the last quarter of 2011, a significant relative rise of 196.5% (95% CI 183.5 to 
208.7) over the 12 year period. The quarterly prevalence of oral selective beta-blocker 
prescribing rose from a low of 0.85% (95% CI 0.80 to 0.90) in the first quarter of 2000 
to a high of 2.84% (95% CI 2.76 to 2.9) in the last quarter of 2011, a significant relative 
rise of 234.1% (95% CI 218.8 to 249.4) over the 12 year period. The quarterly 
prevalence of oral non-selective beta-blocker prescribing rose from a low of 0.31% 
(95% CI 0.28 to 0.34) in the first quarter of 2000 to a high of 0.58% (95% CI 0.54 to 
0.61) in the last quarter of 2011, a significant relative rise of 87.1% (95% CI 64.5 to 
106.5) over the 12 year period. 
 
For individual beta-blocker drugs, the quarterly prevalence of atenolol prescribing rose 
from 0.57% (95% CI 0.53 to 0.61) in the first quarter of 2000 to a high of 0.91% (95% 
CI 0.87 to 0.96) in the fourth quarter of 2004 before starting to fall again to 0.65% (95% 
CI 0.61 to 0.68) by the last quarter of 2011 (figure 38b). In contrast, the quarterly 
prevalence of bisoprolol prescribing rose over the entire 12 year period from 0.16% 
(95% CI 0.14 to 0.19) in the first quarter of 2000 to a high of 1.91% (95% CI 1.85 to 
1.97) in the last quarter of 2011, a significant relative rise of 1093% (95% CI 1038 to 
1144). 
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       Figure 38a. Oral beta-blockers.    Figure 38b. Individual beta-blockers.           Figure 38c. Oral NSAIDs 
 
Figure 38. Drug utilisation trends for oral beta-blockers and NSAIDs in patients from the active asthma cohort. 
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Oral NSAIDs 
A total of 77424 patients from the active asthma cohort (27.5%, 95% CI 27.3 to 27.6) 
were prescribed 471706 oral NSAID prescriptions. Of these77424 patients,: 41033 
patients (53.0%, 95% CI 52.7 to 53.4) were prescribed non-selective NSAIDs; 47938 
patients (61.9%, 95% CI 61.6 to 62.3) were prescribed NSAIDs with <5-fold COX-2 
selectivity; 4600 patients (5.9%, 95% CI 5.8 to 6.1) were prescribed NSAIDs with 5 to 
50-fold COX-2 selectivity; and 8876 patients (11.5%, 95% CI 11.2 to 11.7) were 
prescribed COX-2 inhibitors. Of the 77424 patients prescribed an NSAID, 17378 
patients were prescribed two classes of NSAID (22.5%, 95% CI 22.2 to 22.7), 3155 
patients were prescribed three classes of NSAID (4.1%, 95% CI 3.9 to 4.2) and 460 
patients were prescribed four classes of NSAIDs (0.6%, 95% CI 0.5 to 0.7) during 
follow up. Aspirin was prescribed to 19152 patients from the active asthma cohort 
(6.8%, 95% CI 6.7 to 6.9). 
 
NSAIDs with <5-fold COX-2 selectivity (e.g. diclofenac) were the most frequently 
prescribed class of NSAID (44.3%), followed by non-selective NSAIDs (35.2%), COX-
2 inhibitors (12.2%) and NSAIDs with 5 to 50-fold COX-2 selectivity (8.3%). Oral 
NSAID and aspirin prescribing varied significantly by age and gender (table 20). The 
number of NSAID prescriptions increased with age. People aged 60-69 years were 
issued the most number of prescriptions except for aspirin in which more prescriptions 
were issued to people aged 70 and over. Women were issued more NSAID prescriptions 
than men. 
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Table 20. Number of NSAID and aspirin prescriptions by age, gender and selectivity in patients with active asthma. 
 
 
Variable 
Non- 
selective 
No. (%) 
<5-fold 
selective 
No. (%) 
 
5-50-fold selective 
No. (%) 
 
COX-2 inhibitor 
No. (%) 
 
Aspirin 
No. (%) 
Age group      
 18-29 13869 (8.4) 16748 (8.0) 668 (1.7) 1245 (2.2) 1132 (0.3) 
 30-39 21980 (13.3) 28808 (13.8) 2093 (5.4) 4346 (7.5) 4986 (1.1) 
 40-49 32970 (19.9) 43490 (20.8) 6454 (16.5) 9491 (16.4) 25947 (5.6) 
 50-59 34253 (20.6) 45649 (21.9) 9982 (25.5) 13769 (23.9) 69645 (15.1) 
 60-69 36877 (22.2) 44100 (21.1) 11184 (28.6) 15206 (26.3) 139450 (30.2) 
 >=70 26084 (15.7) 30031 (14.4) 8745 (22.4) 13664 (23.7) 220592 (47.8) 
Gender      
 Male 54237 (32.7) 68008 (32.6) 10630 (27.2) 13771 (23.9) 197481 (42.8) 
 Female 111796 (67.3) 140818 (67.4) 28496 (72.8) 43950 (76.1) 264271 (57.2) 
Total 166033 (100.0) 208826 (100.0) 39126 (100.0) 57721 (100.0) 461752 (100.0) 
    Percentages are column percentages.  
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The quarterly prevalence of oral NSAID and aspirin prescribing in people with active 
asthma is presented in figure 38c. Between the first quarter of 2000 and the last quarter 
of 2011, the quarterly prevalence of non-selective NSAID prescribing rose from 2.9% 
(95% CI 2.8 to 3.1) in the first quarter of 2000 to 4.0% (95% CI 3.9 to 4.1) in the last 
quarter of 2011, a significant relative rise of 36.6% (95% CI to 27.1 to 46.6) over the 12 
year period. Although the quarterly prevalence of NSAID prescribing with <5 fold 
COX-2 selectivity fell from 2.9% (95% CI 2.7 to 3.0) in the first quarter of 2000 to 
1.8% (95% CI 1.7 to 1.9) in the last quarter of 2011, a significant relative fall of 36.8% 
(95% CI to 28.8 to 45.3), prescribing initially increased and then started to fall in 2007. 
Between the first quarter of 2000 and the last quarter of 2011, the quarterly prevalence 
of NSAID prescribing with 5-50 fold COX-2 selectivity did not significantly change 
over the 12 year period (0.44% (95% CI 0.38 to 0.50) in the first quarter of 2000 
compared to 0.39% (95% CI 0.35 to 0.44) in the last quarter of 2011. 
 
Among each class, the most commonly prescribed drugs were: ibuprofen (61.7%) and 
naproxen (29.3%) for non-selective NSAIDs; diclofenac (90.0%) for NSAIDs with <5 
fold COX-2 selectivity; meloxicam (75.0%) for NSAIDs with 5-50 fold COX-2 
selectivity; and celecoxib (47.2%) for COX-2 inhibitors. The quarterly prevalence of 
ibuprofen prescribing fell from 2.1% (95% CI 2.0 to 2.2) in the first quarter of 2000 to 
1.6% (95% CI 1.5 to 1.7) in the last quarter of 2011, a significant relative fall of 23.6% 
(95% CI 13.5 to 33.7) and absolute fall of 0.5% (95% CI 0.3 to 0.7). In comparison, the 
quarterly prevalence of naproxen prescribing rose from 0.5% (95% CI 0.5 to 0.6) in the 
first quarter of 2000 to 2.34% (95% CI 2.3 to 2.5) in the last quarter of 2011, a 
significant relative rise of 345% (95% CI 315.1 to 377.4) and absolute rise of 1.8% 
(95% CI 1.7 to 2.0). The quarterly prevalence of diclofenac prescribing fell from 2.4% 
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(95% CI 2.3 to 2.5) in the first quarter of 2000 to 1.5% (95% CI 1.5 to 1.6) in the last 
quarter of 2011, a significant relative fall of 35.7% (95% CI 26.5 to 45.0) and absolute 
fall of 0.9% (95% CI 0.6 to 1.1). The quarterly prevalence of meloxicam and celecoxib 
prescribing followed similar trends to those of the class effects. The quarterly 
prevalence of aspirin prescribing among patients with active asthma rose from 2.9% 
(95% CI 2.7 to 3.0) in the first quarter of 2000 to 6.0% (95% CI 5.6 to 6.2) in the last 
quarter of 2011, a significant relative rise of 109.7% (95% CI 99.0 to 120.5) and 
absolute rise of 3.2% (95% CI 2.9 to 3.5). 
 
6.6.3 Drug utilisation studies - discussion 
By the end of 2011, the prevalence of selective and non-selective beta-blocker 
prescribing had risen by around 200% and 87% respectively. Selective beta-blockers 
were prescribed more often to older patients more likely to have compelling indications 
for beta-blockade such as ischaemic heart disease and heart failure. My pilot work using 
Scottish electronic medical record data reported a prevalence of selective and non-
selective beta-blocker prescribing of 1.7% and 1.1% respectively during 2005 and 2007 
(84). For selective beta-blockers this remained similar (figure 38a) whereas non-
selective beta-blockers prescribing was greater in my pilot work than observed here. 
This chapter demonstrates the rising pattern of oral beta-blocker prescribing, not 
apparent using a cross-sectional approach. During this time a switch in prescribing 
bisoprolol instead of atenolol occurred probably related to changing recommendations 
for the management of cardiovascular conditions during the study period.  
 
There are three key points to note with regards to oral NSAID and aspirin prescribing 
over the study period. The first is the rise in non-selective NSAID use and fall in the use 
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of NSAIDs with less than 5-fold selectivity (which were similar in size). This was due 
to a rise in naproxen prescribing and a fall in diclofenac prescribing, probably related to 
emerging cardiovascular safety concerns associated with diclofenac. The second 
striking feature is the rise and rapid fall in COX-2 inhibitor prescribing which again 
relates to cardiovascular safety concerns, initially with rofecoxib which led to its 
voluntary withdrawal from the market in the second half of 2004 (216). Although 
celecoxib and etoricoxib are still available, COX-2 inhibitor prescribing in asthma is 
scarce despite their potential safety profile in AERD and in people with asthma with 
unknown AERD status as discussed in chapter 5. The last point to note is reversal of the 
increasing trend in aspirin prescribing possibly as a result of changing recommendations 
for routine use of aspirin for primary prevention of cardiovascular disease. 
 
6.7 Summary 
This chapter described the CPRD active asthma cohort, determined measures of disease 
frequency and assessed risk factors for asthma events to check data accuracy and 
representativeness. Overall, the demographics of people within the CPRD active asthma 
cohort appear representative of people with asthma, and known risk factors which 
modify the incidence of asthma exacerbations were reproduced in the nested case 
control study. This provides some reassurance as to the validity of CPRD data and 
increases confidence in the validity and generalisability of analyses evaluating the risk 
of beta-blockers and NSAIDs using the active asthma cohort. The majority of 
prescriptions for chronic conditions are issued through UK general practice and 
therefore the drug utilisation studies in this chapter are likely to be a valid representation 
of UK clinical practice which demonstrates that a suitable population at risk from beta-
blockers and NSAIDs exists.
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Chapter 7: Adverse Respiratory Effect 
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7.1 Introduction 
Propranolol is a non-selective beta-blocker introduced into clinical practice for the 
management of cardiovascular disease. Propranolol improves exercise tolerance in 
people with angina pectoris by blunting catecholamine-induced increases in heart rate, 
blood pressure and myocardial contractility, thereby reducing myocardial oxygen 
consumption (217). Propranolol can be used to control atrial and ventricular 
arrhythmias with one study showing suppression of chronic ventricular arrhythmias in 
around 88% of people at a mean daily dose of 290 mg (218). Propranolol can also lower 
blood pressure in hypertensive patients and can improve survival following myocardial 
infarction with long term use by around 20% (74, 219). Over time, other selective and 
non-selective beta-blockers have been developed which are currently preferred for the 
management of cardiovascular disease instead of propranolol. However, propranolol is 
still commonly used for the management of several non-cardiac conditions including 
anxiety, migraine, benign essential tremor and the symptoms of thyrotoxicosis. 
 
Anxiety is a common psychological condition associated with several comorbidities 
including asthma. The prevalence of anxiety disorder is greater in people with asthma 
compared to the general population and prevalence of anxiety disorder is thought to 
increase with increasing asthma severity (220). One US study involving over 2000 
young people aged 16 to 21 years of age reported a 21% prevalence of anxiety disorder 
among people with asthma compared to 13.6% in people without, whilst another study 
reported significantly greater anxiety scores among people with treatment-resistant 
asthma compared to other people with asthma measured using the Hospital Anxiety 
Depression Scale (HADS) (221, 222).  
 
187 
 
Anxiety disorder is associated with a number of poor asthma outcomes including worse 
asthma-related quality of life scores, increased health care utilisation and cost, increased 
use of rescue medication and rates of asthma hospitalisation (220). In one UK study, 
asthma hospitalisation rates among people with current comorbid mood disorders 
(depression and anxiety) was 44.5 per 10,000 person years compared to 36.4 per 10,000 
person years in those without (223). 
 
Propranolol is prescribed for anxiety which is a confounder when investigating the risk 
of propranolol in people in asthma (220). Therefore comparing the risk of propranolol 
with other beta-blockers in a single analysis potentially leads to confounded estimates 
because any observed increase in asthma outcomes may be related to the presence or 
absence of anxiety between cases and controls rather than the drug per se (confounding 
by indication). The risk factor analysis conducted in chapter 6 found a significant 
association with PCAE and current anxiety but not with asthma hospitalisation or death. 
The drug utilisation studies presented in the same chapter highlighted an increasing 
prevalence of propranolol prescribing among people with asthma which demonstrates a 
population at risk.  
 
7.2 Aim 
The aim of this chapter was to assess the adverse respiratory effect of propranolol using 
linked electronic health data. 
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7.3 Methods 
Primary analysis using the nested case control study 
Population 
The nested case control study measured the association between propranolol exposure 
and asthma events in a cohort of people with asthma and anxiety derived from the 
CPRD adult active asthma cohort (described in chapter 2, page 66). Entry into the 
asthma anxiety cohort occurred on or after the date of entry to the CPRD active asthma 
cohort. The asthma anxiety cohort consisted of people in the CPRD active asthma 
cohort who additionally had a Read code for anxiety disorder in their electronic medical 
record. Entry into the asthma anxiety cohort was defined as the date of entry into the 
CPRD active asthma cohort if a Read code for anxiety disorder was recorded within the 
previous year. Otherwise entry into the asthma anxiety cohort was defined as the date of 
the anxiety Read code if this occurred for the first time during the CPRD active asthma 
cohort follow-up. Therefore, this definition was more likely to include people with 
current anxiety disorders. Cohort follow-up remained unchanged as previously 
described (chapter 2, page 67). Analysis was restricted to people from practices linked 
to the HES and ONS databases providing full outcome ascertainment.  
 
Case and control selection 
Outcomes consisted of asthma death, asthma hospitalisation and PCAE as previously 
defined (chapter 2, page 67). For each outcome, up to 10 controls were randomly 
selected and matched to each case on age (categorised into deciles), gender, calendar 
year of cohort entry and whether patients were diagnosed with asthma before the age of 
45 using incidence density sampling. When a case could not be matched to one or more 
controls, the matching process was repeated without age. This was a pragmatic decision 
189 
 
to include all cases affecting 2 cases (0.4%) of asthma hospitalisation and 12 cases 
(0.5%) of PCAE. 
 
Exposures 
Propranolol exposure was defined as current incident user, current prevalent user and 
non-user as described in the general methods chapter (chapter2, page 72). Among 
current users, exposure to oral propranolol was evaluated by dose, stratified into low to 
moderate daily dose (≤80 mg) and high daily dose (>80mg). The association with 
propranolol was evaluated using three risk windows consisting of 30, 60 and 90 days. 
 
Confounders and data analysis 
Multiple imputation was used to impute missing data on height, weight and smoking 
status as previously described (chapter 2, page 75). For each analysis, adjustment was 
made for variables listed in table 21, according to clinical relevance and model fit 
(chapter 2, page 73). Chi-squared testing and analysis of variance (ANOVA) was used 
to determine statistically significant differences in patient characteristics. Conditional 
logistic regression was used to estimate odds ratios which provide unbiased estimates of 
the incidence rate ratio for the association between propranolol and asthma events.  
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Table 21. Confounders used for risk adjustment in the nested case control analysis 
between propranolol and asthma death, asthma hospitalisation and primary care asthma 
exacerbation. 
 
Characteristic Death Hospitalisation PCAE 
Exact age
¥
 Yes Yes Yes 
Deprivation
€
 Yes Yes Yes 
Medications*    
 ICS Yes Yes Yes 
 LABA Yes Yes Yes 
 LABAICS Yes Yes Yes 
 Leukotriene antagonist Yes Yes Yes 
 Methylxanthine  Yes Yes Yes 
 No. of SABA¥ Yes Yes Yes 
 Oral steroid Yes Yes No 
 NSAIDs Yes Yes Yes 
Comorbidity    
 Nasal polyps No Yes Yes 
 BMI¥ Yes Yes Yes 
 Charlson co-morbidity 
score
¥
 
Yes Yes Yes 
Smoking status Yes Yes Yes 
Previous asthma hospitalisation  Yes Yes Yes 
RTI* Yes Yes Yes 
Asthma review
δ
 No No Yes 
 
*= In the 90 days prior to index date. €= Index of multiple deprivation decile.  
δ = In the 365 days prior to index date.  
¥  = Continuous variable. PCAE = primary care asthma exacerbation. 
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Sensitivity analyses 
The following sensitivity analyses were performed for asthma hospitalisation and PCAE 
to test the robustness of the results as previously described (chapter 2, page 76):  
 excluding patients hospitalised during the risk period 
 excluding patients over the age of 40 years who smoked 
 excluding patients diagnosed with asthma over the age of 45 
 excluding patients not matched in the first round of control selection (i.e. not 
matched on age, since this is the matching variable dropped in the second round) 
 complete case analysis 
 
Secondary analysis using the self-controlled case series 
The SCCS method has previously described in chapter 2 (page 77). The SCCS was 
conducted over a 360 day study period centred on incident propranolol exposure (first 
prescription in the file in people with at least 1 year of follow up prior to the first 
prescription) as previously defined (chapter 2, page 77). The beginning of the 
observation period was defined as 180 days prior to the date of the incident propranolol 
prescription and the end of the observation period was defined as 180 days following 
this incident prescription. The SCCS was performed for PCAE as previously defined, 
using 30 day, 60 day and 90 day acute risk periods beginning on the incident 
prescription date for propranolol. Exposure beyond these risk windows was categorised 
as chronic exposure. A 30 day pre-risk period was used to account for short-lived event 
dependent exposures. All remaining person time was classed as baseline. 
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Confounders and data analysis 
Time-varying exposure to the following medications issued within 90 day consecutive 
periods was adjusted for in the analysis as previously described (chapter2, page 81): 
ICS; inhaled LABAs; leukotriene antagonists; methlyxanthines; and the total number of 
SABA prescriptions. Additional risk adjustment was also made for seasonal variation. 
Crude and adjusted incidence rate ratios (IRR) were calculated using conditional 
Poisson regression with analyses stratified by dose as previously defined (page 81). 
7.4 Results 
The asthma anxiety cohort consisted of 20093 patients with a mean age at cohort entry 
of 40.6 years (SD 15.4) and more women than men (71.8% vs. 28.2% respectively). 
During follow-up of the asthma anxiety cohort, a total of 12 asthma deaths, 470 asthma 
hospitalisations and 1855 PCAE occurred. Propranolol was prescribed to 1039 patients 
(5.2%) in the asthma anxiety cohort during a mean of 2.9 years of follow-up. 
 
7.4.1 Primary analysis using the nested case control study 
Asthma death 
All cases of asthma death were fully matched to 10 controls. Table 22 describes the 
characteristics of the 12 cases of asthma death matched to 120 controls. There were no 
significant differences in matching criteria between cases and controls. Cases died of 
asthma at a mean age of 53.4 years and were predominantly women (75.0%). Cases had 
a statistically significant higher use of oral steroids and SABAs in the 90 days prior to 
the index date. A greater proportion of cases were current smokers which was 
statistically significant. Cases had a lower mean BMI, were more likely to have 
previously been hospitalised for asthma and hospitalised for any cause within 90 days of 
the index date but were not statistically significant.  
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Table 22. Characteristics of cases and controls for asthma death in the propranolol 
analysis. 
 
Characteristics 
Cases  
N=12 
Controls 
N=120 
 
p-value 
Matching variables    
Age (years, SD) 53.4 (13.5) 53.7 (12.9) 0.948* 
Female gender 9 (75.0) 90 (75.0) 1.000 
Years of follow-up to index date (years, SD) 2.4 (2.7) 2.4 (2.6) 0.983* 
Diagnosed with asthma ≤ age 45 7 (58.3) 70 (58.3) 1.000 
Potential confounders    
Asthma therapy in the 90 days prior to index 
date  
   
 ICS 4 (33.3) 52 (43.3) 0.504 
 LABA 1 (8.3) 7 (5.8) 1.000 
 LABAICS 4 (33.3) 32 (26.7) 0.877 
 Leukotriene antagonist 1 (8.3) 5 (4.2) 1.000 
 Methylxanthine  2 (16.7) 3 (2.5) 0.097 
 Oral steroid 7 (58.3) 11 (9.2) 0.000 
 Mean no. of SABA prescriptions (SD) 2.3 (1.8) 1.4 (1.3) 0.028* 
Comorbidity    
 Nasal polyps 0 (0.0) 1 (0.8) 1.000 
 Mean BMI (SD) 23.8 (6.1) 28.4 (7.2) 0.068* 
 Mean Charlson co-morbidity score (SD) 1.9 (1.2) 1.4 (0.9) 0.065* 
Smoking status    
 Current smoker 7 (58.3) 35 (29.2) 0.039 
 Ex-smoker 3 (25.0) 41 (34.2) 0.748 
 Non-smoker 1 (8.3) 42 (35.0) 0.120 
 Missing 1 (8.3) 2 (1.7)  
Previous hospitalisation for asthma 3 (25.0) 12 (10.0) 0.278 
RTI recorded in the 90 days prior to index date 3 (25.0) 14 (11.7) 0.388 
Hospitalisation in the 90 day risk window 3 (25.0) 13 (10.8) 0.332 
Asthma review in the 365 days prior to index 
date 
5 (41.7) 60 (50.0) 0.582 
*Continuous variable analysed using ANOVA, otherwise variables are categorical analysed using the Chi-
square test.         SD = standard deviation, ICS = inhaled corticosteroid, LABA = long-acting beta2-agonist, 
LABAICS = long-acting beta2-agonist in combination inhaler with ICS, SABA = short-acting beta2-agonist, 
RTI = respiratory tract infection, BMI = Body mass index. Cases and controls matched on age category, 
gender, calendar year of cohort entry and whether patients were diagnosed with asthma under the 
age of 45 years only. 
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Asthma hospitalisation 
A total of 2 cases (0.4%) were included unmatched on age. Table 23 describes the 
characteristics of the 470 cases of asthma hospitalisation matched to 4679 controls. 
There were no significant differences in matching criteria between cases and controls. 
Cases were hospitalised for asthma at a mean age of 42.6 years and were predominantly 
women (78.5%). Cases had significantly higher use of all types of asthma medication 
apart from ICS. A higher proportion of cases had a respiratory tract infection recorded, 
had previously been hospitalised for asthma and had been hospitalised for any cause 
within 90 days of the index date. Cases had a higher mean BMI and a greater proportion 
of patients with nasal polyps. A greater number of cases were current smokers and had 
attended a primary care asthma review within a year of the index date.  
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Table 23. Characteristics of case and controls for asthma hospitalisation in the 
propranolol analysis. 
 
Characteristics 
Cases 
N=470 
Controls 
N=4679 
 
p-value 
Matching variables    
Age (years, SD) 42.6 (15.4) 42.6 (15.4) 0.979* 
Female gender 369 (78.5) 3675 (78.5) 1.000 
Years of follow-up to index date (years, SD) 2.3 (2.5) 2.3 (2.5) 0.977* 
Diagnosed with asthma ≤ age 45 386 (82.1) 3845 (82.2) 0.979 
Potential confounders    
Asthma therapy in the 90 days prior to index 
date  
   
 ICS 191 (40.6) 1803 (38.5) 0.372 
 LABA 74 (15.7) 400 (8.5) 0.000 
 LABAICS 166 (35.3) 982 (21.0) 0.000 
 Leukotriene antagonist 52 (11.1) 147 (3.1) 0.000 
 Methylxanthine  30 (6.4) 54 (1.2) 0.000 
 Oral steroid 201 (42.8) 327 (7.0) 0.000 
 Mean no. of SABA prescriptions (SD) 2.4 (2.2) 1.2 (1.4) 0.000* 
Comorbidity    
 Nasal polyps 23 (4.9) 147 (3.1) 0.043 
 Mean BMI (SD) 29.4 (7.3) 27.9 (6.8) 0.000* 
 Mean Charlson co-morbidity score (SD) 1.4 (1.1) 1.3 (1.0) 0.697* 
Smoking status    
 Current smoker 179 (38.1) 1496 (32.0) 0.007 
 Ex-smoker 127 (27.0) 1390 (29.7) 0.223 
 Non-smoker 150 (31.9) 1626 (34.8) 0.218 
 Missing 14 (3.0) 167 (3.6)  
Previous hospitalisation for asthma 119 (25.3) 224 (4.8) 0.000 
RTI recorded in the 90 days prior to index date 103 (21.9) 409 (8.7) 0.000 
Hospitalisation in the 90 day risk window 62 (13.2) 344 (7.4) 0.000 
Asthma review in the 365 days prior to index 
date 
239 (50.9) 2085 (44.6) 0.009 
*Continuous variable analysed using ANOVA, otherwise variables are categorical analysed using the Chi-square test.         
SD = standard deviation, ICS = inhaled corticosteroid, LABA = long-acting beta2-agonist, LABAICS = long-acting 
beta2-agonist in combination inhaler with ICS, SABA = short-acting beta2-agonist, RTI = respiratory tract infection, 
BMI = Body mass index. Cases and controls matched on age category, gender, calendar year of cohort entry and 
whether patients were diagnosed with asthma under the age of 45 years only. 
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Primary care asthma exacerbations 
A total of 12 cases (0.5%) were included unmatched on age. Table 24 describes the 
characteristics of the 2455 cases of PCAE matched to 23864 controls. There were small 
but statistically significant differences in mean age (44.3 vs. 43.6 years) but not on the 
other matching criteria. PCAEs occurred at a mean age of 44.3 years predominantly in 
women (75.8%). Cases had significantly greater use of all types of asthma medications. 
A higher proportion of cases had attended an asthma review in the previous year and 
had a respiratory tract infection recorded within 90 days of the index date. Cases had 
small but statistically significant differences in BMI and cases had a greater number of 
ex-smokers and fewer non-smokers. 
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Table 24. Characteristics of case and controls for primary care asthma exacerbations in 
the propranolol analysis. 
 
Characteristics 
Cases 
N=2455 
Controls 
N=23864 
 
p-value 
Matching variables    
Age (years, SD) 44.3 (15.3) 43.6 (15.0) 0.027* 
Female gender 1852 (75.8) 18133 (76.3) 0.554 
Years of follow-up to index date (years, SD) 1.6 (2.2) 1.6 (2.2) 0.668* 
Diagnosed with asthma ≤ age 45 1851 (75.4) 18175 (76.2) 0.398 
Potential confounders    
Asthma therapy in the 90 days prior to index 
date  
   
 ICS 1020 (41.8) 8836 (37.2) 0.000 
 LABA 251 (10.3) 1228 (5.2) 0.000 
 LABAICS 599 (24.5) 4083 (17.2) 0.000 
 Leukotriene antagonist 78 (3.2) 386 (1.6) 0.000 
 Methylxanthine  34 (1.4) 124 (0.5) 0.000 
 Mean no. of SABA prescriptions (SD) 1.4 (1.4) 1.0 (1.2) 0.000* 
Comorbidity    
 Nasal polyps 85 (3.5) 492 (2.1) 0.000 
 Mean BMI (SD) 28.3 (6.7) 27.5 (6.7) 0.000* 
 Mean Charlson co-morbidity score (SD) 1.4 (1.0) 1.4 (1.0) 0.894* 
Smoking status    
 Current smoker 779 (31.9) 7225 (30.4) 0.133 
 Ex-smoker 745 (30.5) 6614 (27.8) 0.006 
 Non-smoker 842 (34.5) 8869 (37.3) 0.005 
 Missing    
Previous hospitalisation for asthma 152 (6.2) 648 (2.7) 0.000 
RTI recorded in the 90 days prior to index date 325 (13.3) 1517 (6.4) 0.000 
Hospitalisation in the 90 day risk window 161 (6.6) 1571 (6.6) 0.964 
Asthma review in the 365 days prior to index 
date 
1236 (50.6) 10147 (42.7) 0.000 
*Continuous variable analysed using ANOVA, otherwise variables are categorical analysed using the Chi-square test.         
SD = standard deviation, ICS = inhaled corticosteroid, LABA = long-acting beta2-agonist, LABAICS = long-acting 
beta2-agonist in combination inhaler with ICS, SABA = short-acting beta2-agonist, RTI = respiratory tract infection, 
BMI = Body mass index. Cases and controls matched on age category, gender, calendar year of cohort entry and 
whether patients were diagnosed with asthma under the age of 45 years only. 
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Propranolol exposure 
The crude and adjusted associations between oral propranolol exposure and asthma 
events are shown in table 25. Due to low power for the 30 and 60 day risk windows, it 
was only possible to estimate the relative incidence for asthma death using the 90 day 
risk window for total and prevalent exposure. There was no significant difference found 
for all exposure in the 90 day risk window. It was not possible to estimate relative 
incidence for incident propranolol exposure. There was no significant difference found 
for prevalent propranolol exposure in the 90 day risk window.  
 
Overall, there was no significant increase in the relative incidence of asthma 
hospitalisation or PCAE associated with any propranolol exposure (incident and 
prevalent combined) with any of the risk windows. When stratified by type of exposure, 
the relative incidence of asthma hospitalisation was significantly increased with incident 
propranolol exposure using a 30 day risk window (IRR 13.69 (95% CI 2.28 to 82.17) 
p=0.004) with relative incidence falling as the risk window increased.  
 
No significant differences in PCAE were observed for incident propranolol exposure. 
No significant increase in the relative incidence of asthma death, asthma hospitalisation 
or PCAE was observed with prevalent propranolol exposure.
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Table 25. Crude and adjusted incidence rate ratios for the association between oral propranolol exposure and asthma events. 
*Adjustment for confounders listed in table 21 (page 190). Empty cells = inestimable due to lack of exposure in the risk window.  
 Any Incident Prevalent 
 Crude Adjusted* Crude Adjusted* Crude Adjusted* 
Risk window IRR IRR 95% CI p-value IRR IRR 95% CI p-value IRR IRR 95% CI p-value 
Death             
 30 day - - - - - - - - - - - - 
 60 day - - - - - - - - - - - - 
 90 day 2.50 1.26 0.00-753.6 0.943 - - - - 3.33 1.26 0.00-753.6 0.943 
Hospitalisation             
 30 day 1.39 2.29 0.77-6.78 0.135 5.00 13.69 2.28-82.17 0.004 0.93 1.22 0.30-4.97 0.785 
 60 day 1.18 1.54 0.57-4.20 0.399 1.54 2.78 0.53-14.58 0.226 1.05 1.21 0.35-4.21 0.763 
 90 day 0.97 1.16 0.44-3.07 0.762 1.30 1.79 0.44-7.30 0.415 0.77 0.84 0.22-3.27 0.803 
PCAE             
 30 day 0.77 0.80 0.49-1.28 0.349 0.19 0.25 0.03-1.81 0.169 0.97 0.97 0.60-1.57 0.889 
 60 day 0.88 0.91 0.62-1.33 0.619 0.43 0.50 0.18-1.38 0.182 1.04 1.03 0.69-1.55 0.872 
 90 day 0.84 0.86 0.61-1.23 0.415 0.51 0.57 0.27-1.24 0.157 1.01 0.99 0.66-1.48 0.956 
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The association between oral propranolol exposure and asthma hospitalisation 
according to dose of exposure are shown in table 26. Overall, there was a significant 
increase in the relative incidence of asthma hospitalisation with any (incident and 
prevalent combined) high dose propranolol exposure. This was significant for each of 
the risk windows with relative incidence falling as the risk window increased in 
duration (IRR 7.98 (95% CI 1.82 to 35.02), IRR 7.90 (95% CI 1.88 to 33.24) and IRR 
4.30 (95% CI 1.09 to 16.98) for the 30, 60 and 90 day risk window respectively).  
 
When stratified by type of exposure, incident high dose propranolol exposure was 
associated with a larger significant increase in the relative incidence of asthma 
hospitalisation which was significant for all of the risk windows (IRR 13.37 (95% CI 
1.08 to 165.97), IRR 13.70 (95% CI 1.46 to 128.46) and IRR 7.59 (95% CI 1.30 to 
44.24) for the 30, 60 and 90 day risk window respectively). Incident low to moderate 
dose propranolol exposure was associated with a smaller significant increase in the 
relative incidence of asthma hospitalisation which was significant for the 30 day risk 
window only (IRR 11.13 (95% CI 1.03-119.89)). 
 
Prevalent high dose propranolol exposure was associated with a non-significant increase 
in the relative incidence of asthma hospitalisation (IRR 5.84 (95% CI 0.93 to 36.88), 
IRR 5.08 (95% CI 0.67 to 38.71) and IRR 2.76 (95% CI 0.27 to 27.70) for the 30, 60 
and 90 day risk window respectively).  
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Table 26. Crude and adjusted incidence rate ratios for the association between oral propranolol exposure and asthma events by dose. 
*Adjustment for confounders listed in table 21 (page 190). Empty cells = inestimable due to lack of exposure in the risk window.  
 Any Incident Prevalent 
 Crude Adjusted* Crude Adjusted* Crude Adjusted* 
Risk window IRR IRR 95% CI p-value IRR IRR 95% CI p-value IRR IRR 95% CI p-value 
High dose             
Hospitalisation             
 30 day 3.00 7.98 1.82-35.02 0.006 5.00 13.37 1.08-165.97 0.044 2.50 5.84 0.93-36.88 0.060 
 60 day 3.64 7.90 1.88-33.24 0.005 6.67 13.70 1.46-128.26 0.022 2.50 5.08 0.67-38.71 0.117 
 90 day 2.67 4.30 1.09-16.98 0.037 4.29 7.59 1.30-44.24 0.024 1.25 2.76 0.27-27.70 0.389 
PCAE             
 30 day 1.66 1.50 0.57-3.94 0.415 1.23 1.50 0.18-12.68 0.986 1.82 1.50 0.51-4.45 0.656 
 60 day 1.19 1.15 0.48-2.72 0.759 1.49 1.77 0.51-6.13 0.367 1.00 0.85 0.26-2.82 0.787 
 90 day 0.99 0.94 0.40-2.21 0.891 1.37 1.57 0.54-4.55 0.411 0.64 0.53 0.13-2.25 0.391 
Low to moderate dose             
Hospitalisation             
 30 day 0.77 0.91 0.17-4.93 0.909 3.33 11.13 1.03-119.89 0.047 0.43 0.40 0.04-3.90 0.433 
 60 day 0.47 0.54 0.11-2.68 0.450 0.83 0.83 0.09-7.51 0.870 0.33 0.35 0.04-3.18 0.348 
 90 day 0.60 0.65 0.18-2.38 0.515 0.53 0.62 0.07-5.28 0.664 0.64 0.38 0.06-2.30 0.289 
PCAE             
 30 day 0.67 0.72 0.42-1.23 0.233 - - - - 0.86 0.88 0.51-1.52 0.656 
 60 day 0.84 0.88 0.58-1.32 0.529 0.37 0.43 0.13-1.37 0.152 1.00 1.01 0.65-1.57 0.977 
 90 day 0.88 0.91 0.63-1.32 0.627 0.50 0.57 0.25-1.30 0.178 1.06 1.06 0.70-1.60 0.801 
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The association between oral propranolol exposure and PCAE according to dose of 
exposure are shown in table 26. Overall, there was no significant increase in the relative 
incidence of PCAE with any (incident and prevalent combined) high or low to moderate 
dose propranolol exposure. When stratified by type of exposure, incident high dose 
exposure was not associated with an increase in the relative incidence of PCAE (IRR 
1.50 (95% CI 0.18 to 12.68), IRR 1.77 (95% CI 0.51 to 6.13) and IRR 1.57 (95% CI 
0.54 to 4.55) for the 30, 60 and 90 day risk window respectively). Incident low to 
moderate dose exposure was not associated with a significant increase in the relative 
incidence of PCAE. There was no significant increase in the relative incidence of PCAE 
associated with prevalent high dose or low to moderate dose propranolol exposure. 
 
Nested case control sensitivity analyses 
Results from sensitivity analyses for the two outcomes examined (asthma 
hospitalisation and PCAE) are presented for any propranolol exposure stratified by type 
of exposure and shown in table 27.   
 
1. Excluding patients hospitalised within the risk period 
This was done to assess any impact of immortal time bias. For asthma hospitalisation, 
this involved excluding 31 (6.6%), 55 (11.7%) and 62 (13.2%) of cases for the 30, 60 
and 90 day risk windows respectively whilst for PCAE this involved excluding 64 
(2.6%), 119 (4.9%) and 161 (6.6%) cases for the 30, 60 and 90 day risk windows 
respectively. This analysis produced very similar results to the main analysis (shown in 
table 25) with a significantly increased risk of asthma hospitalisation associated with 
incident propranolol exposure (IRR 13.78 (95% CI 2.28 to 83.12)) and no significant 
increase with any other type of exposure, risk window or event.  
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Table 27. Sensitivity analyses for the propranolol analysis as per methods. 
Sensitivity analyses excluding patients: hospitalised within the risk window; smokers >40 years of age; 
diagnosed with asthma >45 years of age; unmatched on age; complete case analysis. IRR=incidence rate 
ratio.  
 Any Incident Prevalent 
 IRR 95% CI IRR 95% CI IRR 95% CI 
Hospitalised in risk window       
Hospitalisation       
30 day 1.78 0.53-6.00 13.78 2.28-83.12 0.71 0.12-3.99 
60 day 1.33 0.43-4.05 3.05 0.56-16.56 0.88 0.20-3.78 
90 day 1.06 0.36-3.12 2.01 0.48-8.45 0.56 0.10-3.08 
PCAE       
30 day 0.79 0.48-1.30 0.26 0.04-1.89 0.96 0.58-1.61 
60 day 0.96 0.65-1.42 0.56 0.20-1.56 1.09 0.71-1.66 
90 day 0.91 0.63-1.32 0.65 0.30-1.41 1.03 0.68-1.57 
Diagnosed with asthma ≥45       
Hospitalisation       
30 day 2.14 0.62-7.37 18.62 2.72-127.35 0.82 0.14-4.74 
60 day 1.46 0.47-1.04 2.90 0.55-15.44 1.02 0.23-4.50 
90 day 1.12 0.38-3.31 1.80 0.44-7.34 0.66 0.12-3.64 
PCAE       
30 day 0.91 0.52-1.59 0.34 0.05-2.52 1.13 0.64-2.00 
60 day 1.01 0.65-1.55 0.47 0.15-1.52 1.21 0.76-1.92 
90 day 0.89 0.59-1.35 0.49 0.20-1.22 1.11 0.70-1.77 
Smokers over 40 years       
Hospitalisation       
30 day 1.88 0.44-7.99 8.57 0.77-95.17 1.12 0.18-6.99 
60 day 0.87 0.23-3.29 0.57 0.24-5.12 1.10 0.24-5.12 
90 day 0.71 0.20-1.03 0.65 0.11-4.01 0.77 0.13-4.47 
PCAE       
30 day 0.79 0.46-1.35 - - 0.96 0.55-1.66 
60 day 0.95 0.63-1.45 0.46 0.14-1.48 1.12 0.72-1.75 
90 day 0.90 0.61-1.32 0.59 0.26-1.36 1.04 0.67-1.61 
Unmatched on age       
Hospitalisation       
30 day 2.31 0.78-6.86 14.04 2.33-84.66 1.22 0.30-5.03 
60 day 1.55 0.57-2.45 2.86 0.54-15.03 1.21 0.35-4.23 
90 day 1.17 0.44-3.10 1.82 0.45-7.41 0.84 0.22-3.28 
PCAE       
30 day 0.80 0.50-1.30 0.25 0.03-1.79 0.98 0.60-1.59 
60 day 0.91 0.63-1.33 0.50 0.18-1.38 1.04 0.69-1.56 
90 day 0.86 0.61-1.23 0.57 0.27-1.24 0.99 0.66-1.48 
Complete case analysis       
Hospitalisation       
30 day 2.37 0.78-7.18 16.91 2.36-120.95 1.23 0.30-5.17 
60 day 1.66 0.59-4.65 4.42 0.79-24.72 1.22 0.34-4.34 
90 day 1.24 0.46-3.37 2.31 0.52-10.19 0.83 0.21-3.27 
PCAE       
30 day 0.83 0.51-1.37 0.35 0.05-2.58 0.97 0.59-1.59 
60 day 0.92 0.62-1.36 0.62 0.22-1.73 1.00 0.65-1.53 
90 day 0.90 0.62-1.30 0.60 0.26-1.39 1.01 0.67-1.52 
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2. Excluding patients diagnosed with asthma over the age of 45 years 
This was done to assess any impact of including patients who may have unknown fixed 
airway obstruction. For asthma hospitalisation, this involved excluding 84 (17.9%) of 
cases whilst for PCAE this involved excluding 604 (24.6%) of cases. The significant 
association with incident propranolol exposure and asthma hospitalisation was larger 
than in the main analysis (IRR 18.62 (95% CI 2.72 to 127.35)) and less precise (having 
larger confidence intervals). There was no significant increase with any other type of 
exposure, risk window or event as per the main analysis. 
 
3. Excluding patients over the age of 40 years who smoked 
This was done to again assess any impact of including patients who may have unknown 
fixed airway obstruction. For asthma hospitalisation, this involved excluding 65 
(13.8%) of cases whilst for PCAE this involved excluding 324 (13.2%) of cases. This 
analysis produced a non-significant association between incident propranolol exposure 
and asthma hospitalisation although effect estimates were large and in a similar 
direction (IRR 8.57 (95% CI 0.77 to 95.17)) whilst other results remained similar.  
 
4. Excluding patients originally unmatched on age 
This was done to assess for any residual confounding by age. For asthma 
hospitalisation, this involved excluding 2 (0.4%) of cases whilst for PCAE this involved 
excluding 12 (0.5%) of cases. This analysis produced very similar results the main 
analysis (shown in table 8.6) with a significantly increased risk of asthma 
hospitalisation associated with incident propranolol exposure (IRR 14.04 (95% CI 2.33 
to 84.66)) and no significant increase with any other type of exposure, risk window or 
event. 
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5. Complete case analysis 
This was done to assess the impact of multiply imputing data on height, weight and 
smoking status. For asthma hospitalisation, data was missing on height, weight and 
smoking status for 226 (4.4%), 172 (3.3%) and 181 (3.5%) of people respectively whilst 
for PCAE data was missing on height, weight and smoking status for 1062 (4.0%), 920 
(3.5%) and 1125 (4.3%) of people respectively. Again this analysis produced very 
similar results the main analysis with a significantly increased risk of asthma 
hospitalisation associated with incident propranolol exposure (IRR 16.91 (95% CI 2.36 
to 120.95)) and no significant increase with any other type of exposure, risk window or 
event. 
 
8.4.2 Secondary analysis using the self-controlled case series 
The SCCS consisted of 99 patients (mean age 42 years, 86% female) from the CPRD 
active asthma cohort with incident propranolol exposure and a total of 121 PCAEs. The 
number of events, total person time and crude incidence of PCAE for the baseline 
period, the pre-risk period, the acute risk period and the chronic risk period is shown in 
table 29. As expected, the crude incidence of PCAE was lower during the pre-risk 
period (17.3 per 10,000 person days). The crude incidence of PCAE was greater during 
the acute risk period compared to baseline for the 30 and 90 day risk windows only 
(40.8 vs. 34.2, and 38.3 vs. 34.8 per 10,000 person days for the 30 and 90 day acute risk 
windows respectively).  
 
The crude and adjusted relative incidence of PCAE for each risk period and dose is 
shown in table 29. Overall, the relative incidence of PCAE was not significantly 
increased with any propranolol exposure (high and low dose combined) (IRR 1.15 (95% 
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CI 0.62 to 2.13), IRR 0.89 (95% CI 0.53 to 1.48) and IRR 1.03 (95% CI 0.67 to 1.59) 
for the 30, 60 and 90 day acute risk windows respectively). There was no significant 
increase in the relative incidence of PCAE with any chronic propranolol exposure.  
 
When stratified by dose, no significant increase in the relative incidence of PCAE 
occurred with either high dose or low to moderate dose propranolol exposure although 
relative incidences were generally higher for acute high dose exposure compared to low 
to moderate dose exposure.  
 
The relative incidence of PCAE was increased among all risk periods for chronic high 
dose propranolol exposure but was not statistically significant (IRR 2.63 (95% CI 0.35 
to 20.05), IRR 3.95 (95% CI 0.50 to 31.03) and IRR 3.01 (95% CI 0.24 to 37.94) 
respectively). No significant increase in relative incidence of PCAE with low to 
moderate dose propranolol occurred and relative incidences were smaller than with high 
dose exposure. 
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Table 28. Number of events, person time and crude incidence rates according to exposure 
group and risk window used in the propranolol self-controlled case series. 
 
 
 
 
 
 
 
 
 
 
 
 
          *Per 10,000 person days.
Risk  
Period 
 
Events 
Person time 
(Days) 
Crude  
Incidence* 
30 day    
 Pre-risk 5 2888 17.31 
 Baseline 87 25460 34.17 
 Acute 12 2944 40.76 
 Chronic 17 3950 43.04 
60 day    
 Pre-risk 5 2888 17.31 
 Baseline 84 23658 35.51 
 Acute 20 5910 33.84 
 Chronic 12 2785 43.09 
90 day    
 Pre-risk 5 2888 17.31 
 Baseline 75 21562 34.78 
 Acute 34 8876 38.31 
 Chronic 7 1914 36.57 
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Table 29. Adjusted incidence rate ratios for propranolol exposure and primary care asthma exacerbations according to exposure group and dose 
range used in the self-controlled case series. 
  
 
 
 
 
 
 
 
 
 
*Adjusted for use of SABA, LABA, ICS, leukotriene receptor antagonists, methylxanthines and seasonal variation. 
 
  Any  High dose Low to moderate dose 
Risk Period IRR 95% CI p-value IRR 95% CI p-value IRR 95% CI p-value 
30 day          
 Baseline 1.00 - - 1.00 - - 1.00 - - 
 Acute 1.15  0.62-2.13 0.664 1.81 0.47-7.02 0.389 1.01 0.70-1.46 0.964 
 Chronic 1.43  0.73-2.76 0.289 2.63 0.35-20.05 0.350 0.76 0.56-1.05 0.096 
60 day          
 Baseline 1.00 - - 1.00 - - 1.00 - - 
 Acute 0.89  0.53-1.48 0.643 1.10 0.31-3.96 0.881 0.82 0.60-1.11 0.190 
 Chronic 1.34  0.56-3.21 0.513 3.95 0.50-31.03 0.193 0.75 0.52-1.06 0.100 
90 day          
 Baseline 1.00 - - 1.00 - - 1.00 - - 
 Acute 1.03  0.67-1.59 0.899 1.45 0.43-4.92 0.552 0.81 0.62-1.07 0.132 
 Chronic 0.99  0.34-2.90 0.985 3.01 0.24-37.94 0.394 0.84 0.57-1.24 0.381 
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7.5 Discussion 
This study investigated the association between propranolol exposure and asthma death, 
hospitalisation and PCAE. The primary analysis was the nested case control study 
which found a 13-fold increased risk of asthma hospitalisation associated with incident 
propranolol exposure and an 8-fold increased risk associated with high dose propranolol 
exposure. Although effect estimates for the association between asthma hospitalisation 
and prevalent high dose propranolol exposure were increased, they did not reach 
statistical significance. There was also a significant 11-fold increased risk of asthma 
hospitalisation associated with low to moderate incident propranolol exposure using the 
30 day risk period only.  
 
In the nested case control study and the SCCS, there was no significant increase in 
PCAE associated with any type of propranolol exposure although effect estimates were 
generally larger for incident high dose exposure. Similar to the nested case control 
study, chronic high-dose propranolol exposure was associated with a larger but non-
significant increased risk in PCAE in the SCCS. Similar to the nested case control 
study, low to moderate propranolol exposure was not associated with a significant 
increase in PCAE in the SCCS.  
 
The risk of asthma hospitalisation and PCAE in this study appeared to be in keeping 
with a dose response relationship to propranolol. The meta-analysis conducted in 
chapter 3 found that acute exposure to non-selective beta-blockers caused respiratory 
symptoms in around one in 13 people, falls in FEV1 of 20% or greater in around one in 
8 people and a mean fall in FEV1 of around 11% in people with stable mild to moderate 
asthma. However when examining heterogeneity in response, propranolol was shown to 
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produce a greater mean fall in FEV1 of around 17% following single dose exposure 
suggesting that propranolol exposure may be riskier than other non-selective beta-
blockers. The results from this chapter also suggest that risk from propranolol exposure 
in asthma appears to differ according to duration of administration with risk being 
greatest within the first 30 days of propranolol being prescribed. 
 
Strengths and limitations 
It was not possible to properly evaluate the risk of asthma death due to a lack of power 
and effect estimates often had wide confidence intervals demonstrating a lack of 
precision. The large number of calculations performed may increase the likelihood of a 
spuriously statistically significant association as a result of repeat testing. The nested 
case control study was conducted using a cohort of people with active asthma and 
anxiety in order to minimise confounding by indication. Although defining the study in 
this way may help to address confounding by indication in a between-person design, 
people with active anxiety may have higher levels of circulating endogenous 
catecholamines influencing airway smooth muscle tone potentially making beta-
blockers more risky. People with asthma appear to have been prescribed propranolol for 
anxiety despite it being a known contraindication and the exact reason for this is 
unknown. It could be that propranolol was prescribed for symptoms which the clinician 
attributed to anxiety but were in fact symptoms relating to uncontrolled asthma and this 
population would be at greater risk of an adverse respiratory event from beta-blocker 
exposure. Conversely, propranolol may have been prescribed to people with less severe 
asthma and risk may conceivably be greater in people with more severe asthma. 
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The results from this chapter suggest that risk from propranolol exposure in asthma also 
appears to differ according to duration of administration with risk being greatest within 
the first 30 days of exposure. This may be similar to the effects of beta-blockers in heart 
failure, where acute beta-blocker exposure reduces myocardial contractility whilst 
chronic exposure is well tolerated and leads to beta-adrenoceptor up-regulation with 
beneficial effects on ejection fraction and survival. This is discussed in further detail in 
chapter 10. However, the duration of exposure required to develop any potential 
adaptive response is uncertain and could depend upon a number of factors including 
individual response. For this reason, differing durations of risk window were used to 
evaluate risk and as expected the greatest risk occurred shortly following propranolol 
initiation. This risk reduction as treatment duration increases could also be due to 
susceptible people with asthma developing adverse respiratory events from propranolol 
at the start of therapy and propranolol therapy then being discontinued. This population 
would then not go on to experience chronic exposure introducing potential selection 
bias. 
 
The nested case control study was considered the primary analysis in this chapter with 
the SCCS the secondary analysis in an attempt to validate the results. The nested case 
control study is a between-person design whilst the SCCS is a within-person design. 
Although observational studies may suffer from bias and residual confounding, the 
approaches taken in this chapter were chosen to minimize this and be complementary 
because these two methods potentially suffer from different biases and confounding. 
The SCCS did not demonstrate an increased risk of PCAE in keeping with the nested 
case control study.  
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Acute risk periods in this SCCS analysis were based upon duration of time following an 
incident propranolol prescription and not upon known propranolol exposure in terms of 
when the drug was dispensed or when the patient actually took the drug. As such, 
exposure may have ended before the 60 and 90 day acute risk periods in some 
individuals potentially underestimating the relative incidence of PCAE. This was 
chosen: first to better compare with the nested case control study results; second 
because dosing instructions for propranolol were sometimes poorly defined (e.g. one 
tablet four times a day if required); and third because the date of incident propranolol 
exposure was determined by the prescription date which was used as a proxy for 
exposure. It is therefore unknown whether patients had this medication dispensed or 
when patients actually took propranolol for the first time. It was also unknown how 
compliant patients were to their medication regimes, but propranolol for anxiety is 
frequently taken as required rather than as a fixed daily dose making interpretation of 
dose instructions problematic. 
 
Although the SCCS controls for all time-fixed confounders, time-varying confounders 
still need to be controlled for. The most common form of time-varying confounding 
used in the SCCS literature is age. For this SCCS analysis which was conducted over a 
period of one year, age is unlikely to be a strong time-varying confounder given the 
nature of adult asthma and when age was included in the analysis, it had had no 
significant impact on the effect estimate. In contrast, a standard approach using a longer 
study period (e.g. 12 years) may have created significant problems in controlling for 
time-varying confounding first in relation to propranolol exposure, and second in 
relation to changing asthma medication exposure and seasonal variation. It is likely that 
age would be a strong time-varying confounder if a longer study period was used. For 
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this reason, the SCCS design was centred on incident propranolol exposure from which 
the acute risk period (which was of most interest) could be evaluated. 
 
7.6 Summary 
This study demonstrated an increased risk of asthma hospitalisation among people with 
asthma with incident and high dose propranolol exposure in keeping with biological 
plausibility. This increased risk was shown using the nested case control study and no 
statistically significant increase in relative incidence of PCAE was seen although effect 
estimates were generally larger for incident high dose exposure. This inconsistency in 
results could be as a result of unmeasured confounding and/or the fact that propranolol 
tends to cause more severe reactions in susceptible people with asthma and anxiety who 
are possibly more likely to present in secondary care. 
 
Insufficient power meant it was not possible to provide estimates for the association 
with asthma death. The following two chapters will evaluate oral beta-blockers 
commonly used for the management of cardiovascular disease and NSAIDs using a 
similar approach. The discussion section in chapter 10 will provide further detail and a 
comparison of these results with other chapters. 
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Chapter 8: Adverse Respiratory Effect 
of Cardiovascular Beta-Blockers in 
Asthma: Nested Case Control Study 
and Self-Controlled Case Series in 
People with Asthma and 
Cardiovascular Disease 
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8.1 Introduction 
The previous chapter evaluated exposure to propranolol in a subcohort of patients with 
active asthma and anxiety in an attempt to address confounding by indication. This 
analysis demonstrated an increased risk of asthma hospitalisation related to incident 
high dose propranolol exposure. Propranolol is rarely used for the management of 
cardiovascular (CVS) disease in the UK, having been replaced by newer non-selective 
and selective beta-blockers which demonstrate similar CVS effects in relation to 
blunting catecholamine-induced increases in heart rate, blood pressure and myocardial 
contractility (217). In addition, labetalol is a non-selective beta-blocker mainly used for 
the management of pregnancy-induced hypertension. Despite the potential benefit of 
beta-blockers in people with cardiovascular disease (CVD), a European consensus 
statement recommended that all beta-blockers should be contraindicated in people with 
a history of asthma over concerns they may induce bronchospasm (224).  
 
The meta-analysis of randomised blinded placebo-controlled trials presented in chapter 
3 demonstrated that selective beta-blockers were much better tolerated than non-
selective agents. However, they caused small mean falls in FEV1 of around 7%, 
significant falls in FEV1 of 20% or greater affecting around one in 8 people and a non-
significant increase in symptoms affecting one in 33 people suggesting that selective 
beta-blockers still have a small but significant risk among people with asthma. Although 
these clinical trials may have strong internal validity, it is uncertain how generalizable 
these findings are because these trials consist of selected people with stable mild-to-
moderate asthma who received close medical supervision that is not routinely available 
in the community setting. This is especially important given the drug utilisation study 
presented in chapter 6 highlighted an increasing prevalence of beta-blocker prescribing 
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among people with asthma clearly demonstrating a population at risk. Similar to the 
previous chapter, the incidence of asthma events is greater in people cardiovascular 
disease (47). 
 
8.2 Aim 
The aim of this chapter was to assess the adverse respiratory effect of oral beta-blockers 
commonly used for the management of CVD using linked electronic health data. 
 
8.3 Methods 
Primary analysis using the nested case control study 
Population 
The nested case control study measured the association between oral beta-blocker 
exposure (excluding propranolol and labetalol because these are indicated for other 
conditions as previously described) and asthma events in a cohort of people with asthma 
and CVD derived from the CPRD adult active asthma cohort (chapter 2, page 66). Entry 
into the asthma CVD cohort occurred on or after the date of entry to the CPRD active 
asthma cohort. The asthma CVD cohort consisted of people in the CPRD active asthma 
cohort who additionally had a Read code for CVD (ischaemic heart disease, chronic 
heart failure, cardiac arrhythmia, cerebrovascular disease, peripheral vascular disease or 
hypertension) ever recorded in their electronic medical record, AND who were 
prescribed one or more prescriptions for a CVS medication during their period of cohort 
follow-up. Exposure to CVS medication was defined by prescriptions for oral beta-
blockers (excluding patients prescribed propranolol and labetalol), calcium channel 
blockers, diuretics, renin-angiotensin-system inhibitors, nitrates and doxazosin. 
Therefore, this definition included people with actively managed CVD.  
217 
 
 
Entry into the asthma CVD cohort was defined as the date of the first CVS medication 
prescribed on or after entry into the CPRD active asthma cohort. Cohort follow-up 
remained unchanged as previously described (chapter 2, page 67) but the asthma CVD 
cohort was additionally censored at the end of exposure to CVS medication (defined 
below). In circumstances when exposure to CVS medication ceased before the end of 
follow-up, end of exposure was determined as the date of the last CVS prescription with 
the addition of a 90 day grace period. Additionally, in circumstances where there were 
gaps between CVS prescriptions of greater than 180 days, cohort follow-up was 
censored using the prescription date immediately preceding the gap with the addition of 
a 90 day grace period. Analysis was restricted to people from practices which were 
linked to the HES and ONS databases providing full outcome ascertainment. 
 
Case and control selection 
Outcomes consisted of asthma death, asthma hospitalisation and PCAE as previously 
defined (chapter 2, pages 67). For each outcome, up to 10 controls were randomly 
selected and matched to each case on age (categorised into deciles), gender, calendar 
year of cohort entry and whether patients were diagnosed with asthma before the age of 
45 using incidence density sampling. When a case could not be matched to one or more 
controls, the matching process was repeated without age. This was a pragmatic decision 
to include all cases and affected 2 cases (0.3%) of asthma hospitalisation and 8 cases 
(0.2%) of PCAE. 
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Exposures 
Oral beta-blocker exposure was defined as current incident user, current prevalent user 
and non-user as described in the general methods chapter (page 72). Among current 
users, exposure to oral beta-blockers was evaluated by selectivity and dose. Dose was 
stratified into low to moderate daily dose and high daily dose as defined in chapter 2 
(page 72). Oral beta-blocker exposure was evaluated using three risk windows 
consisting of 30, 60 and 90 days. 
 
Confounders and data analysis 
Multiple imputation was used to impute missing data on height, weight and smoking 
status as previously described (chapter 2, page 75). For each analysis, adjustment was 
made for the confounders listed in table 30 according to clinical relevance and model fit 
as previously described (chapter 2, page 73). Chi-squared testing and analysis of 
variance (ANOVA) was used to determine statistically significant differences in patient 
characteristics between cases and controls. Conditional logistic regression was used to 
estimate odds ratios which provide unbiased estimates of the incidence rate ratio for the 
association between oral beta-blockers and asthma events.  
 
Sensitivity analyses 
The following sensitivity analyses were performed for asthma hospitalisation and PCAE 
to test the robustness of the results as previously described (chapter 2, page 76):  
 excluding patients hospitalised during the risk period 
 excluding patients over the age of 40 years who smoked 
 excluding patients diagnosed with asthma over the age of 45 
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Table 30. Confounders used for risk adjustment in the analysis between oral beta-blockers 
and asthma death, asthma hospitalisation and primary care asthma exacerbation. 
 
Characteristic Death Hospitalisation PCAE 
Exact age
¥
 Yes Yes Yes 
Deprivation
€
 Yes Yes Yes 
Medications*    
 ICS Yes Yes Yes 
 LABA Yes Yes Yes 
 LABAICS Yes Yes Yes 
 Leukotriene antagonist Yes Yes Yes 
 Methylxanthine  Yes Yes Yes 
 No. of SABA¥ Yes Yes Yes 
 Oral steroid Yes Yes No 
 NSAIDs Yes Yes Yes 
Comorbidity    
 Nasal polyps No Yes Yes 
 BMI¥ Yes Yes Yes 
 Charlson co-morbidity 
score
¥
 
Yes Yes Yes 
Smoking status Yes Yes Yes 
Previous asthma hospitalisation  Yes Yes Yes 
RTI* Yes Yes Yes 
Asthma review
δ
 No No Yes 
 
*= In the 90 days prior to index date. €= Index of multiple deprivation decile.  
δ = In the 365 days prior to index date.  
¥  = Continuous variable. PCAE = primary care asthma exacerbation. 
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 excluding patients not matched in the first round of control selection (i.e. not 
matched on age, since this is the matching variable dropped in the second round) 
 complete case analysis 
 
Secondary analysis using the self-controlled case series 
The SCCS method has previously defined in chapter 2 (page 77). The SCCS was 
conducted over a 360 day study period centred on incident oral beta-blocker exposure 
(first prescription in the file in people with at least 1 year of follow up prior to the first 
prescription) as previously defined (chapter 2, page 77). The beginning of the 
observation period was defined as 180 days prior to the date of the incident oral beta-
blocker prescription and the end of the observation period was defined as 180 days 
following this incident prescription. The SCCS was performed for PCAE as previously 
defined, using 30 day, 60 day and 90 day acute risk periods beginning on the incident 
prescription date for oral beta-blocker. Exposure beyond these risk windows was 
categorised as chronic exposure. A 30 day pre-risk period was used to account for short-
lived event dependent exposures. All remaining person time was classed as baseline. 
 
Confounders and data analysis 
Time-varying exposure to the following medications issued within each 90 day 
consecutive period was then adjusted for in the analysis as previously described 
(chapter2, page 80): ICS; inhaled LABAs; leukotriene antagonists; methlyxanthines; 
and the total number of SABA prescriptions. Additional risk adjustment was also made 
for seasonal variation. Crude and adjusted incidence rate ratios (IRR) were calculated 
using conditional Poisson regression with analyses stratified by dose as previously 
defined (page 81). 
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8.4 Results 
The asthma CVD cohort consisted of 35502 patients with a mean age at cohort entry of 
60.1 years (SD 11.8) and more women than men (59.7% vs. 40.3% respectively). 
During follow-up of the asthma CVD cohort, a total of 26 asthma deaths, 585 asthma 
hospitalisations and 4234 PCAE occurred. Selective beta-blockers were prescribed to 
5017 patients (14.1%) and non-selective beta-blockers were prescribed to 407 patients 
(1.2%) in the asthma CVD cohort during a mean of 3.5 years of follow-up. 
 
8.4.1 Primary analysis using the nested case control study 
Asthma death 
All cases of asthma death were matched to 10 controls. Table 31 describes 
characteristics of the 26 cases of asthma death compared to the 260 matched controls. 
There were no statistically significant differences in matching criteria between cases 
and controls. Cases died of asthma at a mean age of 71.7 years and were predominantly 
women (76.9%). Cases had a statistically significant higher use of SABAs and oral 
steroids within 90 days of the index date. Cases were more likely to have previously 
been hospitalised for asthma and hospitalised for any cause within 90 days of the index 
date which was statistically significant. 
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Table 31. Characteristics of cases and controls for asthma death in the cardiovascular 
beta-blocker analysis. 
 
Characteristics 
Cases 
N=26 
Controls 
N=260 
 
p-value 
Matching variables    
Age (years, SD) 71.7 (15.2) 70.3 (14.1) 0.631* 
Female gender 20 (76.9) 200 (76.9) 1.000 
Years of follow-up to index date (years, SD) 4.1 (3.7) 4.0 (3.6) 0.872* 
Diagnosed with asthma ≤ age 45 6 (23.1) 60 (23.1) 1.000 
Potential confounders    
Asthma therapy in the 90 days prior to index 
date  
   
 ICS 14 (53.8) 142 (54.6) 0.940 
 LABA 4 (15.4) 29 (11.2) 0.520 
 LABAICS 4 (15.4) 58 (22.3) 0.517 
 Leukotriene antagonist 2 (7.7) 12 (4.6) 0.828 
 Methylxanthine  2 (7.7) 4 (1.5) 0.171 
 Mean no. of SABA prescriptions (SD) 2.7 (2.9) 1.3 (1.6) 0.000* 
 Oral steroid 9 (34.6) 20 (7.7) 0.000 
Comorbidity    
 Nasal polyps 2 (7.7) 14 (5.4) 0.968 
 Mean BMI (SD) 27.8 (5.8) 29.3 (6.1) 0.260* 
 Mean Charlson co-morbidity score (SD) 2.2 (1.1) 2.3 (1.8) 0.740* 
Smoking status    
 Current smoker 4 (15.4) 20 (7.7) 0.328 
 Ex-smoker 10 (38.5) 106 (40.8) 0.819 
 Non-smoker 8 (30.8) 125 (48.1) 0.092 
 Missing 4 (15.4) 9 (3.5)  
Previous hospitalisation for asthma 4 (15.4) 10 (3.8) 0.034 
RTI recorded in the 90 days prior to index date 4 (15.4) 16 (6.2) 0.175 
Hospitalisation in the 90 days prior to index 
date 
13 (50.0) 18 (6.9) 0.000 
Asthma review in the 365 days prior to index 
date 
11 (42.3) 119 (45.8) 0.735 
*Continuous variable analysed using ANOVA, otherwise variables are categorical analysed using the Chi-square test.         
SD = standard deviation, ICS = inhaled corticosteroid, LABA = long-acting beta2-agonist, LABAICS = long-acting 
beta2-agonist in combination inhaler with ICS, SABA = short-acting beta2-agonist, RTI = respiratory tract infection, 
BMI = Body mass index. Cases and controls matched on age category, gender, calendar year of cohort entry and 
whether patients were diagnosed with asthma under the age of 45 years only. 
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Asthma hospitalisation 
A total of two cases (0.3%) were included unmatched on age. Table 32 describes the 
characteristics of the 585 cases of asthma hospitalisation matched to 5818 controls. 
There were no significant differences in matching criteria between cases and controls. 
Cases were hospitalised for asthma at a mean age of 62.0 years and were predominantly 
women (70.3%). Cases had a statistically significant higher use of all types of asthma 
medication. A significantly higher proportion of cases had a respiratory tract infection 
recorded, had previously been hospitalised for asthma and had been hospitalised for any 
cause within 90 days of the index date. Cases had small but statistically significant 
greater mean BMI and Charlson comorbidity score, and had fewer ex-smokers.  
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Table 32. Characteristics of case and controls for asthma hospitalisation in the 
cardiovascular beta-blocker analysis. 
 
Characteristics 
Cases 
N=585 
Controls 
N=5818 
 
p-value 
Matching variables    
Age (years, SD) 62.0 (13.1) 62.2 (13.1) 0.760* 
Female gender 411 (70.3) 4091 (70.3) 0.976 
Years of follow-up to index date (years, SD) 2.8 (2.9) 2.8 (2.9) 0.975* 
Diagnosed with asthma ≤ age 45 197 (33.7) 1952 (33.6) 0.952 
Potential confounders    
Asthma therapy in the 90 days prior to index 
date  
   
 ICS 259 (44.3) 2861 (49.2) 0.024 
 LABA 115 (19.7) 532 (9.1) 0.000 
 LABAICS 218 (37.3) 1296 (22.3) 0.000 
 Leukotriene antagonist 66 (11.3) 182 (3.1) 0.000 
 Methylxanthine  50 (8.5) 100 (1.7) 0.000 
 Mean no. of SABA prescriptions (SD) 2.0 (1.7) 1.1 (1.3) 0.000* 
 Oral steroid 264 (45.1) 400 (6.9) 0.000 
Comorbidity    
 Nasal polyps 32 (5.5) 309 (5.3) 0.870 
 Mean BMI (SD) 31.1 (7.0) 30.1 (6.3) 0.001* 
 Mean Charlson co-morbidity score (SD) 2.0 (1.6) 1.9 (1.4) 0.018* 
Smoking status    
 Current smoker 59 (10.1) 551 (9.5) 0.629 
 Ex-smoker 220 (37.6) 2495 (42.9) 0.014 
 Non-smoker 281 (48.0) 2611 (44.9) 0.144 
 Missing 25 (4.3) 161 (2.8)  
Previous hospitalisation for asthma 83 (14.2) 111 (1.9) 0.000 
RTI recorded in the 90 days prior to index date 106 (18.1) 384 (6.6) 0.000 
Hospitalisation in the 90 days prior to index 
date 
80 (13.7) 449 (7.7) 0.000 
Asthma review in the 365 days prior to index 
date 
273 (46.7) 2803 (48.2) 0.486 
*Continuous variable analysed using ANOVA, otherwise variables are categorical analysed using the Chi-square test.         
SD = standard deviation, ICS = inhaled corticosteroid, LABA = long-acting beta2-agonist, LABAICS = long-acting 
beta2-agonist in combination inhaler with ICS, SABA = short-acting beta2-agonist, RTI = respiratory tract infection, 
BMI = Body mass index. Cases and controls matched on age category, gender, calendar year of cohort entry and 
whether patients were diagnosed with asthma under the age of 45 years only. 
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Primary care asthma exacerbations 
Eight cases (0.2%) were included unmatched on age. Table 33 describes the 
characteristics of the 4234 cases of PCAE matched to 41881 controls. There were no 
significant differences in matching criteria between cases and controls. PCAEs occurred 
at a mean age of 62.8 years predominantly in women (66.5%). Cases had statistically 
significant greater use asthma medications apart from ICS. A significantly higher 
proportion of cases had attended an asthma review in the previous year, had a 
respiratory tract infection recorded within 90 days of the index date and had previously 
been hospitalised for asthma. Cases had a small but statistically significant increase in 
mean BMI, decrease in Charlson comorbidity score and increase in the proportion of 
patients with nasal polyps. 
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Table 33. Characteristics of case and controls for primary care asthma exacerbations in 
the cardiovascular beta-blocker analysis. 
 
Characteristics 
Cases 
N=4234 
Controls 
N=41881 
 
p-value 
Matching variables    
Age (years, SD) 62.8 (11.8) 62.9 (11.7) 0.333* 
Female gender 2815 (66.5) 27898 (66.6) 0.867 
Years of follow-up to index date (years, SD) 2.0 (2.5) 2.0 (2.5) 0.988* 
Diagnosed with asthma ≤ age 45 1131 (26.7) 10932 (26.1) 0.390 
Potential confounders    
Asthma therapy in the 90 days prior to index 
date  
   
 ICS 2074 (49.0) 19995 (47.7) 0.123 
 LABA 421 (9.9) 2734 (6.5) 0.000 
 LABAICS 986 (23.3) 7241 (17.3) 0.000 
 Leukotriene antagonist 108 (2.6) 731 (1.7) 0.000 
 Methylxanthine  80 (1.9) 564 (1.3) 0.004 
 Mean no. of SABA prescriptions (SD) 1.3 (1.3) 1.0 (1.1) 0.000* 
 Oral steroid - -  
Comorbidity    
 Nasal polyps 200 (4.7) 1570 (3.7) 0.002 
 Mean BMI (SD) 30.2 (6.3) 29.7 (6.0) 0.000* 
 Mean Charlson co-morbidity score (SD) 1.8 (1.4) 2.0 (1.5) 0.000* 
Smoking status    
 Current smoker 444 (10.5) 4132 (9.9) 0.198 
 Ex-smoker 1885 (44.5) 18047 (43.1) 0.074 
 Non-smoker 1779 (42.0) 18209 (43.5) 0.068 
 Missing 126 (3.0) 1493 (3.6)  
Previous hospitalisation for asthma 115 (2.7) 602 (1.4) 0.000 
RTI recorded in the 90 days prior to index date 597 (14.1) 2001 (4.8) 0.000 
Hospitalisation in the 90 days prior to index 
date 
311 (7.3) 3200 (7.6) 0.490 
Asthma review in the 365 days prior to index 
date 
2104 (49.7) 18905 (45.1) 0.000 
*Continuous variable analysed using ANOVA, otherwise variables are categorical analysed using the Chi-square test.         
SD = standard deviation, ICS = inhaled corticosteroid, LABA = long-acting beta2-agonist, LABAICS = long-acting 
beta2-agonist in combination inhaler with ICS, SABA = short-acting beta2-agonist, RTI = respiratory tract infection, 
BMI = Body mass index. Cases and controls matched on age category, gender, calendar year of cohort entry and 
whether patients were diagnosed with asthma under the age of 45 years only. 
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Oral non-selective beta-blocker exposure 
The most commonly prescribed non-selective beta-blockers were sotalol and carvedilol.  
The crude and adjusted associations between oral non-selective beta-blocker exposure 
and asthma events are shown in table 34. Due to low power for the 30 day risk 
windows, it was only possible to estimate the relative incidence for asthma death using 
the 60 and 90 day risk window for total and prevalent exposure. The relative incidence 
of asthma death was not significantly increased with non-selective beta-blocker 
exposure using the 60 and 90 day risk window (IRR 9.30 (95%CI 0.43 to 202.56) and 
IRR 10.52 (95%CI 0.46-243.09) respectively). It was not possible to estimate relative 
incidence for incident non-selective beta-blocker exposure. There was no significant 
difference found for prevalent non-selective beta-blocker exposure in the 60 and 90 day 
risk window. All exposure was prevalent exposure and a large but non-significant 
increase in the relative incidence of asthma death was observed.  
 
Overall, there was no significant increase in the relative incidence of asthma 
hospitalisation associated with any non-selective beta-blocker exposure (incident and 
prevalent combined) with any of the risk windows (table 34). When stratified by type of 
exposure, exposure consisted of prevalent exposure only and no significant increase was 
observed. 
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Table 34. Crude and adjusted incidence rate ratios for the association between oral non-selective beta-blocker exposure and asthma events. 
*Adjustment for confounders listed in table 30 (page 219). Empty cells = inestimable due to lack of exposure in the risk window.  
 Any Incident Prevalent 
 Crude Adjusted Crude Adjusted Crude Adjusted 
Risk window IRR IRR 95% CI p-value IRR IRR 95% CI p-value IRR IRR 95% CI p-value 
Death             
 30 day - - - - - - - - - - - - 
 60 day 5.00 9.30 0.43-202.56 0.156 - - - - 5.00 9.30 0.43-202.56 0.156 
 90 day 5.00 10.52 0.46-243.09 0.142 - - - - 5.00 10.81 0.46-253.28 0.139 
Hospitalisation             
 30 day 0.52 0.57 0.06-5.41 0.627 - - - - 0.52 0.57 0.06-5.41 0.627 
 60 day 1.00 1.33 0.32-5.50 0.698 - - - - 1.07 1.38 0.33-5.79 0.658 
 90 day 0.83 1.06 0.27-4.20 0.934 - - - - 0.88 1.09 0.27-4.37 0.901 
PCAE             
 30 day 1.34 1.39 0.89-2.18 0.146 2.79 3.35 0.89-12.58 0.073 1.25 1.28 0.79-2.05 0.316 
 60 day 1.33 1.40 0.95-2.08 0.090 5.19 5.21 1.83-14.90 0.002 1.13 1.20 0.78-1.84 0.419 
 90 day 1.25 1.29 0.88-1.90 0.192 3.83 3.91 1.44-10.63 0.007 1.07 1.12 0.74-1.71 0.596 
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Overall, there was no significant increase in the relative incidence of PCAE associated 
with any non-selective beta-blocker exposure (incident and prevalent combined) with 
any of the risk windows. When stratified by type of exposure, an increase in the relative 
incidence of PCAE was observed with incident non-selective exposure which was 
significant for the 60 and 90 day risk window (IRR 3.35 (95% CI 0.89 to 12.58), IRR 
5.21 (95% CI 1.83 to 14.90) and IRR 3.91 (95% CI 1.44 to 10.63) for the 30, 60 and 90 
day risk windows respectively). No significant increase in the relative incidence of 
PCAE was observed with prevalent non-selective beta-blocker exposure. 
 
The association between oral non-selective beta-blocker exposure and asthma 
hospitalisation and PCAE according to dose are shown in table 35. Overall, there was a 
significant increase in the relative incidence of asthma hospitalisation with high dose 
non-selective beta-blocker exposure which was significant for the 60 and 90 day risk 
windows (IRR 15.79 (95% CI 1.30 to 191.77) and 11.17 (95% CI 1.07 to 116.26) 
respectively). It was not possible to obtain an estimate for the 30 day risk window due 
to an absence of high dose oral non-selective beta-blocker exposure among the cases 
and controls. When stratified by type of exposure, only prevalent high dose non-
selective beta-blocker exposure was present which produced similar significant 
increases in relative incidence of asthma hospitalisation compared to any exposure. 
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Table 35. Incidence rate ratios for the association between oral non-selective beta-blocker exposure and asthma events by dose. 
*Adjustment for confounders listed in table 30 (page 219). Empty cells = inestimable due to lack of exposure in the risk window. 
 Any Incident Prevalent 
 Crude Adjusted Crude Adjusted Crude Adjusted 
Risk window IRR IRR 95% CI p-value IRR IRR 95% CI p-value IRR IRR 95% CI p-value 
High dose             
Hospitalisation             
 30 day - - - - - - - - - - - - 
 60 day 5.00 15.79 1.30-191.77 0.030 - - - - 5.00 15.49 1.27-189.36 0.032 
 90 day 3.33 11.17 1.07-116.26 0.044 - - - - 3.33 11.03 1.06-115.18 0.045 
PCAE             
 30 day 2.50 2.70 1.00-7.29 0.049 - - - - 2.50 2.71 1.00-7.30 0.049 
 60 day 2.50 2.69 1.08-6.67 0.033 - - - - 2.50 2.68 1.08-6.65 0.034 
 90 day 2.92 3.17 1.35-7.45 0.008 10.00 9.72 0.57-165.97 0.116 2.61 2.73 1.09-6.83 0.032 
Low to moderate dose             
Hospitalisation             
 30 day 0.55 0.59 0.06-5.56 0.642 - - - - 0.55 0.59 0.06-5.61 0.645 
 60 day 0.71 0.76 0.14-4.13 0.752 - - - - 0.77 0.79 0.14-4.34 0.783 
 90 day 0.61 0.63 0.12-3.25 0.580 - - - - 0.64 0.64 0.12-3.36 0.601 
PCAE             
 30 day 1.19 1.22 0.74-2.02 0.432 2.79 3.36 0.89-12.58 0.073 1.07 1.08 0.63-1.86 0.783 
 60 day 1.18 1.24 0.80-1.90 0.337 5.19 5.21 1.82-14.92 0.002 0.94 0.99 0.60-1.62 0.960 
 90 day 1.10 1.13 0.74-1.73 0.574 3.60 3.54 1.31-9.51 0.012 0.90 0.89 0.54-1.46 0.642 
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Overall, there was a significant increase in the relative incidence of PCAE with high 
dose non-selective beta-blocker exposure for all risk windows (IRR 2.70 (95% CI 1.00 
to 7.29), IRR 2.69 (95% CI 1.08 to 6.67) and IRR 3.17 (95% CI 1.35 to 7.45) for the 30, 
60 and 90 day risk windows respectively). When stratified by type of exposure, 
prevalent high dose non-selective beta-blocker exposure produced similar significant 
increases in relative incidence of PCAE compared to any exposure. It was possible to 
calculate relative incidence of PCAE for incident high dose exposure using a 90 day 
risk window only and was non-significant (IRR 9.72 (95% CI 0.57 to 165.97)). 
 
Overall, there was no significant increase in the relative incidence of PCAE with any 
low to moderate dose non-selective beta-blocker exposure for any of the risk windows 
evaluated. When stratified by type of exposure, an increase in the relative incidence of 
PCAE was observed with incident non-selective exposure which was significant for the 
60 and 90 day risk window (IRR 3.35 (95% CI 0.89 to 12.58), IRR 5.21 (95%CI 1.82 to 
14.92) and IRR 3.54 (95% CI 1.31 to 9.51) for the 30, 60 and 90 day risk windows 
respectively). No significant increase in the relative incidence of PCAE was observed 
with prevalent low to moderate dose non-selective beta-blocker exposure. 
 
Oral selective beta-blocker exposure 
The most commonly prescribed selective beta-blockers were atenolol and bisoprolol.  
The crude and adjusted associations between oral selective beta-blocker exposure and 
asthma events are shown in table 36. It was only possible to estimate the relative 
incidence for asthma death using the 90 day risk window which was not significantly 
different. This exposure consisted of prevalent exposure only and therefore it was not 
possible to estimate relative incidence for incident selective beta-blocker exposure.
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Table 36. Crude and adjusted rate ratios for the association between oral selective beta-blocker exposure and asthma events. 
*Adjustment for confounders listed in table 30 (page 219). Empty cells = inestimable due to lack of exposure in the risk window. 
 Any Incident Prevalent 
 Crude Adjusted Crude Adjusted Crude Adjusted 
Risk window IRR IRR 95% CI p-value IRR IRR 95% CI p-value IRR IRR 95% CI p-value 
Death             
 30 day - - - - - - - - - - - - 
 60 day - - - - - - - - - - - - 
 90 day 0.42 1.43 0.16-12.72 0.746 - - - - 0.50 1.72 0.19-15.94 0.635 
Hospitalisation             
 30 day 0.84 1.08 0.66-1.79 0.753 0.98 0.88 0.07-10.89 0.920 0.83 1.09 0.66-1.82 0.731 
 60 day 0.76 0.99 0.62-1.56 0.948 2.07 1.71 0.47-6.26 0.419 0.67 0.92 0.56-1.51 0.747 
 90 day 0.83 1.01 0.66-1.54 0.980 1.70 2.00 0.65-6.13 0.225 0.74 0.92 0.58-1.45 0.721 
PCAE             
 30 day 0.81 0.87 0.75-1.01 0.061 1.03 1.00 0.50-2.04 0.989 0.81 0.86 0.74-1.00 0.056 
 60 day 0.89 0.96 0.85-1.09 0.563 0.85 0.86 0.50-1.47 0.578 0.89 0.97 0.85-1.10 0.622 
 90 day 0.89 0.98 0.87-1.10 0.698 0.66 0.69 0.43-1.11 0.130 0.91 1.00 0.88-1.13 0.996 
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Overall, there was no statistically significant increase in the relative incidence of asthma 
hospitalisation associated with any oral selective beta-blocker exposure (incident and 
prevalent combined) with any of the risk windows overall (table 36). There was no 
statistically significant increase in the relative incidence of asthma hospitalisation 
associated with prevalent selective beta-blocker exposure. 
 
Overall, there was no statistically significant increase in the relative incidence of PCAE 
associated with any oral selective beta-blocker exposure (incident and prevalent 
combined) with any of the risk windows overall (table 36). When stratified by type of 
exposure, there was no statistically significant increase in the relative incidence of 
asthma hospitalisation associated with incident or prevalent oral selective beta-blocker 
exposure. 
 
The association between oral non-selective beta-blocker exposure and asthma 
hospitalisation and PCAE according to dose are shown in table 37. There was no 
statistically significant increase in the relative incidence of asthma hospitalisation with 
any dose of selective beta-blocker exposure. When stratified by type of exposure, there 
was no statistically significant increase in the relative incidence of asthma 
hospitalisation associated with high dose incident selective beta-blocker exposure 
although effect estimates were generally larger. It was not possible to calculate the 
relative incidence for incident exposure using a 30 day risk window due to a lack of 
power. There was no statistically significant increase in the relative incidence of asthma 
hospitalisation associated with any dose of prevalent selective beta-blocker exposure. 
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Table 37. Incidence rate ratios for the association between oral selective beta-blocker exposure and asthma events by dose. 
*Adjustment for confounders listed in table 30 (page 219). Empty cells = inestimable due to lack of exposure in the risk window.  
 Any Incident Prevalent 
 Crude Adjusted Crude Adjusted Crude Adjusted 
Risk window IRR IRR 95% CI p-value IRR IRR 95% CI p-value IRR IRR 95% CI p-value 
High dose             
Hospitalisation             
 30 day 1.11 1.54 0.51-4.63 0.443 - - - - 1.18 1.61 0.53-4.87 0.403 
 60 day 0.89 1.31 0.44-3.88 0.633 2.00 3.77 0.42-34.24 0.238 0.75 1.01 0.29-3.52 0.984 
 90 day 0.89 1.13 0.43-3.01 0.804 1.43 2.43 0.28-21.22 0.422 0.82 0.95 0.32-2.80 0.926 
PCAE             
 30 day 0.89 0.96 0.69-1.34 0.792 0.90 1.03 0.24-4.50 0.964 0.89 0.94 0.67-1.33 0.744 
 60 day 0.99 1.09 0.82-1.43 0.561 0.49 0.52 0.12-2.18 0.369 1.03 1.13 0.85-1.49 0.403 
 90 day 1.01 1.10 0.85-1.43 0.477 0.52 0.57 0.18-1.83 0.344 1.06 1.16 0.88-1.51 0.293 
Low to moderate dose             
Hospitalisation             
 30 day 0.79 1.00 0.57-1.73 0.985 0.89 0.79 0.07-9.21 0.849 0.79 1.01 0.57-1.79 0.969 
 60 day 0.74 0.98 0.60-1.60 0.943 1.52 1.56 0.43-5.63 0.498 0.67 0.91 0.54-1.55 0.736 
 90 day 0.80 1.01 0.64-1.59 0.965 1.34 1.81 0.59-5.57 0.301 0.73 0.91 0.55-1.51 0.721 
PCAE             
 30 day 0.81 0.86 0.73-1.01 0.063 1.33 1.25 0.67-2.34 0.489 0.78 0.83 0.70-0.99 0.039 
 60 day 0.87 0.95 0.82-1.09 0.419 1.02 0.98 0.60-1.60 0.926 0.86 0.95 0.82-1.09 0.448 
 90 day 0.88 0.96 0.84-1.09 0.529 0.81 0.82 0.54-1.27 0.378 0.89 0.98 0.85-1.12 0.757 
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There was no statistically significant increase in the relative incidence of PCAE with 
any dose of selective beta-blocker exposure. When stratified by type of exposure, there 
was no statistically significant increase in the relative incidence of PCAE associated 
with incident or prevalent selective beta-blocker exposure with any dose. 
 
Nested case control sensitivity analyses 
Results from sensitivity analyses are presented in tables 38 and 39 for oral non-selective 
and selective beta-blocker exposure respectively.   
 
1. Excluding patients hospitalised within the risk period 
This was done to assess any impact of immortal time bias. For asthma hospitalisation, 
this involved excluding 43 (7.4%), 63 (10.8%) and 80 (13.7%) cases for the 30, 60 and 
90 day risk windows respectively whilst for PCAE this involved excluding 111 (2.6%), 
201 (4.8%) and 311 (7.4%) cases for the 30, 60 and 90 day risk windows respectively. 
This analysis produced similar results to the main analysis (shown in tables 38 and 39). 
For oral non-selective beta-blockers, effect estimates were slightly larger for both 
asthma hospitalisation and PCAE although the number of estimates which were 
significant remained unchanged.  
 
2. Excluding patients diagnosed with asthma over the age of 45 years 
This was done to assess any impact of including patients who may have unknown fixed 
airway obstruction. For asthma hospitalisation, this involved excluding 388 (66.3%) of 
cases whilst for PCAE this involved excluding 3103 (73.3%) of cases. For non-selective 
beta-blockers, this analysis produced effect estimates which were larger than the main 
analysis although all were non-significant due to a reduction in power 
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Table 38. Non-selective cardiovascular beta-blocker sensitivity analyses as per methods. 
Sensitivity analyses excluding patients: hospitalised within the risk window; smokers >40 years of age; 
diagnosed with asthma >45 years of age; unmatched on age; complete case analysis.   
 Any Incident Prevalent 
 IRR 95% CI IRR 95% CI IRR 95% CI 
Hospitalised in risk window       
Hospitalisation       
30 day 0.63 0.06-6.35 - - 0.63 0.06-6.36 
60 day 1.51 0.34-6.33 - - 1.51 0.34-6.34 
90 day 1.63 0.37-7.13 - - 1.63 0.37-7.14 
PCAE       
30 day 1.46 0.93-2.26 3.64 0.95-13.92 1.32 0.82-2.13 
60 day 1.44 0.96-2.16 6.19 1.61-23.83 1.29 0.84-1.99 
90 day 1.41 0.94-2.10 4.24 1.18-15.16 1.28 0.84-1.97 
Diagnosed with asthma ≥45       
Hospitalisation       
30 day - - - - - - 
60 day 3.06 0.35-26.67 - - 3.06 0.35-26.67 
90 day 1.81 0.20-16.20 - - 1.81 0.20-16.19 
PCAE       
30 day 1.09 0.33-3.61 7.75 0.42-142.11 0.77 0.18-3.28 
60 day 1.50 0.58-3.87 7.70 0.42-140.92 1.26 0.44-3.60 
90 day 1.26 0.49-3.24 2.64 0.25-28.02 1.12 0.40-3.19 
Smokers over 40 years       
Hospitalisation       
30 day 0.53 0.06-5.08 - - 0.53 0.06-5.08 
60 day 1.28 0.31-5.35 - - 1.33 0.31-5.63 
90 day 1.06 0.26-4.27 - - 1.08 0.26-4.45 
PCAE       
30 day 1.52 0.96-2.39 5.06 1.23-20.79 1.36 0.84-2.21 
60 day 1.45 0.97-2.17 7.37 2.35-23.12 1.21 0.77-1.89 
90 day 1.34 0.90-1.99 4.85 1.69-13.89 1.14 0.74-1.76 
Unmatched on age       
Hospitalisation       
30 day 0.56 0.06-5.33 - - 0.56 0.06-5.33 
60 day 1.32 0.32-5.47 - - 1.37 0.33-5.77 
90 day 1.06 0.27-4.20 - - 1.09 0.27-4.37 
PCAE       
30 day 1.34 0.85-2.10 3.35 0.89-12.57 1.22 0.75-1.98 
60 day 1.36 0.91-2.02 5.22 1.83-14.90 1.15 0.74-1.78 
90 day 1.25 0.85-1.85 3.92 1.44-10.63 1.08 0.70-1.66 
Complete case analysis       
Hospitalisation       
30 day 0.62 0.06-6.10 - - 0.62 0.06-6.11 
60 day 1.49 0.35-6.39 - - 1.56 0.36-6.83 
90 day 1.14 0.28-4.63 - - 1.18 0.29-4.84 
PCAE       
30 day 1.43 0.91-2.27 3.13 0.83-11.75 1.32 0.81-2.15 
60 day 1.47 0.98-2.19 4.96 1.74-14.14 1.25 0.80-1.94 
90 day 1.37 0.92-2.02 3.74 1.38-10.14 1.19 0.77-1.83 
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Table 39. Selective cardiovascular beta-blocker sensitivity analyses as per methods. 
Sensitivity analyses excluding patients: hospitalised within the risk window; smokers >40 years of age; 
diagnosed with asthma >45 years of age; unmatched on age; complete case analysis. 
 
 Any Incident Prevalent 
 IRR 95% CI IRR 95% CI IRR 95% CI 
Hospitalised in risk window       
Hospitalisation       
30 day 1.13 0.67-1.91 - - 1.15 0.68-1.95 
60 day 1.02 0.62-1.68 1.89 0.44-8.25 0.95 0.56-1.63 
90 day 0.92 0.56-1.53 0.41 0.04-3.79 0.97 0.58-1.63 
PCAE       
30 day 0.86 0.74-1.01 0.93 0.42-2.05 0.86 0.74-1.01 
60 day 0.96 0.84-1.09 0.78 0.41-1.50 0.96 0.84-1.10 
90 day 0.97 0.85-1.10 0.55 0.29-1.04 1.00 0.87-1.14 
Diagnosed with asthma ≥45       
Hospitalisation       
30 day 0.53 0.15-1.85 1.58 0.07-36.27 0.44 0.10-1.87 
60 day 0.62 0.21-1.83 0.64 0.05-8.23 0.62 0.19-2.04 
90 day 0.86 0.35-2.10 0.63 0.06-6.46 0.91 0.35-2.37 
PCAE       
30 day 0.72 0.50-1.04 0.59 0.14-2.57 0.73 0.50-1.07 
60 day 0.85 0.63-1.15 0.79 0.31-2.02 0.86 0.63-1.18 
90 day 0.88 0.66-1.16 0.62 0.27-1.43 0.92 0.68-1.24 
Smokers over 40 years       
Hospitalisation       
30 day 1.00 0.58-1.73 1.03 0.06-17.41 1.00 0.57-1.75 
60 day 0.88 0.53-1.46 2.23 0.56-8.81 0.73 0.41-1.28 
90 day 0.89 0.56-1.42 2.47 0.78-7.89 0.72 0.43-1.22 
PCAE       
30 day 0.89 0.76-1.04 1.14 0.56-2.34 0.88 0.75-1.03 
60 day 0.99 0.87-1.14 0.93 0.54-1.61 1.00 0.87-1.14 
90 day 1.00 0.88-1.14 0.78 0.48-1.26 1.02 0.89-1.17 
Unmatched on age       
Hospitalisation       
30 day 1.09 0.66-1.80 0.89 0.07-11.12 1.10 0.66-1.84 
60 day 0.99 0.63-1.57 1.72 0.47-6.32 0.93 0.57-1.52 
90 day 1.01 0.66-1.55 2.02 0.66-6.19 0.92 0.58-1.46 
PCAE       
30 day 0.87 0.75-1.01 1.01 0.50-2.04 0.86 0.74-1.01 
60 day 0.97 0.85-1.10 0.86 0.50-1.47 0.97 0.85-1.10 
90 day 0.98 0.87-1.11 0.70 0.43-1.12 1.00 0.88-1.14 
Complete case analysis       
Hospitalisation       
30 day 1.09 0.66-1.82 0.88 0.08-10.49 1.11 0.66-1.86 
60 day 1.00 0.63-1.59 1.65 0.43-6.31 0.94 0.57-1.55 
90 day 1.02 0.66-1.57 2.03 0.64-6.47 0.93 0.59-1.48 
PCAE       
30 day 0.87 0.74-1.01 1.00 0.49-2.03 0.86 0.74-1.01 
60 day 0.96 0.84-1.09 0.90 0.52-1.55 0.96 0.84-1.10 
90 day 0.98 0.86-1.11 0.74 0.46-1.18 1.00 0.88-1.13 
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3. Excluding patients over the age of 40 years who smoked 
This was done to again assess any impact of including patients who may have unknown 
fixed airway obstruction. For asthma hospitalisation, this involved excluding 46 (7.9%) 
of cases whilst for PCAE this involved excluding 395 (9.3%) of cases. For the 
association between non-selective beta-blockers and PCAE, effect estimates were larger 
than the main analysis with incident exposure being significant for all three risk 
windows (IRR 5.06 (95% CI 1.23 to 20.79), 7.37 (95% CI 2.35 to 23.12) and 4.85 (95% 
CI 1.69 to 13.89) for the 30, 60 and 90 day risk windows respectively). For selective 
beta-blockers, effect estimates for asthma hospitalisation and PCAE were slightly larger 
than the main analysis although no changes in overall significance were observed.  
 
4. Excluding patients originally unmatched on age 
This was done to assess for any residual confounding by age. For asthma 
hospitalisation, this involved excluding 2 (0.3%) of cases whilst for PCAE this involved 
excluding 8 (0.2%) of cases. This analysis produced almost identical results the main 
analysis with no overall changes in significance. 
 
5. Complete case analysis 
This was done to assess the impact of multiply imputing missing data. For asthma 
hospitalisation, data was missing on height, weight and smoking status for 78 (1.2%), 
71 (1.1%) and 186 (2.9%) of people respectively whilst for PCAE data was missing on 
height, weight and smoking status for 604 (1.3%), 526 (1.1%) and 1619 (3.5%) of 
people respectively. Results were very similar to the main analysis with a significantly 
increased risk of PCAE with incident oral non-selective beta-blocker exposure. 
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8.4.2 Secondary analyses using the self-controlled case series 
The two SCCS analyses consisted of 27 patients (mean age 68.6 years, 48% women) 
with incident non-selective beta-blocker exposure experiencing a total of 36 PCAEs, 
and 185 patients (mean age 64.0 years, 49% women) with incident selective beta-
blocker exposure experiencing 239 PCAEs during the study period. Non-selective beta-
blockers consisted of carvedilol and sotalol whilst the most common selective beta-
blockers were bisoprolol and atenolol. The number of events, total person time and 
crude incidence of PCAE for the baseline period, pre-risk period, acute risk period and 
the chronic risk period is shown in table 40. As expected, the crude incidence of PCAE 
was lower during the pre-risk period for both non-selective and selective beta-blocker 
exposure.  
 
For non-selective and selective beta-blockers, the crude incidence of PCAE was greater 
during the acute risk period compared to baseline for each analysis (table 40). The crude 
and adjusted relative incidence of PCAE associated with oral beta-blocker exposure is 
shown in table 41. For both analyses only low to moderate dose exposure could be 
evaluated. Overall, the relative incidence of PCAE increased among all acute risk 
periods with non-selective beta-blocker exposure, which was statistically significant 
using the 30 day risk period only and became smaller with increasing risk period 
duration (IRR 3.14 (95% CI 1.28 to 7.74), IRR 1.82 (95% CI 0.78 to 4.23) and IRR 1.32 
(95% CI 0.59 to 2.96) for the 30, 60 and 90 day acute risk periods respectively). No 
significant increase was observed with chronic non-selective beta-blocker exposure. In 
contrast, there was no significant increase in the relative incidence of PCAE with 
selective beta-blocker exposure using any duration of risk period. 
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Table 40. Number of events, person time and crude incidence rates according to exposure 
group and risk window used in the cardiovascular beta-blocker self-controlled case series. 
 
*Person time (days). 
¥
Per 10,000 person years. 
 
 
Table 41. Adjusted incidence rate ratios for oral non-selective and selective beta-blocker 
exposure and primary care asthma exacerbations used in the self-controlled case series.  
*Adjusted for use of SABA, LABA, ICS, leukotriene receptor antagonists, methylxanthines and 
seasonal variation.
 Non-selective beta-blocker Selective beta-blocker 
 
Risk period 
 
Events 
Person  
Time*  
Crude  
Incidence
¥
 
 
Events 
Person  
Time*  
Crude  
Incidence
¥
 
30 day       
 Pre-risk 2 782 25.58 14 5254 26.65 
 Baseline 22 6139 35.84 150 37477 40.02 
 Acute 8 806 99.26 20 5583 35.82 
 Chronic 4 1847 21.66 55 18380 29.92 
60 day       
 Pre-risk 2 782 25.58 14 5254 26.65 
 Baseline 22 5834 37.71 147 36277 40.52 
 Acute 10 1615 61.92 36 11196 32.15 
 Chronic 2 1343 14.89 42 13964 30.08 
90 day       
 Pre-risk 2 782 25.58 14 5254 26.65 
 Baseline 22 5447 40.39 139 34432 40.37 
 Acute 12 2397 50.06 51 16800 30.36 
 Chronic 0 934 - 34 10185 34.36 
 Non-selective beta-blocker Selective beta-blocker 
Risk period IRR 95% CI p-value IRR 95% CI p-value 
30 day       
 Baseline 1.00   1.00   
 Acute 3.14 1.28-7.74 0.013 0.87 0.51-1.48 0.600 
 Chronic 0.69 0.20-2.37 0.553 0.74 0.49-1.11 0.147 
60 day       
 Baseline 1.00   1.00   
 Acute 1.82 0.78-4.23 0.165 0.77 0.50-1.19 0.241 
 Chronic 0.44 0.09-2.16 0.309 0.80 0.51-1.24 0.314 
90 day       
 Baseline 1.00   1.00   
 Acute 1.32 0.59-2.96 0.501 0.71 0.48-1.06 0.093 
 Chronic - - - 0.97 0.60-1.58 0.907 
241 
 
8.5 Discussion 
This study investigated the association between oral beta-blockers commonly used for 
the management of CVD and asthma death, hospitalisation and PCAE. The primary 
analysis was the nested case control study which found an 11- to 15-fold increased risk 
of asthma hospitalisation associated with prevalent high dose non-selective beta-blocker 
exposure using a 60 and 90 day risk window.  In contrast, no significant increase in 
asthma hospitalisation was seen with prevalent low dose non-selective beta-blocker 
exposure. In the nested case control study, a significant 3.5- to 5-fold increased risk of 
PCAE occurred with incident low to moderate dose non-selective beta-blocker exposure 
and a 2.7-fold increased risk of PCAE occurred with prevalent high dose non-selective 
beta-blocker exposure. In contrast, no significant increase in PCAE was seen with 
prevalent low to moderate dose non-selective beta-blocker exposure. These findings 
could be interpreted as a dose-response relationship for non-selective beta-blockers. The 
secondary analysis was the SCCS which found a significant 3-fold increased relative 
incidence of PCAE within 30 days of the first non-selective beta-blocker prescription 
only with risk falling with increasing risk period duration.  
 
In the nested case control study, no significant increase in asthma hospitalisation or 
PCAE was associated with oral selective beta-blocker exposure although effect 
estimates were generally larger for incident high dose exposure and the association with 
asthma hospitalisation. No significant increase in the relative incidence of PCAE was 
seen in the secondary analysis using the SCCS. These findings suggest that selective 
beta-blockers prescribed to people with asthma in primary care did not lead to 
significantly increased numbers of serious asthma exacerbations. 
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Strengths and limitations 
It was not possible to properly evaluate the risk of asthma death due to a lack of power. 
It was also not possible to properly evaluate the risk of asthma hospitalisation and of 
PCAE associated with incident non-selective beta-blocker exposure using the nested 
case control study due to a lack of power. This analysis was limited by the fact that high 
non-selective beta-blocker doses were not commonly prescribed to people in the asthma 
CVD cohort. In this analysis, non-selective beta-blockers consisted mainly of sotalol 
and carvedilol which have a 12-fold and 4.5-fold greater affinity for the beta2- versus 
beta1-adrenoceptor respectively (72).  Although selective beta-blockers were not 
associated with an increased risk of asthma events in this analysis, a dose response 
relationship in respect to mean falls in FEV1 was demonstrated for selective beta-
blockers in the meta-analysis reported in chapter 3. Chapter 6 described the prevalence 
of beta-blocker prescribing in the CPRD active asthma cohort and showed that beta-
blockers were prescribed at an average dose of 112mg for sotalol, 21mg for carvedilol, 
47mg for atenolol and 4mg for bisoprolol. It was not possible to investigate the effect of 
high dose exposure using the SCCS because of a lack of patients with this exposure.  
 
Effect estimates often had wide confidence intervals demonstrating a lack of precision 
in the size of the effect estimates. The large number of calculations performed may 
increase the likelihood of spuriously statistically significant findings as a result of repeat 
testing. On average, patients in the asthma CVD cohort were older than in the CPRD 
active asthma cohort which could raise concerns about the validity of results. This is 
because some patients may have a degree of fixed air-flow obstruction potentially 
underestimating the relative incidence of asthma events because selective beta-blockers 
are considered to be better tolerated as demonstrated by a meta-analysis of randomised 
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blinded placebo controlled trials in people with COPD where no significant fall in 
FEV1 occurred following selective beta-blocker exposure (87).  
 
Two sensitivity analyses were chosen to test this assumption by first excluding patients 
over the age of 40 who smoked and second excluding people diagnosed with asthma 
over the age of 45 creating a population in which COPD is much less likely to occur 
unless a rare genetic condition such as alpha-1 anti-trypsin deficiency is present. For 
incident non-selective beta-blocker exposure, these sensitivity analyses produced 
slightly larger effect estimates than the main analysis suggesting some misclassification 
bias may be present. In contrast, these sensitivity analyses did not significantly change 
the results for selective beta-blockers. It is also uncertain from this analysis whether 
careful beta-blocker dose titration occurred in this population which may have 
minimized risk from non-selective beta-blockers.  
 
The increased risk of PCAE using the SCCS presented in this chapter was observed 
using only a small sample size. However, the SCCS was originally designed to be used 
with small sample sizes to investigate rare adverse events associated with vaccine 
exposure (126). An increased risk of PCAE occurred within 30 days of incident non-
selective beta-blocker prescribing in the SCCS with the effect estimates falling when 
the duration of the acute risk period increased. In contrast, a significantly increased risk 
of PCAE was detected in the nested case control study during the 60 and 90 day risk 
windows respectively. These differences in statistically significant effect estimates may 
be related to differences in study design and residual confounding or selection bias in 
the nested case control study. Despite these potential limitations, both study designs 
detected a significant increased risk from incident non-selective beta-blocker exposure. 
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For the nested case control study, the cohort of people with asthma and CVD was 
chosen to better ensure controls were sampled from a representative population. As 
previously discussed, beta-blockers may have been prescribed to people with less severe 
asthma and risk may be greater in people with more severe asthma. It remains unknown 
whether patients had this medication dispensed, when patients actually started taking 
their medication for the first time and how compliant people were with their medication 
regimes. 
  
8.6 Summary 
This chapter demonstrated in increased risk of adverse respiratory events associated 
with prevalent high dose and incident low to moderate dose non-selective beta-blocker 
exposure. In contrast, no significant increased risk of serious asthma exacerbations was 
observed with oral selective beta-blockers. This study suggests that people with asthma 
and CVD should be prescribed a selective rather than a non-selective beta-blocker and 
that people currently established on selective beta-blocker therapy for the management 
of CVD should not have their medication discontinued unless asthma symptoms are 
thought to be attributed to beta-blocker exposure. This study also suggests that selective 
beta-blockers should be more widely considered in people with asthma when clinically 
indicated and no alternatives exist. However, insufficient power meant it was not 
possible to properly evaluate the risk of asthma death. The different but complementary 
analytical approaches used provide some validity in the results although this is restricted 
to PCAE only. The following chapter will evaluate NSAID exposure using a similar 
approach whilst the discussion section in chapter 10 will provide further detail and a 
comparison of these results with other chapters.
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Chapter 9: Adverse Respiratory Effect 
of NSAIDs in Asthma: Nested Case 
Control and Self-Controlled Case 
Series in People with Asthma Issued 
Low Strength Analgesics 
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9.1 Introduction 
This chapter will evaluate the association between different types of NSAID prescribing 
and asthma mortality and morbidity. Aspirin and other NSAIDs trigger exacerbations in 
susceptible people with asthma. Chapter 4 estimated the prevalence of aspirin-
exacerbated respiratory disease (AERD) from studies performing oral provocation 
challenge tests and population studies measuring self-reported history of AERD. The 
findings were that around 9% of people with asthma have AERD which is triggered at 
clinically relevant doses of aspirin. Chapter 5 measured the adverse respiratory effect 
from clinical trials evaluating acute selective NSAID and COX-2 inhibitors exposure in 
people with AERD, and showed that in this population COX-2 inhibitors did not trigger 
any adverse respiratory effects whilst selective NSAIDs triggered symptoms in 
approximately 8% of people with AERD. Although appropriately conducted clinical 
trials of COX-2 inhibitors in AERD have strong internal validity, real world assessment 
of the effect of NSAID exposure in the general asthma population is lacking. The drug 
utilisation study presented in chapter 6 also highlighted that NSAID prescribing among 
people with asthma is relatively common although COX-2 inhibitors are rarely 
prescribed despite their apparent better tolerability. 
 
9.2 Aim 
The aim of this chapter was to assess the adverse respiratory effect of oral NSAIDs and 
COX-2 inhibitors using linked electronic health data. 
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9.3 Methodology 
Primary analysis using the nested  case control study 
Population 
The nested case control study measured the association between oral NSAID exposure 
and asthma events in a cohort of people with asthma prescribed analgesic medications 
derived from the CPRD adult active asthma cohort (described in chapter 2, page 66). 
Entry into the asthma analgesic cohort occurred on or after the date of entry to the 
CPRD active asthma cohort. The asthma analgesic cohort consisted of people in the 
CPRD active asthma cohort who were prescribed one or more low strength analgesic 
prescriptions during cohort follow-up defined as prescriptions for oral NSAIDs, oral 
paracetamol and compound preparations containing paracetamol and low strength 
opiates (co-codamol and co-dydramol prescriptions). Low strength analgesic 
prescriptions were chosen so that comparisons were made between people requiring 
similar levels of pain control in the absence of specific clinical indications. Therefore, 
the asthma analgesic cohort contains people with asthma and actively managed low 
level painful conditions.  
 
Entry into the asthma analgesic cohort was defined as the date of the first low strength 
analgesic prescription prescribed on or after entry into the CPRD active asthma cohort. 
Cohort follow-up remained unchanged as previously described (chapter 2, page 67) but 
the asthma analgesic cohort was additionally censored at the end of exposure to low 
strength analgesic medication (defined below). In circumstances when exposure to low 
strength analgesic medication ceased before the end of follow-up, end of exposure was 
determined as the date of the last analgesic prescription with the addition of a 180 day 
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grace period. Analysis was restricted to people from practices which were linked to the 
HES and ONS databases providing full outcome ascertainment. 
 
Case and control selection 
Outcomes consisted of asthma death, asthma hospitalisation and PCAE as previously 
defined (chapter 2, pages 67). For each outcome, up to 10 controls were randomly 
selected and matched to each case on age (categorised into deciles), gender, calendar 
year of cohort entry and whether patients were diagnosed with asthma before the age of 
45 using incidence density sampling. When a case could not be matched to one or more 
controls, the matching process was repeated without age. This was a pragmatic decision 
to include all cases and affected 3 cases (0.1%) of PCAE only. 
 
Exposures 
Oral NSAID exposure was defined as current incident user, current prevalent user and 
non-user as described in the general methods chapter (chapter2, page 72). Among 
current users, exposure to oral NSAIDs was evaluated by selectivity as defined in 
chapter 2 (page 72). The association with oral NSAID exposure was evaluated using 
three risk windows consisting of 30, 60 and 90 days. 
 
Confounders and data analysis 
Multiple imputation was used to impute missing data on height, weight and smoking 
status as previously described (chapter 2, page 74). For each analysis, adjustment was 
made for the confounders listed in table 42 according to clinical relevance and model fit 
as previously described (chapter 2, page 73).  
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Table 42. Confounders used for risk adjustment in the nested case control analysis 
between NSAIDs and asthma death, asthma hospitalisation and primary care asthma 
exacerbation. 
Characteristic Death Hospitalisation PCAE 
Exact age
¥
 Yes Yes Yes 
Deprivation
€
 Yes Yes Yes 
Medications*    
 ICS Yes Yes Yes 
 LABA Yes Yes Yes 
 LABAICS Yes Yes Yes 
 Leukotriene antagonist Yes Yes Yes 
 Methylxanthine  Yes Yes Yes 
 No. of SABA¥ Yes Yes Yes 
 Oral steroid Yes Yes No 
 NSAIDs Yes Yes Yes 
Comorbidity    
 Nasal polyps No Yes Yes 
 BMI¥ Yes Yes Yes 
 Charlson co-morbidity 
score
¥
 
Yes Yes Yes 
Smoking status Yes Yes Yes 
Previous asthma hospitalisation  Yes Yes Yes 
RTI* Yes Yes Yes 
Asthma review
δ
 No No Yes 
*= In the 90 days prior to index date. €= Index of multiple deprivation decile.  
δ = In the 365 days prior to index date.  
¥  = Continuous variable. PCAE = primary care asthma exacerbation. 
 
Chi-squared testing and analysis of variance (ANOVA) was used to determine 
statistically significant differences in patient characteristics between cases and controls. 
Conditional logistic regression was used to estimate odds ratios which represent 
incidence rate ratios for the association between NSAID exposure and asthma events. 
 
Nested case control sensitivity analyses 
The following sensitivity analyses were performed to test the robustness of the results:  
 excluding patients hospitalised within the risk period 
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 excluding patients over the age of 40 years who smoked 
 excluding patients diagnosed with asthma over the age of 45 
 excluding patients not originally matched on age (i.e. not matched on age, since this 
is the matching variable dropped in the second round) 
 complete case analysis 
 
Secondary analysis using the self-controlled case series 
The SCCS method has previously defined in chapter 2 (page 77). The SCCS was 
conducted over a 360 day study period centred on incident oral NSAID exposure (first 
prescription in the file in people with at least 1 year of follow up prior to the first 
prescription) as previously defined (chapter 2 page 77). The beginning of the 
observation period was defined as 180 days prior to the date of the incident oral NSAID 
prescription and the end of the observation period was defined as 180 days following 
this incident prescription. The SCCS was performed for PCAE as previously defined, 
using 30 day, 60 day and 90 day acute risk periods beginning on the incident 
prescription date for oral NSAID. Exposure beyond these risk windows was categorised 
as chronic exposure. A 30 day pre-risk period was used to account for short-lived event 
dependent exposures. All remaining person time was classed as baseline. 
 
Confounders and data analysis 
Time-varying exposure to the following medications issued within 90 day consecutive 
periods was adjusted for in the analysis as previously described (chapter2, page 81): 
ICS; inhaled LABAs; leukotriene antagonists; methlyxanthines; and the total number of 
SABA prescriptions. Additional risk adjustment was made for seasonal variation. Crude 
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and adjusted incidence rate ratios (IRR) were calculated using conditional Poisson 
regression with analyses stratified by selectivity as previously defined (page 69). 
 
9.4 Results 
The asthma analgesic cohort consisted of 148443 patients with a mean age at cohort 
entry of 43.9 years (SD 16.5) and more women than men (64.2% vs. 35.8% 
respectively). During follow-up of the asthma analgesic cohort, a total of 27 asthma 
deaths, 583 asthma hospitalisations occurred and 5302 PCAE occurred. Non-selective 
NSAIDs were prescribed to 30281 (39.3%), NSAIDs with <5-fold COX-2 selectivity 
were prescribed to 37902 (49.2%), NSAIDs with 5- to 50-fold COX-2 selectivity were 
prescribed to 3026 (3.9%) and COX-2 inhibitors were prescribed to 5898 (7.6%) in the 
asthma analgesic cohort during mean follow-up of 2.2 years. 
 
9.4.1 Primary analysis using the nested case control study 
Asthma death 
All cases of asthma death were matched to controls. Table 43 describes characteristics 
of the 27 cases of asthma death matched to 259 controls. There were no statistically 
significant differences in matching criteria between cases and controls. Cases died of 
asthma at a mean age of 64.9 years and were predominantly women (74.1%). Cases had 
a statistically significant higher use of LABA prescribed as a separate inhaler, SABAs 
and oral steroids within 90 days of the index date. A statistically greater proportion of 
cases had a previous asthma hospitalisation, were hospitalised for any cause and had a 
respiratory tract infection within 90 days of the index date. Cases had a statistically 
lower average BMI. 
 
252 
 
Table 43. Characteristics of cases and controls for asthma death in the NSAID analysis. 
 
Characteristics 
Cases 
N=27 
Controls 
N=259 
 
p-value 
Matching variables    
Age (years, SD) 64.9 (14.9) 63.4 (13.5) 0.580* 
Female gender 20 (74.1) 200 (77.2) 0.712 
Years of follow-up to index date (years, SD) 2.5 (3.0) 2.3 (2.8) 0.714* 
Diagnosed with asthma ≤ age 45 10 (37.0) 98 (37.8) 0.935 
Potential confounders    
Asthma therapy in the 90 days prior to index 
date  
   
 ICS 12 (44.4) 129 (49.8) 0.596 
 LABA 7 (25.9) 29 (11.2) 0.028 
 LABAICS 5 (18.5) 46 (17.8) 0.922 
 Leukotriene antagonist 3 (11.1) 9 (3.5) 0.168 
 Methylxanthine  3 (11.1) 10 (3.9) 0.217 
 Mean no. of SABA prescriptions (SD) 2.4 (2.9) 1.3 (1.4) 0.001* 
 Oral steroid 12 (44.4) 16 (6.2) 0.000 
Comorbidity    
 Nasal polyps 0 (0.0) 7 (2.7) 0.833 
 Mean BMI (SD) 26.3 (5.7) 29.4 (6.3) 0.022* 
 Mean Charlson co-morbidity score (SD) 2.0 (1.0) 1.7 (1.2) 0.248* 
Smoking status    
 Current smoker 5 (18.5) 38 (14.7) 0.595 
 Ex-smoker 6 (22.2) 91 (35.1) 0.177 
 Non-smoker 11 (40.7) 103 (39.8) 0.922 
 Missing 5 (18.5) 27 (10.4)  
Previous hospitalisation for asthma 4 (14.8) 8 (3.1) 0.017 
RTI recorded in the 90 days prior to index date 9 (33.3) 14 (5.4) 0.000 
Hospitalisation in the 90 days prior to index 
date 
13 (48.1) 27 (10.4) 0.000 
Asthma review in the 365 days prior to index 
date 
10 (37.0) 101 (39.0) 0.842 
*Continuous variable analysed using ANOVA, otherwise variables are categorical analysed using the Chi-square test.         
SD = standard deviation, ICS = inhaled corticosteroid, LABA = long-acting beta2-agonist, LABAICS = long-acting 
beta2-agonist in combination inhaler with ICS, SABA = short-acting beta2-agonist, RTI = respiratory tract infection, 
BMI = Body mass index. Cases and controls matched on age category, gender, calendar year of cohort entry and 
whether patients were diagnosed with asthma under the age of 45 years only. 
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Asthma hospitalisation 
All cases of asthma hospitalisation were matched to controls. Table 44 describes the 
characteristics of the 583 cases of asthma hospitalisation matched to 5765 controls. 
There were no statistically significant differences in matching criteria between cases 
and controls. Cases were hospitalised for asthma at a mean age of 47.5 years and were 
predominantly women (81.0%). Cases had a statistically significant higher use of all 
types of asthma medication. A greater proportion of cases had a respiratory tract 
infection recorded, had previously been hospitalised for asthma and had been 
hospitalised for any cause within 90 days of the index date which was statistically 
significant. Cases had clinically small but a statistically significant greater mean BMI. 
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Table 44. Characteristics of cases and controls for asthma hospitalisation in the NSAID 
analysis. 
 
Characteristics 
Cases 
N=583 
Controls 
N=5765 
 
p-value 
Matching variables    
Age (years, SD) 47.5 (17.2) 47.5 (17.3) 0.964* 
Female gender 472 (81.0) 4699 (81.5) 0.745 
Years of follow-up to index date (years, SD) 1.4 (2.3) 1.3 (2.3) 0.668* 
Diagnosed with asthma ≤ age 45 376 (64.5) 3710 (64.4) 0.946 
Potential confounders    
Asthma therapy in the 90 days prior to index 
date  
   
 ICS 299 (51.3) 2510 (43.5) 0.000 
 LABA 126 (21.6) 476 (8.3) 0.000 
 LABAICS 175 (30.0) 976 (16.9) 0.000 
 Leukotriene antagonist 68 (11.7) 153 (2.7) 0.000 
 Methylxanthine  67 (11.5) 123 (2.1) 0.000 
 Mean no. of SABA prescriptions (SD) 2.3 (2.0) 1.2 (1.4) 0.000* 
 Oral steroid 255 (43.7) 367 (6.4) 0.000 
Comorbidity    
 Nasal polyps 14 (2.4) 121 (2.1) 0.629 
 Mean BMI (SD) 30.9 (9.0) 29.6 (7.2) 0.000* 
 Mean Charlson co-morbidity score (SD) 1.5 (1.3) 1.5 (1.1) 0.077* 
Smoking status    
 Current smoker 150 (25.7) 1510 (26.2) 0.808 
 Ex-smoker 173 (29.7) 1703 (29.5) 0.946 
 Non-smoker 211 (36.2) 2205 (38.2) 0.330 
 Missing 49 (8.4) 347 (6.0)  
Previous hospitalisation for asthma 143 (24.5) 192 (3.3) 0.000 
RTI recorded in the 90 days prior to index date 127 (21.8) 518 (9.0) 0.000 
Hospitalisation in the 90 days prior to index 
date 
109 (18.7) 581 (10.1) 0.000 
Asthma review in the 365 days prior to index 
date 
225 (38.6) 2044 (35.5) 0.132 
*Continuous variable analysed using ANOVA, otherwise variables are categorical analysed using the Chi-square test.         
SD = standard deviation, ICS = inhaled corticosteroid, LABA = long-acting beta2-agonist, LABAICS = long-acting 
beta2-agonist in combination inhaler with ICS, SABA = short-acting beta2-agonist, RTI = respiratory tract infection, 
BMI = Body mass index. Cases and controls matched on age category, gender, calendar year of cohort entry and 
whether patients were diagnosed with asthma under the age of 45 years only. 
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Primary care asthma exacerbations 
Three cases (0.1%) were included unmatched on age. Table 45 describes the 
characteristics of the 5302 cases of PCAE matched to 52381 controls. There were no 
statistically significant differences in matching criteria between cases and controls. 
PCAEs occurred at a mean age of 50.3 years predominantly in women (73.0%). Cases 
had a statistically significant greater use of all asthma medications. A greater proportion 
of cases had attended an asthma review in the previous year, had a respiratory tract 
infection recorded within 90 days of the index date and had previously been hospitalised 
for asthma which was statistically significant. Cases had a small but statistically 
significant higher mean BMI and lower Charlson comorbidity score. Cases had a 
statistically significant greater proportion of people with nasal polyps and people who 
were current smokers.  
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Table 45. Characteristics of cases and controls for primary care asthma exacerbations in 
the NSAID analysis. 
 
Characteristics 
Cases 
N=5302 
Controls 
N=52381 
 
p-value 
Matching variables    
Age (years, SD) 50.3 (16.9) 50.2 (16.9) 0.599* 
Female gender 3868 (73.0) 38450 (73.4) 0.479 
Years of follow-up to index date (years, SD) 0.8 (1.8) 0.8 (1.8) 0.453* 
Diagnosed with asthma ≤ age 45 2916 (55.0) 28700 (54.8) 0.806 
Potential confounders    
Asthma therapy in the 90 days prior to index 
date  
   
 ICS 2565 (48.4) 21946 (41.9) 0.000 
 LABA 557 (10.5) 3667 (7.0) 0.000 
 LABAICS 1161 (21.9) 7725 (14.7) 0.000 
 Leukotriene antagonist 197 (3.7) 1013 (1.9) 0.000 
 Methylxanthine  117 (2.2) 783 (1.5) 0.000* 
 Mean no. of SABA prescriptions (SD) 1.4 (1.5) 1.1 (1.2) 0.000 
 Oral steroid - -  
Comorbidity    
 Nasal polyps 186 (3.5) 1168 (2.2) 0.000 
 Mean BMI (SD) 29.6 (6.9) 29.2 (7.4) 0.000* 
 Mean Charlson co-morbidity score (SD) 1.4 (1.0) 1.5 (1.1) 0.000* 
Smoking status    
 Current smoker 1363 (25.7) 12094 (23.1) 0.000 
 Ex-smoker 1701 (32.1) 16752 (32.0) 0.880 
 Non-smoker 1960 (37.0) 20031 (38.2) 0.069 
 Missing 278 (5.2) 3504 (6.7)  
Previous hospitalisation for asthma 370 (7.0) 1630 (3.1) 0.000 
RTI recorded in the 90 days prior to index date 808 (15.2) 3937 (7.5) 0.000 
Hospitalisation in the 90 days prior to index 
date 
498 (9.4) 4967 (9.5) 0.832 
Asthma review in the 365 days prior to index 
date 
2142 (40.4) 18679 (35.7) 0.000 
SD = standard deviation, ICS = inhaled corticosteroid, LABA = long-acting beta2-agonist, LABAICS = long-acting 
beta2-agonist in combination inhaler with ICS, SABA = short-acting beta2-agonist, RTI = respiratory tract infection, 
BMI = Body mass index. Cases and controls matched on age category, gender, calendar year of cohort entry and 
whether patients were diagnosed with asthma under the age of 45 years only. 
 
257 
 
Oral NSAID exposure 
The most commonly prescribed NSAIDs according to selectivity were: ibuprofen for 
non-selective NSAIDs; diclofenac for NSAIDs with <5-fold CXO-2 selectivity; 
meloxicam for NSAIDs with 5- to 50-fold COX-2 selectivity; and celecoxib for COX-2 
inhibitors. The association between oral NSAID exposure and asthma events is shown 
in tables 46 to 49. It was not possible to estimate the relative incidence of asthma death 
for NSAIDs with 5- to 50-fold COX-2 selectivity due to a lack of NSAID exposure 
among the cases. Among the remaining classes of NSAID, the association with asthma 
death could only be determined for prevalent exposure. There was an increase in the 
relative incidence of asthma death with non-selective NSAIDs which was significant 
using the 90 day the risk window only (IRR 7.79 (95% CI 1.35 to 44.90), table 46). 
There was no significant increase in the relative incidence of asthma death with any 
other type of NSAID. 
 
Overall, there was no significant increase in the relative incidence of asthma 
hospitalisation with any type of oral NSAID exposure (incident and prevalent 
combined, tables 46 to 49). When stratified by duration of administration (incident and 
prevalent), there was again no significant increase in the relative incidence of asthma 
hospitalisation with any class of oral NSAID. It was not possible to estimate the relative 
incidence of asthma hospitalisation with incident exposure to NSAIDs with ≥5-fold 
COX-2 selectivity due to a lack of power.  
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Table 46. Crude and adjusted incidence rate ratios for the association between non-selective NSAID exposure and asthma events. 
*Adjustment for confounders listed in table 42 (page 249). Empty cells = inestimable due to lack of exposure in the risk window.  
 
 
 
 Any Incident Prevalent 
 Crude Adjusted Crude Adjusted Crude Adjusted 
Risk window IRR IRR 95% CI p-value IRR IRR 95% CI p-value IRR IRR 95% CI p-value 
Death             
 30 day 1.31 3.31 0.38-29.19 0.280 - - - - 1.66 5.79 0.65-50.16 0.115 
 60 day 1.54 1.97 0.29-13.63 0.491 - - - - 1.93 5.97 0.95-37.42 0.056 
 90 day 1.66 2.87 0.52-15.77 0.226 - - - - 2.36 7.79 1.35-44.90 0.022 
Hospitalisation             
 30 day 0.73 0.97 0.65-1.44 0.860 1.00 1.21 0.66-2.23 0.532 0.60 0.82 0.49-1.38 0.462 
 60 day 0.82 1.08 0.80-1.48 0.613 0.80 0.98 0.61-1.58 0.946 0.84 1.15 0.78-1.70 0.475 
 90 day 0.74 0.99 0.74-1.31 0.917 0.78 0.99 0.66-1.48 0.957 0.71 0.98 0.67-1.42 0.902 
PCAE             
 30 day 0.87 0.93 0.54-1.60 0.784 0.84 0.84 0.71-1.01 0.056 0.88 0.86 0.75-0.99 0.039 
 60 day 0.86 1.01 0.74-1.37 0.970 0.88 0.89 0.79-1.01 0.076 0.85 0.85 0.75-0.95 0.006 
 90 day 0.89 1.05 0.84-1.33 0.652 0.93 0.95 0.86-1.06 0.370 0.84 0.83 0.74-0.93 0.001 
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Table 47. Crude and adjusted incidence rate ratios for the association between NSAIDs with <5-fold COX-2 selectivity and asthma events. 
*Adjustment for confounders listed in table 42 (page 249). Empty cells = inestimable due to lack of exposure in the risk window.  
 
 
 
 
 Any Incident Prevalent 
 Crude Adjusted Crude Adjusted Crude Adjusted 
Risk window IRR IRR 95% CI p-value IRR IRR 95% CI p-value IRR IRR 95% CI p-value 
Death             
 30 day 0.93 1.70 0.22-13.12 0.612 - - - - 1.06 2.11 0.27-16.80 0.479 
 60 day 1.13 2.53 0.52-12.25 0.250 - - - - 1.53 4.60 0.62-34.09 0.135 
 90 day 1.12 2.26 0.49-10.31 0.293 - - - - 1.37 4.36 0.57-33.52 0.158 
Hospitalisation             
 30 day 0.84 0.99 0.71-1.38 0.932 0.80 1.05 0.57-1.95 0.871 0.86 0.96 0.65-1.41 0.824 
 60 day 0.77 0.98 0.74-1.30 0.881 0.78 1.07 0.70-1.63 0.754 0.77 0.93 0.65-1.31 0.665 
 90 day 0.74 0.93 0.72-1.20 0.591 0.77 1.05 0.74-1.49 0.791 0.71 0.84 0.60-1.18 0.311 
PCAE             
 30 day 0.86 0.96 0.56-1.65 0.883 0.87 0.92 0.79-1.08 0.300 0.86 0.87 0.76-0.98 0.027 
 60 day 0.90 1.10 0.81-1.51 0.539 0.92 1.00 0.89-1.12 0.957 0.88 0.91 0.82-1.02 0.092 
 90 day 0.89 1.13 0.89-1.42 0.315 0.92 1.01 0.92-1.11 0.855 0.86 0.90 0.82-1.00 0.039 
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Table 48. Crude and adjusted incidence rate ratios for the association between NSAIDs with 5-50-fold COX-2 selectivity and asthma events. 
*Adjustment for confounders listed in table 42 (page 249). Empty cells = inestimable due to lack of exposure in the risk window.  
 
 
 
 
 
 Any Incident Prevalent 
 Crude Adjusted Crude Adjusted Crude Adjusted 
Risk window IRR IRR 95% CI p-value IRR IRR 95% CI p-value IRR IRR 95% CI p-value 
Death             
 30 day - - - - - - - - - - - - 
 60 day - - - - - - - - - - - - 
 90 day - - - - - - - - - - - - 
Hospitalisation             
 30 day 0.42 0.52 0.18-1.49 0.222 - - - - 0.50 0.60 0.21-1.75 0.351 
 60 day 0.60 0.70 0.32-1.52 0.361 - - - - 0.74 0.80 0.36-1.78 0.587 
 90 day 0.53 0.66 0.32-1.36 0.260 - - - - 0.69 0.80 0.38-1.70 0.568 
PCAE             
 30 day 0.83 0.88 0.49-1.59 0.668 1.08 1.11 0.62-1.98 0.731 0.79 0.76 0.58-1.01 0.057 
 60 day 0.82 0.95 0.66-1.37 0.788 0.91 0.94 0.60-1.12 0.770 0.80 0.79 0.62-1.01 0.057 
 90 day 0.86 1.01 0.76-1.35 0.937 0.87 0.90 0.62-1.31 0.583 0.85 0.84 0.67-1.06 0.147 
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Table 49. Crude and adjusted incidence rate ratios for the association between COX-2 inhibitors and asthma events. 
*Adjustment for confounders listed in table 42 (page 249). Empty cells = inestimable due to lack of exposure in the risk window.  
 Any Incident Prevalent 
 Crude Adjusted Crude Adjusted Crude Adjusted 
Risk window IRR IRR 95% CI p-value IRR IRR 95% CI p-value IRR IRR 95% CI p-value 
Death             
 30 day 1.74 2.05 0.15-27.68 0.589 - - - - 1.74 2.57 0.18-36.91 0.488 
 60 day 1.29 2.20 0.16-29.62 0.551 - - - - 1.50 5.92 0.30-115.35 0.240 
 90 day 0.92 1.39 0.13-15.27 0.786 - - - - 1.02 2.11 0.17-26.84 0.567 
Hospitalisation             
 30 day 1.01 0.78 0.41-1.45 0.412 2.26 1.83 0.59-5.65 0.297 0.79 0.55 0.26-1.21 0.137 
 60 day 0.99 0.85 0.50-1.45 0.548 1.92 1.31 0.52-3.28 0.566 0.74 0.70 0.367-1.36 0.292 
 90 day 0.91 0.83 0.49-1.39 0.474 1.54 1.38 0.63-3.04 0.422 0.65 0.61 0.31-1.21 0.156 
PCAE             
 30 day 1.05 1.18 0.67-2.06 0.569 1.02 1.08 0.74-1.58 0.695 1.06 1.09 0.87-1.36 0.452 
 60 day 1.01 1.21 0.87-1.69 0.256 1.11 1.17 0.89-1.53 0.267 0.96 1.00 0.82-1.21 0.962 
 90 day 1.03 1.25 0.97-1.61 0.079 1.16 1.21 0.97-1.51 0.088 0.94 0.98 0.81-1.19 0.836 
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Overall, there was no significant increase in the relative incidence of PCAE with any 
type of oral NSAID exposure (incident and prevalent combined, tables 46 to 49). When 
stratified by duration of administration (incident and prevalent), there was again no 
significant increase in the relative incidence of PCAE with any class of oral NSAID.  
 
A significant decrease in the relative incidence of PCAE was observed with prevalent 
exposure to non-selective NSAIDs (IRR 0.86 (95% CI 0.75 to 0.99), 0.85 (95% CI 0.75 
to 0.95) and 0.83 (95% CI 0.74 to 0.93) for the 30, 60 and 90 day risk windows 
respectively, table 46) and NSAIDs with <5-fold COX-2 selectivity (IRR 0.87 (95% CI 
0.76 to 0.98), 0.91 (95% CI 0.82 to 1.02) and 0.90 (95% CI 0.82 to 1.00) for the 30, 60 
and 90 day risk windows respectively, table 47). 
 
Nested case control sensitivity analyses 
Results from sensitivity analyses are presented in tables 50 to 53.   
 
1. Excluding patients hospitalised within the risk period 
This was done to assess any impact of immortal time bias. For asthma hospitalisation, 
this involved excluding 51 (8.8%), 79 (13.6%) and 109 (18.7%) cases for the 30, 60 and 
90 day risk windows respectively whilst for PCAE this involved excluding 181 (3.4%), 
330 (6.2%) and 498 (9.4%) cases for the 30, 60 and 90 day risk windows respectively. 
This analysis produced similar results to the main analysis. For incident COX-2 
inhibitor exposure, effect estimates were larger for asthma hospitalisation but remained 
non-significant.  
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Table 50. Non-selective NSAID sensitivity analyses as per methods. 
Sensitivity analyses excluding patients: hospitalised within the risk window; smokers >40 years of age; 
diagnosed with asthma >45 years of age; unmatched on age; complete case analysis.
 Any Incident Prevalent 
 IRR 95% CI IRR 95% CI IRR 95% CI 
Hospitalised in risk window       
Hospitalisation       
30 day 0.96 0.63-1.46 1.16 0.60-2.23 0.84 0.49-1.45 
60 day 1.10 0.78-1.54 1.08 0.65-1.78 1.11 0.72-1.70 
90 day 0.98 0.71-1.34 1.00 0.64-1.56 0.96 0.63-1.46 
PCAE       
30 day 0.84 0.74-0.95 0.85 0.71-1.01 0.84 0.73-0.97 
60 day 0.85 0.78-0.93 0.88 0.77-1.00 0.83 0.73-0.94 
90 day 0.88 0.81-0.96 0.93 0.83-1.04 0.83 0.74-0.94 
Diagnosed with asthma ≥45       
Hospitalisation       
30 day 1.10 0.69-1.75 1.20 0.59-2.42 1.01 0.55-1.85 
60 day 1.10 0.76-1.59 0.90 0.52-1.57 1.26 0.79-2.02 
90 day 0.96 0.68-1.35 0.88 0.55-1.41 1.05 0.66-1.65 
PCAE       
30 day 0.81 0.70-0.94 0.79 0.64-0.98 0.82 0.67-1.00 
60 day 0.83 0.74-0.93 0.83 0.72-0.93 0.82 0.70-0.97 
90 day 0.86 0.78-0.96 0.93 0.82-1.05 0.77 0.66-0.91 
Smokers over 40 years       
Hospitalisation       
30 day 0.87 0.56-1.35 0.99 0.50-1.96 0.78 0.45-1.37 
60 day 0.96 0.68-1.35 0.86 0.51-1.45 1.03 0.66-1.58 
90 day 0.88 0.64-1.21 0.88 0.57-1.37 0.88 0.56-1.33 
PCAE       
30 day 0.84 0.75-0.95 0.85 0.71-1.03 0.83 0.71-0.97 
60 day 0.87 0.79-0.96 0.90 0.79-1.03 0.84 0.74-0.96 
90 day 0.90 0.83-0.98 0.97 0.87-1.08 0.82 0.73-0.93 
Unmatched on age       
Hospitalisation       
30 day 0.97 0.65-1.44 1.21 0.66-2.23 0.82 0.49-1.38 
60 day 1.08 0.80-1.48 0.98 0.61-1.58 1.16 0.78-1.70 
90 day 0.99 0.74-1.31 0.99 0.66-1.48 0.98 0.67-1.42 
PCAE       
30 day 0.86 0.77-0.96 0.84 0.71-1.00 0.86 0.75-0.99 
60 day 0.86 0.79-0.95 0.89 0.79-1.01 0.85 0.75-0.95 
90 day 0.90 0.83-0.97 0.95 0.86-1.06 0.83 0.74-0.93 
Complete case analysis       
Hospitalisation       
30 day 0.97 0.63-1.50 1.29 0.67-2.48 0.80 0.46-1.41 
60 day 1.11 0.80-1.55 0.97 0.58-1.62 1.21 0.80-1.82 
90 day 1.04 0.77-1.41 1.00 0.65-1.55 1.07 0.72-1.59 
PCAE       
30 day 0.85 0.76-0.96 0.87 0.72-1.04 0.84 0.73-0.98 
60 day 0.86 0.79-0.95 0.90 0.79-1.03 0.83 0.73-0.94 
90 day 0.89 0.82-0.97 0.95 0.85-1.07 0.83 0.73-0.93 
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Table 51. NSAIDs with <5-fold COX-2 selectivity sensitivity analyses as per methods. 
Sensitivity analyses excluding patients: hospitalised within the risk window; smokers >40 years of age; 
diagnosed with asthma >45 years of age; unmatched on age; complete case analysis.
 Any Incident Prevalent 
 IRR 95% CI IRR 95% CI IRR 95% CI 
Hospitalised in risk window       
Hospitalisation       
30 day 0.99 0.70-1.40 1.19 0.64-2.23 0.92 0.61-1.39 
60 day 1.03 0.76-1.39 1.27 0.82-1.97 0.89 0.61-1.31 
90 day 0.97 0.73-1.29 1.17 0.80-1.72 0.82 0.56-1.19 
PCAE       
30 day 0.88 0.80-0.98 0.91 0.77-1.07 0.87 0.76-0.99 
60 day 0.95 0.87-1.03 0.98 0.87-1.10 0.92 0.82-1.02 
90 day 0.95 0.86-1.02 0.98 0.89-1.09 0.91 0.82-1.01 
Diagnosed with asthma ≥45       
Hospitalisation       
30 day 0.78 0.51-1.20 0.81 0.40-1.68 0.76 0.45-1.28 
60 day 0.81 0.57-1.15 0.89 0.55-1.45 0.74 0.47-1.19 
90 day 0.80 0.58-1.09 0.95 0.64-1.41 0.66 0.42-1.03 
PCAE       
30 day 0.81 0.70-0.92 0.85 0.71-1.03 0.76 0.63-0.92 
60 day 0.89 0.81-0.99 0.93 0.82-1.07 0.85 0.73-0.99 
90 day 0.91 0.82-1.00 0.96 0.86-1.08 0.83 0.72-0.95 
Smokers over 40 years       
Hospitalisation       
30 day 1.02 0.71-1.47 0.92 0.46-1.84 1.05 0.69-1.60 
60 day 1.03 0.76-1.40 1.14 0.72-1.80 0.97 0.66-1.43 
90 day 0.99 0.75-1.31 1.10 0.75-1.61 0.91 0.63-1.31 
PCAE       
30 day 0.91 0.82-1.01 0.96 0.82-1.14 0.88 0.76-1.01 
60 day 0.97 0.89-1.05 1.03 0.91-1.16 0.92 0.82-1.03 
90 day 0.96 0.89-1.04 1.02 0.92-1.13 0.90 0.81-1.01 
Unmatched on age       
Hospitalisation       
30 day 0.99 0.71-1.38 1.05 0.57-1.95 0.96 0.65-1.41 
60 day 0.98 0.74-1.30 1.07 0.70-1.63 0.93 0.65-1.31 
90 day 0.93 0.72-1.20 1.05 0.74-1.49 0.84 0.60-1.18 
PCAE       
30 day 0.89 0.80-0.98 0.92 0.78-1.07 0.87 0.76-0.98 
60 day 0.95 0.88-1.03 1.00 0.89-1.11 0.91 0.82-1.01 
90 day 0.95 0.89-1.03 1.01 0.91-1.11 0.90 0.82-1.00 
Complete case analysis       
Hospitalisation       
30 day 1.07 0.75-1.52 1.26 0.66-2.40 1.00 0.67-1.51 
60 day 1.05 0.78-1.41 1.27 0.82-1.97 0.92 0.63-1.34 
90 day 1.01 0.77-1.32 1.22 0.84-1.76 0.85 0.59-1.22 
PCAE       
30 day 0.90 0.81-1.01 0.97 0.72-1.04 0.86 0.76-0.99 
60 day 0.96 0.88-1.04 1.02 0.90-1.14 0.92 0.82-1.02 
90 day 0.97 0.90-1.05 1.03 0.93-1.15 0.91 0.82-1.01 
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Table 52. NSAIDs with ≥5-fold COX-2 selectivity sensitivity analyses as per methods. 
Sensitivity analyses excluding patients: hospitalised within the risk window; smokers >40 years of age; 
diagnosed with asthma >45 years of age; unmatched on age; complete case analysis.
 Any Incident Prevalent 
 IRR 95% CI IRR 95% CI IRR 95% CI 
Hospitalised in risk window       
Hospitalisation       
30 day 0.59 0.21-1.71 - - 0.76 0.26-2.21 
60 day 0.85 0.38-1.88 - - 0.99 0.44-2.24 
90 day 0.73 0.33-1.61 - - 0.95 0.42-2.15 
PCAE       
30 day 0.84 0.65-1.08 1.10 0.62-1.98 0.79 0.59-1.05 
60 day 0.85 0.68-1.05 0.98 0.63-1.53 0.81 0.63-1.04 
90 day 0.93 0.76-1.14 1.00 0.68-1.45 0.90 0.71-1.14 
Diagnosed with asthma ≥45       
Hospitalisation       
30 day 0.26 0.03-2.01 - - 0.34 0.04-2.72 
60 day 0.46 0.13-1.60 - - 0.58 0.16-2.07 
90 day 0.53 0.18-1.58 - - 0.71 0.23-2.19 
PCAE       
30 day 0.73 0.48-1.11 1.04 0.44-2.42 0.67 0.42-1.08 
60 day 0.79 0.59-1.11 1.00 0.55-1.84 0.71 0.47-1.07 
90 day 0.90 0.67-1.23 1.09 0.67-1.78 0.80 0.54-1.18 
Smokers over 40 years       
Hospitalisation       
30 day 0.76 0.25-2.30 - - 0.86 0.28-2.66 
60 day 1.00 0.44-2.31 - - 1.18 0.50-2.77 
90 day 0.91 0.42-1.98 - - 1.16 0.52-2.58 
PCAE       
30 day 0.80 0.60-1.07 0.84 0.40-1.75 0.79 0.58-1.08 
60 day 0.81 0.63-1.03 0.82 0.49-1.37 0.80 0.61-1.05 
90 day 0.84 0.67-1.04 0.77 0.50-1.18 0.86 0.66-1.11 
Unmatched on age       
Hospitalisation       
30 day 0.52 0.18-1.49 - - 0.60 0.21-1.75 
60 day 0.70 0.32-1.52 - - 0.80 0.36-1.78 
90 day 0.66 0.62-1.36 - - 0.80 0.38-1.70 
PCAE       
30 day 0.80 0.62-1.04 1.11 0.62-1.98 0.75 0.57-1.00 
60 day 0.82 0.66-1.01 0.94 0.60-1.46 0.78 0.61-1.00 
90 day 0.86 0.70-1.05 0.90 0.62-1.31 0.83 0.66-1.06 
Complete case analysis       
Hospitalisation       
30 day 0.39 0.12-1.31 - - 0.46 0.14-1.55 
60 day 0.62 0.27-1.43 - - 0.71 0.31-1.66 
90 day 0.52 0.23-1.19 - - 0.63 0.27-1.47 
PCAE       
30 day 0.82 0.63-1.07 1.07 0.57-2.01 0.78 0.58-1.04 
60 day 0.84 0.67-1.05 0.93 0.59-1.49 0.81 0.62-1.04 
90 day 0.88 0.71-1.08 0.87 0.59-1.30 0.87 0.68-1.11 
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Table 53. COX-2 inhibitor sensitivity analyses as per methods. 
Sensitivity analyses excluding patients: hospitalised within the risk window; smokers >40 years of age; 
diagnosed with asthma >45 years of age; unmatched on age; complete case analysis
 Any Incident Prevalent 
 IRR 95% CI IRR 95% CI IRR 95% CI 
Hospitalised in risk window       
Hospitalisation       
30 day 0.79 0.40-1.55 2.11 0.61-7.39 0.57 0.26-1.29 
60 day 1.03 0.59-1.81 1.84 0.69-4.95 0.84 0.41-1.62 
90 day 0.98 0.56-1.73 1.59 0.65-3.86 0.75 0.36-1.55 
PCAE       
30 day 1.07 0.88-1.31 1.06 0.71-1.57 1.08 0.86-1.35 
60 day 1.02 0.86-1.21 1.11 0.84-1.48 0.97 0.80-1.20 
90 day 1.08 0.92-1.25 1.19 0.95-1.51 1.00 0.81-1.22 
Diagnosed with asthma ≥45       
Hospitalisation       
30 day 0.82 0.36-1.86 2.09 0.64-6.88 0.43 0.14-1.36 
60 day 0.88 0.43-1.79 1.73 0.62-4.82 0.52 0.19-1.46 
90 day 0.81 0.40-1.61 1.23 0.48-3.18 0.54 0.19-1.50 
PCAE       
30 day 1.11 0.80-1.53 1.34 0.78-2.33 1.01 0.68-1.50 
60 day 1.02 0.78-1.34 1.23 0.82-1.87 0.90 0.63-1.28 
90 day 1.06 0.84-1.35 1.14 0.80-1.62 1.00 0.72-1.38 
Smokers over 40 years       
Hospitalisation       
30 day 0.87 0.45-1.68 2.39 0.71-8.03 0.62 0.28-1.38 
60 day 0.89 0.50-1.57 1.39 0.53-3.63 0.73 0.36-1.47 
90 day 0.86 0.50-1.48 1.41 0.63-3.16 0.62 0.30-1.29 
PCAE       
30 day 1.09 0.88-1.34 1.09 0.73-1.64 1.09 0.85-1.38 
60 day 1.05 0.88-1.25 1.22 0.92-1.63 0.97 0.78-1.21 
90 day 1.06 0.90-1.25 1.21 0.96-1.54 0.96 0.78-1.19 
Unmatched on age       
Hospitalisation       
30 day 0.77 0.41-1.45 1.81 0.58-5.60 0.55 0.26-1.21 
60 day 0.85 0.50-1.45 1.30 0.52-3.25 0.70 0.37-1.36 
90 day 0.83 0.49-1.39 1.37 0.62-3.02 0.61 0.31-1.21 
PCAE       
30 day 1.09 0.90-1.32 1.08 0.74-1.58 1.09 0.87-1.36 
60 day 1.05 0.89-1.24 1.16 0.89-1.52 1.00 0.82-1.22 
90 day 1.07 0.93-1.24 1.21 0.97-1.51 0.98 0.81-1.19 
Complete case analysis       
Hospitalisation       
30 day 0.76 0.40-1.47 1.82 0.58-5.77 0.54 0.25-1.20 
60 day 0.80 0.46-1.39 1.04 0.39-2.78 0.70 0.36-1.37 
90 day 0.78 0.45-1.33 1.18 0.51-2.72 0.61 0.30-1.22 
PCAE       
30 day 1.09 0.89-1.33 1.06 0.71-1.60 1.09 0.87-1.37 
60 day 1.04 0.88-1.23 1.15 0.87-1.53 0.97 0.80-1.20 
90 day 1.06 0.91-1.24 1.19 0.94-1.50 0.99 0.81-1.20 
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2. Excluding patients diagnosed with asthma over the age of 45 years 
This was done to assess any impact of including patients who may have unknown fixed 
airway obstruction. For asthma hospitalisation, this involved excluding 376 (64.5%) of 
cases whilst for PCAE this involved excluding 2386 (45.0%) of cases. This analysis 
produced similar results to the main analysis and no significant increases in events were 
seen with any class of NSAID. 
 
3. Excluding patients over the age of 40 years who smoked 
This was done to again assess any impact of including patients who may have unknown 
fixed airway obstruction. For asthma hospitalisation, this involved excluding 64 
(11.0%) of cases whilst for PCAE this involved excluding 688 (13.0%) of cases. This 
analysis once again produced similar results to the main analysis although the 
significantly reduced incidence of PCAE associated with non-selective NSAID and 
NSAIDs with <5-fold COX-2 selectivity became non-significant (tables 9.10 and 9.11). 
 
4. Excluding patients originally unmatched on age 
This was done to assess for any residual confounding by age. This only affected 0.1% of 
cases of PCAE and results were therefore almost identical to those of the main analysis. 
 
5. Complete case analysis 
This was done to assess the impact of multiply imputing data on height, weight and 
smoking status. For asthma hospitalisation, data was missing on height, weight and 
smoking status for 279 (4.4%), 211 (3.3%) and 396 (6.2%) of people respectively whilst 
for PCAE data was missing on height, weight and smoking status for 2397 (4.2%), 1971 
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(3.4%) and 3782 (6.6%) of people respectively. Again this analysis produced very 
similar results to the main analysis. 
 
9.4.2 Self-controlled case series 
The five SCCS consisted of:  
 918 patients (mean age 44.8 years, 66% female) with incident exposure to non-
selective NSAID experiencing 2677 PCAEs;  
 1106 patients (mean age 42.6 years, 66% female) with incident exposure to NSAIDs 
with <5-fold COX-2 selectivity experiencing 3350 PCAEs;  
 44 patients (mean age 51.9 years, 80% female) with incident exposure to NSAIDs 
with ≥5-fold COX-2 selectivity experiencing 153 PCAEs; and  
 136 patients (mean age 54.4 years, 71% female) with incident exposure to COX-2 
inhibitors experiencing 603 PCAEs.  
 
The most common NSAIDs were ibuprofen, diclofenac, meloxicam and celecoxib for 
each class of NSAID respectively. The number of events, total person time and crude 
incidence of PCAE for the baseline period, pre-risk period, acute risk period and the 
chronic risk period is shown in table 54. As expected, the crude incidence of PCAE was 
lower during the pre-risk periods for all classes of NSAID. The crude and adjusted 
relative incidence of PCAE associated with oral NSAID exposure is shown in table 55. 
Overall, no significant increase in the relative incidence of PCAE occurred for any class 
of NSAID using any acute risk period with any type of exposure. Non-selective 
NSAIDs were associated with a significant reduced relative incidence of PCAE during 
the 30 and 90 day acute risk period (IRR 0.76 (95% CI 0.60 to 0.95) and IRR 0.86 (95% 
CI 0.75 to 0.98) respectively). 
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Table 54. Crude incidence rates according to class of NSAID, exposure group and risk window. 
 Non-selective <5 fold selectivity 5-50 fold selectivity COX-2 inhibitors 
 
Risk Period 
 
Events 
 
Days 
Crude 
Incidence* 
 
Events 
 
Days 
Crude  
Incidence* 
 
Events 
 
Days 
Crude  
Incidence* 
 
Events 
 
Days 
Crude  
Incidence* 
Pre-risk 87 27431 31.72 84 32937 25.50 2 1318 15.17 6 4053 14.80 
30 day             
Baseline 989 256277 38.59 1189 308721 38.51 50 11171 44.76 140 36131 38.75 
Acute 82 27494 29.82 119 33102 35.95 7 1319 53.07 17 4073 41.74 
Chronic 75 18399 40.76 73 22307 32.73 4 1904 21.01 16 4548 35.18 
60 day             
Baseline 905 234407 38.61 1087 282523 38.47 48 10321 46.51 124 33455 37.06 
Acute 185 54922 33.68 244 66236 36.84 11 2638 41.70 39 8140 47.91 
Chronic 56 12766 43.87 50 15339 32.60 2 1434 13.95 10 3152 31.73 
90 day             
Baseline 824 211346 38.99 986 254638 38.72 43 9451 45.50 113 30370 37.21 
Acute 280 82415 33.97 365 99331 36.75 16 3946 40.55 53 12212 43.40 
Chronic 42 8307 50.56 30 10052 29.84 2 992 20.16 7 2157 32.45 
*Per 10,000 person years. 
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Table 55. Association between type of NSAID exposure and primary care asthma exacerbations using the self-controlled case series. 
 Non-selective <5 fold selectivity 5-50 fold selectivity COX-2 inhibitors 
Risk Period IRR  95% CI p-value IRR  95% CI p-value IRR  95% CI p-value IRR  95% CI p-value 
30 day             
Acute 0.76 0.60-0.95 0.017 0.92 0.76-1.11 0.364 1.33 0.59-2.97 0.494 1.06 0.64-1.76 0.831 
Chronic 0.89 0.67-1.18 0.417 0.78 0.59-1.04 0.088 0.69 0.21-2.29 0.544 0.88 0.47-1.66 0.690 
60 day             
Acute 0.86 0.73-1.01 0.062 0.94 0.82-1.08 0.377 0.99 0.51-1.94 0.977 1.27 0.88-1.84 0.208 
Chronic 0.97 0.70-1.34 0.860 0.77 0.55-1.07 0.118 0.40 0.09-1.89 0.249 0.74 0.35-1.58 0.436 
90 day             
Acute 0.86 0.75-0.98 0.027 0.93 0.82-1.05 0.227 0.99 0.54-1.81 0.977 1.14 0.81-1.60 0.461 
Chronic 1.12 0.78-1.60 0.559 0.67 0.45-1.01 0.054 0.64 0.14-3.06 0.576 0.69 0.29-1.66 0.412 
       Adjusted for use of SABA, LABA, ICS, leukotriene receptor antagonists, methylxanthines and seasonal variation. 
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9.5 Discussion 
The aim of this chapter was to assess the adverse respiratory effect of NSAIDs 
prescribed to people with asthma. These analyses found no strong evidence that oral 
NSAID exposure was associated with an increase in the incidence of asthma death, 
hospitalisation and PCAE. Based upon the general understanding around the 
pathogenesis of reactions in people with AERD, adverse respiratory effects from 
NSAIDs are more likely to be observed with incident rather than prevalent NSAID 
exposure. This is because most people issued repeat NSAID prescriptions are likely to 
have NSAID-tolerant asthma and be at lower risk of asthma morbidity. NSAID-induced 
reactions are typically thought to occur within the first few hours of ingestion and 
therefore people who develop respiratory reactions shortly following NSAID exposure 
are likely to avoid NSAIDs in the future. This may partly explain the reduced relative 
incidence of PCAE associated with prevalent exposure to non-selective NSAIDs and 
NSAIDs with <5-fold COX-2 selectivity. However, this would rely upon people 
correctly attributing respiratory symptoms to NSAID exposure which may not always 
be the case, especially if symptoms are mild or exposure occurs at the same time as 
uncontrolled asthma symptoms (such as during a respiratory tract infection). This was 
shown by a European wide cross-sectional study involving 500 people with AERD 
which found that only 15% of people became aware of sensitivity to aspirin following a 
provocation challenge test (98). 
 
Strengths and limitations 
Although a significant association with asthma death and prevalent NSAID exposure 
was observed, it was only significant using a single risk window and effect sizes 
became smaller when shorter risk windows were applied. It is likely that this association 
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is non-causal and more related to other factors such as residual confounding or a 
spurious statistically significant result due to multiple testing. If this association were 
causal, one would expect similar associations with asthma hospitalisation and PCAE or 
with incident exposure to be observed. In fact, prevalent non-selective NSAID exposure 
was associated with a significantly reduced risk of PCAE in the nested case control 
study.  
 
No increased risk of PCAE was observed with any type of NSAID in the SCCS and was 
consistent with findings from the nested case control study. The systematic review of 
clinical trials presented in chapter 5 demonstrates tolerability of COX-2 inhibitors in 
people with AERD and this study supports this observation. However, no significant 
increase in events was seen with non-selective NSAIDs. People with AERD are at 
increased risk of asthma morbidity compared to people with NSAID-tolerant asthma. It 
is therefore possible that people with AERD or more severe asthma would be prescribed 
COX-2 inhibitors instead other types of NSAIDs because clinicians thought they were 
safer. Confounding by indication could therefore affect observational studies comparing 
the risk from different classes of NSAIDs, since the British National Formulary has 
long carried a ‘blue box’ warning of this risk and it is therefore likely to have been 
widely known among prescribers over the period of this analysis. This is an important 
consideration for the nested case control study which is a between-person design, but is 
unlikely to affect the SCCS due to its within person design controlling for all fixed-
confounders. Non-causal associations could also occur if there are large differences in 
clinical indication for COX-2 inhibitors versus other types of NSAIDs which seems 
unlikely. It was not possible to determine the exact clinical indication for NSAID 
prescribing in order to make better comparisons to test this assumption. The asthma 
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analgesic cohort consisted of people prescribed NSAIDs, paracetamol or paracetamol-
containing preparations with low dose opiates in an attempt to identify people with 
broadly similar indications for mild to moderate analgesics. However, NSAIDs are 
prescribed at step two of the analgesic ladder it is possible that comparisons between 
people prescribed other types of analgesics may have been better. No attempt was made 
to determine whether a dose-response relationship exists for NSAIDs because of 
difficulty in defining the exact dose and the pattern in which patients took their 
analgesics.  
 
Assessing the risk from oral NSAID prescribing in asthma using observational data is 
also difficult because oral NSAIDs are available over-the-counter. Incident NSAID 
exposure was defined as an NSAID being prescribed in the risk window with no 
exposure in the year before. It is therefore possible that true incident exposure was not 
being evaluated in some of these people resulting in bias to the null for reasons 
described above. It has long been recognised that NSAIDs may trigger exacerbations in 
susceptible people with asthma and UK national asthma guidelines recommend that 
patients with asthma are asked about NSAID-induced reactions prior to prescribing 
which is likely to result in selection bias. Most clinicians will therefore avoid 
prescribing NSAIDs in people with a history of AERD, in those with unknown AERD 
status, or in those with more severe asthma which would lead to a bias to the null. These 
factors make it difficult to quantify the true risk of oral NSAID exposure in asthma 
using electronic health care records from the UK. However, it does suggest that the 
current practice of oral NSAID prescribing to selected people with asthma in the UK is 
by and large safe. 
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9.6 Summary 
This chapter observed no strong evidence of an increased risk of asthma events with 
oral NSAIDs prescribed in the community irrespective of selectivity. This analysis is 
likely to be affected by the way clinicians choose to prescribe NSAIDs to people with 
asthma in primary care because of historic safety concerns. This results in selection 
bias, and a bias to the null when performing observational studies quantifying the risk of 
NSAID exposure in asthma using routinely health care data from the UK. It is therefore 
not possible to make any general recommendations about how risky NSAIDs are or 
whether more people could safely be prescribed these agents. This is the last results 
chapter in this thesis and is followed by the discussion chapter. The discussion chapter 
will provide an overview of the work presented in this thesis and will attempt to put it 
into context in terms of clinical implications.  It will also discuss several limitations and 
ways in which different approaches could have been taken. Finally it will discuss the 
gaps in current evidence and future work.
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The aim of this thesis was to evaluate the risk of beta-blockers and NSAIDs in asthma 
using two different approaches. In the first half of this thesis, three systematic reviews 
and meta-analyses of clinical trial evidence evaluating acute exposure to beta-blockers 
and NSAIDs were performed. This was done to synthesize evidence with strong internal 
validity. In the second half of the thesis new pharmacoepidemiological studies were 
performed using linked electronic primary care data generating evidence with external 
validity. 
 
Beta-blockers – systematic review studies 
The first chapter in this thesis evaluated acute exposure to beta-blockers using a 
systematic review and meta-analysis of randomised, blinded placebo-controlled trials 
(chapter 3). The outcomes in this meta-analysis were mean percentage change in FEV1, 
falls in FEV1 of 20% or greater, incidence of respiratory symptoms and mean 
percentage FEV1 response to SABA following beta-blockade.  
 
This meta-analysis found that acute selective beta-blocker exposure caused a mean fall 
in FEV1 of 7%, statistically significant falls in FEV1 of 20% or greater affecting around 
1 in 8 people with asthma, and a non-significant increase in respiratory symptoms 
affecting 1 in 33 people with asthma. The mean FEV1 response to SABA following 
acute exposure to selective beta-blockers was blunted by around 10% compared to 
placebo. Despite this significant blunting, mean FEV1 values increased well beyond 
baseline levels following acute selective beta-blocker exposure. 
 
In contrast, acute non-selective beta-blocker exposure caused a mean fall in FEV1 of 
around 10%, a statistically significant increase in respiratory symptoms affecting around 
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1 in 13 people with asthma and a non-significant increase in falls in FEV1 of 20% or 
greater affecting around 1 in 9 people with asthma. The mean FEV1 response to SABA 
following acute exposure to non-selective beta-blockers was blunted by around 20% 
compared to placebo and mean FEV1 values did not increase beyond baseline levels 
unlike acute exposure to selective agents.  
 
In the beta-blocker meta-analysis, acute exposure to selective and non-selective beta-
blockers both produced similar falls in FEV1 of 20% or greater. This outcome was 
included because subsets of people more susceptible to the effects of beta-blockade may 
exist in which evaluation based upon the sole use of mean changes in FEV1 may be 
misleading. In this regard, a mean fall in FEV1 of 5% for a group could occur either if 
all patients experience a 5% fall, or if one patient had a fall of 23% and the remaining 9 
patients had a fall of 3%, which significantly alters the appreciation of risk. It is 
therefore possible that the presence of other factors may be important to trigger a 
clinically significant asthma exacerbation following beta-blockade. Such factors may 
include uncontrolled airway inflammation in patients not adhering to inhaled 
corticosteroids resulting in increased airway hyper-responsiness (AHR) or genetic 
factors such as the arginine-16 beta2-adrenoceptor polymorphism (Arg-16). 
Approximately 15% of Caucasian asthmatics possess two copies of the Arg-16 
polymorphism which predisposes to asthma exacerbations in people using regular 
salmeterol in conjunction with ICS (225).  
 
The systematic review also demonstrated that higher doses of selective beta-blockers 
caused greater mean reductions in FEV1 which is in keeping with a loss of beta1-
adrenoceptor selectivity at higher doses. In a study by Nuttal et al. increasing doses of 
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atenolol caused greater beta2-adrenoceptor blocking activity as defined by changes in 
serum potassium, glucose and insulin concentrations following an infusion of the beta2-
agonist terbutaline (226). The beta-blocker meta-analysis also demonstrated clinically 
important differences in treatment effect between individual drugs within each class. 
Acute exposure to celiprolol and labetalol did not cause a significant mean change in 
FEV1, whilst acute exposure to acebutolol and propranolol caused the largest mean 
change in FEV1 compared to placebo. Although celiprolol and labetalol appeared to be 
well tolerated in terms of mean change in FEV1, it was not possible to calculate falls in 
FEV1 of 20% or greater, incidence of respiratory symptoms, or response to SABA for 
them because of the lack of data and there was insufficient routine data to perform 
observational studies specifically looking at these.  
 
The beta-blocker systematic review process found no eligible studies evaluating topical 
beta-blocker eye drops used for the treatment of glaucoma. It is plausible that risk from 
topical therapy might be greater than with oral administration because rapid absorption 
of topical eye drops into the systemic circulation may occur, without undergoing first-
pass metabolism in the liver as is the case for orally administered drugs. In this sense, 
topical beta-blocker eye drops may have similar effects to that of intravenous 
administration in terms of beta2-adrenoceptor occupancy and cardiopulmonary effects 
(227). Given the widespread use of topical beta-blockers for glaucoma, the paucity of 
high quality trials on the safety of these agents in patients with reversible airways 
disease was surprising. 
 
In summary, this systematic review demonstrates that the adverse respiratory response 
from beta-blockers in asthma varies according to selectivity and dose of administration. 
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Although selective beta-blockers are much better tolerated in people with asthma acute 
exposure at the doses administered is not risk free. The clinical significance of the 
degree of the blunted response to beta2-agonists with acute selective bet-blocker 
exposure is uncertain as mean FEV1 values still increased beyond baseline levels.  
 
Beta-blockers – drug utilisation study 
The drug utilisation study in chapter 6 found that the prevalence of selective beta-
blocker prescribing in people with active asthma increased by around 200% over the 12 
year study period, whilst the prevalence of non-selective beta-blocker prescribing in 
people with active asthma increased by around 90% over this same period. This increase 
in beta-blocker prescribing to people with active asthma clearly demonstrated a 
population at risk in which to perform new observational studies.  
 
Beta-blockers – observational pharmacoepidemiology studies 
The first of these observational studies evaluated propranolol exposure in a cohort of 
people with asthma and anxiety using a nested case control study together with all 
people with active asthma and incident propranolol exposure experiencing a PCAE 
using the SCCS design (chapter 7). The NCC study found that propranolol exposure 
was associated with a large statistically significant increase in asthma hospitalisation 
which primarily related to incident propranolol exposure and high dose propranolol 
exposure. The SCCS conducted in the same chapter evaluated PCAE as an outcome 
only and no statistically significant increased risk of PCAE occurred within 30 days of 
incident propranolol prescribing. 
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The next chapter evaluated exposure to oral beta-blockers commonly used for the 
management of CVD using a cohort of people with asthma and CVD, again using a 
nested case control and SCCS design (chapter 8). This nested case control study found 
that prevalent high dose non-selective beta-blocker exposure was associated with a 
statistically significant increased risk of asthma hospitalisation and PCAE. There was 
also a significantly elevated risk of PCAE associated with incident low to moderate 
dose non-selective beta-blocker exposure. In this nested case control analysis, various 
types of exposure could not be properly evaluated such as the association between 
incident non-selective beta-blocker exposure and asthma hospitalisation due to a lack of 
power (lack of exposure among the cases). The SCCS in this chapter demonstrated a 
significantly increased risk of PCAE within 30 days of incident non-selective beta-
blocker prescribing. In contrast, there was no significant increase in the relative 
incidence of any of the asthma outcomes associated with any type of selective beta-
blocker exposure or dose using the nested case control study or the SCCS approach. 
 
In summary, these observational studies demonstrated that the adverse respiratory 
response to beta-blockers in asthma varied according to selectivity, by duration of 
administration and by dose of administration. In contrast to non-selective beta-blocker 
exposure, treatment with selective beta-blockers was not associated with a significantly 
increased risk of adverse respiratory events in people with asthma. 
 
Beta-blockers – clinical implications 
The risk from non-selective beta-blockers in these observational studies appeared to be 
related in part to duration of administration. This may be similar to the effects of beta-
blockers in heart failure, whereby acute beta-blocker exposure reduces myocardial 
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contractility whilst chronic exposure is well tolerated and leads to beta-adrenoceptor up-
regulation with beneficial effects on ejection fraction and survival. If a similar adaptive 
response did occur in people with asthma, the duration of exposure required to develop 
it could depend on a number of factors including individual response. Studies 
investigating the chronic effects of non-selective beta-blocker exposure have tended to 
use a selected population of well controlled mild-to-moderate asthmatics in which non-
selective beta-blockers were initiated at low dose and the dose gradually up titrated, 
often using inhaled muscarinic antagonist cover to prevent bronchoconstriction as a 
result of unopposed increased cholinergic tone (228). Compared to people in those 
trials, it is likely that some people in the CPRD active asthma cohort had uncontrolled 
asthma as a result of unrecognised symptoms meaning beta-blocker exposure is likely to 
be riskier.  In this regard, it may be difficult to identify and exclude these people 
because formal assessment of AHR and measures of active airway inflammation (such 
as exhaled breath nitric oxide - FENO) are not routinely performed in primary care.  
 
Perhaps unsurprisingly, prevalent high dose non-selective beta-blocker exposure was 
associated with an increased risk of asthma hospitalisation and PCAE in the asthma 
CVD cohort. This apparent increase in asthma events goes against the idea of an 
adaptive response occurring with chronic beta-blocker exposure in asthma, but the 
trigger for an adaptive response could be dose related with high doses leading to 
complete beta2-adrenoceptor blockade not widely tolerated in people with asthma. In 
this regard, only a small amount of beta2-adrenoceptor blockade may be required to 
trigger improvements in AHR such as that seen with metoprolol in a murine model of 
asthma (229). Although prevalent low to moderate dose non-selective beta-blocker 
exposure appeared to be generally well tolerated in the observational studies reported 
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here, no strong evidence was found to support the hypothesis that chronic non-selective 
beta-blockade actually improves asthma outcomes. This however is an issue that can 
only really be examined in well-designed clinical trials. 
 
Although low to moderate dose incident non-selective beta-blocker exposure was 
associated with a significant increase in PCAE in chapter 8, initiation of low dose non-
selective beta-blockers in asthma can be tolerated by some people in keeping with the 
idea there is a population of susceptible people at higher risk (165, 230). It is uncertain 
in these observational studies whether gradual beta-blocker dose-titration occurred or 
whether using inhaled muscarinic antagonist therapy may have reduced risk from non-
selective beta-blockers further. Although inhaled muscarinic antagonists have been used 
to prevent bronchoconstriction following beta-blocker exposure in asthma, they are 
currently not routinely indicated for the management of asthma. Instead, people from 
these analyses would have relied upon SABA reliever therapy, efficacy of which was 
shown to be significantly blunted in the beta-blocker meta-analysis.  
 
Aspirin/NSAIDs – systematic review studies 
The systematic review and meta-analysis in chapter 4 estimated the prevalence of 
AERD and the mean provocative dose triggering adverse respiratory reactions in people 
with AERD. The prevalence of AERD in asthma was found to be 9% in adults as 
determined by falls in FEV1 of 20% or greater using blinded, placebo-controlled oral 
provocation challenge tests and 9.6% as determined using surveys reliant upon self-
reported history. In this study, the mean provocative dose of aspirin was around 89 mg 
which is a clinically recommended dose. 
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The next systematic review and meta-analysis measured the incidence of respiratory 
symptoms and changes in FEV1 of 20% or greater from blinded placebo-controlled 
clinical trials evaluating acute exposure to selective NSAIDs and COX-2 inhibitors in 
people with AERD (chapter 5). This study found that acute exposure to COX-2 
inhibitors did not cause any significant adverse respiratory effects compared to placebo 
in people with AERD. In contrast a small but statistically significant increased risk of 
lower respiratory tract reactions occurred with selective NSAIDs in approximately 1 in 
13 people with AERD. Despite the apparent safety of COX-2 inhibitors, the drug 
utilisation study in chapter 6 found that the prevalence of COX-2 inhibitor prescribing 
to people with active asthma was only 0.3% by 2011. 
 
In summary, AERD is relatively common in people with asthma and may be triggered 
by clinically relevant doses of aspirin. COX-2 inhibitors were well tolerated in people 
with AERD but are not routinely prescribed to people with asthma. 
 
Aspirin/NSAIDs - observational pharmacoepidemiology studies 
The final study was the nested case control study investigating the adverse respiratory 
effect of oral NSAIDs and COX-2 inhibitors in a cohort of people with asthma 
prescribed analgesic medications and a SCCS study using all people with active asthma 
prescribed incident NSAID exposure experiencing a PCAE. These analyses found no 
strong evidence that oral NSAID exposure was associated with an increase in asthma 
events. Although a significant association with asthma death and prevalent NSAID 
exposure was observed in the nested case control study, this association is likely to be 
non-causal. This is because a significant increase in the relative incidence of asthma 
death was observed in only one of the risk windows; no increase in asthma 
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hospitalisation or PCAE occurred with prevalent NSAID exposure; and no significant 
increase was found with incident NSAID exposure which is expected to have a greater 
risk in light of the known pathophysiology. No currently published observational 
studies were found assessing the risk of NSAID prescribing in asthma in order to 
compare with the findings from that chapter. 
 
In summary, these observational studies found no strong evidence of an increased risk of 
asthma events with oral NSAIDs prescribed in the community irrespective of 
selectivity. However, this analysis is likely to be affected by the way clinicians choose 
to prescribe NSAIDs to people with asthma in the community because of historic safety 
concerns.  
 
AERD/NSAIDs – clinical implications 
Recommendations in clinical asthma guidelines regarding the safe use of NSAIDs in 
people with asthma and an unknown AERD phenotype appear to lack specific guidance. 
Challenge tests are considered the gold standard for confirming AERD in individual 
people but these are not widely recommended or used in routine clinical practice (2, 
101). Meanwhile, regulatory agencies such as the MHRA in the UK and the FDA in the 
US recommend that all NSAIDs are contraindicated in people with AERD regardless of 
selectivity, whilst clinical guidelines simply recommend asking people with asthma if 
they have suffered any adverse respiratory effects from NSAIDs prior to prescribing.  
 
The findings from the systematic review evaluating selective NSAIDs and COX-2 
inhibitors in people with AERD found that acute exposure to COX-2 inhibitors appears 
to be safe, at least when initiated at low doses in stable mild to moderate asthmatics. As 
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such it could be important to optimise asthma control with preventer therapy such as 
with ICS or leukotriene receptor antagonists to further reduce the risk of adverse events 
in this population if concerns remained. Up to 90% of people with AERD demonstrate 
upper respiratory (nasal) responses to aspirin or non-selective NSAIDs, which do not 
appear to occur with COX-2 inhibitors. Although not considered as clinically important 
as potentially life-threatening lower respiratory reactions, nasal reactions in people with 
asthma do significantly affect quality of life (190, 231). Ultimately, the use of any drug 
depends upon its risk and benefit.  As with other types of NSAIDs, COX-2 inhibitors 
are associated with an increased cardiovascular risk and an overall risk assessment 
would need to be made in order avoid unintended consequences in people with asthma 
(232). As is the case with any medication, the lowest effective dose should be used for 
the shortest period of time with scheduled medical review. However, given the 
limitations associated with the NSAID observational study it has not been possible to 
externally validate the risk of NSAIDs in people with asthma using this data although it 
does suggest that the current practice of oral NSAID prescribing to people with asthma 
in the UK is by and large safe. 
 
Limitations and alternative methodological approaches – systematic reviews 
The systematic reviews in this thesis could have been improved in several ways. Firstly, 
only English language publications were included in each systematic review which may 
have introduced language bias, however this is likely to have a limited effect overall 
because the number of included studies was relatively large. Secondly, only published 
data were included in each systematic review which may have introduced reporting bias 
because not all studies reported all of the outcomes evaluated and additional information 
was not requested. This may have been overcome by requesting additional information 
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from the study authors and a decision was made not to do this because many of the 
included studies were over 15 years old. This process would have been time consuming 
and probably would have resulted in little additional information being provided. 
Thirdly, analysing individual patient data would have increased the robustness of the 
results which were often restricted to the analysis of mean group effects which is a 
general problem with many systematic reviews and meta-analyses. A meta-analysis of 
observational studies evaluating risk of exposure was not performed because the 
number of studies identified on scoping was small and meta-analysis would have been 
methodologically more complex. As such, it is possible some high quality observational 
data might have been missed. 
 
Finally, although the meta-analyses in this thesis used subgroup analysis to investigate 
possible statistical heterogeneity, alternative approaches exist such as meta-regression. 
Meta-regression is a method for evaluating possible explanations for statistical 
heterogeneity in a meta-analysis and is used principally to investigate associations 
between study-level characteristics and treatment effects (233). Meta-regression can 
help to quantify the extent to which statistical heterogeneity is explained by the study 
characteristic i.e. the proportion of between study variance explained by the study 
characteristics is calculated and is presented as the adjusted R
2
 (such as exposure to ICS 
or baseline FEV1 values which could modify risk of beta-blocker exposure or the mean 
percentage fall in FEV1 which is observed respectively). However, meta-regression 
looks at observational relationships between study characteristics even if those studies 
are randomised placebo-controlled trials. As such relationships may not be causal and 
meta-regression may suffer from confounding, lack of power (with resulting false 
negatives or type II errors) and bias such as aggregation bias in which relationships 
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across studies may not represent relationships within studies (the ecological fallacy). 
Meta-regression can also suffer from lack of power if the number of included studies is 
low. 
 
Limitations and alternative methodological approaches – observational studies 
Observational studies may suffer from residual confounding and bias, which was the 
rationale for including a clinical trial evidence synthesis as a comparison, although 
clinical trial evidence is typically done in very selected populations. The primary 
observational analysis was the nested case control study in which time-varying 
confounding relating to the exposure of interest and changes in asthma medication 
could be adjusted for more efficiently than with a traditional cohort analysis. However, 
the nested case control study may suffer from residual time-fixed confounding due to its 
between-person design. In contrast, the SCCS is a within-person design that controls for 
all time-fixed confounding but may still suffer from residual time-varying confounding. 
Both study designs could therefore suffer from bias and confounding, but the specific 
types of bias and confounding are likely to be different suggesting that consistency in 
results using both designs increases the strength of evidence for a causal relationship. 
 
The observational studies in this thesis could have been improved in several ways. The 
nested case control studies were designed to address confounding by indication and to 
ensure that controls were sampled using a more representative population. However, 
this reduced the size of the cohort from which cases and controls were identified thereby 
affecting the power of the study. For this reason, several types of beta-blocker exposure 
and doses could not be properly evaluated. The nested case control study used a cohort 
of people with asthma and anxiety because propranolol is primarily thought to be 
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prescribed for the management of anxiety in the UK and there is reportedly an 
association between anxiety and asthma control. This analysis potentially could have 
been improved by including people with other indications for propranolol and matching 
cases and controls by their indication in order to increase the power of the study whilst 
still dealing with the issue of confounding by indication.  
 
Choosing different cohort designs may have introduced bias in these nested case control 
studies. The NSAID analysis conducted in chapter 9 used a cohort of people with 
asthma prescribed NSAIDs and other low-strength analgesics because clinical 
indications for NSAIDs where thought to be poorly recorded in CPRD. However, 
NSAIDs are traditionally prescribed at step 2 of the analgesic ladder and it may have 
been appropriate to include people prescribed higher strength analgesic preparations. 
However, the SCCS generally produced consistent results in terms of PCAE suggesting 
that any bias may not be influential. 
 
The SCCS studies could also have been improved in several ways. The SCCS approach 
used in this thesis included people with active asthma receiving incident beta-blocker or 
NSAID exposure experiencing a PCAE during the observation period (case-exposure 
approach). It would not have been possible to use a case-exposure approach for asthma 
death and hospitalisation in this thesis due to the small numbers of people with incident 
exposure who experienced the event of interest during the observation period. However, 
this could have been improved by including cases without the exposure of interest in the 
analysis thus providing additional information relating to baseline incidence and time 
varying confounders (126).  
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The choice of outcome in the SCCS was restricted to PCAE due to concerns over event-
dependent exposures which are likely to be more severe when beta-blockers cause 
asthma hospitalisation or death. Although including cases of asthma hospitalisation 
without the exposure of interest would have made this more feasible, issues relating to 
event-dependent exposures would have remained. The SCCS method requires that 
events arise in a non-homogenous Poisson distribution and that observation periods 
should be independent of when an event occurs. A pre-risk period was included in the 
analysis to account for short-lived event-dependent exposures which occurred as 
demonstrated by a reduced incidence of PCAE during this period. A pre-risk period is 
an approach recommended to deal with short-lived event-dependent exposures in the 
SCCS and ignoring this approach would have overestimated the relative incidence of 
events (126). In hindsight it may have been worth investigating the risk of asthma 
hospitalisation using a pre-risk period as well. More recently, an extension to the SCCS 
methodology which removes this independence assumption has been proposed and it is 
possible that implementing this new approach may have allowed a better assessment of 
asthma hospitalisation and PCAE (234).  
 
Additionally, the observation period was restricted to a period of 1 year. In contrast, a 
longer study observation period could have been used in order to increase the number of 
people eligible for the SCCS analysis. However, this would have increased the effect of 
time-varying confounding relating to the exposure of interest and changing patterns of 
asthma medication. The SCCS is not recommended for evaluating the effects of chronic 
exposure, and the SCCS was principally used in this thesis to evaluate the acute risk 
period. However, chronic exposure was defined in order to partition it from baseline 
incidence which may otherwise be biased.  
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Alternative between-person and within-person study designs could have been used to 
investigate the risk from beta-blockers and NSAIDs in this thesis, such as a cohort 
analysis using propensity scores and the case-crossover study respectively. Propensity 
scores use patient covariates to predict the propensity for being prescribed the exposure 
of interest in an attempt to evaluate how comparable exposed and unexposed groups are. 
Propensity scores can then be used for confounding adjustment or matching exposed 
and unexposed patient groups. However, a cohort analysis using propensity scores 
would still be susceptible to time-varying confounding in relation to the exposure of 
interest and changing patterns of asthma medication. One approach in dealing with 
time-dependent confounding in cohort studies is to consider using inverse probability 
weighted marginal structural models which are used to estimate the effect of an 
exposure on an outcome if time-varying confounders are themselves affected by the 
exposure (235). An alternative within-person design is the case-crossover study. Like 
the SCCS, the case-crossover design uses only cases in order to eliminate time-fixed 
confounding and control selection bias. The case-crossover design compares the risk of 
exposure in a time period immediately before the outcome to one or more control time 
periods in the past using the same individual (236). However, this design is again not 
thought to be appropriate for investigating chronic conditions or chronic exposures.  
 
Confounding by contraindication is an important type of confounding which could 
affect the validity of results from these observational studies. Confounding by 
contraindication occurs when a drug is withheld over concerns it may worsen a person’s 
condition. Prescribing beta-blockers and NSAIDs in asthma is therefore a classic 
example of this whereby these agents could be prescribed to people with less severe 
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asthma and with a lower risk of exacerbations. The effect of confounding by 
contraindication would be to produce a bias to the null or an apparent protective effect 
which may not actually exist. One way of dealing with this would be to investigate the 
relationship between beta-blocker and NSAIDs and asthma events at a time when the 
potential risk was unknown or not widely known. However, this was not possible 
because these agents have long been known to trigger exacerbations in susceptible 
people with asthma. This is another rationale for performing the meta-analyses of 
clinical trial evidence in thesis. 
 
Asthma is a clinical diagnosis based upon history, clinical examination, the presence of 
reversible or variable airflow obstruction, or results from bronchial provocation 
challenge tests. In the absence of a single diagnostic test for asthma in primary care it is 
therefore possible that misdiagnosis may occur potentially affecting the validity of the 
results. In general, diagnoses within CPRD have high validity with one systematic 
review reporting an overall median positive predictive value across diagnoses of 89% 
(range 24 to 100%) with a specific figure for diseases of the respiratory system of 88% 
(116). A recent study by Quint et al. demonstrated that people with COPD can be 
accurately identified in CPRD. This study validated COPD recording using 
questionnaires from general practitioners to gather additional information and compared 
this to specific clinical codes which demonstrated a positive predictive value 
approaching 90% (237). In contrast, no such validation study has specifically been 
performed for asthma recording in CPRD which would be important to strengthen the 
validity in these results. International Classification of Disease codes recorded as the 
underlying cause of death (recorded in cause 1, cause 2 or cause 3) were used to define 
cases of asthma death. This was considered synonymous to part 1a, 1b and 1c of UK 
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ONS requirements for death registration. However, the linked dataset provided by 
CPRD contains up to nine recorded causes of death per patient. Additionally, asthma 
hospitalisation was defined as a code for asthma recorded in the primary position on the 
discharge script provided by CPRD (main reason for admission). These definitions were 
chosen in order to increase the validity that a case was a case. As such, it is possible that 
some cases may not have been included if asthma exacerbations had been recorded in 
other positions. This would potentially underestimate the incidence of asthma death and 
asthma hospitalisation among the active asthma cohort (calculated in chapter 6) when 
compared to national statistics if incidence rates in national statistics are calculated 
using codes for asthma recorded anywhere in the death certificate or hospital discharge 
record. Other potentially reasons for discrepancies include inaccuracy in coding, 
excluding people with other respiratory conditions which may lower the threshold for 
death and hospitalisation and the representativeness of the CPRD population. Many of 
the effect estimates had large confidence intervals indicating a lack of precision and that 
power was lacking to properly evaluate risk associated with certain types of exposures, 
dose and asthma death. Much larger linked datasets would therefore be required to 
evaluate these properly.  
 
In an ideal situation, large randomised clinical trials would be performed to answer 
these questions which are not always ethical or feasible when assessing the adverse 
effects of medicines, especially if these adverse effects are rare. However, given the 
findings for selective beta-blockers a clinical safety trial to assess the risk versus benefit 
in people with asthma who have strong clinical indications is perhaps more justifiable, 
since there is a plausible case that beta-blockers might have chronic beneficial effects 
293 
 
and the studies reported here are consistent with the risk of some beta-blockers being 
low enough to be manageable in the right trial design.  
 
Potential further research 
This study was unable to evaluate certain types of beta-blocker exposure in people with 
asthma such as the risk of asthma hospitalisation and asthma death associated with 
incident exposure because of a lack of power. Unless the size of CPRD was to increase 
substantially through the incorporation of general practices using EMIS system of 
electronic medical records, proper evaluation would only be possible by repeating the 
analyses in other datasets and meta-analysing the results. Such datasets could be created 
by linking Scottish health care data to the community dispensed Prescribing Information 
System and Scottish Morbidity Records (SMR) which in future will also contain data 
from general practices through linkage to the Scottish Primary Care Information 
Resource (SPIRE). Alternatively, national European datasets could be also be used for 
this purpose. Indeed, a comparison using dispensed prescription data versus issued 
prescription data would also be valuable as not all prescriptions for beta-blockers or 
NSAIDs issued to people with asthma may have been dispensed by the community 
pharmacist. 
 
The lack of randomised blinded placebo-controlled clinical trials evaluating topical 
beta-blocker eye drops in people with asthma highlights a potential evidence gap. The 
systematic review process could be repeated with less strict inclusion criteria in an 
attempt to identify and assess additional studies evaluating topical beta-blocker 
exposure irrespective of the quality of their design and risk of bias. It would also be 
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worth using observational data using a similar approach taken in this thesis to evaluate 
the risk of asthma exacerbations associated with topical beta-blocker exposure.  
 
People with asthma in the UK are not routinely screened for AERD creating potential 
prescribing dilemmas for physicians and uncertainties for patients. This in turn results in 
people with asthma avoiding NSAIDs despite strong clinical indications for their use, 
the majority of which may not have AERD. Further research evaluating the best method 
of diagnosing AERD would be helpful especially if this could be readily applied in a 
primary care setting. Finally, the increasing incidence of asthma exacerbations over the 
last 12 years is a potential cause for concern and further research is required to 
investigate the reasons behind this increase and to develop interventions aimed at 
preventing asthma exacerbations. This may involve determining whether rises are 
attributable to an increase in the absolute number of people experiencing asthma 
exacerbations or whether rises are attributable to an increase in the rate of recurrent 
asthma exacerbations experienced by a subset of people, possibly as a result of poor 
asthma management or difficulty accessing healthcare services. 
 
Conclusion 
The work undertaken in this thesis has demonstrated to me the importance of evaluating 
different sources of evidence when quantifying the adverse effects of medicines and 
also to consider ways of challenging findings from observational studies in order to test 
the validity of results, an approach I will apply in the future.  
 
Most prescribing interventions carry some degree of risk and prescribing beta-blockers 
to people with asthma is no exception. However, risk from beta-blockers in asthma 
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should be balanced against the potential benefits which are greatest to people with 
cardiovascular disease. The beta-blocker meta-analysis demonstrated that selective beta-
blockers may trigger significant changes in lung function in people with asthma and that 
risk appears to be greater with high doses when selectivity may be lost. In general 
however, risk from initiating beta-blockers in people with asthma appears to be low 
when using a selective beta-blocker, which could be commenced at low dose and 
gradually up titrated depending upon tolerability because SABAs still appear to be 
effective should any respiratory symptoms develop. Although some people with asthma 
may tolerate acute exposure to non-selective beta-blockers, risk is clearly greater and 
SABA rescue therapy is less effective suggesting their risk outweighs any potential 
benefits for existing clinical indications and should be avoided.  
 
Around 9% of people with asthma appear to have AERD which can be triggered by 
aspirin and other NSAIDs. However, no specific diagnostic test for AERD is available 
in routine clinical care. The currently available evidence suggests that COX-2 inhibitors 
appear to be safe in people with AERD whilst selective NSAIDs appear to carry a small 
risk. Therefore, COX-2 inhibitors could be a suitable alternative in people with AERD 
or in those people with asthma who are unwilling to accept the risk of incident NSAID 
exposure when testing for AERD is not routinely available. However, limitations of 
observational data make it difficult to assess the generalizability of these findings.
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Appendix 1.1. MEDLINE search strategy for the systematic review of acute beta-blocker exposure in asthma (chapter 3). 
Search Term Search Term 48 double-blind.ti,ab. 
1 adrenergic*.af. 26 Labetalol.af. 49 (double adj2 blind).ti,ab. 
2 antagonist*.af. 27 Levobunolol.af. 50 (controlled adj3 study).ti,ab. 
3 block*.af. 28 Metipranolol.af. 51 (comparative adj3 study).ti,ab. 
4 beta-receptor*.af. 29 Metoprolol.af. 52 randomized controlled trial.pt. 
5 beta-adrenergic*.af. 30 Nadolol.af. 53 controlled clinical trial.pt. 
6 beta-blocker*.af. 31 Oxprenolol.af. 54 43 or 44 or 45 or 46 or 47 or 48  
7 1 and 2 32 Penbutolol.af.  or 49 or 50 or 51 or 52 or 53 
8 1 and 3 33 Pindolol.af. 55 exp animals/ not humans.sh. 
9 1 and 4 34 Practolol.af. 56 54 not 55 
10 3 and 5 35 Propranolol.af. 57 asthma*.af. 
11 1 and 6 36 Sotalol.af. 58 (bronchial adj3 hyperreactivity*).af. 
12 7 or 8 or 9 or 10 or 11 37 Timolol.af. 59 (bronchial adj3 hyper-reactivity*).af. 
13 blockader*.af. 38 Esmolol.af. 60 (bronchial adj3 hyperrespons*).af. 
14 sympatholytic*.af. 39 Carvedilol.af. 61 (bronchial adj3 hyper-respons*).af. 
15 Acebutolol.af. 40 Nebivolol.af. 62 (airway adj3 hyperreactivity*).af. 
16 Alprenolol.af. 41 13 or 14 or 15 or 16 or 17 or 18 or 19 or  63 (airway adj3 hyper-reactivity*).af. 
17 Atenolol.af.  20 or 21 or 22 or 23 or 24 or 25 or 26 or  64 (airway adj3 hyperrespons*).af. 
18 Betaxolol.af.  27 or 28 or 29 or 30 or 31 or 32 or 33 or 65 (airway adj3 hyper-respons*).af. 
19 Bisoprolol.af.  34 or 35 or 36 or 37 or 38 or 39 or 40 66 'respiratory sounds'.af. 
20 Bupranolol.af. 42 12 or 41 67 wheez*.af. 
21 Butoxamine.af. 43 placebo*.ti,ab. 68 (reversible adj3 obstruction).af. 
22 Carteolol.af. 44 trial.ti,ab. 69 57 or 58 or 59 or 60 or 61 or 62 or 63  
or 64 or 65 or 66 or 67 or 68 23 Celiprolol.af. 45 random*.ti,ab. 
24 Dihydroalprenolol.af. 46 single-blind.ti,ab. 70 42 and 56 and 69 
25 Iodocyanopindolol.af. 47 (single adj2 blind).ti,ab.   
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Appendix 1.2. MEDLINE search strategy for the systematic review of prevalence and mean provocative dose in aspirin-
exacerbated respiratory disease (chapter 4). 
 
Search Oral Provocation Challenge Tests and Mean Provocative Dose Search Population Studies 
1 asthma*.af. 49 aspirin-like.ti,ab,sh. 1 “Aspirin-exacerbated respiratory disease”.ti,ab,sh 
2 (bronchial adj3 hyperreactivity*).af. 50 (aspirin adj2 like).ti,ab,sh. 2 “Aspirin exacerbated respiratory disease”.ti,ab,sh 
3 (bronchial adj3 hyper-reactivity*).af. 51 33 and (49 or 50) 3 “Aspirin-sensitive asthma”.ti,ab,sh 
4 (bronchial adj3 hyperrespons*).af. 52 nsaid*.ti,ab,sh. 4 “Aspirin sensitive asthma”.ti,ab,sh 
5 (bronchial adj3 hyper-respons*).af. 53 34 or 35 or 39 or/40-42 or/46-48 or 51 or 52 5 “Aspirin-induced asthma”.ti,ab,sh 
6 (airway adj3 hyperreactivity*).af. 54 inhibitor*.ti,ab,sh. 6 “Aspirin induced asthma”.ti,ab,sh 
7 (airway adj3 hyper-reactivity*).af. 55 antagonist*.ti,ab,sh. 7 “Aspirin-intolerant asthma”.ti,ab,sh 
8 (airway adj3 hyperrespons*).af. 56 cyclooxygenase*.ti,ab,sh. 8 “Aspirin intolerant asthma”.ti,ab,sh 
9 (airway adj3 hyper-respons*).af. 57 cyclo-oxygenase*.ti,ab,sh. 9 AERD.ti,ab,sh 
10 (reversible adj3 obstruction).af. 58 (cyclo adj2 oxygenase*).ti,ab,sh. 10 AIA.ti,ab,sh 
11 'respiratory sounds'.af. 59 cox*.ti,ab,sh. 11 “NSAID-exacerbated respiratory disease”.ti,ab,sh 
12 wheez*.af. 60 (prostaglandin adj2 synth*).ti,ab,sh. 12 “NSAID exacerbated respiratory disease”.ti,ab,sh 
13 or/1-12 61 (prostaglandin-endoperoxide adj2 synth*).ti,ab,sh. 13 “NSAID -sensitive asthma”.ti,ab,sh 
14 random*.af. 62 54 and (or/56-61) 14 “NSAID sensitive asthma”.ti,ab,sh 
15 factorial*.af. 63 55 and (or/56-61) 15 “NSAID -induced asthma”.ti,ab,sh 
16 crossover*.af. 64 Aspirin.ti,ab,sh. 16 “NSAID induced asthma”.ti,ab,sh 
17 cross-over*.af. 65 Aceclofenac.ti,ab,sh. 17 “NSAID -intolerant asthma”.ti,ab,sh 
18 placebo*.af. 66 acemetacin.ti,ab,sh. 18 “NSAID intolerant asthma”.ti,ab,sh 
19 (singl* adj blind*).af. 67 Azoproprazone.ti,ab,sh. 19 or/1-18 
20 (doubl* adj blind*).af. 68 Celecoxib.ti,ab,sh. 20 Prevalence.ti,ab,sh 
21 single-blind*.af. 69 Dexibuprofen.ti,ab,sh. 21 Incidence.ti,ab,sh 
22 double-blind*.af. 70 Dexketoprofen.ti,ab,sh. 22 Frequency.ti,ab,sh 
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23 assign$.af. 71 Diclofenac.ti,ab,sh. 23 Occurrence.ti,ab,sh 
24 allocat$.af. 72 Etodolac.ti,ab,sh. 24 or/20-23 
25 volunteer$.af. 73 Etoricoxib.ti,ab,sh. 25 19 and 24 
26 randomized controlled trial.pt. 74 Fenbufen.ti,ab,sh. 26 Morbidity.ti,ab,sh 
27 controlled clinical trial.pt. 75 Fenoprofen.ti,ab,sh. 27 Hospitalisation.ti,ab,sh 
28 or/14-27 76 Fluribuprofen.ti,ab,sh. 28 Hospitalization.ti,ab,sh 
29 analgesi*.ti,ab,sh. 77 Ibuprofen.ti,ab,sh. 29 Emergency.ti,ab,sh 
30 anti-inflammator*.ti,ab,sh. 78 Indomethacin.ti,ab,sh. 30 “asthma attack”.ti,ab,sh 
31 antiinflammator*.ti,ab,sh. 79 Ketorolac.ti,ab,sh. 31 “asthma exacerbation”.ti,ab,sh 
32 (anti adj2 inflammator*).ti,ab,sh. 80 Ketoprofen.ti,ab,sh. 32 “severity” OR “severe” OR “uncontrolled” 
33 agent.ti,ab,sh. 81 Mefenamic acid.ti,ab,sh. 33 or/26-32 
34 29 and (30 or 31 or 32) 82 Meloxicam.ti,ab,sh. 34 19 and 33 
35 33 and (30 or 31 or 32) 83 Nabumetone.ti,ab,sh.   
36 non-steroidal*.ti,ab,sh. 84 Naproxen.ti,ab,sh.   
37 nonsteroidal*.ti,ab,sh. 85 Parecoxib.ti,ab,sh.   
38 (non adj2 steroidal*).ti,ab,sh. 86 Piroxicam.ti,ab,sh.   
39 36 and (30 or 31 or 32) 87 Rofecoxib.ti,ab,sh.   
40 37 and (30 or 31 or 32) 88 Sulindac.ti,ab,sh.   
41 38 and (30 or 31 or 32) 89 Tenoxicam.ti,ab,sh.   
42 33 and (36 or 37 or 38) 90 Tolfenamic acid.ti,ab,sh.   
43 antirheumatic.ti,ab,sh. 91 Tiaprofenic acid.ti,ab,sh.   
44 anti-rheumatic.ti,ab,sh. 92 Phenylbutazone.ti,ab,sh.   
45 (anti adj2 rheumatic).ti,ab,sh. 93 or/64-92   
46 43 and (or/36-38) 94 53 or 62 or 63 or 93   
47 44 and (or/36-38) 95 13 and 28 and 94   
48 45 and (or/36-38)     
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Appendix 1.3. MEDLINE search strategy for the systematic review of acute exposure to selective NSAIDs or COX-2 inhibitors in 
people with aspirin-exacerbated respiratory disease (chapter 5). 
 
Search Search type Search Search type Search  
1 asthma*.af. 33 agent.ti,ab,sh. 64 Aspirin.ti,ab,sh. 
2 (bronchial adj3 hyperreactivity*).af. 34 29 and (30 or 31 or 32) 65 Aceclofenac.ti,ab,sh. 
3 (bronchial adj3 hyper-reactivity*).af. 35 33 and (30 or 31 or 32) 66 acemetacin.ti,ab,sh. 
4 (bronchial adj3 hyperrespons*).af. 36 non-steroidal*.ti,ab,sh. 67 Azoproprazone.ti,ab,sh. 
5 (bronchial adj3 hyper-respons*).af. 37 nonsteroidal*.ti,ab,sh. 68 Celecoxib.ti,ab,sh. 
6 (airway adj3 hyperreactivity*).af. 38 (non adj2 steroidal*).ti,ab,sh. 69 Dexibuprofen.ti,ab,sh. 
7 (airway adj3 hyper-reactivity*).af. 39 36 and (30 or 31 or 32) 70 Dexketoprofen.ti,ab,sh. 
8 (airway adj3 hyperrespons*).af. 40 37 and (30 or 31 or 32) 71 Diclofenac.ti,ab,sh. 
9 (airway adj3 hyper-respons*).af. 41 38 and (30 or 31 or 32) 72 Etodolac.ti,ab,sh. 
10 (reversible adj3 obstruction).af. 42 33 and (36 or 37 or 38) 73 Etoricoxib.ti,ab,sh. 
11 'respiratory sounds'.af. 43 antirheumatic.ti,ab,sh. 74 Fenbufen.ti,ab,sh. 
12 wheez*.af. 44 anti-rheumatic.ti,ab,sh. 75 Fenoprofen.ti,ab,sh. 
13 or/1-12 45 (anti adj2 rheumatic).ti,ab,sh. 76 Fluribuprofen.ti,ab,sh. 
14 random*.af. 46 43 and (36 or 37 or 38) 77 Ibuprofen.ti,ab,sh. 
15 factorial*.af. 47 44 and (36 or 37 or 38) 78 Indomethacin.ti,ab,sh. 
16 crossover*.af. 48 45 and (36 or 37 or 38) 79 Ketorolac.ti,ab,sh. 
17 cross-over*.af. 49 aspirin-like.ti,ab,sh. 80 Ketoprofen.ti,ab,sh. 
18 placebo*.af. 50 (aspirin adj2 like).ti,ab,sh. 81 Mefenamic acid.ti,ab,sh. 
19 (singl* adj blind*).af. 51 33 and (49 or 50) 82 Meloxicam.ti,ab,sh. 
20 (doubl* adj blind*).af. 52 nsaid*.ti,ab,sh. 83 Nabumetone.ti,ab,sh. 
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21 single-blind*.af. 53 34 or 35 or 39 or 40 or 41 or  84 Naproxen.ti,ab,sh. 
22 double-blind*.af.  42 or 46 or 47 or 48 or 51 or 52 85 Parecoxib.ti,ab,sh. 
23 assign$.af. 54 inhibitor*.ti,ab,sh. 86 Piroxicam.ti,ab,sh. 
24 allocat$.af. 55 antagonist*.ti,ab,sh. 87 Rofecoxib.ti,ab,sh. 
25 volunteer$.af. 56 cyclooxygenase*.ti,ab,sh. 88 Sulindac.ti,ab,sh. 
26 randomized controlled trial.pt. 57 cyclo-oxygenase*.ti,ab,sh. 89 Tenoxicam.ti,ab,sh. 
27 controlled clinical trial.pt. 58 (cyclo adj2 oxygenase*).ti,ab,sh. 90 Tolfenamic acid.ti,ab,sh. 
28 or/14-27 59 cox*.ti,ab,sh. 91 Tiaprofenic acid.ti,ab,sh. 
29 analgesi*.ti,ab,sh. 60 (prostaglandin adj2 synth*).ti,ab,sh. 92 Phenylbutazone.ti,ab,sh. 
30 anti-inflammator*.ti,ab,sh. 61 (prostaglandin-endoperoxide adj2 synth*).ti,ab,sh. 93 or/64-92 
31 antiinflammator*.ti,ab,sh. 62 54 and (56 or 57 or 58 or 59 or 60 or 61) 94 53 or 62 or 63 or 93 
32 (anti adj2 inflammator*).ti,ab,sh. 63 55 and (56 or 57 or 58 or 59 or 60 or 61) 95 13 and 28 and 94 
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Appendix 2: Read codes 
2.1 Asthma 
H33..00,663..11,H333.00,H33z100,H33z011,14B4.00,H330.12,H33..11,H330.11,663V100, 
663V300,663V000,H331.11,H33z.00,H33zz11,H33z000,9Q21.00,H331.00,H330011,173A.00, 
H330111,8H2P.00,H330.00,663P.00,663N.00,H330.14,H33z111,663J.00,663j.00,1O2..00, 
H33z200,663V.00,663V200,H330000,H330.13,H33zz001,H33zz13,H331111,663p.00,663n.00,
H33zz12,173c.00,663d.00,663v.00,H330100,H331000,H33z.11,H334.00,1780.00,H331z00, 
H330z00,H331100,173d.00 
 
ICD10 codes: J45.0,J45.1,J45.8,J45.9,J46,493,493.0,493.1,493.9.  
 
2.2 COPD 
H31..00,H310.00,H310000,H310z00,H311.00,H311000,H311100,H311z00,H312.00,H312000,
H312011,H312100,H312200,H312z00,H313.00,H31y.00,H31y000,H31y100,H31yz00,H31z.0,
H32..00,H320.00,H320000,H320100,H320200,H320300,H320311,H320z00,H321.00,H322.00,
H32y.00,H32y000,H32y100,H32y111,H32y200,H32yz00,H32z.00,H3...00,H3...11,H36..00, 
H37..00,H38..00,H39..00,H3z..00,H3z..11,H3y..00,H3y..11,H3y0.00,H3y1.00. 
 
ICD10 codes: J41,J41.0,J41.1,J41.8,J42,J43,J43.1,J43.2,J43.8,J43.9,J44,J44.0,J44.1,J44.8,J44.9. 
 
2.3 Bronchiectasis 
H34..00 ,H340.00,H341.00,H34z.00 
 
ICD10 codes: J47,J47.0,J47.1,J47.9. 
 
2.4 Restrictive lung disease 
H35..00 ,H350.00,H351.00,H352.00,H352000,H352100,H352z00, 
H353.00,H354.00,H355.00,H356.00,H357.00,H35y.00,H35y000,H35y100,H35y200, 
H35y500,H35y600,H35y700,H35y800,H35yz00,H35z.00,H35z000,H35z100,H35zz00 
 
ICD10 codes: J84.1,J84,J84.0,J84.2,J84.3,J84.9,J84.10,J84.11,J84.111,J84.112,J84.113, 
J84.114,J84.115,J84.116,J84.117,J84.8,J84.89,J61,J60,J62,J63,J64,J65,J66,J67,J68,J69,J70, 
J62.0,J62.8,J63.0,J63.1,J63.2,J63.3,1.J63.4,J63.5,J63.6,J66.0,J66.1,J66.8,J67.0,J67.1,J67.2, 
J67.3,J67.4,J67.5,J67.6,J67.7,J67.8,J67.9,J70.0,J70.1,J70.2,J70.3,J70.4. 
 
2.5 Atrial fibrillation and flutter 
G573.00,G573000,G573100,G573200,G573300,G573400,G573500,G573z00 
 
2.6 Cardiovascular disease 
G30..00 ,G30..11,G30..12,G30..14,G30..15,G30..16,G30..17,G300.00,G301.00,G301000, 
G301100,G301z00,302.00,G303.00,G304.00,G305.00,G306.00,G307.00,G307000,G307100, 
G308.00,G309.00,G30B.00,G30X.00,G30X000,G30y.00,G30y000,G30y100,G30y200, 
G30yz00,G30z.00,G30..13,G30A.00,G35..00,G350.00,G351.00,G353.00,G35X.00, 
G38..00 ,G380.00,G381.00,G384.00,G38z.00,G311.00,G311.11,G311.12,G311.13,G311.14, 
G311100,G311200,G311500,G311z00,G312.00,G31y.00,G31y000,G31y100,G31y200, 
G31y300,G31yz00,G3...00,G3...11,G3...12,G3...13,G311300,G311400,G32..00,G32..11, 
G32..12,G33..00,G330.00,G330000,G330z00,G33z.00,G33z000,G33z100,G33z200,G33z300,G
G33z400,G33z500,G33z600,G33z700,G33zz00,G340.00,G340.11,G340.12,G340000,G340100, 
G342.00,G343.00,G344.00,G34y.00,G34y000,G34y100,G34yz00,G34z.00,G34z000,G3z..00. 
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2.7 Cerebrovascular disease 
G63y000,G63y100,G64..00,G64..11,G64..12, 
G64..13 ,G676000,G6W..00,G6X..00,Gyu6300,Gyu6400,Gyu6500,Gyu6600,Gyu6F00, 
Gyu6G00,G65..00,G65..12,G65..13,G656.00,G65y.00,G65z.00,G65z100,G65zz00,G65z000 
 
2.8 Peripheral artery disease 
G73..00 ,G73..11,G73..12,G73..13, 
G733.00,G73y.00,G73yz00,G73z.00,G73z012,G73zz00,G73z000,G73z011,Gyu7400 
 
2.9 Chronic kidney disease 
1Z1..00 ,1Z10.00,1Z11.00,1Z12.00,1Z13.00, 
1Z14.00,1Z15.00,1Z16.00,1Z17.00,1Z17.11,1Z18.00,1Z19.00,1Z19.11,1Z1A.00,1Z1A.11, 
1Z1B.00,1Z1B.11,1Z1C.00,1Z1C.11,1Z1D.00,1Z1D.11,1Z1E.00,1Z1E.11,1Z1F.00,1Z1F.11, 
1Z1G.00,1Z1G.11,1Z1H.00,1Z1H.11,1Z1J.00,1Z1J.11,1Z1K.00,1Z1K.11,1Z1L.00,1Z1L.11 
 
2.10 Anxiety 
E200.00, 
E200300,Eu41111,E200400,E200z00,E200500,E200200,Eu41.00,E200000,Eu41211,Eu41000, 
Eu60600,Eu40.00,E202.12,Eu41100,Eu41200,Eu34114,Eu05400,Eu41z00,Eu41y00,Eu93100,
Eu41z11,Eu40y00,Eu41y11,Eu93200,E2D0.00,Eu40z00,Eu41112,Eu41300, 
Eu41113,Eu93y12,E200111,E202100,E200100,Eu41012,Eu41011,1B1V.00,Eu40012,225J.00
  
2.11 Heart failure 
G58..00,G58..11,G1yz100,662f.00,662g.00,662h.00,662i.00,585f.00,585g.00,G5yy900, 
G5yyA00. 
 
2.12 Nasal polyps 
7406000,H110.00,H11..00,2D33.00,7402911,H110z00,H11z.00,H11y.11,7402900 
 
2.13 Seropositive arthritis 
N040.00,N065z11,N040T00,N047.00,N04X.00,43b9.00,N040200,M160200,N04..00,N040S00,
N040900,N040800,N040100,N040000,N040700,N040B00,N040D00,N040K00,N040F00, 
Nyu1G00,N040500,F371200,N040A00,N040600,Nyu1200,N040H00,N040G00,N040L00, 
N040C00,N040400,Nyu1100,N040J00 
 
